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Abstract	
An estimated 2.6 million newborns die each year, mostly from largely preventable 
causes – prematurity, intrapartum-related complications and infections. Data on 
neonatal infection aetiology and pathways of acquisition of infection are lacking 
particularly in sub-Saharan Africa (sSA), yet are essential to inform prevention. In a 
systematic review of neonatal infection aetiology studies in sSA, Klebsiella species, 
Escherichia coli, Staphylococcus aureus, Group B Streptococci, and Enterococcus were the 
top five reported bacterial pathogens across all regions. Application of the 
Strengthening the Reporting of Observational Studies in Epidemiology for Newborn 
Infection (STROBE-NI) checklist highlighted wide variation in clarity and completeness 
of reporting, impeding comparability and utility. 
A four-year audit of neonatal admissions and quality of care at The Gambia’s largest 
referral hospital showed that possible serious bacterial infection (pSBI) accounted for 
44% (2166/4944) of admissions. There was a striking mismatch of high antibiotic use 
(95%) and low microbiological investigation for infection (1% blood culture and 2% 
lumbar puncture) was evident.  
A hospital-based matched case-control study was undertaken in the three main referral 
health facilities in The Gambia to describe neonatal infection aetiology, and evaluate the 
role of maternal bacterial colonisation. Sick newborn-mother pairs (n=203) and healthy 
newborn-mother pairs (n=203) were recruited. Pathogenic bacteria were isolated from 
blood cultures of 45% (91/202) of the sick newborns, and the most frequently 
identified isolates were S.	 aureus,	 Klebsiella,	 and	 Burkholderia	 cepacia. There was 
notable lack of GBS detected by culture but in the molecular sub-study, GBS was 
identified in 5% (2/42) of cases. Klebsiella demonstrated near universal resistance to 
WHO-recommended first- and second-line antibiotics. For 14 mother-infant pairs, the 
isolates from infant blood and maternal rectovaginal cultures matched suggesting 
possible vertical transmission  
This PhD shows that infections are a major problem among hospitalised newborns in 
The Gambia. Programmatic implications and priorities for research are outlined. 
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CHAPTER	1.	INTRODUCTION	TO	GLOBAL	BURDEN	AND	CASE	
DEFINITIONS	FOR	NEONATAL	INFECTIONS	
 
 
 
 
 
 
 
Picture on the wall at the entrance to the neonatal ward, Edward Francis 
Small Teaching Hospital, Banjul, The Gambia (used	with	permission) 
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Overview	
This chapter presents the global burden and case definitions for neonatal infection, as 
well as a description of the different diagnostic methods and the challenges associated 
with each diagnostic method. It also summarises the pathogens associated with 
neonatal infection in developed countries, known risk factors for infection, and the 
potential sources of transmission of infection in the newborn in these settings. 
1.1 Global	burden	for	neonatal	infections	
In 2016, 2.6 million newborns died from largely preventable causes; an estimated 1 
million neonatal deaths occurred on the day of birth, and nearly 2 million died in the 
first week of life.1 During the 25-year era of the Millennium Development Goals (1990 – 
2015) with global targets set for health priorities, a significant overall reduction in 
under-five mortality was achieved. However, the decline in mortality during the 
neonatal period (the first 27 days after birth) was much slower than that of post-
neonatal under-five mortality resulting in a shift in the concentration of deaths.1 
Consequently, the proportion of child deaths which occur in the neonatal period has 
increased in all World Health Organisation (WHO) regions over the last 25 years from 
40% in 1990 to 46% in 2016, and is projected to increase to 52% in 2030 if current 
trends continue.1 Reducing neonatal mortality is therefore increasingly important for 
ongoing progress for child survival, and also because the health interventions needed to 
address the major causes of neonatal deaths generally differ from those needed to 
address other under-five deaths.2  
Infections are the third most common and preventable cause of global neonatal deaths 
after prematurity and intrapartum–related conditions (previously termed “birth 
asphyxia”),  making up 23% of neonatal deaths.3 In high neonatal mortality settings (30 
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or more neonatal deaths per 1000 live births) infections cause up to 50% of neonatal 
deaths.4 The burden of neonatal infections is not limited to mortality and for those 
neonates who are treated and survive, there is substantial long-term morbidity in the 
form of neurodevelopmental impairment and disability after meningitis.5 Reducing 
newborn morbidity and mortality will therefore require better prevention and case 
management of severe infections, preterm births, and inpatient supportive care of ill 
and small newborn babies including the promotion of kangaroo mother care (KMC). To 
develop research priorities and appropriate strategies for prevention and case 
management of infection, there is a need to better understand the aetiology of these 
infections and acquisition pathways. 
1.2 Case	definitions	
Infectious	syndromes	
Neonatal infection encompasses several infectious syndromes during the neonatal 
period specifically; Septicaemia (overwhelming infection without much localization), 
meningitis (predominantly localised to the meninges) and pneumonia (predominantly 
localized to the lung).6 Given the “invasive” nature of these infections within normally 
sterile body sites and their systemic manifestation, they are considered “serious” as 
opposed to superficial infections of non-sterile sites such as the skin and umbilicus. 
Providing standardised definitions of neonatal infections is relevant for global efforts to 
address neonatal mortality, and a variety of definitions have been proposed and applied 
in both community and hospital studies.6 Standardised definitions for global use must 
be relevant to all populations and settings, specifically developing countries where 
diagnostic services are limited and where the majority of newborn deaths occur.  
However, the lack of a standardised clinical or laboratory diagnosis for neonatal 
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infections, even in high-income settings where laboratory services are readily 
available,7 makes it difficult to tailor a one-size-fits-all approach.  
The definition proposed by the WHO Young Infant Clinical Signs Study Group (YICSSG) 
is the most widely applied in developing country settings.8  It comprises seven clinical 
“danger” signs, which when used alone or in combination with the others reliably 
predicts the need for hospitalisation in young infants presenting to health facilities 
particularly in the first week of life (sensitivity 85%, specificity 75%). These signs 
formed the basis for the WHO Integrated Management of Childhood Illness (IMCI) 
referral decision algorithm used at the primary-care level in low-income settings.9  The 
presence of any one of these signs and symptoms signals the presence of a serious 
illness or possible serious bacterial infection (pSBI) thereby prompting health workers 
to initiate empiric broad-spectrum antibiotic treatment before referral to the next level 
of care.  Although this approach prioritises sensitivity at the expense of specificity, it is 
justified in developing-country settings where neonatal mortality rates are high and the 
majority of those caring for newborns even at hospital levels are health workers with 
limited training and skills.10  The limited specificity of these signs however, makes it 
difficult to disaggregate pSBI from overlapping disorders including viral respiratory and 
other infections  as well as non-infectious syndromes which do not require antibiotic 
treatment (Figure 1.1 below).11   
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The proportion of neonatal respiratory distress attributable to pneumonia for example, 
depends on the source population (tertiary hospital, district hospital, or community), 
the stage in the perinatal period, the gestational age of the babies and the availability of 
intensive care, and the definition of pneumonia.12  Fast breathing has low specificity as a 
single sign13 and the environment may influence temperature.14 In clinical trial settings, 
low specificity may introduce misclassification of disease.15 In order to increase the 
specificity of diagnosis of clinically diagnosed severe infection, recent clinical trials for 
simplified antibiotic treatment in Africa and South Asia modified the YICSSG algorithm; 
excluding fast breathing as a single cause for pSBI, increasing the temperature cut-off 
for fever from 37.5°C to ≥38°C, and requiring that poor feeding be confirmed by 
observation.16  One shortcoming of the YICSSG definition is that the presence of any one 
of the clinical signs does not provide a distinct diagnosis for sepsis, meningitis, or 
pneumonia but only gives a reasonable basis for initiating empiric treatment. 
Furthermore, different pathogens such as bacteria, viruses, fungi or parasites often 
Figure	1.1	Possible	serious	bacterial	infection	(pSBI)	and	overlap	with	other	clinical	syndromes	
in	the	newborn.		
Source: Seale et al 2014 (Adapted	to	be	consistent	with	the	terminology	of	“serious”) 
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present in a clinically indistinguishable pattern in neonates, and localised infections 
may present with systemic signs making the clinical diagnosis difficult and often 
impossible without imaging confirmation and/or laboratory support.6  
In developed or high-income countries, several case definitions for neonatal infections 
particularly focused on preterm infants have been produced and applied, due to 
advances in neonatal intensive care.17-20 More recently, case definitions for neonatal 
infections have been driven by the need to establish safety and efficacy standards for 
vaccine trials to protect newborns against specific infections.6 The Brighton 
Collaboration Neonatal Infections Working Group recently proposed separate 
definitions for the three different infection syndromes during the neonatal period 
(invasive bloodstream infections; meningitis and respiratory tract infections) each with 
three or more diagnostic levels.6 Primarily intended to improve data comparability in 
clinical trials and epidemiological surveillance studies of vaccines in pregnancy, these 
definitions are also applicable in clinical trials and interventions aimed at reducing 
neonatal morbidity and mortality. The diagnostic levels do not reflect the different 
grades of clinical severity but diagnostic certainty within the definition context, with 
level one being highly specific for the condition. This is to enable capture of all possible 
cases of neonatal infections regardless of the setting or population in which they are 
assessed. 
Time	of	onset		
Traditionally neonatal infections are classified as early-onset and late-onset infections, 
according to time and mode of onset. Opinions differ as to what is the appropriate age 
for differentiating between them and the range is between 2 – 7 days.21-23 In developed-
country settings, early-onset infections are often caused by pathogens acquired by 
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vertical transmission from the mother, while late-onset infections are caused by 
pathogens acquired vertically or by horizontal transmission from the home or hospital 
environment.21 The distinction in terms of acquisition pathway is blurred in developing-
country settings where inadequate hygiene and aseptic measures during delivery and 
initial care of the baby in health facilities contribute to early-onset infections as well as 
transmission of pathogens from one mother in labour to another21 In these settings 
therefore, early-onset infections may be “maternally-acquired” or “hospital-acquired”. 
Making the distinction between the possible sources of acquisition is often difficult and 
has led some to classify infections in newborns in developing countries according to the 
place of birth irrespective of the time of onset; hence, any infection in hospital-born (in-
born) baby is regarded as a hospital-acquired infection and any in a home-born (out-
born) baby is community-acquired.21 The advantage of this approach is that it enables 
the identification of neonates exposed to the health-care environment and facilitates the 
assessment of the adequacy of hospital-based infection control practices during labour 
and delivery. The disadvantage is that it fails to take account of the inherent differences 
in aetiology between infections acquired from the maternal genital tract and those from 
the hospital environment, which is important as the means of prevention are potentially 
different.  
1.3 Diagnosis	
Traditional	microbiological	methods	
Bloodstream	infections		
Blood culture is often considered to be the “gold standard” for the detection of 
microorganisms in the blood. The isolation of an organism confers many advantages, 
including pathogen identification and antibiotic susceptibility testing, which facilitate 
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correct diagnosis and adjustment of empiric antibiotic therapy as well as the optimal 
choice and duration of antibiotic treatment.24, 25  Negative results enable 
discontinuation of antibiotics thereby reducing the selection of resistant bacteria.  
Blood cultures have a higher specificity but lower sensitivity compared to clinical 
signs.26, 27  In some reports, only 5-10% of cases of suspected serious infections were 
positive for any bacterial aetiology by blood culture.28 The aetiology of more than 90% 
of suspected serious neonatal infections therefore remains unknown, and many of these 
infections may possibly be due to bacteria or viruses that are currently unrecognised as 
causes of infection.29 The positivity rate of blood cultures is affected by laboratory 
capabilities, volume of blood inoculated, and administration of antibiotics prior to 
sampling.26, 30 False negative results may also arise from administration of intrapartum 
antibiotics to the mother. The use of automated blood culture systems has improved the 
sensitivity of blood cultures and has decreased time to detection of positive cultures 
compared with conventional methods by the use of enriched culture media containing 
antibiotic-binding resins that facilitate growth and recovery of organisms.31  Sensitivity 
is however still less than optimal particularly with blood volumes less than the 
recommended 1.0mL (common from critically ill premature infants); when there is low-
level bacteraemia (≤10 Colony-forming units (CFU)/mL), as many as 60% of cultures 
will be falsely negative with 0.5mL sample volumes. 24, 25, 32, 33  
Meningitis	
Culture of the cerebrospinal fluid (CSF) is critical to establishing the diagnosis of 
meningitis. Some estimated 15-30% of infants with CSF culture-proven meningitis will 
have negative blood cultures in the presence of normal CSF parameters (white blood 
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cells, glucose, and protein).34, 35 No single CSF parameter value can therefore reliably 
exclude meningitis.36, 37   
Pneumonia	
Where laboratory facilities are available to identify causative organisms, blood culture 
has been the primary means of aetiological diagnosis. The diagnostic yield from blood 
cultures is however low and will therefore underestimate the proportion of pneumonia 
that is bacterial.38, 39 Lung aspiration with culture or molecular diagnostics provides a 
higher diagnostic yield and is more specific for causative pathogen than blood culture 
but is rarely performed in neonates.40-43 Chest radiographic imaging is a useful adjunct 
despite the potentially limited predictive value of radiographic findings.  
Molecular	diagnostic	methods	
An ideal diagnostic test for neonatal sepsis should be rapid, sensitive, and specific, while 
providing detection of all organisms relevant in neonatal sepsis and limiting the effects 
of maternal antibiotics. The use of molecular methods to identify pathogens causing 
serious neonatal infections offers higher detection and rapid results and is a valuable 
adjunct to blood cultures.44, 45 The sensitivity of molecular methods used to diagnose 
neonatal sepsis ranges from 41% to 100%, and specificity from 77% to 100% in 
comparison with blood culture.46, 47 These variations have been attributed to differences 
in methodology and study design, including DNA extraction methods, as well as the 
characteristics of the population studied (term vs preterm infants). State-of-the-art 
molecular diagnostics are mainly available in well-resourced settings and not in the 
regions where the burden of neonatal infections is greatest. The positive and negative 
predictive value of a diagnostic test also depends on the prevalence of sepsis in the 
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population studied and will therefore differ between resource-limited and resource-rich 
settings. 
An appropriate molecular method is important for simultaneous detection of diverse 
bacterial and viruses in multiple specimen types to determine the aetiology of 
infection.48 Different molecular diagnostic platforms/methods have been developed 
based on real-time multiplex or multiple singleplex polymerase chain reactions (PCR) 
for simultaneous identification of multiple aetiological agents. Nucleic acid amplification 
techniques such as pan-bacterial (16S rRNA) or pan-fungal (18 rRNA) PCR assays are 
useful when followed by sequencing or microarray/probe hybridization.49, 50 More 
advanced multiplex PCR approaches that utilize multiple primer pairs for multiple 
targets in a single PCR reaction allow for the simultaneous identification of more than 
one pathogen, with rapid detection times less than 5 hours and up to 90% concordance 
rates with blood cultures.51 In addition to the requirement of small sample volumes  and 
rapid diagnosis, molecular diagnostic techniques offer the ability to evaluate virulence 
and antibiotic resistance markers that may inform antibiotic therapy.47 However, in a 
recent systematic review assessing the diagnostic accuracy of various molecular 
methods for the diagnosis of culture-positive bacterial and fungal sepsis in neonates, 
molecular tests did not have sufficient sensitivity (>0.98) to replace microbial cultures 
but were useful add-on tests in the diagnostic work-up.52 
One technology that has emerged as a useful method for multiple pathogen detection is 
the TaqMan® Array Card (TAC), (Life Technologies, Foster City, CA, USA). TAC is a 384-
well microfluidic card pre-loaded with dried-down individual singleplex real-time PCR 
(rtPCR) reactions for simultaneous detection of multiple pathogen targets from a single 
specimen therefore conserving samples, and significantly shortening testing and 
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response times.53 One major advantage of the TAC is that total nucleic acids from one 
clinical specimen can be combined with PCR enzyme-mix, loaded once into a TAC port, 
and separated by microfluidics into 48 separate reactions capable of amplifying either 
DNA or RNA. This format allows for 1 – 8 samples (clinical specimen or control 
material) to be run in parallel against multiple pathogen targets.53   
TAC has been successful in the detection of respiratory,54 and enteropathogens,55-57 and 
was therefore selected for use in the Aetiology of Neonatal Infection in South Asia 
(ANISA) study which aims to identify the leading causes of neonatal infections in 5 
population-based sites (rural and suburban) in Bangladesh, India, and Pakistan.58 ANISA 
is the first study to employ the use of advanced molecular diagnostics for the diagnosis 
of neonatal sepsis in a high neonatal mortality setting.58  Two cards – a respiratory card 
and a blood card - were customised to include common invasive pathogens associated 
with neonatal infections in the region based on organisms identified as the highest 
priority for testing in respiratory samples (nasopharyngeal and oropharyngeal swabs), 
and blood samples. In addition to common respiratory pathogens, specific genomic 
signatures for K.	pneumoniae	and E.	coli	were also put on the respiratory card as they 
are common colonisers as well as common invasive pathogens among the neonates of 
South Asia.  One challenge in the use of the TAC by ANISA was that its utility for 
pathogen detection in human blood samples had not previously been investigated. 
Studies involving blood from murine infection models had demonstrated low sensitivity 
of TAC for detection of several bacterial agents.59 This necessitated modification and 
optimization of the TAC methodology to improve its sensitivity for pathogen detection 
particularly in blood samples.53 The highly-anticipated results from the ANISA study 
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will provide insights as to the suitability of expanding TAC technology to the clinical 
setting.48, 58 
Haematological	indices	and	biomarkers	
Haematological indices such as total and differential leucocyte count, neutrophil count 
and immature neutrophil to total neutrophil ratio, have been investigated as adjunct 
markers of infection in newborns.60 In spite of the advantage of not requiring aseptic 
collection of blood samples, these indices are unreliable especially in the septic 
newborn where they may be falsely low.45 
Biological biomarkers (e.g. acute phase reactants, cytokines, genes, proteins) which 
reflect the host’s inflammatory response to infection are useful adjuncts to good clinical 
acumen and improved molecular diagnostic techniques in confirming serious bacterial 
infection in young infants and children.61-69 This is particularly useful in cases of 
persisting clinical symptoms and in the absence of a confirmatory positive blood culture 
result. One of the major drawbacks with biomarkers is the difficulty in differentiating 
sepsis-associated inflammation from non-infectious inflammation. In the newborn, cord 
and postnatal blood cytokines, for example, can be depressed in the presence of 
maternal pregnancy-induced hypertension and can rise after induced vaginal or urgent 
caesarean delivery, delivery room intubation and muscular damage.70 Another difficulty 
is defining the “zero hour” for measurement in order to characterise the biomarker as a 
detector of early or late-onset infection.66 In a systematic review of the potential of 
biomarkers as a point-of-care diagnostic for neonatal infection, most studies based the 
definition on the time of blood collection rather than the first onset of illness or time of 
presentation.66 This is important given the differences in time course of release, time to 
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measurable levels following ‘infection,’ the half-life, and time to normalise after 
eradication of the infectious agent. 
1.4 Aetiology		
Historical reviews from high-income countries have shown an evolution in the 
bacteriologic profile of pathogens responsible for neonatal infections with time.71-74 In 
the USA, Escherichia	coli	and Staphylococcus	aureus	were the principal causes of sepsis 
in early infancy until the 1970s when Group B streptococci (GBS) emerged as the 
leading cause of neonatal sepsis.74 Following the recommendations for risk-based 
screening for GBS with introduction of intrapartum antibiotic prophylaxis (IAP) to 
reduce GBS in 1996 and universal screening in 2002, rates of GBS early-onset serious 
bacterial infection have declined but reflect a continued burden of disease as GBS 
remains the most frequent pathogen in term infants.75, 76 Increased administration of 
IAP has also led to a change in the epidemiology of early-onset infection among very low 
birth-weight (<1500 g birth-weight) infants; E.	 coli is now the most common cause of 
early-onset serious bacterial infection in this population,77, 78 and coagulase-negative 
staphylococci (CoNS) the most common cause of late-onset infection.79 The 
epidemiology of neonatal infection in the UK is similar: GBS and E. coli are the most 
common organisms causing early-onset serious bacterial infection while CoNS, 
Enterobacteriaceae and S.	aureus are the most common organisms associated with late-
onset infections.73 Table 1.1 shows the range of pathogens associated with neonatal 
infections in developed countries.  
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Table	1.1	Pathogens	associated	with	neonatal	infections	in	developed	countries	
Recognised	bacterial	pathogens	a	
	 Opportunistic	bacterial	
pathogens	b,c	
Achromobacter	spp	
A.	xylosoxidans	
Acinetobacter	spp:		
Acinetobacter	baumannii	
Acinetobacter	lwoffii	
Aeromonas species  
Alcaligenes species  
Bacillus	cereus		
Bordetella	spp	
Bordetella	bronchiseptica	
Bordetella	parapertussis	
Bordetella	pertussis	
	
Burkholderia	cepacia	
Campylobacter	spp	
Campylobacter	fetus	
Campylobacter	jejuni	
Chryseobacterium species 
Citrobacter	spp.	
Citrobacter	koseri	
Citrobacter	diversus	
Citrobacter	freundii	
Clostridium	spp.	
Clostridium	difficile	
Clostridium	perfringens	
Eikenella	corrodens	
Enterococcus	spp.	
Enterococcus	faecalis	
Enterococcus	faecium	
Enterococcus	gallinarum	
Enterobacter	spp	
Enterobacter	aerogenes	
Enterobacter	agglomerans	
Enterobacter	cloacae	
Escherichia	coli	
Flavobacterium	spp	
Haemophilus	spp.	
Haemophilus	influenzae	
Haemophilus	parainfluenzae	
Klebsiella	spp.	
Klebsiella	aerogenes	
Klebsiella	oxytoca	
Klebsiella	pneumonia	
Lactobacillus	spp.	
Listeria	monocytogenes 
Moraxella	spp	
Moraxella.	catarrhalis	
Mycobacterium	spp.	
Mycobacterium	tuberculosis		
Morganella	morganii	
Neisseria	spp.	
Neisseria	meningitidis	
Neisseria	gonorrhoeae	
Nocardia	spp	
Nocardia	asteroides	
Pantoea	spp	
Pasteurella	species		
Plesiomonas	shigelloides	
Prevotella	spp	
Proteus	spp.	
Proteus	mirabilis	
Proteus	vulgaris		
Providencia	spp	
Providencia	rettgeri	
Providencia	stuartii	
Pseudomonas	spp	
Pseudomonas	aeruginosa	
Pseudomonas	cepacia	
Pseudomonas	stutzeri	
Ralstonia	spp	
Salmonella	spp.		
Shigella	spp.	
Shigella	dysenteriae	
Shigella	flexneri	
Shigella	sonnei	
Serratia	spp.	
Serratia	liquefaciens	
Serratia	marcescens	
Staphylococcus	aureus	(MSSA	
or	MRSA)	
Streptococcus	agalactiae	or	
group	B	streptococcus	
Streptococcus	pneumoniae	
Streptococcus	pyogenes	
Stenotrophomonas	maltophilia	
Ureaplasma	spp	
	 Bacillus	spp.	(other	than	B.	cereus)	
Bacteroides	spp.	
Bacteroides	fragilis	
Coagulase-negative	staphylococci	
Corynebacterium	spp.	
Diphtheroids	
Micrococcus	spp.	
Propionibacterium	spp.	
Propionibacterium	acnae	
Peptococcus	spp.	
Peptostreptococcus	spp.	
Peptostreptococcus	magnus	
Peptostreptococcus	micros	
Streptococcus	spp.	
Streptococcus	acidominimus	
Streptococcus	anginosus	
Streptococcus	bovis	
Staphylococcus	capitis	
Streptococcus	constellatus	
Staphylococcus	epidermidis	
Streptococcus	equinus	
Staphylococcus	haemolyticus	
Staphylococcus	hominis	
Streptococcus	mitis	
Streptococcus	mutans	
Streptococcus	oralis	
	
Fungi	 Viruses	 	 Protozoa	
Aspergillus	spp	
Aspergillus	flavus	
Aspergillus	fumigatus	
Aspergillus	glaucus	
Aspergillus	niger	
Aspergillus	terreus	
Aspergillus	versicolor		
	
Candida	spp.	
Candida	albicans	
Candida	dubliniensis	
Candida	glabrata	
Candida	guilliermondii	
Candida	kefyr	
Candida	krusei	
Candida	parapsilosis	
Candida	tropicalis	
Cryptococcus	spp.	
Cryptococcus	neoformans	
Adenovirus 
Bocavirus 
Coronavirus 
Enteroviruses 
Herpes simplex viruses  
Human metapneumovirus 
Influenza 
Parainfluenza 
Parechoviruses 
Parvovirus 
Respiratory Syncytial Virus 
Rhinovirus 
Varicella zoster virus 
 Plasmodium falciparum 
Plasmodium knowlesi 
Plasmodium malariae 
Plasmodium ovale  
Plasmodium vivax 
Toxoplasma gondii 
Trypanosoma cruzii 
spp = species 
a, b Source: Vergnano et al 2016;6 Vermont-Oxford Network 201780     
C Considered opportunistic in the neonatal period 
1.5 Risk	factors		
Maternal, host and environmental factors determine which infant exposed to a 
potentially pathogenic organism will develop sepsis. An estimated 30-40% of infections 
resulting in neonatal sepsis deaths are transmitted at the time of childbirth and have 
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early-onset of symptoms, emphasizing the need to address maternal and environmental 
sources of infection.28, 81 Several pre-partum and intra-partum obstetric complications 
have been associated with an increased risk of infection in the newborn; the most 
significant of which are premature onset of labour, prolonged rupture of membranes, 
chorioamnionitis and maternal fever.  The immature immune system of the newborn 
infant is less equipped to provide a robust defence against virulent organisms, 
particularly the premature and low birth-weight infant due to lack of protective 
maternal antibodies, underdeveloped innate immunity, and fragile, easily damaged 
skin.82  
In developing countries, the likelihood of infection is increased due to other additional 
risk factors (Table 1.2).  
Table	1.2	Risk	factors	for	neonatal	infections	in	developing	countries	
Maternal	Factors	a	 Environmental	a	 Neonatal	factors	a	
• Poor antenatal care 
- Maternal infections 
- Bacterial vaginosis 
- Urinary tract infection 
- Genital tract colonisation 
• Maternal malnutrition (especially micronutrient 
deficiency) 
• Premature or prolonged rupture of membranes 
• Poor obstetric care and hygiene 
• Intrapartum related events (including birth asphyxia) 
• Environmental contamination 
• Poor cord care 
• Poor hand washing 
• Artificial feeding 
• Overcrowding 
• Poor newborn care practices 
(e.g. early bathing, removal of 
vernix caseosa, prelacteal 
feeds, discarding colostrum) 
• Complications of 
prematurity and low 
birth-weight	
 
 
 
 
a Adapted from Bhutta ZA.83  
Unsafe birthing practices are common; whereas in the other WHO regions over 70% to 
99% of all births are attended by skilled health personnel, only 50% of births in sub-
Saharan African (sSA) region are attended by a skilled birth attendant,84 often resulting 
in unhygienic practices such as delivery onto an unsterile floor, unsterile cord cutting 
and potentially unsafe cultural customs such as spreading dung on the newborn’s 
umbilicus.85 Although these risk factors have been linked to poor neonatal outcomes in 
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sSA,86 they have not studied in relation to early-onset neonatal bacterial sepsis in the 
context of high rates of HIV, maternal undernutrition, foetal anaemia, and placental 
malaria. 
1.6 Acquisition	pathways		
Maternal	transmission	
The close relationship between mothers and their newborns leads to common risk 
factors and aetiologies of infectious diseases. Endogenous bacteria (or flora) that 
commonly colonise the maternal genital tract, and which may or may not cause disease 
in the mother, can cause “vertical” early-onset infection in the newborn.87, 88 The 
maternal genital tract flora normally includes several bacterial species including 
Bacteriodes, Lactobacillus species, Bifidobacterium species,	 E.	 coli, GBS, Streptococcus 
spp, Staphylococci, Klebsiella and Enterobacter	 species.89 Newborns come into direct 
contact with the bacterial flora in the vaginal canal and perineum during labour and 
delivery, in which case newborns may acquire infection through the eyes (e.g. 
gonococcal conjunctivitis), mouth, the umbilicus, or a break in the skin.90 Ascending 
infections from the mother to the foetus may occur during labour, when colonised 
organisms from the maternal perineum spread through the vaginal canal to the 
placenta, and into the once sterile amniotic fluid.87  The amniotic fluid, which bathes the 
foetus, also circulates through its lungs and intestinal tract, which are potential hot 
spots for bacterial translocation.91 Figure 1.2 summarises sources of maternal microbial 
transmission to the foetus and newborn. 
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In high-income countries, maternal colonisation with GBS is the most extensively 
studied in relation to infection in the newborn.74, 92 Approximately 10%–35% of women 
are asymptomatic carriers of GBS in the genital and gastrointestinal tracts.93 At birth, 1 
in 2 infants who are born to colonised  mothers will themselves be colonised on the skin 
or mucosal surfaces.94 Approximately 98% of colonised newborns are without 
symptoms, but 1%–2% develop early-onset disease, in which sepsis, pneumonia, or 
meningitis occur during the first week after birth. The odds of laboratory-confirmed 
GBS infection among newborns of mothers with GBS colonisation are more than nine 
times higher than newborns of non-colonised mothers.88  
Environmental	transmission	and	nosocomial	outbreaks	
In developed countries, late onset sepsis is considered environmental in origin mostly 
due to invasive infection by community- or hospital-acquired organisms that colonize 
the infant's skin, respiratory tract, conjunctivae, gastrointestinal tract and umbilicus. In 
these settings, advances in medical technology that have occurred over the last few 
Uterus	
Prenatal and perinatal transfer 
via ascension from the vaginal 
and/or via the blood stream (for 
bacteria of intestinal or oral 
origin) 
Figure	1.2	Sources	of	maternal	microbial	transmission	to	the	newborn.		
Source: Adapted from - Funkhouser LJ. Bordenstein SR, (2013) Mom knows best: The universality of maternal microbial 
transmission. PLoS Biol 11(8): e1001631) 
Vagina 
Direct transfer perinatally in 
vaginal deliveries 
Breast 
The sebaceous skin of the breast is an 
external source of microbes for breast 
milk. An entero-mammary pathway 
brings gut bacteria to the mammary 
gland via blood and lymph circulation 
Gut 
Prenatal translocation from 
the gastrointestinal tract 
Mouth 
Prenatal transfer of oral bacteria to the 
uterus via the bloodstream (especially 
if gingivitis present) 
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decades have improved the survival and quality of life for neonates, particularly those 
infants born with extreme prematurity or with congenital defects. These infants are 
usually hospitalized in the neonatal intensive care unit (NICU) where they can be 
exposed to and acquire infections from both human and inanimate sources.95 The most 
common source of infection in health care facilities are the colonized hands of health 
care workers, contaminated intravenous solutions, tubing, and supplies such as suction 
bottles and catheters, feeding tubes, and various environmental surfaces (incubators, 
mattresses, wash-basins),21 
In addition to sepsis, pneumonia, infections such as tetanus, and diarrhoea make up a 
substantial proportion of newborn deaths and are directly related to water, sanitation 
and hygiene (WASH) conditions during childbirth and the immediate postpartum 
period through practices such as birth attendant handwashing, cleanliness of the 
perineum and delivery surface, hygienic cord cutting/care, bathing and feeding 
practices.96 Aetiological data on sepsis in developing countries implicate lack of 
appropriate hygiene during labour, delivery, and post-natal care as major contributors 
in the development of overwhelming neonatal infections and death both in the hospital 
and in the community.97, 98 Unclean practices during delivery and initial care of the 
baby, at home or in the hospital can also lead to very early onset infections, as well as 
transmission of pathogens from one mother in labour to another.21 This makes it 
difficult to ascribe early-onset infection as “maternally-acquired” or “hospital-acquired”, 
which has implications for prevention strategies as these differ according to the source 
of infection.  
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CHAPTER	2.	AIM	AND	OBJECTIVES	
2.1	Aim	
The aim of this PhD is to describe the aetiology of neonatal infections and the potential 
role of maternal bacterial colonisation in acquisition of neonatal infections in The 
Gambia from the perspective of inpatient care by focusing on sick neonates admitted 
with pSBI. 
2.2	Objectives	
1. To systematically review the available data on the aetiology of serious neonatal 
infections and antimicrobial resistance within sSA. 
2. To describe The Gambian context for serious neonatal infections reviewing 
historical data on neonatal infection aetiology. 
3. To retrospectively audit neonatal inpatient care between 2009 and 2013 at The 
Gambia’s largest hospital with a focus on newborns admitted with pSBI, 
examining outcomes and risk factors for infection. 
4. To prospectively recruit cases with pSBI in order to describe the pathogens 
associated with serious neonatal infections utilising standard microbiological 
techniques, and explore novel molecular diagnostic methods in a pilot study. 
5. To compare the epidemiological profiles of cases with neighbourhood-matched 
controls. 
6. To describe maternal colonisation in the infant cases with pSBI and; 
a) To determine what proportion of symptomatic bacterial infections in neonates 
are maternally acquired, comparing bacterial isolates from mother-newborn 
case pairs in order to study the extent to which the same isolates are found in 
both mother and newborn for the following comparisons: 
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i. Baby blood culture vs mother recto-vaginal flora 
ii. Baby nasopharyngeal flora vs mother recto-vaginal flora 
iii. Baby nasopharyngeal flora vs mother nasopharyngeal flora 
iv. Baby blood culture vs baby rectal flora 
b) Compare recto-vaginal colonisation with GBS, Escherichia	 coli, Staphylococcus	
aureus and Klebsiella species between mothers of neonates with culture-
confirmed bacterial infection and mothers of healthy newborns.   
7. To describe implications of these results for practice and research in the Gambia 
and beyond. 
2.3	Outline	of	Thesis	
This is a “Book style” thesis with the objectives presented as chapters. There is no 
overall methods chapter because the methods used to address each objective differ. 
Detailed methods for each objective are presented in the respective chapter to avoid 
repetition. By necessity, each chapter also includes a discussion of the 
results/conclusions presented therein. 
Chapter	 three presents a systematic review of neonatal infection aetiology studies in 
sSA. It proposes reasons for the ‘invisibility’ of African biomedical research in large 
electronic databases. Through a comprehensive search of major medical databases 
including African databases, the review describes the overall and regional difference in 
reported aetiology of serious neonatal infections and antimicrobial resistance within 
sSA. It also presents an assessment of the quality of reporting across identified studies 
by applying the Strengthening the Reporting of Observational Studies in Epidemiology 
for Newborn Infection (STROBE-NI) checklist. 
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Chapter	four describes The Gambian context for neonatal mortality in the millennium 
development goal era (1990 and 2016) as well as the paucity of local neonatal infection 
aetiology data, and presents a background to the research questions addressed in the 
case-control study. 
Chapter	five describes the audit of neonatal inpatient care that was carried out at the 
neonatal ward of the national tertiary referral hospital in The Gambia. The clinical care 
audit contextualises the efforts of the case-control study to describe the aetiology of 
serious infection among hospitalised newborns. audit has been published in Paediatrics 
and International Child Health99 and the printed version is presented in Appendix 3.  
Chapter	 six addresses objectives 4 – 6 and presents the results of a hospital-based 
case-control study carried out in three major urban/periurban health facilities in The 
Gambia to describe neonatal infection aetiology, and evaluate the role of maternal 
bacterial colonisation. This chapter contains only a brief discussion of some of the study 
findings which are presented in detail in the subsequent chapter. 
Chapter	seven synthesizes the main findings from the case-control study in relation to 
the results and conclusions from earlier chapters. 
Finally, chapter	 eight discusses the combined implications of this PhD work for 
researchers and policy makers in The Gambia, and provides recommendations for The 
Gambia to improve neonatal infection outcomes, and for future research on this topic. 
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CHAPTER	3.	SYSTEMATIC	REVIEW	OF	NEONATAL	INFECTION	
AETIOLOGY	IN	SUB-SAHARAN	AFRICA	
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Overview		
Nearly a quarter of all neonatal deaths sSA are due to serious infections.100 There is also 
a significant need-to-treat population with an estimated 2.6 million cases in need of 
treatment based on a clinical diagnosis of pSBI.101 The impact of infection-related 
mortality and the long-term morbidity from neurodevelopmental impairment among 
survivors on regional health systems already strained by limited resources and shortage 
of skilled personnel is considerable as neonatal sepsis and infections account for 2.5% 
disability-adjusted life years in the WHO Africa region.102 Knowledge of neonatal 
infection aetiology is critical for the development of appropriate interventions and 
programme priorities at national and regional level. 
3.1	Sub-Saharan	African	burden	for	serious	neonatal	infections	–	the	data	gap	
There is a significant gap in aetiology-specific data for neonatal infections in sSA, 
including historical data on the evolution and causative organisms. Pathogens 
associated with neonatal infection are likely to differ between countries in sSA and from 
other regions of the world, particularly in the context of cultural and geographic 
diversity, high rates of maternal HIV infection, and different neonatal care setting and 
practices; these differences may be of programmatic relevance.  
One reason for this paucity of data is the apparent ‘invisibility’ of African biomedical 
research in large electronic databases. Primarily due to difficulties accessing them, 
African research papers have been under-utilised, under-valued and under-cited in the 
international and African research arenas.103, 104 The main information resources, 
published journals and journal articles available to and used by African researchers are 
the same as those used in Europe and America, and these do not adequately reflect the 
research output of Africa. Information from the developed world is usually more readily 
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available than that of developing countries simply because major biomedical databases 
do not sufficiently include peer-reviewed journals published from developing countries.  
Although access to global information resources is essential; equally important and 
essential is access to the local research output from the continent. African regional 
research databases such as Africa Wide Information105 and African Index Medicus103, 106-
108 were launched to improve and facilitate access to African health information, and 
give greater local, regional and international visibility to African health and biomedical 
research. Africa Wide Information is an aggregation of 50 databases sourced from 
Africa, Europe and North America on research and publications by Africans about 
Africa. The WHO-hosted African Index Medicus consists of grey literature, technical 
reports, theses and dissertations as well as medical journals (some with full-text 
articles). African Journals Online (AJOL) provides an online system for the aggregation 
of African-published scholarly journals and offers global access to, and visibility of, the 
research output of the continent. The mission of AJOL is to support African research and 
counter the "North-South" and "West-East" inequality of information flow by facilitating 
awareness of, and access to, research published in Africa.109, 110 AJOL hosts over 350 
African-published, peer-reviewed scholarly journals from 27 African countries covering 
a variety of disciplines including health, science and technology, for free – and includes 
both open access and subscription-based journals. Searches of these African databases 
are scarcely included in the highly cited reviews on neonatal infections in developing 
countries,21, 22, 111-113 and as a result of this limitation in the search strategy, relatively 
few studies from sSA were included in those reviews. 
Widespread health system challenges in providing even the most basic microbiological 
support in the form of laboratory equipment (e.g. blood culture bottles and culture 
44 
 
media) as well as appropriately trained personnel (e.g. microbiologists and laboratory 
technicians), even in tertiary referral facilities, have further contributed to the 
underestimation of the true burden of neonatal infections in the sSA.99 In the absence of 
microbiological confirmation, treatment of neonatal infection remains empirical and in 
such settings, the majority of cases do not receive treatment with the appropriate 
antibiotic or for the necessary duration.114 This is further compounded by high 
uncontrolled rates of antimicrobial prescribing and limited antimicrobial availability 
because of the essential medicines list.99 The treatment of neonatal infection is 
therefore threatened by the steady increase in the prevalence of antimicrobial 
resistance (AMR) and its potential for excess morbidity and mortality.115 Estimates from 
South Asia indicate that up to 60,000 neonates die each year from resistance-
attributable neonatal sepsis caused by bacteria resistant to first-line antibiotics.116 
Where data is available, variation in the clarity and quality of reporting hampers 
interpretation of burden, distribution, and risk factors. The Strengthening the Reporting 
of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI) checklist 
(Appendix 1) was developed in 2016 to improve scientific reporting of neonatal 
infection studies and therefore to facilitate reliable comparison of newborn infection 
data across settings.117 STROBE-NI is an extension of the 22-item STROBE (The 
Strengthening the Reporting of Observational Studies in Epidemiology)118 checklist with 
28 additional elements relating to neonatal infection. Implementation of STROBE-NI 
recommendations and the linked checklist will also increase data utility, allowing meta-
analyses and much-needed pathogen-specific burden estimates to inform policy and 
targeted interventions. 
45 
 
Detailed consideration of neonatal infection aetiology in sSA is needed to guide policy 
decisions regarding appropriate treatment and prevention. The objective of this review 
is to synthesize the available data on the aetiology of serious neonatal infections within 
sSA, antimicrobial resistance, and the quality of data applying the STROBE-NI criteria, in 
order to inform policy, programme and research priorities in the region.  
3.2	Methods	
3.2.1	Search	strategy	and	selection	criteria 
Studies for this review were identified through searches of the following six databases: 
Medline, Embase, Global Health, PubMed, African Index Medicus (accessed through 
WHO) and Africa Wide Information. Search terms, identified from Medical Subject 
Headings (MeSH) related to age, clinical syndromes, and geographical descriptors, as 
well as terms used for systematic reviews on similar topics, included the following in 
various combinations: “neonatal”, “newborn”, “infant”, “sepsis”, “infection”, “pathogen”, 
“bacteria”, “virus”, “aetiology”, “Africa”, “sub-Saharan”.  A compound search strategy 
was developed for Medline, Embase, and Global Health and these were searched 
through Ovid. Separate search strategies were developed respectively for PubMed, 
Africa Wide Information, and African Index Medicus. The search strategy for each 
database is presented in Appendix 2. 
Abstracts and titles from the search and in all languages, were compiled into Endnote 
(Thomson Reuters) and reviewed individually by myself and a second reviewer (Dr. 
Edem Akpalu) with a goal to locate articles that seemed to report on laboratory-
confirmed serious neonatal infection. All articles flagged by either reviewer as 
possibilities for inclusion were retrieved in full text (where available) and their 
reference lists were again independently assessed by both reviewers by use of PubMed 
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and African Journals Online (AOL) to obtain abstracts as needed. Each article identified 
by this process as eligible for inclusion was retrieved as full text. I developed a checklist 
of predetermined inclusion and exclusion criteria which was used for independent 
assessment of each of the full-text articles by both reviewers. We both made a decision 
on inclusion versus exclusion, and disagreements were resolved by consensus. Studies 
were included if they met the following criteria: (1) reported data originating from sSA; 
and (2) reported microbiological data on infections (bacteraemia/sepsis/septicaemia, 
meningitis or pneumonia) in neonates. Studies of infections in children were also 
included where separate neonatal data were presented. Infection was categorized as 
sepsis/bacteraemia, meningitis, or pneumonia as reported by the authors.  
During the abstract review, we excluded obvious case reports/series and studies 
investigating a single pathogen (as these would lead to a biased estimate of the 
significance of such a pathogen); studies presenting data for only very high-risk 
neonatal populations (e.g. very low birth-weight, extremely premature, 
encephalopathy); and studies focusing on fungal infection, malaria, tetanus, syphilis, 
tuberculosis, HIV, or other congenital infection. During the full-text review, we further 
excluded studies with erroneous, incomplete, or internally inconsistent data, and 
studies that assessed the diagnostic accuracy of any particular test using only positive 
samples and not in the clinical context of suspected neonatal infection were also 
excluded. For full-texts not available in the public domain, we made every attempt to 
contact the authors for copies of the articles. Where the full-text of the article could not 
be retrieved, but sufficient detail was presented in the abstract, we used data from the 
abstract. Grey literature (theses and dissertations) were not excluded. The review was 
restricted to studies published after 1980 in keeping with other published reviews. 
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3.2.2	Data	extraction	and	synthesis	
Descriptive and quantitative data from each paper were extracted individually by both 
reviewers and entered into a Microsoft Excel 2007 spreadsheet; this included country, 
hospital setting and location, region of sSA according to regional groupings detailed by 
the African Union,119 year of data collection and study time frame, year of publication, 
specific inclusion or exclusion criteria, and culture techniques. Quantitative data 
collected included number of neonates, pathogens and contaminants isolated, 
antimicrobial susceptibilities. To account for variation across studies, the neonatal 
period was defined as the day of birth up to 30 days of age. Inconsistencies between 
reviewers after data extraction were resolved by return to the original papers. 
3.2.3	Statistical	analysis	
Data on the number of blood and cerebrospinal fluid (CSF) cultures performed and the 
number of sample-specific positive cultures from individual studies were compiled to 
compare the prevalence of bacteraemia and meningitis across regions. The numbers of 
specific pathogens reported by each study and their antimicrobial resistance (AMR) 
patterns were also compiled to compare the prevalence of pathogens and AMR across 
regions. Meta-analysis was not carried out as it was made inappropriate by the 
existence of marked heterogeneity across studies.  
3.3	Results	
The online database search done on June 17, 2016, yielded 9052 articles located in at 
least one of the five databases (Figure 3.1).  
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During screening of titles and abstracts, most of these articles were excluded on the 
basis of irrelevance. Fifty-one articles were further excluded due to inability to locate 
the full-text as well as not having sufficient data in the abstract. Four hundred and 
twenty-two full text articles (75 in French, the rest in English) were obtained for 
detailed evaluation, 87 of these (mostly French articles) had been identified through a 
9052 articles identified through database searches:  
4693 articles from Medline/Embase/Global Health 
509 articles from PubMed 
3826 articles from Africa-wide Information 
24 articles from African Index Medicus 
 
87 additional 
records 
identified 
through other 
sources  
9139 articles in total 
136 studies from 135 articles 
included in review 
8666 excluded during review of titles and abstracts: 
- 6456 were not relevant 
- 1997 were duplicate articles 
- 119 were not carried out in sub-Saharan Africa 
- 74 were non-human studies 
- 20 were case reports/case series 
51 excluded due inability to obtain full article 
287 excluded after review of full articles 
- 17 did not disaggregate aetiology data 
• by participant age (n=8) 
• by sample type (n=7) 
• by study location (n=2) 
- 72 did not report aetiology 
- 18 had data published elsewhere 
- 4 reported insufficient data 
- 48 did not report neonatal data 
- 20 did not include neonates 
- 12 were published before 1980 
- 84 reported data on only a single pathogen 
- 12 had a specific group of only high-risk neonates 
Figure	3.1	Selection	of	eligible	articles	
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review of references. During detailed screening, 287 articles were excluded. Among 
these, 72 were excluded because they did not report aetiology data, 48 because they did 
not report neonatal data, and 17 because they did not disaggregate data by age, sample 
type or study location (for multicountry studies). Eighteen studies were excluded based 
on the same data having been published in another journal. In all, 135 studies, including 
9 theses/dissertations carried out between 1984 and 2016 were eligible for inclusion; 
however, one multi-country study with two West African country sites was counted as 
two separate studies bringing the total number of included studies to 136 (121 in 
English and 15 in French). Seven studies were from Central Africa, 32 from East Africa, 
33 from Southern Africa, and 64 from West Africa. (Figure 3.2). 
 
Figure	3.2	Variation	between	countries	within	sub-Saharan	Africa	in	the	number	of	studies	
reporting	microbiological	data	on	serious	neonatal	infections	(bacteraemia/sepsis,	meningitis	
or	pneumonia	
Source of data on annual births: State of The World’s Children 2016 Report  
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The publication ratio (number of studies per 100 000 births) was calculated for each 
country as an indicator of the reporting of neonatal infection aetiology. Although 
Nigeria, South Africa and Kenya had the most studies, the publication ratio was highest 
in The Gambia with 3.61 publications per 100,000 births. 
All studies were facility-based; however, 10 studies - five from Kenya,120-124 two from 
Mozambique,125, 126 two from Nigeria,127, 128 and one from Cameroon129 - reported data 
from predominantly rural populations. Seventy-six studies were prospective studies of 
newborns admitted with clinically suspected invasive bacterial disease, sepsis, 
septicaemia, and/or meningitis, and one South African study involved a neonatal cohort 
recruited in during a randomised controlled trial investigating the efficacy of maternal 
and newborn chlorhexidine washes in preventing neonatal sepsis.130 The remaining 
studies were retrospective reviews of laboratory and clinical records of neonatal 
inpatients. The characteristics of included studies are summarised in Table3.1 
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Table	3.1	Summary	of	136	hospital-based	studies	of	neonatal	sepsis,	meningitis	and	pneumonia	in	sub-Saharan	Africa,	1980	-	2016	
Region	 Author	(year)	 Data	
collection	
period	
Data	
collection	
Location	 Source	of	case	
capture	
Population	(or	neonatal	
sub-population	where	
reported)	
Culture	
category	
Organisms	
Central 
Africa 
Chiabi (2011)131 2008-2009 Retrospective   Yaounde Gynaeco-
Obstetric and 
Pediatric Hospital, 
Cameroon 
Admissions to 
urban tertiary 
referral hospital 
218 inborn and outborn 
neonatal sepsis 
admissions (0-28 days)  
Blood & 
CSF 
Blood:	Klebsiella spp 9, E.	coli	5, GBS 2, 
Enterobacter spp 2, Citrobacter spp 1, P.	
mirabilis 1 A.	baumanii 2, , Chryseomonas	luteola 
1, Non-Group A or B Streptococcus 1, GDS 1, GAS 
1, 
CSF: Enterobacter spp 1, GBS 1 
Chiabi (2005)129 1998-2000 Prospective Rural Hospital, 
Yaounde, 
Cameroon 
Admissions to rural 
hospital 
154 neonatal sepsis 
admissions 
Blood E.	coli	10, Others 2 
Kago (1990)132 1985-1986 Retrospective Hopital central de 
Yaounde, 
Cameroon 
Admissions to 
urban tertiary 
referral hospital 
56 inborn and outborn 
neonatal bacterial 
meningitis admissions (0-
30 days) 
CSF GBS 15, S.	pneumoniae 9, E.	coli	7, Acinetobacter 
spp 5, E.	cloacae 1, Flavobacterium 1,                    
P.	mirabilis 2, GGS 2, GDS 1, L.	monocytogenes 1, 
H.	influenzae 1, Pseudomonas 1, Serratia 1, 
Pasturella	pneumotropica 1 
Kemeze 
(2016)133 
2015 Prospective Laquitinie 
Hospital, Douala, 
Cameroon 
Admissions to 
district referral 
hospital 
300 neonates with 
suspected bacterial 
infection (0-28 days) 
Blood & 
CSF 
Sepsis	: S.	aureus	10,	E.	coli	6 
Meningitis: E.	coli	1, Klebsiella spp 1,  
Bercion 
(2008)134 
2004-2005 Prospective Complexe 
Pediatrique de 
Bangui, Central 
African Republic 
Admissions to 
urban tertiary 
referral hospital 
417 paediatric CSF 
samples collected (1 day-
16 years) 
CSF S.	pneumoniae	3, H.	influenzae	2, Salmonella spp 
2, GBS 2, Others 1 
Ekouya Bowassa 
(2015)135 
2014 Prospective CHU de Brazaville, 
Congo 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
130 early neonatal 
admissions (0-4 days) 
Blood K.	pneumoniae	7, K. terrigena 4, Klebsiella spp 1,  
S.	aureus	3, Staphylococcus	haemolyticus 3, 
Staphylococcus	hominis 1, Staphylococcus	lentus 
1, Staphylococcus	cohnii 1, E.	cloacae 2, E.	coli	2, 
Streptococcus	equinus 2, GAS 1,           
Streptococcus spp 1  
Shatalov 
(2015)136 
2013-2015 Prospective La Paz Medical 
Center, Malabo, 
Equatorial Guinea 
Admissions to 
urban tertiary 
referral hospital 
293 inborn and outborn 
neonatal sepsis 
admissions (0-28 days)  
Blood K.	pneumoniae 16, Acinetobacter spp 4,	E.	coli	4, 
CoNS 4 
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Table	3.1	Summary	of	136	hospital-based	studies	of	neonatal	sepsis,	meningitis	and	pneumonia	in	sub-Saharan	Africa,	1980	–	2016	(continued)	
Region Author	(year) Data	
collection	
period 
Data	
collection 
Location Source	of	case	
capture 
Population	(or	neonatal	
sub-population	where	
reported) 
Culture	
category 
Organisms 
East Africa Ghiorghis 
(1997)137 
1993-1993 Retrospective Ethio-Swedish 
Childrens' 
Hospital, Addis 
Ababa, Ethiopia 
Admissions to 
urban tertiary 
referral hospital 
542 inborn and outborn 
neonatal sepsis 
admissions 
Blood Klebsiella spp 34, E.	coli 9, Pseudomonas spp 5, 
S.	epidermidis 13 
Dagnew 
(2013)138 
2006-2012 Retrospective   University of 
Gondar Hospital, 
Gondar, Ethiopia 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
34 neonatal admissions 
with suspected 
septicaemia (< 28 days) 
Blood CoNS 7, S.	aureus	2, E.	coli	1, Klebsiella spp 1, 
Salmonella spp 1 
Gebrehiwot 
(2012)139 
2011-2012 Prospective Gondar University 
Hospital, Gondar, 
Ethiopia 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
181 inborn and outborn 
neonatal sepsis 
admissions (0-28 days)  
Blood S.	aureus	17, K.	pneumoniae	5, Klebsiella	ozaenae 
10, Klebsiella spp 1, E.	coli	6, CoNS 4, Salmonella 
spp 2, Shigella spp 2, Serratia spp 1, 
Enterobacter spp 1, α-haemolytic Streptococci 1, 
Citrobacter spp 1, other Gram negatives 7, 
Gebremariam 
(1998)140 
1987-1996 Retrospective   Tertiary Hospital, 
Addis Ababa, 
Ethiopia 
Admissions to 
urban tertiary 
referral hospital 
55 neonatal meningitis 
admissions (0-28 days) 
CSF K.	pneumoniae	9, E.	coli	7, Enterobacter spp 4,            
S.	aureus	2, Salmonella spp 2, S.	pneumoniae	2,           
S.	epidermidis 2, GAS 1, Haemophilus spp 1 
Muhe (1999)141 1991-1993 Prospective Ethio-Swedish 
Childrens' 
Hospital, Addis 
Ababa, Ethiopia 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
405 sick and 411 well 
young infants enrolled 
(<91 days); 440 infants 
investigated 
Blood & 
CSF 
Blood: GAS 9, E.	coli	9, S.	pneumoniae	4, 
Salmonella spp 3, H.	influenzae	1, K.	pneumoniae	
1, S.	aureus	1 
CSF: S.	pneumoniae	1, GAS 1, E.	coli	1. 
Mulu (2005)142 2002-2003 Retrospective   Gondar University 
Hospital, Gondar, 
Ethiopia 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
35 neonates with 
suspected meningitis 
investigated by lumbar 
puncture 
CSF N.	meningitidis	2 
Mulu (2014)143 2013-2014 Prospective   Tikur Anbessa and 
Yekatit 12 
specialized 
hospitals, Addis 
Ababa, Ethiopia 
Admissions to a 
paediatric ward of 
an urban tertiary 
referral hospital 
154 inborn and outborn 
neonatal admissions with 
suspected meningitis 
investigated by lumbar 
puncture (1 - 30 days) 
CSF S.	pneumoniae 4, N.	meningitidis 1, Citrobacter 
spp1, Proteus spp 1, Acinetobacter spp 1, P.	
aeruginosa 1 
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Table	3.1	Summary	of	136	hospital-based	studies	of	neonatal	sepsis,	meningitis	and	pneumonia	in	sub-Saharan	Africa,	1980	–	2016	(continued)	
Region Author	(year) Data	
collection	
period 
Data	
collection 
Location Source	of	case	
capture 
Population	(or	neonatal	
sub-population	where	
reported) 
Culture	
category 
Organisms	
East Africa 
(continued) 
Negussie 
(2015)144 
2011-2012 Prospective Tikur Anbessa 
Specialized 
University Hospital 
and Yekatit-12 
Hospital, Addis 
Ababa, Ethiopia 
Admissions to 
paediatric ward of 
urban tertiary 
referral hospital 
147 neonatal outpatients 
and inpatients (0-28 
days) 
Blood S.	marcescens	12, S aureus 9, K.	pneumoniae	5, 
Klebsiella	terrigena	4, CoNS 8, Salmonella	
Paratyhi	C 3, E.	cloacae	2, A.	baumanii	1, 
Pseudomonas	luteola 1, Enterococcus spp 1. 
Shitaye (2010)145 2006-2007 Prospective Tikur Anbessa 
Specialized 
University 
Hospital, Addis 
Ababa, Ethiopia 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
302 neonates with 
suspected sepsis (0-28 
days) 
Blood K.	pneumoniae	50, Klebsiella	terrigena	3, S.	
aureus	30, E.	coli	10, CoNS 10, Enterococcus spp 
7, GAS 6, S.	pneumoniae	6, S.	marcescens	5, P.	
mirabilis	4, Serratia	ficaria 4  
Zewdie (2014)146 2013-2014 Prospective   Tikur Anbessa 
Specialized 
Hospital, Addis 
Ababa, Ethiopia 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
115 inborn and outborn 
neonatal admissions with 
suspected meningitis 
investigated by lumbar 
puncture (0 - 28 days) 
CSF P.	aeruginosa 1, E.	coli 1. S.	pneumoniae 2, 							K.	
pneumoniae 1, Acinetobacter 1. 
Berkley  
(2005) 120 
1998-2002 Prospective Kilifi District 
Hospital, Kenya 
Admissions to 
paediatric ward of 
rural district 
referral hospital 
867 inborn and outborn 
neonates (0-6 days)  
Blood E.	coli	25, Acinetobacter spp 16, Klebsiella spp 
13, GBS 11.	S.	aureus	7, Pseudomonas spp 6, S.	
pneumoniae	5, GAS 3, NTS 1, H.	influenzae	1, 
other Gram negative 30, Other Gram positive 11. 
English 
(2003) 121 
1999-2001 Prospective Kilifi District 
Hospital, Kenya 
Admissions to 
paediatric ward of 
rural district 
referral hospital 
692 inborn and outborn 
neonates (0-30 days) 
Blood & 
CSF 
GBS 12, Klebsiella spp 10, E.	coli	9, S.	
pneumoniae	7, Pseudomonas spp 6, GAS 5, S.	
aureus	4, Enterococcus spp 4, P.	mirabilis	4, H.	
influenzae	1, Others 3 
Kasiyere-Banda 
(1983)147 
1982-1983 Prospective   Kenyatta National 
Hospital, Nairobi, 
Kenya 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
939 inborn and outborn 
neonatal admissions 
Blood/CSF Klebsiella species 28, Staphylococcus albus 22, 		
E.	coli	8, Streptococcus fecalis 8, S.	aureus 5, 
Citrobacter species 5, P.	aeruginosa 3, GBS 3, 
Salmonella typhimurium 2, Acinetobacter 
species 3. 
Kumar (2010) 148 2005 Prospective 
 
Kenyatta National 
Hospital, Nairobi, 
Kenya 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
310 inborn and outborn 
neonatal sepsis 
admissions  
Blood & 
CSF 
Enterobacter	agglomerans 22, K.	pneumoniae	11, 
CoNS 11, Citrobacter 10, Acinetobacter spp 7, E.	
coli	5, S.	aureus	4, Enterococcus 4, Salmonella	
typhi 1, 
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Table	3.1	Summary	of	136	hospital-based	studies	of	neonatal	sepsis,	meningitis	and	pneumonia	in	sub-Saharan	Africa,	1980	–	2016	(continued)	
Region Author	(year) Data	
collection	
period 
Data	
collection 
Location Source	of	case	
capture 
Population	(or	neonatal	
sub-population	where	
reported) 
Culture	
category 
Organisms 
East Africa 
(continued) 
Kohli-Kochhar 
(2011) 149 
2000-2009 Retrospective   Aga Khan 
University 
Hospital, Nairobi, 
Kenya 
Admissions to 
NICU of urban 
tertiary referral 
private hospital 
665 inborn and outborn 
neonatal sepsis 
admissions  
Blood S. epidermidis 52, S.	aureus	41, Klebsiella spp 14, 
Streptococcus spp 12, Enterococcus spp 12, 
Kluyvera spp 2, Aeromonas spp 2, P.	aeruginosa	
1, E.	coli	2, B.	cepacia 2, Pasturella spp 1, 
Acinetobacter spp 1, Enterobacter spp 2, 
Acrobacterium spp 1, Serratia spp 1, GBS 1.          
S.	pneumoniae	1,  
Laving (2003) 150 1999 Prospective Kenyatta National 
Hospital, Nairobi, 
Kenya 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
84 inborn and outborn 
neonatal sepsis 
admissions 
Blood & 
CSF 
CSF	culture	positive	- K.	pneumoniae	2, GBS 1,  
E.	cloacae	1  
(Latex	particle	agglutination	&	Gram	stain:										
E.	coli	7,	GBS	3,	H.	influenzae	1,	S.	pneumoniae	1)	
Musoke  
(2000) 151 
1997-1998 Retrospective   Kenyatta National 
Hospital, Nairobi, 
Kenya 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
192 inborn and outborn 
neonatal sepsis 
admissions 
Blood Klebsiella spp 38, Citrobacter spp 26, 
Enterobacter spp 19, S.	epidermidis 19, S.	aureus	
9, E.	coli	4, Enterococci 4,	Salmonella	
typhimurium 2, 
Mwangi  
(2002) 122 
1994-2000 Prospective Kilifi District 
Hospital, Kenya 
Admissions to 
paediatric ward of 
rural district 
referral hospital 
390 paediatric meningitis 
admissions (78 neonates 
with confirmed, probable 
or possible meningitis) 
CSF S.	pneumoniae	13, H.	influenzae	2, NTS 3, other 
Enterobacteriaceae 11, GAS/GBS 14 
Mwaniki  
(2011) 123 
2001-2005 Prospective Kilifi District 
Hospital, Kenya 
Admissions to 
paediatric ward of 
rural district 
referral hospital 
1790 inborn and outborn 
neonates (0-6 days); 845 
lumbar punctures 
performed 
CSF Enterobacter spp 3, GBS 2, GDS2, S.	viridans	1,    
S.	aureus	1, E.	coli	1, H.	influenzae	1, P.	
aeruginosa	1,    S.	pneumoniae	1, K.	pneumoniae	
1, Acinetobacter spp 1, Aeromonas spp 1, 
Kluyvera spp 1, Vibrio	Cholera 1, other Gram 
positive 2. 
Simiyu (2003) 152 2000 Retrospective  Kenyatta National 
Hospital, Nairobi, 
Kenya 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
219 Inborn and outborn 
neonatal sepsis 
admissions (0-28 days)  
Blood CoNS 8, Citrobacter 6, S.	aureus	5, Klebsiella 3, 
Alkaligenes	fecalis 1, Acinetobacter 1, 
Enterococci 1, P.	aeruginosa	1, E.	coli	1,  
Razafindralambo 
(2004)153 
1988-1990 Prospective Antatanarivo, 
Madagascar 
Admissions to 
urban tertiary 
referral hospital 
134 children with 
culture-confirmed 
meningitis (0-15 years) 
CSF S.	pneumoniae	2, N.	meningitidis	2 
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East Africa 
(continued) 
Talbert  
(2010) 124 
2001-2009 Prospective Kilifi District 
Hospital, Kenya 
Admissions to 
paediatric ward of 
rural district 
referral hospital 
4467 outborn infants 
with invasive bacterial 
infection (0-60 days) 
Blood & 
CSF 
Bacteraemia: Klebsiella spp 46, S.	aureus	44, 
Acinetobacter spp 38, E.	coli	36, Enterobacter 
spp 31, GAS 30, GBS 29, GDS 24, S.	pneumoniae	
22, Aeromonas spp 21, Salmonella spp 20, S.	
viridans	15, P.	aeruginosa	9, Vibrio spp 8, 
Proteus spp 5, GGS 4, GCS 1, H.	influenzae	2,	N.	
meningitidis	1, Others 9 
Meningitis: GBS 14, S.	pneumoniae	12, 
Salmonella spp 8, Enterobacter spp 6, E.	coli	6, 
GAS 4, GDS 1, Klebsiella spp 4, Vibrio spp 4, P.	
mirabilis	1, Aeromonas	sobria 1, N.	meningitidis	
1, S.	viridans	1, other Gram-negative rods 2. 
Andrianarivelo 
(2010) 154 
2009 Prospective CHU 
d'Antatanarivo, 
Madagascar 
Admissions to 
NICU of urban 
tertiary referral 
hospital 
105 inborn and outborn 
neonates investigated by 
blood cultures 
Blood CoNS 51, K.	pneumoniae	18, Enterobacter	
aerogenes 8, Enterobacter gergoviae 8, 
Enterobacter	sakazaki 1, Enterococcus 9	K.	
oxytoca	7, E.	coli	6, S.	aureus	5, Serratia 2, 
Escherichia	vulneris 1, Pseudomonas sp 1, 
Corynebacteriae 1, other Streptococci 2 
Blomberg 
(2007)155 
2001-2002 Prospective Muhimbili National 
Hospital, Dar es 
Salaam, Tanzania 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
535 inborn and outborn 
neonates (0-28 days) 
Blood Klebsiella spp 24, S	aureus 11, E	coli 9, 
Enterococci 7, Enterobacter spp 5, GBS 3, 
Acinetobacter spp 1, other non-
Enterobacteriaceae 4, other Gram-negative 2, 
other Streptococcus 1, other Enterobacteriaceae 
1. 
Kayange 
(2010)156 
2009 Prospective Bugando Medical 
Centre, Mwanza, 
Tanzania 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
300 inborn and outborn 
neonatal sepsis 
admissions.  
Blood K.	pneumoniae	50, S.	aureus	32, E.	coli	22, CoNS 
14, GBS 2, Listeria spp 5, Enterococcus spp 9, 
Other Gram negatives 15 (Acinetobacter spp, 
Enterobacter spp) 
Klingenberg 
(2003)157 
1998-1999 Prospective Kilimanjaro 
Christian Medical 
Centre, Moshi, 
Tanzania 
Admissions to 
SCBU of an urban 
tertiary referral 
hospital 
246 inborn and outborn 
neonatal admissions; 148 
investigated by blood 
culture) 
Blood S.	aureus	6, CoNS 5, Gram negative rods 2, 
Enterococcus faecium 1, K.	pneumoniae	1, 
Enterococcus faecalis 1 
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East Africa 
(continued) 
John (2015)158 2013 Prospective Kidera Health 
Centre, Kidera 
County, Buyende 
district, Uganda 
Admissions to 
urban tertiary 
referral hospital 
174 inborn and outborn 
neonatal sepsis 
admissions (1-27 days) 
Blood S.	aureus	12, N.	meningitidis	11, E.	coli	5, GAS 4,      
H.	influenzae	2, Salmonella spp 2, K.	pneumoniae	
1,    S.	pneumoniae	1	
Mhada (2012)159 2009-2010 Prospective Muhimbili National 
Hospital, Dar es 
Salaam, Tanzania 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
330 inborn and outborn 
neonatal sepsis 
admissions (0-28 days) 
Blood S.	aureus	27, Klebsiella spp 22, E.	coli	14, S.	
epidermidis 6, GBS 1, Pseudomonas spp 2, 
Streptococcus spp 2.  
Mkoney 
(2014)160 
2012-2013 Prospective Muhimbili National 
Hospital, Dar es 
Salaam, Tanzania 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
208 Inborn and outborn 
neonatal sepsis 
admissions (0-28 days) 
Blood Klebsiella spp 14, E.	coli	12, CoNS 9, S.	aureus	4,      
P.	aeruginosa	1 
Onken (2015)161 2012-2013 Prospective Mnazi Mmoja 
Hospital, Zanzibar, 
Tanzania 
Admissions to 
urban tertiary 
referral hospital 
113 neonatal admissions 
with suspected bacterial 
infection (≤ 1 month) 
Blood E.	coli	6, K.	pneumoniae	8, Enterococcus	faecalis 
4,    S.	aureus	3, Enterococcus	faecium 1, GBS 1, 
Rhodococcus	equi 1, Other Enterobacteriaceae 5, 
non-Enterobacteriaceae 11, Unidentified Gram-
negative rods 3, 
Kiwanuka 
(2013)162 
2010 Prospective Mbarara Hospital, 
Uganda 
Admissions to 
paediatric ward of 
urban tertiary 
referral hospital 
80 inborn and outborn 
neonatal sepsis 
admissions (< 1 month) 
Blood & 
CSF 
Sepsis: S.	aureus	16, E.	coli	4, Klebsiella spp 2, 
Unidentified coliforms 3, GBS 1 
Meningitis: S.	pneumoniae	1, Coliform 1 
Mugalu (2006)163 2002 Prospective Mulago Hosptital, 
Kampala, Uganda 
Admissions to 
SCBU of a urban 
tertiary referral 
hospital 
293 inborn and outborn 
neonatal sepsis 
admissions (0-28 days) 
Blood S.	aureus	69, E.	coli	17, GBS 7, Salmonella spp 3,       
P.	mirabilis	3, Pseudomonas	putida 2, Klebsiella	
planticola 2, K.	pneumoniae	1, S.	epidermidis 1,          
H.	influenzae	1, E.	agglomerans 1, S.	pneumoniae	
1, Non-haemolytic streptococcus 1, E. faecalis 1,  
Southern 
Africa 
Mudzikati 
(2015)164 
2012 Retrospective   Princess Marina 
Hospital, 
Gaborone, 
Botswana 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
909 inborn and outborn 
neonatal sepsis 
admissions (0-28 days)  
Blood K.	pneumoniae	27, K.	oxytoca 8, Klebsiella spp 8,   
GBS 15, E.	coli	11, S.	aureus	8, Enterococcus spp 
4, Enterobacter spp 4, S.	pneumoniae	2, GCS 1, 
Other Gram negative bacteria 4. 
Molyneux 
(1998)165 
1996-1997  Prospective Queen Elizabeth 
Central Hospital, 
Blantyre, Malawi 
Admissions to 
district referral 
hospital 
Paediatric meningitis 
admissions (1 day-14 
years). 1120 lumbar 
punctures performed 
CSF GBS 14, Salmonella	typhimurium 9, S.	
pneumoniae	7, H.	influenzae	1, other Gram 
negative rods 7, others 23	
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(continued) 
Gwee (2012)166 2002-2007  Retrospective   Queen Elizabeth 
Central Hospital, 
Blantyre, Malawi 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
6399 inborn and outborn 
neonates investigated by 
blood cultures (0-28 
days) 
Blood S.	aureus	123, GBS 118, E.	coli	86, NTS 74, α-
haemolytic Streptococci 55, Klebsiella spp 50, 
GDS 42, Enterobacter spp 40, S.	pneumoniae	31, 
GAS 27, Citrobacter 22, Acinetobacter spp 19, P.	
aeruginosa	16, Group B haemolytic 
Streptococcus 15, other Gram negatives 33, 
other Gram positives 17. 
Milledge  
(2005) 167 
1996-2001 Retrospective  Queen Elizabeth 
Central Hospital, 
Blantyre, Malawi 
Admissions to 
district referral 
hospital 
784 inborn and outborn 
neonatal sepsis 
admissions (0-30 days)  
Blood & 
CSF 
Bacteraemia: S.	aureus	85, GBS 76, NTS 77, E.	
coli	57, Klebsiella spp 54, GAS 49, S.	pneumoniae	
32, other Gram positive 61, other Gram negative 
91. 
Meningitis: GBS 60, S.	pneumoniae	47, NTS 33, 
E.	coli	10, GAS 7, Klebsiella spp 6, S.	aureus	2, 
other Gram positive 11, other Gram negative 26.  
Swann (2014)168 2002-2008 Retrospective  Queen Elizabeth 
Central Hospital, 
Blantyre, Malawi 
Admissions to 
district referral 
hospital 
259 inborn infants with 
suspected meningitis (≤ 
60 days) 
CSF GBS 27, S.	pneumoniae	13, S.	enterica serovar	
Typhimurium 7, E.	coli	3, E.	cloacae	3, K.	
pneumoniae	3, P.	aeruginosa	1,	H.	influenzae	type 
b 1, GDS 1, Enterobacter spp 1. 
Walsh (2000)169 1996-1997 Prospective Queen Elizabeth 
Central Hospital, 
Blantyre, Malawi 
Admissions to 
district referral 
hospital 
10508 children (1 day-15 
years)  
Blood GBS 10, NTS 5, Enteric Gram-negative bacteria 
21. 
Sigauque 
(2008)126 
1998-2003 Prospective Manhiça District 
Hospital, 
Mozambique 
Admissions to 
paediatric ward of 
rural district 
referral hospital 
48 neonatal CSF samples 
collected (<29 days) 
CSF S.	pneumoniae 2, GBS 1, S.	aureus	1 
Sigauque 
(2009)125 
2001-2006 Prospective Manhiça District 
Hospital, 
Mozambique 
Admissions to 
paediatric ward of 
rural district 
referral hospital 
952 blood cultures from 
neonates (<28 days) 
Blood S.	aureus	60, GBS 31, NTS 9, E.	coli	9, GDS 10, S.	
pneumoniae	7, GAS7, Enterobacter spp 6, H.	
influenzae	1, N.	meningitidis	1, Klebsiella spp 1, 
Pseudomonas spp 1, other Gram negative 8, 
other Gram positive 3. 
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Southern 
Africa 
(continued)	
Mengistu 
(2013)170	
2009-2012	 Retrospective  	 33 State Hospitals 
in Namibia, 
Namibia	
Laboratory data 
from admissions to 
urban tertiary 
referral hospital	
503 positive bacterial 
CSF cultures	
CSF	 ESBL K.	pneumoniae	4, S.	pneumoniae	2, 
Neisseria spp 2, E.	coli	1, 	
Adhikari 
(1995)171 
1988-1991 Retrospective   King Edward VIII 
Hospital, Durban, 
South Africa 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
60 inborn and outborn 
neonatal meningitis 
admissions 
CSF GBS 21, K.	pneumoniae	17, E.	coli	10, S.	
pneumoniae	4, P.	aeruginosa	2, Salmonella spp 2, 
P.	mirabilis	2, E. cloacae 1, Acinetobacter	
anitratus 1 
Ballot (2012)172 2009-2010 Retrospective   Charlotte Maxeke 
Johannesburg 
Academic Hospital, 
South Africa 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
181 inborn and outborn 
neonatal sepsis 
admissions (≤28 days)  
Blood CoNS 62, ESBL	K.	pneumoniae	34, K.	pneumoniae	
12, K.	oxytoca	1, A.	baumanii 27, Acinetobacter 
spp 2, E.	faecalis 13, E.	faecium	11, E.	coli 23, 
MRSA 16, MSSA 7, S.	viridans	5, P.	aeruginosa	4, 
GBS 3, Stenotrophomonas	maltophilia 1, 
Aeromonas	caviae 1, P.	mirabilis	1. 
Cutland 
(2009)173 
2004-2007 Prospective Chris Hani-
Baragwanath 
Hospital, Soweto, 
South Africa 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
8129 neonates enrolled 
(0-28 days). 289 
neonates with suspected 
sepsis 
Blood A.	baumanii	& lwoffi 3, Enterococcus	faecalis	&	
faecium 3, S. viridans 2, K.	pneumoniae	1, 
Enterobacter 1, E.	coli	1, S.	aureus 1, 
Coovadia 
(1989)174 
1981-1987 Retrospective   King Edward VIII 
Hospital, Durban, 
South Africa 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
97 inborn and outborn 
neonates with culture-
proven meningitis (≤1 
month) 
CSF K.	pneumoniae	40, E.	coli	17, GBS 15, P.	mirabilis	
5, Enterobacter spp 3P.	aeruginosa	2, 
Acinetobacter	anitratus 2, S.	pneumoniae	2, 
Enterococcus	faecalis 2, L.	monocytogenes 2, 
Streptococcus	lactis 1, Alcaligenes	faecalis 1, 
Salmonella spp 1, Flavobacterium	
meningosepticum 1, other Gram-negative bacilli 
3 
Donald (1996)175 1985- 1993 Prospective Tyberg Hospital, 
Western Cape 
Province, South 
Africa 
Admissions to 
urban tertiary 
referral hospital 
117 culture -confirmed 
neonatal meningitis 
admissions 
CSF GBS 27, E.	coli	21, Klebsiella spp 11, S.	
marcescens	9, S.	pneumoniae	2, H.	influenzae 2, N.	
meningitidis	4, Others 26	
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Southern 
Africa 
(continued) 
Dhlamini 
(2013)176 
2009-2010 Prospective Rahima Moosa, 
Chris Hani 
Baragwanath & 
Charlotte Maxeke 
Academic 
Hospitals, 
Johannesburg, 
South Africa 
Admissions to 
urban tertiary 
referral hospitals 
76 neonates inborn and 
outborn neonatal sepsis 
admissions 
Blood EBSL K.	pneumoniae (1) 
Dramowski 
(2015)177 
2009-2013 Retrospective   Tygerberg 
Hospital, Western 
Cape Province, 
South Africa 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
neonatal unit 
23,920 neonates with 
suspected nosocomial 
blood stream infection 
(6521 investigated) 
Blood 
 
K.	pneumoniae	235, S.	aureus	112, Enterococcus 
spp 88, S.	marcescens	84, A.	baumanii	69, E.	coli	
58, GBS 36, Enterobacter spp 15, P.	aeruginosa	
12, CoNS 5, other Gram positives 3, other Gram 
negatives 46. 
Friedland 
(1992)178 
1988-1990 Retrospective 
& 
Prospective 
Chris Hani-
Baragwanath 
Hospital, Soweto, 
South Africa 
Admissions to 
urban tertiary 
referral hospital 
Neonatal ward 
admissions investigated 
by blood and/or CSF 
culture 
Blood & 
CSF 
Klebsiella spp 192, Pseudomonas spp 37, 
Serratia spp 30, Other Gram-negatives 136. 
Haffejee 
(1991)179 
1986-1989 Retrospective R.K. Khan Hospital, 
Durban, South 
Africa 
Admissions to 
neonatal unit of an 
urban district 
referral hospital 
2171 inborn and outborn 
neonatal sepsis 
admissions investigated 
by blood culture; 277 
investigated by lumbar 
puncture 
Blood & 
CSF 
Blood	:	GBS 36, Streptococcus	sanguis 26, 
Streptococcus	salavirius 19, S.	faecalis 16, 
Streptococcus	mitis 9, S.	aureus	32, E.	coli	9, 
Others 20  
CSF:	GBS 8, Streptococcus faecalis 1.  
Kitambala 
(2012)180 
2011 Prospective   Kalafong Hospital, 
Gauteng Province, 
South Africa 
Admissions to 
neonatal unit of a 
district referral 
hospital 
53 neonatal admission 
with nosocomial infection  
Blood CoNS 7, MRSA 1, Enterococcus faecalis 4, 
Enterococcus faecium 2, Klebsiella oxytoca 2,       
P.	aeruginosa 1, Enterobacter cloacae 1, Proteus 
mirabilis 1, GBS 1, 
Lebea (2015)181 2012 Retrospective Charlotte Maxeske 
Johannesburg 
Hospital, 
Johannesburg, 
South Africa 
Laboratory data 
from admissions to 
a neonatal unit of 
an urban tertiary 
referral hospital 
196 neonates inborn and 
outborn neonatal sepsis 
admissions 
Blood ESBL K.	pneumoniae 76, A.	baumanii 20, E.	coli 
14, Klebsiella. oxytoca 2, CoNS 56, GBS 3, MRSA 
31, E.	faecalis 7, E.	faecium 2, E.	cloacae 1, L.	
monocytogenes 1, K.	pneumoniae 2,  
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Africa 
(continued) 
Liebowitz 
(1984)182 
1980-1982 Retrospective   JG Strijdom 
Hospital, Hillbrow, 
Baragwanath and 
Coronation 
Hospitals, 
Johannesburg, 
South Africa 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
All hospital admissions 
due to confirmed acute 
bacterial meningitis 
CSF GBS 25, E.	coli	20,	S.	pneumoniae	6, N.	
meningitidis	2, H.	influenzae	1 
Morkel (2014)183 2008 Retrospective   Tygerberg 
Children's 
Hospital, Western 
Cape Province, 
South Africa 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
503 Neonatal intensive 
care unit admissions, 354 
investigated: 
Blood CoNS 22, MRSA 5, S.	pneumoniae	1, E.	faecalis 2, 
Bacillus	cereus 1, A.	baumanii 14, K.	pneumoniae 
17, E.	coli	2, P.	aeruginosa	1, S.	marcescens	1, E.	
cloacae 2, P.	mirabilis	1  
Motara (2005)184 2002-2003 Retrospective   Johannesburg 
General Hospital, 
South Africa 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
1129 neonatal 
admissions 
Blood CoNS 65, E.	coli	20, Klebsiella sp 12, 
Enterobacter spp 9, GBS 2, E.	faecalis 4, S.	
viridans	4, P.	aeruginosa	2, H. influenzae 1, 
Citrobacter spp1, P.	mirabilis	1  
Nel (2000)185 1981-1992 Retrospective   Tygerberg 
Hospital, Western 
Cape Province, 
South Africa 
Admissions to 
urban tertiary 
referral hospital 
88 inborn and outborn 
neonatal meningitis 
admissions (0-28 days) 
CSF GBS 28, E.	coli	20, K.	pneumoniae	13, N.	
meningitidis	2, H.	influenzae	1, L.	monocytogenes 
1, other Gram positives 8, other Gram negatives 
4 
Potter (1984)186 1981 Prospective Teaching Hospitals 
of Cape Peninsula, 
South Africa 
Admissions to 
urban tertiary 
referral hospital 
213 children less than 13 
years of which 2 
neonates with confirmed 
meningitis  
CSF N.	meningitidis	1, Pneumococci 1 
Schrag (2012)130 2004-2007 Prospective Chris Hani-
Baragwanath 
Hospital, Soweto, 
South Africa 
Admissions to 
urban tertiary 
referral hospital 
323 neonatal sepsis 
admissions (0-28 days); 
289 early-onset (0-2 
days) and 34 late-onset 
(3-28 days) 
Blood & 
CSF 
GBS 21, E. faecalis 3, E.	coli	10, S.	aureus	4, 
Klebsiella spp 2, K.	pneumoniae 1, A.	baumanii 2, 
Acinetobacter	lwoffi 1, S.	viridans 2, Enterococcus	
faecium 2, Streptococcus spp 1 
White (2007)187 2004 Prospective Johannesburg 
General Hospital, 
South Africa 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
194 inborn and outborn 
neonatal early-onset 
sepsis admissions (0-6 
days) 
Blood GBS 1 and E.	coli	1 
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(continued) 
Thomas KM 
(2013)188 
2005 - 
2010 
Retrospective Government 
Hospitals in The 
Eastern Cape, The 
Free State, 
Gauteng, Limpopo, 
Mpumalanga, The 
Northern Cape, 
North West and 
The Western Cape, 
South Africa 
Laboratory data 
from admissions to 
government 
hospitals  
1178 neonates with 
positive CSF bacterial 
culture (0 - 28 days) 
CSF GBS 359, S.	aureus 47, N.	meningitidis 6,      MRSA 
23, H.	influenzae 5, S.	pneumoniae 94, Viridans 
Streptococcus 11, other Gram-negative bacilli 
378, other Streptococci 35, Enterococcus 59, 
CoNS 148, L.	monocytogenes 2, others 11.	
Wolzak (2012)189 2007-2009 Retrospective   Tygerberg 
Children's 
Hospital, Western 
Cape Province, 
South Africa 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
62 neonatal admissions 
with suspected 
meningitis investigated 
by lumbar puncture 
CSF K.	pneumoniae	11, GBS 7, E.	coli	4, S.	marcescens	
3, S.	pneumoniae	2, N.	meningitidis	1, Others 8 
Fubisha 
(2012)190 
2002-2003 Prospective  University 
Teaching Hospital, 
Lusaka, Zambia 
Admissions to a 
paediatric ward 
and NICU of an 
urban tertiary 
referral hospital 
444 inborn and outborn 
neonatal 
sepsis/meningitis 
admissions (0 – 28 days) 
CSF K.	pneumoniae 7, S.	pneumoniae 5, Streptococcus 
spp 2, Acinetobacter 1, CoNS 1, Pseudomonas 1, 
Salmonella 1, Others 4 
Kabwe (2016)191 2013-2014 Prospective University 
Teaching Hospital, 
Lusaka, Zambia 
Admissions to 
NICU of urban 
tertiary referral 
hospital 
313 inborn and outborn 
neonatal sepsis 
admissions 
Blood Klebsiella spp 77, CoNS 7, S.	aureus	6, E.	coli	5, 
Acinetobacter 1. Bacillus spp 1, Gram negative 
diplococcus 1 
Aiken (1992)192 1989-1990 Prospective Mpilo Maternity 
Hospital, 
Zimbabwe 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
3272 neonatal 
admissions (0-28 days) 
Blood GBS 39, S.	epidermidis 37, Klebsiella spp 27, S.	
aureus	20, GDS 12, E.	coli	10, Coliforms 7, GAS 4, 
Proteus spp 2, S.	pneumoniae	1, Pseudomonas 
spp 1, Salmonella spp 1. H.	influenzae	1 
Nathoo (1990)193 1987-1988 Prospective Harare Central 
Hospital, 
Zimbabwe 
Admissions to 
neonatal unit of an 
urban district 
referral hospital 
94 inborn and outborn 
neonates with culture-
positive meningitis 
CSF S.	aureus 51, S.	epidermidis 18, GBS 18, Klebsiella 
spp 9, E. coli 6, Salmonella sp 2, Pseudomonas 
spp 2, Proteus spp 1, Listeria 1, Coliforms 31, 
other streptococci 15, others 6. 
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Southern 
Africa 
(continued) 
Nathoo (1991)194 1987 Retrospective   Harare Central 
Hospital, 
Zimbabwe 
Admissions to 
neonatal unit of an 
urban district 
referral hospital 
161 inborn and outborn 
neonatal sepsis 
admissions with positive 
blood cultures (0-28 
days) 
Blood GBS 57, S.	pneumoniae	8, other Streptococci 8, 
Klebsiella spp 6, Salmonella spp 4, E.	coli	3, 
Proteus spp 1, Coliforms 7 
West Africa Agossou 
(2016)195 
2013 Prospective Borgou Regional 
University 
Teaching Hospital, 
Parakou, Benin 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
203 neonatal admission 
with suspected bacterial 
infection (95 had blood 
culture & 85 had lumbar 
puncture) 
Blood & 
CSF 
E.	coli	5, S.	aureus	3, K.	pneumoniae 2, GBS 1,   P.	
aeruginosa	1, S.	saprophyticus 1,                      S.	
epidermidis 1, 
Balaka (2004)196 1991-1996  Retrospective   CHU Souro Sanou, 
Bobo-Dioulasso, 
Burkina-Faso 
Admissions to 
urban tertiary 
referral hospital 
37 neonatal bacterial 
meningitis admissions (0-
28 days) 
CSF E.	coli	8, Enterobacter 5, GBS 4, K.	pneumoniae	4, 
S.	pneumoniae	3, S.	aureus	2,	Salmonella	
enteritidis 2 
Hein (2001)197 1995 - 
1999 
Retrospective Centre Hospitalier 
Yalgado 
Ouedraogo, 
Ouagadougou, 
Burkina Faso 
Admissions to 
urban tertiary 
referral hospital 
10 neonatal meningitis 
admissions (<1 month) 
CSF S.	Pneumoniae 3, Others 2 
Akoua-Koffi 
(2001)198 
1995-1998 Retrospective  CHU de Yopougon, 
Abidjan, Cote 
d'Ivoire 
Admissions to 
urban tertiary 
referral hospital 
309 paediatric CSF 
samples (0-15 years) 
CSF GBS 15, S.	pneumoniae	3, others 1 
Do Rego 
(1988)199 
1985-1986 Retrospective  Multicentric, Cote 
d'Ivoire 
Admissions to 
urban tertiary 
referral hospital 
87 neonatal admissions 
with suspected 
meningitis investigated 
by lumbar puncture (0-
30 days) 
Blood & 
CSF 
Blood:	K.	pneumoniae	1, P.	aeruginosa	1, 
Citrobacter spp 1, E.	cloacae	1. 
CSF:	H.	influenzae	2, P.	mirabilis	1, K.	
pneumoniae	1, E.	coli	1, P.	aeruginosa 1,  
Orega (1997)200 1985-1989 Retrospective   CHU Trechville, 
Abidjan, Cote 
d'Ivoire 
Admissions to 
urban tertiary 
referral hospital 
521 children with 
bacterial meningitis (25 
neonates)  
CSF H.	influenzae	1, S.	pneumoniae	1, Streptococcus 
spp 1, Staphylococcus spp 2, K.	pneumoniae	3  
Acquah (2013)201 2011-2012 Prospective Tamale Teaching 
Hospital, Ghana 
Admissions to 
NICU of urban 
tertiary referral 
hospital 
63 inborn and outborn 
neonates with blood 
cultures (< 30 days) 
Blood CoNS 10, Coagulase positive staphylococci 8, K.	
pneumoniae	2, E.	coli	2, Klebsiella spp 2, 
Acinetobacter spp 2,	NTS 1,	P.	aeruginosa	1	
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(continued) 
Adetunde 
(2014)202 
2008-2011 Retrospective   Komofo Anokye 
Teaching Hospital, 
Kumasi, Ghana 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
107 children with 
culture-positive 
meningitis (0-12 years)  
CSF S.	pneumoniae	14, Pseudomonas spp 3, 
Coliforms 3, Salmonella spp 2, N.	meningitidis	2,       
E.	coli	2 
Anyebuno 
(1995)203 
1991-1992 Retrospective   Korle Bu Teaching 
Hospital, Ghana 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
2833 neonatal 
admissions 
Blood Enterobacter spp 131, S.	faecalis 64, S.	aureus	48, 
Klebsiella spp 40, Acinetobacter spp 42, E.	coli	
39, Salmonella spp 28, Pseudomonas spp 23, 
GBS 8, Proteus spp 6, Citrobacter spp 5, Non-
group B streptococcus 9 
Enweronu-
Laryea (2007)204 
2001-2002 Retrospective   Korle Bu Teaching 
Hospital, Ghana 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
4213 neonatal 
admissions 
Blood CoNS 80, Enterobacter spp 59, Klebsiella spp 31, 
S.	aureus	27, Acinetobacter spp 16, E.	coli	9, 
Pseudomonas spp 8, Citrobacter spp 8, S.	faecalis 
7, Salmonella spp 5, Non-group B streptococcus 
1  
Campagne 
(1999)205 
1981-1997 Retrospective   Hopital National de 
Niamey, Niger 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
1481 children with 
bacterial meningitis (0-
16 years) 
CSF S.	pneumoniae	34, N.	meningitidis	12, H.	
influenzae type b 10, Others 47	
Owusu (2012)206 2008-2010 Retrospective   Komofo Anokye 
Teaching Hospital, 
Kumasi, Ghana 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
163 confirmed meningitis 
cases (all age groups) 
CSF S.	pneumoniae	8, P.	aeruginosa 2, Salmonella spp 
1, E.	coli	1, N.	meningitidis	1, Enterobacter spp 1, 
Coliforms 1 
Choketu 
(2005)207 
2002-2003 Retrospective   CHU Gabriel Touré, 
Bamako, Mali 
Admissions to a 
NICU of an urban 
tertiary referral 
hospital 
367 neonates (0 - 28 
days) 
Blood/CSF Blood:	S.	aureus 21, S.	pneumoniae 17, E.	coli 12, 
Salmonella typhi 5, H.	influenzae 3, Others 12. 
CSF: S.	aureus 21, S.	pneumoniae 4, E.	coli 2,    H.	
influenzae 3, N.	meningitidis 2, Others 3. 
Adesiyun 
(2012)208 
Not 
specified 
Prospective University of Ilorin 
Teaching Hospital, 
Ilorin, Nigeria 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
193 inborn and outborn 
neonatal sepsis 
admissions (0-28 days) 
Blood S.	aureus	18, S.	faecalis 10, Klebsiella aeruginosa 
6, CoNS 6, E.	coli 3, S.	pneumoniae	2, Coliforms 
20,  
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Airede (1993)209 1988-1992 Prospective Jos University 
Teaching Hospital, 
Jos, Nigeria 
Admissions to 
SCBU of an urban 
tertiary referral 
hospital 
36 inborn and outborn 
neonatal meningitis 
admissions  
CSF S.	aureus	11, Klebsiella spp 4, S.	pneumoniae	3, E.	
coli	3, Staphylococcus	albus 2, Citrobacter spp 1, 
Pseudomonas spp 1, Non-haemolytic 
Streptococcus 1 
Airede (1992)210 1987-1989 Prospective Jos University 
Teaching Hospital, 
Jos, Nigeria 
Admissions to 
SCBU of an urban 
tertiary referral 
hospital 
99 Inborn and outborn 
neonatal septicaemia 
admissions.  (0-28 days) 
Blood Klebsiella spp 27. S.	aureus	27, Others 72 
Airede (2008)211 1992-1995 Prospective University of 
Maiduguri 
Teaching Hospital, 
Maiduguri, Nigeria 
Admissions to 
SCBU of an urban 
tertiary referral 
hospital 
69 inborn and outborn 
neonatal meningitis 
admissions  
CSF S.	aureus	13, E.	coli	11, K.	oxytoca	7, S.	
pneumoniae	4, S.	epidermidis 4, N.	meningitidis	2, 
Citrobacter spp 2, P.	aeruginosa	1. H.	influenzae	
type b 1, S.	faecalis 1,	H.	influenzae	untyped 1, 
Coliform spp 3, 
Ajayi (1997)212 1998-1990 Retrospective 
& 
Prospective 
University of Ilorin 
Teaching Hospital, 
Ilorin, Nigeria 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
713 inborn and outborn 
neonatal meningitis 
admissions  
CSF S.	pneumoniae 10, Klebsiella spp 8, 
Pseudomonas spp 7, E.	coli 5, N.	meningitidis	1, S.	
faecalis	1,	Coliforms 3. 
Ambe (2007)213 1995-1999 Retrospective  University of 
Maiduguri 
Teaching Hospital, 
Maiduguri, Nigeria 
Admissions to 
SCBU of an urban 
tertiary referral 
hospital 
813 Inborn and outborn 
neonatal sepsis 
admissions. (358 blood 
cultures and 14 lumbar 
punctures performed) 
Blood & 
CSF 
Sepsis:		S.	aureus	54,	Klebsiella	spp	29,	Proteus	
spp	14,	E.	coli	8,	Coliform	7,	Salmonella	3,	
Pseudomonas	spp	1,	S.	pneumoniae	1.		
Meningitis:	Klebsiella	spp	2,	H.	influenzae	3,	S.	
pneumoniae	1	
Ako-Nai 
(1999)214 
1994-1995 Prospective Obafemi Awolowo 
University 
Teaching Hospital, 
Ile-Ife, Nigeria 
Admissions to 
urban tertiary 
referral hospital 
107 inborn and outborn 
neonates with suspected 
sepsis (0-28 days) 
Blood & 
CSF 
Blood:	S.	aureus 21, P.	aeruginosa	11, CoNS 11, 
L.	monocytogenes 5, K.	pneumoniae 6,        E.	coli	
3, Citrobacter	freundii 1, Enterobacter	aerogenes 
2, Salmonella spp 1, Proteus spp 1. 
CSF: P.	aeruginosa	7, K.	pneumoniae 5, 
Citrobacter	freundii 5, E.	coli	3, S.	aureus 2, 
Enterobacter	aerogenes 1, Salmonella spp 1.  
Anah (2008)215 2002-2004 Retrospective  University of 
Calabar Teaching 
Hospital, Calabar, 
Nigeria 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
717 inborn and outborn 
neonates with blood 
cultures 
Blood S.	aureus	197, Coliforms 72, Streptococcus spp 
30, Enterobacteriaceae 20, C. violaceum 18,                      
K.	pneumoniae	12, P.	aeruginosa	9, Salmonella	
typhi 7, P.	mirabilis	2 
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(continued) 
Antia-Obong 
(1992)216 
1989 Retrospective  University of 
Calabar Teaching 
Hospital, Calabar, 
Nigeria 
Admissions to 
SCBU of a urban 
tertiary referral 
hospital 
132 inborn and outborn 
neonatal sepsis 
admissions (0-28 days) 
Blood & 
CSF 
Sepsis: S.	aureus	15, Streptococcus spp 6, 
Pseudomonas spp 3, P.	aeruginosa	1, Klebsiella 
spp 1, Proteus spp 1, Coliforms 52, 
Meningitis:	Coliforms 3, Klebsiella spp 1 
Antia-Obong 
(1991)217 
1985-1987 Prospective University of 
Calabar Teaching 
Hospital, Calabar, 
Nigeria 
Admissions to an 
urban tertiary 
referral hospital 
275 Inborn and outborn 
neonatal sepsis 
admissions 
Blood S.	aureus 46, GDS 5, Klebsiella spp 7, E.	coli	3, 
Streptococcus spp 3, Salmonella spp 2,  Proteus 
spp 1, Pseudomonas spp 1, S.	pyogenes 1, 
Enterobacter	aerogenes 1, Coliforms 30, 
Egbule (2016)218 2015 Prospective Delta State 
University, Abraka, 
Nigeria 
Admissions to 
NICU of urban 
tertiary referral 
hospital 
98 neonatal blood 
cultures 
Blood E.	coli	30, K.	pneumoniae	20, S.	aureus	18 
Egri-Okwaji 
(1996)219 
1996 Prospective Lagos University 
Teaching Hospital, 
Lagos, Nigeria 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
250 outborn neonatal 
sepsis admissions (0-28 
days) 
Blood S.	aureus	24, K.	pneumoniae	17, Burkholderia	
cepacia 12, E.	cloacae 7, E.	coli	6, Flavimonas	
oryzihabitans 5, E	.faecalis 4, , Chryseomonas	
luteola 4, Acinetobacter calcoaceticus 4,  CoNS 1, 
P.	mirabilis	3, Salmonella spp 3, P.	aeruginosa	2, 
Citrobacter	freundii 2, Stenotrophomonas	
maltophilia 2, Enterobacter	agglomerans 1, 
Morganella	marganii 1, Salmonella	arizonae 1, 
Shigella spp 1, Acinetobacter spp 1, 
Enterococcus spp 1, Pasturella spp 1, 
Sphingobacterium	multivorum 1, Flavobacterium	
meningosepticum 1,  
Emele (2000)220 1987- 1992 Prospective Usman Danfodio 
University 
Teaching Hospital, 
Sokoto, Nigeria 
Admissions to 
urban tertiary 
referral hospital 
11 neonates with CSF 
samples 
CSF S.	pneumoniae	3, S.	aureus	3, Coliform bacilli 5 
Fadero (2007)221 2004-2005 Prospective Ladoke Akintola 
University 
Teaching Hospital, 
Osogbo, Nigeria 
Admissions to 
SCBU of an urban 
tertiary referral 
hospital 
63 inborn and outborn 
neonates investigated by 
blood culture (< 30 days) 
Blood S.	aureus 18, Proteus spp 6, Klebsiella spp 3, E.	
coli	2, CoNS 2 
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Iregbu (2013)222 2010-2012 Retrospective   National Hospital, 
Abuja, Nigeria 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
special care baby 
unit 
245 neonatal blood 
culture samples, 127 CSF 
samples 
Blood & 
CSF 
Blood	: S.	aureus	62, Klebsiella spp 8, 
Enterococcus spp 6, P.	aeruginosa	5, CoNS 4, S.	
marcescens	2, E.	coli	1, Citrobacter	freundii 1, 
Morganella	marganii 1, L.	monocytogenes 1, 
Proteus spp 1,  
CSF:	S.	aureus	4, Enterococcus spp 1, Klebsiella 
spp 1, Neisseria spp 1 
Iregbu (2006)223 2002-2004 Retrospective   National Hospital, 
Abuja, Nigeria 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
390 neonatal blood 
cultures (0-28 days) 
Blood K.	pneumoniae	37, S.	aureus	34, CoNS 2, 
Acinetobacter spp 1, P.	aeruginosa	4.	
Enterococcus spp 1, S.	pneumoniae	1, E.	coli	1, α-
haemolytic streptococci 1, E.	faecalis 1	
Longe (1984)224 1974-1982 Prospective University of Benin 
Teaching Hospital, 
Benin City, Nigeria 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
53 inborn and outborn 
neonatal sepsis 
admissions 
CSF S.	aureus	13, E.	coli	9, S.	pneumoniae	4, Klebsiella 
spp 4, Pseudomonas spp 3, Coliforms 3, 
Salmonella spp 2, Proteus spp 2, Non-haemolytic 
streptococcus 2, Staphylococcus	albus 2 
Achromobacter 1 
Meremikwu 
(2005)225 
1996-2002 Prospective University of 
Calabar Teaching 
Hospital, Calabar, 
Nigeria 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
533 inborn and outborn 
neonatal sepsis 
admissions (≤1 month)  
Blood S.	aureus	138, Pseudomonas spp 16, 
Chromobacterium spp 15, β-haemolytic 
Streptococci 5, Other Streptococci 8, Salmonella 
spp 5, CoNS 1, Proteus spp 1, other Gram 
negatives 18, Coliforms 63 
Mokuolu 
(2002)226 
1995-1996 Retrospective  University of Ilorin 
Teaching Hospital, 
Ilorin, Nigeria 
Admissions to 
NICU of urban 
tertiary referral 
hospital 
198 Inborn and outborn 
neonates (0-28 days) 
Blood S.	aureus	18, CoNS 15, K.	pneumoniae	10, E.	coli	
4, Acinetobacter spp 3, E.	faecalis 2, P.	
aeruginosa	1, Coliforms 16 
Mordi (2010) 227 2008-2009 Prospective University of Benin 
Teaching Hospital, 
Benin City, Nigeria 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
700 inborn and outborn 
neonatal admissions 
Blood S.	aureus	54, K.	pneumoniae	20, E.	coli	5, P.	
mirabilis	4, Providencia	stuartii 4, Acinetobacter	
calcoaceticus 3, Enterobacter	aerogenes 3, 
Citrobacter	freundii 3, P.	aeruginosa	2,	P.	vulgaris 
1 
Nottidge  
(1985) 228 
1976-1980 Retrospective 
& 
Prospective  
University College 
Hospital, Ibadan, 
Nigeria 
Admissions to 
urban tertiary 
referral hospital 
463 children with 
culture-confirmed 
meningitis (0-15 years) 
CSF S.	pneumoniae	10, H.	influenzae	2 
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Nwadioha 
(2015) 229 
2012-2015 Retrospective   Ekiti State 
University 
Teaching Hospital, 
Nigeria 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
51 neonatal blood 
cultures (≤ 28 days) 
Blood S.	aureus	6, Klebsiella spp 6, Enterococci 3, 
Proteus spp 2, E.	coli	1 
Nwadioha 
(2013) 230 
2006-2009 Retrospective   Amino Kano 
Teaching Hospital, 
Kano, Nigeria 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
special care baby 
unit 
250 neonatal CSF 
samples (0-28 days)  
CSF E.	coli	7, GBS 4, Enterococcus spp 3, S. 
epidermidis 1, Klebsiella spp 1, Salmonella spp 
1,  
Nwadioha 
(2010) 231 
2006-2008 Retrospective   Amino Kano 
Teaching Hospital, 
Kano, Nigeria 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
special care baby 
unit 
1270 neonatal blood 
culture samples (0-28 
days)  
Blood E.	coli	180, S.	aureus	90, Klebsiella spp 40, 
Proteus spp 14, S.	pneumonia 1, Enterococcus 
spp 1 
Nwankwo 
(2011) 232 
2007-2008 Prospective Aminu Kano 
Teaching Hospital, 
Kano, Nigeria 
Admissions to 
SCBU of a urban 
tertiary referral 
hospital 
547 inborn and outborn 
neonatal sepsis 
admissions (0-28 days) 
Blood S.	aureus	38, K.	pneumoniae	32, E.	coli	24, 
Streptococcus spp 18,	Salmonella spp 15, E.	
faecalis 7, P.	aeruginosa	7, P.	mirabilis	4,            S.	
epidermidis 4, P.	vulgaris 2, Citrobacter	freundii 
1,  
Ogundare  
(2016) 127 
2008-2009 Prospective Wesley Guild 
Hospital, Ilesa, 
Nigeria 
Admissions to 
SCBU of a rural 
referral hospital 
360 inborn and outborn 
neonatal sepsis 
admissions (0-28 days) 
Blood S.	aureus	53, Klebsiella spp 8, α-haemolytic 
Streptococci 6, Pseudomonas 5, E.	coli	2, Proteus 
spp 1 (extrapolated	from	data) 
Ogunlesi  
(2010) 233 
2006-2008 Retrospective 
& 
Prospective  
Olabisi Onabanjo 
University 
Teaching Hospital, 
Sagamu, Nigeria 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
527 Inborn and outborn 
neonatal sepsis 
admissions 
Blood S.	aureus	54, Klebsiella 40, CoNS 22, E.	coli	19, 
Proteus 11, P.	aeruginosa	7, Enterococcus 4, 
Unclassified coliforms 17 
Ojide (2013) 234 2011-2012 Prospective University of Uyo 
Teaching Hospital, 
Nigeria 
Admissions to 
urban tertiary 
referral hospital 
357 neonatal sepsis 
admissions (0 -28 days) 
Blood S.	aureus	39, E.	coli	23, K.	pneumoniae	15, 
Enterobacter spp 5, CoNS 4, P.	mirabilis	3, 
Enterococcus faecalis 2  
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(continued) 
Ojukwu  
(2005) 235 
2002-2003 Prospective Ebonyi State 
University 
Teaching Hospital, 
Abakiliki, Nigeria 
Admissions to 
SCBU of a urban 
tertiary referral 
hospital 
138 inborn and outborn 
neonatal sepsis 
admissions (0-28 days) 
Blood S.	aureus	15, E.	coli	5, Streptococcus spp 3,    
Klebsiella spp 3, S.	paratyphi A 2, Proteus spp 
1, Enterobacter spp 1, H.	influenzae	1, 
Pseudomonas spp 1. 
Okolo (1985) 236 1978-1983 Retrospective   University of Benin 
Teaching Hospital, 
Benin City, Nigeria 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
177 inborn and outborn 
neonatal sepsis 
admissions (0 -28 days) 
Blood S.	aureus	50, Klebsiella 38, Pseudomonas 34, 
Staphylococcus	albus 23, E.	coli	21,             
Alcalogenes	faecalis 10, Proteus 8, Salmonella 
spp 4, Acinetobacter 3, Providence A, 3, 
Diptheroids, 1, Citrobacter 1, S.	viridans	1, S.	
faecalis 1, Haemolytic streptococcus 1, 
Coliforms 24, 
Okon (2014) 237 2008-2009 Retrospective   University of 
Maiduguri 
Teaching Hospital, 
Maiduguri, Nigeria 
Laboratory data 
from admissions to 
urban tertiary 
referral hospital 
special care baby 
unit 
2134 children (< 12 
years)  
Blood S.	aureus	39, Klebsiella spp 15, Salmonella spp 
1,       E.	coli	6, Pseudomonas spp 2, Proteus 
spp 1, Coliforms 5, CoNS 1, 
Omoregie  
(2013) 238 
2010-2011 Prospective University of Benin 
Teaching Hospital, 
Benin City, Nigeria 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
534 inborn and outborn 
neonatal sepsis 
admissions (1-28 days) 
Blood Klebsiella spp 74, S.	aureus	66, Alcaligenes spp 
12,    E.	coli	10, Acinetobacter spp 9, P.	
mirabilis	8,             P.	aeruginosa	8, Providencia 
spp 6, Citrobacter spp 5, Proteus vulgaris 5, 
Enterobacter spp 4 
Onalo (2011) 239 2004-2005 Prospective Ahmadu Bello 
University 
Teaching Hospital, 
Zaria, Nigeria 
Admissions to 
SCBU of a urban 
tertiary referral 
hospital 
211 neonatal septicaemia 
admissions (0-28 days). 
Inborn (69) and outborn 
(142)   
Blood S.	aureus	33, E.	coli	15, Streptococcus spp 8, K.	
pneumoniae	6, P.	mirabilis	5, Others 10  
Onyedibe  
(2016) 240 
2011 Prospective Jos University 
Teaching Hospital, 
Jos, Nigeria 
Admissions to 
SCBU of a urban 
tertiary referral 
hospital 
165 inborn and outborn 
neonatal sepsis 
admissions  
Blood & 
CSF 
Blood:	K.	pneumoniae	22, S.	aureus	20, E.	coli	
8, CoNS 5, Citrobacter spp 3, P.	aeruginosa	1, 
Enterobacter spp 2, E.	faecalis 2, L.	
monocytogenes 1, NTS 1, P.	mirabilis	1, 
Salmonella typhi 1, S.	pneumoniae	1.		
CSF:	K.	pneumoniae	1, E.	coli	1, S.	pneumoniae	
1 
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Table	3.1	Summary	of	136	hospital-based	studies	of	neonatal	sepsis,	meningitis	and	pneumonia	in	sub-Saharan	Africa,	1980	–	2016	(continued)	
Region Author	(year) Data	
collection	
period 
Data	
collection 
Location Source	of	case	
capture 
Population	(or	neonatal	
sub-population	where	
reported) 
Culture	
category 
Organisms	
West Africa 
(continued) 
Onyedibe 
(2015)241 
2011 Prospective Jos University 
Teaching Hospital, 
Jos, Nigeria 
Admissions to 
SCBU of an urban 
tertiary referral 
hospital 
218 inborn and outborn 
neonatal sepsis 
admissions (0-28 days)  
Blood K.	pneumoniae	24, S.	aureus	23, E.	coli	8, CoNS 
5, Citrobacter spp 3, P.	aeruginosa	3, 
Enterobacter spp 2, E.	faecalis 2, P.	mirabilis	2, 
Salmonella spp 2, S.	pneumoniae	1 
Osinupebi 
(2014)242 
2008 Prospective Olabisi Onobanjo 
University 
Teaching Hospital, 
Sagamu, Nigeria 
Admissions to 
SCBU of an urban 
tertiary referral 
hospital 
356 Inborn and outborn 
neonatal admissions.  (0-
28 days) 
Blood Community-acquired:	S.	aureus	8, Klebsiella 
spp 8, Pseudomonas spp 3, E.	coli	2, Proteus 
spp 2, Atypical coliforms 3. 
Nosocomial: Klebsiella spp 10, Proteus spp 5, 
S.	aureus	4, E.	coli	2, Pseudomonas spp 1, 
Coliforms 2 
Owa (1988)128 1986 Prospective Wesly Guild 
Hospital, Ilesha, 
Nigeria 
Admissions to 
SCBU of a rural 
referral hospital 
101 inborn and outborn 
neonatal sepsis 
admissions (1-28 days) 
investigated by blood 
culture 
Blood S.	aureus 8, E.	coli	4, Klebsiella spp 4, P.	
aeruginosa	2, Streptococcus faecalis 2, 
Clostridium	welchi 2, Citrobacter spp 1, H.	
influenzae	1, S.	epidermidis 1, Atypical coliform 
6, 
Peterside 
(2015)243 
2011-2013 Retrospective   Niger Delta 
University 
Teaching Hospital, 
Bayelsa, Nigeria 
Admissions to 
SCBU of an urban 
tertiary referral 
hospital 
223 neonates (0-28 days) Blood S.	aureus	50, E.	coli	16, K.	pneumoniae	14,                  
P.	mirabilis	8, P.	aeruginosa	7, S.	pyogenes 2	
Pius (2016)244 2012 Prospective University of 
Maiduguri 
Teaching Hospital, 
Maiduguri, Nigeria 
Admissions to 
SCBU of an urban 
tertiary referral 
hospital 
110 inborn and outborn 
neonatal sepsis 
admissions (0-28 days) 
Blood S.	aureus	16,	E.	coli	9, K.	pneumoniae	7, S.	
pyogenes 5, S.	epidermidis 1, S.	pneumoniae	1, 
H.	influenzae	1, Salmonella spp 1, Coliforms 5 
Rabasa (2007)245 1991 Prospective University of Benin 
Teaching Hospital, 
Benin City, Nigeria 
Admissions to 
SCBU of an urban 
tertiary referral 
hospital 
141 inborn and outborn 
neonatal sepsis 
admissions 
Blood & 
CSF 
S.	aureus	13, Coliform spp 26 
Shittu (2014)246 2012-2014 Prospective Outreach 
Childrens' 
Hospital, Festac 
Town, Lagos, 
Nigeria 
Admissions to 
private referral 
hospital 
432 inborn and outborn 
neonates with suspected 
sepsis (0-28 days) 
Blood Klebsiella spp 33, S.	aureus 27, E.	coli	18, 
Pseudomonas spp 6, Proteus spp 3, CoNS 9 
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Table	3.1	Summary	of	136	hospital-based	studies	of	neonatal	sepsis,	meningitis	and	pneumonia	in	sub-Saharan	Africa,	1980	–	2016	(continued)	
Region Author	(year) Data	
collection	
period 
Data	
collection 
Location Source	of	case	
capture 
Population	(or	neonatal	
sub-population	where	
reported) 
Culture	
category 
Organisms	
West Africa 
(continued) 
Uzodimma 
(2013)247 
2011-2012 Prospective Lagoon Hospital, 
Lagos, Nigeria 
Admissions to 
urban tertiary 
referral hospital 
36 neonates with 
suspected sepsis (<4 
weeks) 
Blood S.	aureus	9, Streptococcus spp 2, Klebsiella spp 
3, E.	coli	1, Enterococci 1 
West (2012) 248 2007 Prospective University of Port 
Harcourt Teaching 
Hospital, Port 
Harcourt, Nigeria 
Admissions to 
SCBU of an urban 
tertiary referral 
hospital 
406 inborn and outborn 
neonatal septicaemia 
admissions.  (0-28 days) 
Blood Klebsiella 99, S.	aureus	33, E.	coli	13,            
Proteus spp 9, P.	aeruginosa	8, E.	faecalis 3,          
S.	epidermidis 3, Streptococcus spp 1 
Camara  
(2003) 249 
1995-2000 Retrospective   L'hopital d'enfants 
Albert-Royer, CHU 
de Fann, Dakar, 
Sénégal 
Admissions to 
urban tertiary 
referral hospital 
1095 children with 
bacterial meningitis (0-
15 years) 
CSF Streptococcus 13, Staphylococci 9, E.	coli 9,                
S.	pneumoniae	6, K.	pneumoniae 4, Citrobacter 
4,        P.	aeruginosa	2, Salmonellae 2, 
Enterobacteriaceae 2, 
Cisse (2001) 250 1997-1998 Retrospective   CHU de Dakar, 
Sénégal 
Admissions to 
urban tertiary 
referral hospital 
2312 neonates with 
suspected bacterial 
infection 
Blood K.	pneumoniae	134, Enterobacter spp 25, 
Staphylococcus 19, E.	coli	13, GBS 12, 
Enterobacteria 9, Pseudomonas spp 6,  
Cisse (1992) 251 1983-1991 Prospective Pediatric Hospital 
Albert Royer, 
Dakar, Sénégal 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
471 neonatal blood 
cultures (0-30 days) 
Blood Klebsiella spp 41, Enterobacteriaceae 30, E.	
coli	28, S.	aureus	25, GBS 7, S.	pneumoniae	2, 
GDS 2, GAS 1, Gram-negative bacilli 7 
Landre-Peigne 
(2011) 252 
2005 Retrospective 
& 
Prospective  
Hôpital Principal 
de Dakar, Senegal 
Admissions to 
urban tertiary 
referral hospital 
273 neonatal admissions 
with suspected sepsis 
Blood ESBL K.	pneumoniae 9, K.	pneumoniae 1,	E.	
cloacae 2, Acinetobacter spp 1, MRSA 1 
Le Doare (2016) 
253 
2014-2015 Prospective MRC Hospital, 
Fajara, The Gambia 
Admissions to 
urban secondary 
referral hospital  
51 infants with suspected 
infection (0-89 days) 
CSF GBS 1 
Mulholland 
(1999) 254 
1990-1991, 
1992 
Prospective MRC Hospital, 
Fajara & Royal 
Victoria Hospital, 
Banjul, The Gambia 
Admissions to 
urban tertiary 
referral hospital 
695 sick and 63 well 
young infants enrolled 
(<91 days); 476 infants 
investigated 
Blood & 
CSF 
Blood: S.	aureus	9, S.	pneumoniae	1, 
Salmonella spp 4, P.	mirabilis	1, Enterobacter 
spp 1, GAS 1, GBS 1, GGS 1 
CSF:	S.	pneumoniae	4, E.	cloacae	2, E.	coli	1, 
GBS 1, Salmonella spp 1.  
Palmer  
(1999) 255 
1991-1994 Retrospective  Royal Victoria 
Hospital, Banjul, 
The Gambia 
Admissions to 
neonatal unit of an 
urban tertiary 
referral hospital 
420 paediatric meningitis 
admissions (0-15 years) 
CSF S.	pneumoniae	15, E.	coli	7, E.	cloacae 7, H.	
influenzae 1, GAS 1, GBS 1, Klebsiella spp 1, P.	
mirabilis	1, Salmonella spp 1, Coliform 1 
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Table	3.1	Summary	of	136	hospital-based	studies	of	neonatal	sepsis,	meningitis	and	pneumonia	in	sub-Saharan	Africa,	1980	–	2016	(continued)	
Region Author	(year) Data	
collection	
period 
Data	
collection 
Location Source	of	case	
capture 
Population	(or	neonatal	
sub-population	where	
reported) 
Culture	
category 
Organisms	
West Africa 
(continued) 
Balaka (2004) 256 1987-1993 Retrospective   CHU Lomé, Togo Admissions to 
urban tertiary 
referral hospital 
41 neonatal bacterial 
meningitis admissions (0-
28 days) 
CSF E.	coli	6, Enterobacter 4, K.	pneumoniae	2, S.	
enteritidis 2, P.	mirabilis	2, Citrobacter 1,              
H.	influenzae	2, GBS 2, S.	pneumoniae	2,               
S.	aureus	2, N.	meningitidis	2  
Balaka (2004) 196 1993-1995 Retrospective   CHU Lomé, Togo Admissions to 
urban tertiary 
referral hospital 
433 inborn and outborn 
neonates with suspected 
sepsis (0-28 days) 
Blood E.	coli	15, K.	pneumoniae	6, Enterobacter 4, S.	
aureus	14, S.	epidermidis 8, P.	aeruginosa	1, 
Salmonella spp 2 
SCBU= Special Care Baby Unit; NICU=Neonatal Intensive Care Unit; spp = species; ESBL=Extended spectrum β-lactamase producing; CoNS=Coagulase negative Staphylococci; GBS=Group B Streptococcus; 
GAS=Group A Streptococcus; GCS=Group C Streptococcus; GGS=Group G Streptococcus; MRSA=Methicillin Resistant Staphylococcus aureus;  
 
 
 
72 
 
Characteristics	of	included	studies	and	quality	of	reporting	
The quality of the data and completeness of reporting was assessed by applying selected 
key items regarding methods and results, from the STROBE-NI checklist to all published 
studies excluding the grey literature. Each study was assessed independently by both 
reviewers, and the reporting of each item was classified as either “‘not 
reported/unclear” or “some information mentioned but insufficient” or “clear and 
detailed information provided”. The heat map showing grading of the completeness of 
reporting of selected STROBE-NI across studies is presented in Table 3.2. 
Table	3.2	Heat	map	showing	grading	of	the	completeness	of	reporting	of	selected	STROBE-
Neonatal	Infection	items	in	118	studies	on	neonatal	infections	in	sub-Saharan	Africa	
STROBE-NI	checklist	item	
Assessment	
Not	
reported/	
Unclear	
Some	
information	
provided	but	
insufficient	
Clear	and	
detailed	report	
of	STROBE-NI	
item	
Methods		
(Study	design)	 
 
STROBE-NI	4.1 (Case ascertainment)    
STROBE-NI	4.3 (Distinction between CAI and HAI)    
STROBE-NI	4.5 (Sampling strategy)    
STROBE-NI	4.6 (Microbiological methods)    
Methods	(Setting) STROBE-NI	5.2 (Newborn population included in the 
study) 
   
STROBE-NI	5.5 (Facility characteristics and level of 
neonatal care) 
   
Methods	
(Variables) 
STROBE-NI	7.1 (Clinical significance of pathogens)    
Results		
(Descriptive	data) 
STROBE-NI	14.2a (Key neonatal characteristics - 
Gestational age at birth) 
   
STROBE-NI	14.2b (Key neonatal characteristics 
birth-weight) 
   
Results		
(Outcome	data) 
STROBE-NI	15.1 (Microbiological results in context 
of participants) 
   
STROBE-NI	15.3 (Timing of infection)    
CAI = Community-acquired infection; HAI = Hospital-acquired infection 
 ≤10 studies  11 – 58 studies  59 – 99 studies  ≥ 100 studies 
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Case	ascertainment	(STROBE-NI	Item	4.1)	
There was significant variation in case ascertainment across studies. Twenty-three 
studies identified cases from retrospective review of culture data from laboratory 
databases, 38 studies from retrospective reviews of clinical and laboratory records, and 
the remainder were prospective studies of newborns admitted with clinically suspected 
invasive bacterial disease, sepsis, septicaemia, and/or meningitis.  
Distinction	between	community	and	hospital-acquired	infection	(STROBE-NI	Item	
4.3)	
Fewer than 10 studies indicated if the study focused on community-acquired infection 
(CAI), hospital-acquired infection (HAI) or both, and defined HAI using an international 
standard.  
Sampling	strategy	(STROBE-NI	item	4.5)	
Less than half of the studies provided some information on the microbiological 
sampling – strategy (clinical indication vs routine); number of participants from whom 
samples were taken and sample type. Thirty-seven studies reported the blood sample 
volume which ranged from 0.4 mL – 3.5 mL, but only 12 of these reported on the timing 
of sampling in relation to antimicrobial administration. Forty-five studies used manual 
culture methods to isolate and identify bacteria and 21 used automated methods 
namely the BACTEC, BacT/Alert 3D, and Oxoid Signal systems. After excluding 
contaminants (where this information was available (including CoNS where 
mentioned), the proportion of positive cultures ranged from 4.2% - 44% among studies 
using automated culture methods and from 1.0% - 69% among studies using manual 
methods. Egbule and colleagues218 reported 69% blood culture positivity rate among 98 
neonates investigated for sepsis in a Teaching Hospital in Nigeria. For each neonate, 2 
ml of venous blood was collected and aseptically introduced into two culture bottles. 
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Organisms were considered pathogens if the same organism was obtained in the two 
broth culture bottles, and contaminants if either the growth was obtained in only one 
culture bottle or a mixed growth obtained. Interpretation of detection rates and 
comparison to determine whether automated methods are superior to manual methods, 
especially for organisms such as GBS, is complicated by differences in the years of data 
collection, the use of different inclusion criteria, sampling volume, microbiological 
capability, and overall data quality. 
Microbiological	methods	(STROBE-NI	item	4.6)	
Two studies reported that they used advanced pathogen identification methods using 
the automated VITEK II system,161, 177 including Matrix-Assisted Laser 
Desorption/Ionization Time-Of-Flight (MALDI-TOF), Mass spectrometry and 16S rDNA 
polymerase chain reaction (PCR) sequencing.161 In sSA, molecular methods have not 
been widely used as adjunct tests  in the diagnosis of neonatal sepsis unlike in the 
diagnosis of pneumonia,257 meningitis,258 and diarrhoea.57  
Newborn	population	included	in	the	study	(STROBE-NI	item	5.2)	
Sick newborns present to health-care services through several pathways, and therefore 
acquire infection from several settings. Consequently, stratification into “inborn" or 
“outborn” does not provide adequate information regarding place of birth (i.e. home vs 
the admitting facility or a referral facility) or take account of timing of admission (i.e. 
admission from birth vs return to the facility following discharge).  Seventeen studies 
categorised their study population as either “inborn” or “outborn”.124, 127, 131, 156, 157, 172, 
177, 191, 208, 214, 219, 221, 226, 235, 239, 242, 244  Only eight studies provided specific place of birth 
categories of their study population such as “born at this facility”, “born at another 
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facility”, or “born at home”.121, 130, 152, 164, 167, 169, 199, 216  The remaining reports did not 
include data on place of birth.  
Facility	characteristics	and	level	of	neonatal	care	(STROBE-NI	Item	5.5)	
All 137 studies were facility-based, and all but 19 were carried out in tertiary referral 
hospitals;120-126, 129, 133, 165, 167-169, 179, 180, 193, 194, 246, 253  however, 10 studies reported data 
from predominantly rural populations - five from Kenya,120-124 two from 
Mozambique,125, 126 two from Nigeria,127, 128 and one from Cameroon.129 Only two 
studies: one from Malawi167 and another from South Africa,177 provided detailed 
information on the level of neonatal care available including invasive respiratory 
support and indwelling devices. Figure 3.3 shows regional variation in reported level of 
neonatal care. Few studies included information on the number of healthcare staff 
(nurse-to-patient ratio) on the neonatal unit. 
 
 
Figure	3.3	Regional	variation	in	levels	of	neonatal	care	reported	in	studies	of	serious	
neonatal	infection	in	sub-Saharan	Africa.	
Abbreviations. NICU=Neonatal Intensive Care Unit; NHDU=Neonatal High Dependency Unit; PICU=Paediatric 
Intensive Care Unit; PHDU=Paediatric High Dependency Unit 
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Clinical	significance	of	pathogens	(STROBE-NI	item	7.1)	
The majority of studies listed all detected organisms, but no study categorised 
organisms (as suggested in the STROBE-NI checklist) as being clinically significant, 
probably significant, and clinically non-significant (the preferred term to 
“contaminant”). Some studies listed organisms considered to be “contaminants” but did 
not mention the criteria259, 260 used to define these organisms as contaminants. 
Key	neonatal	characteristics	–	gestational	age	at	birth	and	birth	weight	(STROBE-
NI	item	14.2)	
More than half of the studies reported on key neonatal characteristics – gestational age 
at birth and birthweight – presenting the data in discrete categories with appropriate 
summary statistics (medians and ranges) for each numeric variable. 
Microbiological	results	in	the	context	of	samples	taken	(STROBE-NI	item	15.1)	
Seventy-three studies reported blood culture positivity rates. These are presented by 
country, in Table 3.3. 
Table	3.3	Reported	blood	culture	positivity	rates	among	neonates	investigated	for	suspected	
sepsis	from	73	studies	in	sub-Saharan	Africa,	by	country	
Country	 Number	of	
studies	
Number	of	blood	
samples	cultured	
Number	of	
positive	cultures	a	
%	of	positive	cultures		
Median	(Range)a	
Benin 1 95 14 14.7 
Botswana 1 1119 91 8.1 
Cameroon 2 343 38 10.8 (7.8 – 13.8) 
Congo 1 130 29 22.3 
Equatorial Guinea 1 293 28 9.6 
Ethiopia 5 1206 402 32.0 (31.3 – 35.3) 
Ghana 1 63 28 44.4 
Kenya 5 2077 495 26.8 (22.3 – 60.5) 
Madagascar 1 105 55 52.4 
Mali 1 367 70 19.1 
Mozambique 1 952 154 16.2 
Nigeria 32 9742 3407 35.8 (27.0 – 44.0) 
Senegal 3 3056 373 9.4 (5.1 – 29.9) 
South Africa 7 9658 949 8.1 (1.3 – 15.3) 
Tanzania 6 1634 391 20.8 (12.9 – 38.1) 
Togo 1 433 50 11.5 
Uganda 3 547 174 32.5 (21.8 – 37.5) 
Zambia 1 313 102 32.6 
IQR= Interquartile range 
a Excluding contaminants where mentioned 
b Median (IQR) only presented for countries with >1 study reporting data on number of blood samples cultured and number of 
culture positive cases 
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CSF	positivity	
Fifty-eight studies reported data on CSF cultures among neonates with suspected 
meningitis, 45% (26/58) of which reported on the number of neonates investigated by 
lumbar puncture and the CSF culture positivity rate (Table 3.4). 
Table	3.4	Reported	CSF	culture	positivity	rates	among	neonates	investigated	for	suspected	
meningitis	from	26	studies	in	sub-Saharan	Africa	
Author	(year)	 Country	 Region	 Number	of	LP	performed	
Number	of	positive	CSF	
cultures	(%)	
Chiabi (2011) Cameroon Central Africa 180 2 (1%) 
Mulu (2014) Ethiopia East Africa 154 9 (6%)  
Zewdie (2014) Ethiopia East Africa 112 6 (5%) 
Gebremariam (1998) Ethiopia East Africa 55 30 (55%) 
Mulu (2005) Ethiopia East Africa 35 2 (6%) 
Mwaniki (2011) Kenya East Africa 845 20 (2%) 
Laving (2003) Kenya East Africa 84 4 (5%) 
Sigauque (2008) Mozambique Southern Africa 48 4 (8%) 
Haffejee (1991) South Africa Southern Africa 277 9 (3%) 
Wolzak (2012) South Africa Southern Africa 62 36 (58%) 
Adhikari (1995) South Africa Southern Africa 60 55 (92%) 
Fubisha (2012) Zambia Southern Africa 447 22 (5%) 
Agossou (2016) Benin West Africa 85 0 (0%) 
Balaka (2004) Burkina-Faso West Africa 37 28 (76%) 
Do Rego (1988) Cote d'Ivoire West Africa 87 6 (7%) 
Choketu (2005) Mali West Africa 367 35 (10%) 
Ajayi (1997) Nigeria West Africa 747 32 (4%) 
Onyedibe (2015) Nigeria West Africa 165 3 (2%) 
Iregbu (2006) Nigeria West Africa 127 7 (6%) 
Airede (2008) Nigeria West Africa 69 50 (72%) 
Longe (1984) Nigeria West Africa 53 45 (85%) 
Airede (1993) Nigeria West Africa 36 26 (72%) 
Ambe (2007) Nigeria West Africa 14 6 (43%) 
Camara (2003) Sénégal West Africa 71 52 (73%) 
Palmer (1999) The Gambia West Africa 54 30 (56%) 
Le Doare (2016) The Gambia West Africa 1 1 (100%) 
a Excluding contaminants where mentioned 
 
Aetiology	of	neonatal	infection	
Table 3.5 summarises the top five bacterial isolates (blood and CSF) reported across all 
136 studies by country, and Figure 3.4 shows the top five bacterial isolates by sub-
Saharan African region. 
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Table	3.5	Summary	of	studies	reporting	microbiologically-confirmed	neonatal	infection	aetiology	in	
sub-Saharan	Africa	(1980	–	2016),	with	the	top	5	bacterial	pathogens	isolated	by	country	
Region/Country	
(number	of	studies) NMR	 Top	five	bacterial	pathogens	by	country	(number	of	isolates) 
Central	Africa	(n=7)   
Cameroon (n=4) 24 E.	coli	(29), GBS (18), S.	aureus	(10), Klebsiella sp. (10), S. pneumoniae (9), Acinetobacter sp. (7) 
CAR (n=1) 42 S.	pneumoniae	(3), GBS (2), H.	influenzae	(2), Salmonella (2) 
Congo (n=1) 21 Klebsiella sp. (12), Streptococcus sp. (4), S.	aureus (3), E.	coli	(2), Enterobacter (2) 
Equatorial Guinea (n=1) 32 Klebsiella sp. (16), Acinetobacter sp. (4), E.	coli	(4), CoNS (4) 
East	Africa	(n=32)   
Kenya (n=11) 23 Klebsiella sp. (170), S.	aureus	(120), E.	coli	(104), Enterobacter (84), GBS (76) 
Ethiopia (n=10) 28 Klebsiella sp. (124), S.	aureus	(61), E.	coli	(44), CoNS (29), S.	pneumoniae	(19) 
Tanzania (n=6) 22 Klebsiella sp. (119), S.	aureus	(83), E.	coli	(63), CoNS (28), Enterococcus (23) 
Uganda (n=3) 21 S.	aureus	(97), E.	coli	(26), N.	meningitidis	(11), GBS (8), Klebsiella sp. (6) 
Madagascar (n=2) 19 CoNS (51), Klebsiella sp. (25), Enterobacter sp. (17), Enterococcus (9), E.	coli	(6) 
Southern	Africa	(n=33)	  
South Africa (n=19) 12 Klebsiella sp. (681), GBS (593), CoNS (365), S.	aureus (278),	E.	coli	(229) 
Malawi (n=5) 23 GBS (305), S.	aureus	(210), NTS (189)	E.	coli	(156), S.	pneumoniae (130) 
Zimbabwe (n=3) 23 GBS (114), S.	aureus	(71), S.	epidermidis	(55), Klebsiella sp. (42),	E.	coli	(19) 
Botswana (n=1) 26 Klebsiella sp. (43), GBS (15), E.	coli	(11), S.	aureus	(8) 
Mozambique (n=2) 27 S.	aureus	(61), GBS (32), Enterococcus (10), NTS (9), E.	Coli	(9),	S.	pneumoniae (9), Enterobacter 
sp (6) 
Zambia (n=2) 23 Klebsiella sp. (84), CoNS (7) S.	aureus	(6), E.	coli	(5), S.	pneumoniae	(5), Acinetobacter sp (1) 
Namibia (n=1) 18 Klebsiella sp. (4), S.	pneumoniae	(2), N.	meningitidis (2), E.	coli	(1) 
West	Africa	(n=64)   
Nigeria (n=43) 34 S.	aureus	(1484), Klebsiella sp. (738), E.	coli	(492), Pseudomonas sp. (170), CoNS (83) 
Ghana (n=4) 27 Enterobacter sp. (191), CoNS (90), Klebsiella sp (75), S.	aureus	(75), Enterococcus (71), 
Acinetobacter	(60) 
The Gambia (n=3) 28 S.	pneumoniae	(20), Enterobacter sp.	(10), S.	aureus (9), E.	coli	(8), Salmonella	sp.	(6) 
Burkina Faso (n=2) 26 E.	coli	(8), S.	pneumoniae	(6), Enterobacter sp. (5), GBS/Klebsiella sp. (4), S.	aureus	(2),	
Salmonella (2) 
Cote d’Ivoire (n=3) 37 GBS (15), Klebsiella sp. (5), S.	pneumoniae (4), H.	influenza	(3), Pseudomonas (2) 
Senegal (n=4) 21 Klebsiella sp. (189), E.	coli	(50), Enterobacter	sp.	(27), S.	aureus (26), GBS (19) 
Togo (n=2) 26 E.	coli	(21), S.	aureus	(16), Klebsiella sp. (8), Enterobacter	sp.	(8), S.	epidermidis	(8), Salmonella 
(4), GBS (2), S.	pneumoniae	(2), H.	influenzae	(2), N.	meningitidis (2) 
Benin (n=1) 31 E.	coli	(5), S.	aureus	(3), Klebsiella sp. (2), GBS (1), Pseudomonas (1), S.	epidermidis (1) 
Mali (n=1) 36 S.	aureus	(42), S.	pneumoniae (21), E.	coli (14), H.	influenzae (6), Salmonella (5) 
Niger (n=1) 26 S.	pneumoniae	(34), N.	meningitidis	(12), H.	influenza	type b (10) 
CAR = Central African Republic; sp. = species 
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Antimicrobial	resistance	
AMR was reported in most studies although some studies did not disaggregate 
resistance data by pathogen. Table 3.6 shows the reported AMR for Klebsiella, E.	coli, S.	
aureus and GBS pooled from 25 studies where this disaggregated data was available. 
AMR data for Enterococcus was not reported by any study. 
WHO-recommended first-line antibiotics for the treatment of neonatal infections are 
ampicillin and gentamicin. Klebsiella are intrinsically resistant to ampicillin, and the 
average reported gentamicin-resistance rate was 59%. Resistance to the third-
generation cephalosporins, which are second-line treatment, was as high as 87% for 
ceftazidime but nearly 50% lower for more commonly used ceftriaxone. Just over 60% 
of reported S.	 aureus isolates were reportedly resistant to methicillin. Reported GBS 
resistance to gentamicin was 93%; however, resistance to ampicillin was low. 
 
Figure	3.4	Top	5	reported	neonatal	infection	aetiologies	in	sub-Saharan	Africa	by	region	
(1980	–	2016).		
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Table	3.6	Reported	antimicrobial	resistance	in	organisms	causing	neonatal	infections	in	sub-Saharan	Africa		
	 Klebsiella	species	 Escherichia	coli	 Staphylococcus	aureus	 Group	B	Streptococcus	
	 No.	Tested	 No.	Resistant	 No.	Tested	 No.	Resistant	 No.	Tested	 No.	Resistant	 No.	Tested	 No.	Resistant	
Penicillins	             
Ampicillin 582 449 (77% ) 262 221 (84%) 342 266 (78%) 31 8 (26%) 
Amoxicillin a 524 366 (70% ) 191 119 (62%) 429 185 (43%) 20 7 (35%) 
Cloxacillin 67 59 (88% ) 34 30 (88%) 410 259 (63%) - -  
Methicillin - -  - -  45 28 (62%) - -  
Penicillin 73 72 (97%) 30 28 (93%) 264 226 (86%) 153 3 (22%) 
Piperacillin-tazobactam 119 46 (39%) 22 3 (15%) 1 0 (0%) - -  
Cephalosporins	             
Cefotaxime  326 248 (87%) 129 40 (31%) 60 11 (18%) 14 5 (36%) 
Ceftazidime  342 203 (59%) 160 74 (46%) 510 277 (54%) 9 5 (56%) 
Ceftriaxone  337 142 (42%) 180 58 (32%) 638 272 (43%) 10 5 (50%) 
Aminoglycosides	             
Gentamicin 747 439 (59%) 309 125 (40%) 773 203 (26%) 158 147 (93%) 
Amikacin 339 49 (14%) 62 5 (8%) 46 0 (0%) 14 0 (0%) 
Fluoroquinolone	             
Ciprofloxacin 368 113 (31%) 127 32 (25%) 247 42 (17%) 1 0 (0%) 
Carbapenem	             
Imipenem/ Meropenem 256 13 (5%) 71 7 (10%) 9 1 (11%) 1 0 (0%) 
Others	             
Vancomycin 13 12 (92%) 14 14 (100%) 156 26 (17%) 17 1 (6%) 
a Includes Amoxicillin/Clavulanate 
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3.4	Discussion	
This systematic review has shown that aetiology-specific data for neonatal infections 
are challenging to combine and interpret due to the considerable variation in case 
ascertainment, data recording, and reporting. However, the most commonly reported 
bacterial causes of serious neonatal infection from facility-based studies in sSA are, in 
ranked order; S.	aureus, Klebsiella species, and E.	coli.  
Facility-based neonatal infection studies have the advantage of optimising the potential 
for case finding if the majority of births in the study population occur in the hospital, 
increasing the probability of rapid identification of early onset infection; if the majority 
of infants return to the same hospital in a timely manner if they become ill after 
postnatal discharge; and if the hospital is a specialist referral centre to which infants 
born elsewhere are referred if presenting with pSBI.261 In many sub-Saharan African 
countries however, the majority of women still give birth at home without a skilled 
attendant despite progress in scaling up skilled care at delivery.262 Many of these 
newborns die in the community within the first week primarily due to delays in 
recognising problems, deciding to seek care, and in transportation to reach appropriate 
care.  
Few studies clearly distinguished between community-acquired and nosocomial 
infections, which is important as associated pathogens and antimicrobial resistance 
patterns differ according to the source of infection. Developing country hospital 
environments are usually reservoirs of infection with highly drug resistant pathogens; 
hospital-born babies will therefore acquire different pathogens than those born in the 
community.21 Klebsiella species, E.	coli and S.	aureus were reported as major pathogens 
responsible for culture-confirmed neonatal bloodstream infection and meningitis across 
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all regions, with some inter-regional variation. Klebsiella predominated in all regions 
except West Africa where S.	aureus was most predominant. Although Klebsiella can be 
part of the normal maternal gastrointestinal and vaginal flora, the extended spectrum β-
lactamase (ESBL)-producing K.	pneumoniae infections reported in several studies136, 154, 
170, 172, 177, 183, 184 are usually acquired from heavily contaminated hospital environments. 
S.	aureus was most commonly reported across West Africa however, 90% of reported 
cases were from Nigerian studies and it is unclear what proportion of these were 
nosocomial outbreaks. S.	 aureus is both a human commensal and a major cause of 
community and HAIs and usually spread through the hands of health-care providers.82  
Given the context of studies in this review (facility-based studies of predominantly 
facility-born infants), these reported high rates of neonatal Klebsiella and S.	 aureus 
infections in sSA further support the view that the vast majority of infections among 
facility-born neonates in developing countries may be hospital-acquired. 21  
Notable were the inter- and intra-regional differences in the reported occurrence of 
infection due to GBS. The Southern African region recorded the most number of GBS 
isolates (1059), although almost 60% of isolates were reported by 15 studies from 
South Africa130, 171, 172, 174, 175, 177, 179-182, 184, 185, 187-189 where the incidence of invasive GBS 
disease has been shown to vary markedly by province.261 Within the region, GBS was 
also the top reported pathogen in studies from  Malawi165-169 and Zimbabwe;192-194  but 
no single isolate was reported in studies from Namibia170 and Zambia.190, 191 GBS was 
also not reported in studies from Congo,135 Equatorial Guinea,136 Ethiopia,137-146 
Tanzania,155-157, 159-161 Madagascar,153, 154 and Niger.205 This might be explained by the 
small number of eligible studies from these countries (two or less, with the exception of 
Tanzania where there were six studies). The lowest number of isolates overall were 
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reported from West Africa (58). Surprisingly, although Nigeria had the most number of 
published neonatal infection studies overall, only two studies reported isolation of 
GBS.230, 235 These findings may reflect true geographic differences in disease 
epidemiology, empiric antibiotic treatment before referral or operational factors such 
as sampling techniques, blood culturing practices, variability in laboratory capacity, and 
the quality of microbiological investigations.99, 112, 261 In South Africa,263 Kenya264 and 
Malawi,265 GBS serotypes III and Ia cause over 75% of both early and late-onset disease. 
A recent meta-analysis of GBS serotype distribution in sub-Saharan Africa showed that 
serotypes III and Ia contribute over 70% and 90% to the overall serotype distribution 
for early-onset and late-onset GBS disease respectively with serotype III being 
predominant.266 The authors did not report regional differences in serotype distribution 
for invasive disease, possibly due to the paucity of serotype data. 
Few studies have reported the contribution of viruses to neonatal infection morbidity in 
sSA. In a prospective study of viral pneumonia aetiology among infants and children in 
Kenya, Berkley et	 al. reported respiratory syncytial virus (RSV)  as the most common 
cause of neonatal pneumonia with an incidence rate of 2.46 per 1,000 live births.267  
Other reported viruses were; human coronavirus 229E (0.51 per 1,000 live births); 
influenza type A (0.31 per 1,000 live births); parainfluenza virus 3 (0.10 per 1,000 live 
births); adenovirus (0.10 per 1,000 live births); and human metapneumovirus (0.10 per 
1,000 live births). The fact that viruses other than RSV were as common among well 
infants and children and those with mild URTI as among those with severe disease led 
the authors to infer that these make only a minor contribution to the burden of severe 
clinical pneumonia in rural Kenya. In Nigeria, Okuonghae and colleagues268 reported 
RSV infection among 14 out of 56 newborns admitted to a neonatal nursery, with 11 of 
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the 14 cases being nosocomially acquired. Two other studies have reported nosocomial 
outbreaks of viral infection in neonatal units involving RSV269 and adenovirus.270  
Antimicrobial resistance is a global threat and has reached alarming levels in neonatal 
units in developing countries. The reported high rates of resistance of the leading 
pathogens to WHO-recommended first-line antibiotics, with increasing resistance of 
Klebsiella to second-line antibiotics is worrisome for developing countries with limited 
treatment options. Even more worrying is the fact that in places where newer 
alternative antibiotics are available, such as meropenem and piperacillin-tazobactam, 
moderate rates of resistance are already being reported. 
This is the first systematic review of neonatal infection aetiology in sSA, employing a 
comprehensive search strategy with the inclusion of African databases, grey literature, 
and no language restrictions. Another strength of this review is in the assessment of the 
quality of reporting among published studies using the STROBE-NI guidelines. Except 
for differences in the reported occurrence of GBS, these data suggest that the major 
pathogens associated with neonatal infection in sSA are similar within and between 
regions but differ from that observed in neonates in developed regions where GBS, E.	
coli and coagulase-negative staphylococci (CoNS) are the predominant pathogens.73, 79, 
271, 272 Further research would provide a more current picture of aetiological 
distribution and allow for regular guideline updates.  
Aetiology-specific data for neonatal infections are however challenging to combine or 
interpret due to inconsistencies in data recording and reporting.117 This review 
however has several limitations. Excluding studies before 1980 to narrow the literature 
review may have resulted in missing some relevant studies. Noteworthy is the fact that 
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a third (43/136) of studies were based in Nigeria, and there were little or no data for 
other countries with comparable neonatal mortality levels. 
The data showed a wide range of positive blood cultures; several studies had very low 
culture positivity rates, resulting in small numbers of organisms being reported. This 
might be related to different study criteria for doing blood cultures, with selective 
culture of the sickest newborns, or only those with risk factors versus all admissions. 
Nearly all studies were carried out in routine clinical settings where the costs of 
investigations are borne by the parents. In some studies, the inability of several parents 
to pay for the blood cultures (even when the cost had been reduced by half) resulted in 
blood culture not being performed for all the newborns in the study.195 Some studies 
presented considerably larger numbers of isolated organisms than others, thereby 
giving greater weight to their reported aetiological data. The potential to generalise 
results is limited by small sample sizes. 
Case ascertainment was ill-defined across studies and included mixed neonatal 
populations (preterm vs term) with incomplete reporting of pathogens and clinical 
significance of isolates in relation to gestational age and birthweight. The risk of 
infection increases greatly with decreasing birthweight but variables such as gestational 
age, birthweight and level of care provided were not defined in most of the studies. The 
risk of hospital-acquired infections is higher among preterm infants admitted to 
intensive care units due to the use of invasive devices. Another limitation in the data is 
the population representability due to the lack of community-based studies. Infection-
related early neonatal deaths among home-births not presenting to hospital are not 
reflected in facility-based research, especially GBS-related deaths. Research shows that 
the aetiology of neonatal sepsis is continually evolving, and therefore continuing 
86 
 
updating of aetiological data are necessary to inform appropriately targeted 
management and interventions.  
The largest numbers of studies found by this review (n=90) were conducted between 
2011 and 2010 and only 27 studies were relevant to the most recent period of 2011-
2015, although several studies spanned different periods, highlighting the need for new 
research in this area and implying potential issues with the representativeness of data 
presented here particularly with regard to a possible epidemiological evolution in 
aetiology of neonatal infection. This further made it difficult to examine whether the 
introduction of childhood vaccines against Haemophilus	 influenzae type b and 
Streptococcus	pneumoniae may have had effect on aetiology especially as these vaccines 
were deployed at different times across countries in the region. Although these vaccines 
do not have a direct effect on the newborn as they are not given in the neonatal period 
or antenatally to the mother like the tetanus vaccine, the resultant herd immunity may 
potentially have an indirect effect on the newborn.  
Despite decades of literature on neonatal infection aetiology in sSA, burden and risk 
factors, appropriate treatment algorithms and effective interventions are still not well 
understood. The findings from this review further emphasize the need to improve the 
data on neonatal infection aetiology (bacterial, viral and fungal), antimicrobial 
sensitivity and outcomes.117 The recently published Strengthening the Reporting of 
Observational Studies in Epidemiology for Newborn Infection (STROBE-NI) statement 
will improve scientific reporting of observational neonatal infection studies, to increase 
comparability and to strengthen research in this area.117 Future research should focus 
on areas of high disease burden with relative paucity of data. 
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CHAPTER	4.	THE	GAMBIAN	CONTEXT	FOR	SERIOUS	NEONATAL	
INFECTIONS	
	
 
 
 
	
Map	of	The	Gambia	
Source:	https://www.worldofmaps.net/en/africa/map-the-gambia/map-regions-gambia.htm 
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Overview	
The Gambia is the smallest country in mainland Africa extending 400km inland from the 
West African coast along the Gambia River. It is surrounded on three sides by Senegal 
and its entire western extremity is marked by coastline on the Atlantic Ocean.  
Agriculture and tourism are economic foundations for The Gambia, which has a gross 
national income per capita of $US610, half the average for sub-Saharan Africa, with half 
the population under the national poverty line. The population is predominantly 
Muslim, and ethnically there are over a dozen tribes the largest of which are the 
Mandinka and Wollof.  
4.1	Health	service	delivery	
In the public sector, health service delivery is organised into a three-tier system: 
Primary (Village Health Services; VHS), Secondary (minor and major health centres) 
and Tertiary (Hospitals).273  The VHS consist of community health workers traditional 
birth attendants (TBA) and village health workers (VHW) who are often the first point 
of contact between individuals, families and communities within the health system. 
These community health workers are supervised by trained community health nurses 
(CHN). TBAs provide care for pregnant women, conduct normal deliveries, identify and 
refer obstetrics emergencies. The VHWs on the other hand are involved in health 
promotion and prevention measures, the treatment of minor ailments, and refer cases 
beyond their scope of management. The VHS are complemented by the Reproductive 
and Child Health (RCH) trekking visits from the health centres. The RCH package 
includes: antenatal care, child immunization, growth monitoring, registration of births 
and deaths, and limited treatment for sick children.  
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The minor health centre is the unit for the delivery of basic health services including 
basic emergency obstetric care. The national standard for a minor health centre is 20-40 
beds per 15,000 population. The minor health centre is to provide up to 70 percent of 
the Basic Health Care Package need of the population. The major health centre serves as 
the referral point for minor health centres for comprehensive emergency obstetric care 
(surgical, blood transfusion services and further medical care). Additionally, they also 
offer services such as infant welfare and antenatal services, surveillance and dental 
services. The standard bed capacity for major health centres ranges from 110 -150 beds 
per 150,000 - 200,000 population.  
The general and regional hospitals serve as referral points for the Major health centres 
as they provide specialised services. The Edward Francis Small Teaching Hospital 
(EFSTH) also serves as the referral hospital for the general hospitals. There are 
currently 38 minor and 6 major health centres, 5 general hospitals, 1 regional eye 
hospital and a university teaching hospital spread across 8 local government areas and 
43 districts.273 Access to health facilities is relatively good, and over 85% of the 
population live within three kilometres of a primary health-care or outreach health post 
and 97% of the population within five kilometres.274 
4.2	Progress	during	the	era	of	the	Millennium	Development	Goals		
During the era of the Millennium Development Goals (MDGs), considerable progress 
was made in reducing under-five mortality but much less in reducing neonatal mortality 
(Figure 4.2).  Data from the Farafenni Demographic Surveillance System located in a 
rural area on the North Bank region of The Gambia showed a 56% drop in under-five 
mortality between 1992 and 2008 but the corresponding decline in neonatal mortality 
was only 38%.275 Nevertheless, neonatal deaths now account for 45% of under-five 
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mortality compared to 31% in 1990.276 The neonatal mortality rate (NMR) of 30 deaths 
per 1000 live births ranks 8th in descending order among the 18 countries of West 
Africa, and is two and a half times the Sustainable Development Goals (SDGs) target of 
12 neonatal deaths per 1000 live births in 2030. 277   
 
Over the same period, there has been a marked improvement in maternal and child 
health despite high levels of poverty, limited resources and a shortage of adequately and 
appropriately trained staff.278-284 (Table 4.1).  
 
 
Figure	4.1	Trends	in	Under-5	and	neonatal	mortality	in	The	Gambia,	1990-2015.		
 
Data sources: Child Mortality Estimates.  http://www.childmortality.org/; A Promise Renewed Progress Reports 2012 – 
2015. http://www.apromiserenewed.org/publications/ 
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Table	4.1	Maternal,	Newborn	&	Child	Health	in	The	Gambia	
Total population (2015) 1 991 000 
Mothers,	newborns	and	children	  
Annual births (2015) 83 000 
Maternal mortality ratio per 100,000 live births (2015) 706 
Annual number of maternal deaths (2015) 590 
Still birth rate per 1000 total births (2013) 27 
Annual number of stillbirths (2013) 1734 
Neonatal mortality rate per 1000 live births (2015) 30 
Annual number of newborn deaths (2015) 2168 
Neonatal deaths as a proportion of all under-5 deaths (2015) 45% 
Infant mortality rate per 1000 live births (2015) 48 
Annual number of infant deaths (2015) 4000 
Under-5 mortality rate per 1000 live births (2015) 69 
Annual number of under-5 deaths (2015) 6000 
Human	resources	for	health285	  
Physicians density (general and specialist) per 10,000 population (2008) 1.07 
Nursing & Midwifery personnel density per 10,000 population (2008) 8.65 
Coverage	indicators	  
Institutional delivery (women 15 – 49 years who gave births in a health facility; 2015) 63% 
Skilled attendant at birth (doctor, nurse or midwife; 2015) 57% 
Antenatal care coverage – at least 1 visit (2015) 86% 
Antenatal care coverage – at least 4 visits (2015) 78% 
Births by caesarean section (2015) 2% 
Context 
Increasing urban migration with higher urbanized population  
Low literacy rate and high poverty 
1Adapted and updated from Okomo et	al.99 
There is also limited neonatal infection aetiology data for the same period. Although 
pathogens associated with infection in Gambian newborns have been described within 
the context of studies investigating infections in infants and children (Table 4.2), with 
the earliest study in 1999 being part of the first WHO multicentre study of aetiology and 
clinical signs of serious infections in young infants in developing countries,254 no formal 
study on the aetiology of neonatal infections in The Gambia has been conducted to date. 
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Table	4.2	Summary	of	studies	reporting	neonatal	infection	aetiology	in	The	Gambia	(1990	–	2015)	
First	author		
(year)	
Study	
period	
Study	site(s)	 Study	design	and	population	
(neonatal	sub-population	
where	reported)	
Neonatal	isolates	(n)	
Mulholland  
(1999)254 
1990 – 1991, 
1992 
MRC Unit, Fajara 
&  
The Royal 
Victoria 
Hospital, Banjula 
Prospective study of serious infections 
in very young infants (0 – 90 days) 
476 infants investigated for possible 
sepsis (unspecified number of 
neonates < 1 month) 
9	CSF	culture	positive: 
S.	pneumoniae (4), E.	cloacae (2),  
E.	coli (1), Salmonella spp (1),  
GBS (1)  
19	Blood	culture	positive:	
S.	pneumoniae (1), P.	mirabilis (2), 
Enterobacter	spp (1), GBS (1), GAS (1) 
Salmonella spp (4), 
S. aureus (9) 
Palmer  
(1999)255 
1991 - 1994 Royal Victoria 
Hospital, Banjula 
Retrospective case review of 
paediatric meningitis admissions 
420 children with suspected 
meningitis  
(54 neonates < 1 month) 
31	CSF	culture	positive:	
S.	pneumoniae (15), E.	coli (7),  
GAS (1), Hib (1), P.	mirabilis (1), 
Klebsiella spp (1), Coliform (1) 
Salmonella spp (1), GBS (1),	 
E.	cloacae (1), Bacillus spp (1),  
Goetghebuer 
 (2000)286 
1990 - 1995  Retrospective study of prevalence & 
severity of late sequelae after Hib and 
Pneumococcal meningitis. 
257 children with culture-positive 
meningitis. (33 neonates ≤ 1 month) 
33	CSF	culture	positive:	
S.	pneumoniae	(32), Hib (1) 
Le Doare 
 (2016)253 
2014 - 2015  Prospective longitudinal cohort study 
of GBS carriage in mother/infant pairs. 
750 mother/infant pairs (41 neonates 
with signs of systemic infection) 
1	CSF	culture	positive:	
GBS (1) 
Darboe et al 
(Unpublished) 
2005 - 2015 MRC Unit, Fajara Retrospective laboratory surveillance 11	CSF	culture	positive	:	
S.	pneumoniae (6), E.	coli (3),  
S.	aureus (2) 
67	Blood	culture	positive	b	:	
S.	pneumoniae (4), S. aureus (33) 
Proteus	spp (1), GBS (3), E. coli (3), 
Pseudomonas	spp (4), Shigella (1), 
Enterobacter	spp (2), Coliforms (3), 
Acinetobacter (1), Klebsiella spp (11), 
Raoultella	ornithinolytica (1) 
a Now called Edward Francis Small Teaching Hospital 
b Excluding 9 blood culture isolates from my PhD study pilot study patients reported later in this thesis 
In these studies, the most important causes of serious neonatal infections were S.	
pneumoniae, S.	aureus, and E.	coli. With improved maternal and perinatal care over the 
last two decades as well as the introduction of several vaccines (Haemophilus	influenza 
type b and pneumococcal conjugate vaccines), it is possible that the demographics, 
pathogens, and outcome associated with serious neonatal infections in The Gambia have 
changed. The use of novel molecular techniques for diagnosing serious neonatal 
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infections has also not been studied in West Africa, and may provide interesting insight 
into potentially missed bacterial and viral aetiologies. 
Determining the aetiology of serious neonatal infections and identifying acquisition 
pathways, particularly the role of maternal colonisation is an important step towards 
understanding the epidemiology of neonatal infections. This is necessary to inform and 
prioritize appropriate intervention strategies in this setting, such as the decision to 
either target treatment of maternal colonisation, and or prophylactic treatment of 
newborns of high-risk mothers as a means of preventing a significant proportion of 
early-onset serious newborn infections.88 It will also inform the development of 
standardised protocols to improve aseptic practices in the labour rooms, maternity and 
neonatal units, as well as protocols for the management of neonatal infections.  
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CHAPTER	5.	AUDIT	OF	NEONATAL	ADMISSIONS,	QUALITY	OF	CARE	
AND	OUTCOME	AT	THE	GAMBIA’S	TEACHING	HOSPITAL	
The Edward Francis Small Teaching Hospital, Banjul, The Gambia with staff and 
patients at the Neonatal Unit 
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Overview	
Patterns in newborn survival are a sensitive indicator of the functionality of a health 
system and its response to its most vulnerable population.287 In order to be credible, 
referral facilities must be capable of providing appropriate, affordable and quality 
care.288 National facility-based neonatal mortality audits provide a formal assessment of 
inpatient care and are an important source of data to identify gaps in the quality of care 
and therefore, areas for improvement in relation to service delivery and patient 
outcomes.  
5.1	Audit	methods	
5.1.1	Setting	
The Edward Francis Small Teaching Hospital (EFSTH), is the national teaching hospital 
and the only tertiary government referral hospital for health facilities in The Gambia.279 
Built in 1853 and located in the capital city of Banjul, it was originally called the Royal 
Victoria Hospital but was renamed the Royal Victoria Teaching Hospital between 1999 
and 2013, when it became part of the newly founded Faculty of Medicine of 
the University of the Gambia and began providing clinical education for medical 
students. It is the largest hospital in The Gambia, and the maternity unit delivers an 
average of 6000 newborns each year. Until 2016, it was the only hospital in The Gambia 
with neonatal care facilities and is staffed by a neonatologist, two medical officers and 
several house officers. In-house departmental training is occasionally conducted for 
medical and house officers as well as midwives, sometimes in conjunction with visiting 
foreign medical personnel. Trained nurses assisted by nurse attendants provide nursing 
care. There are usually between two and four trained nurses with an equal number of 
nurse attendants during the day (morning and afternoon shifts), and only one trained 
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nurse and one nurse attendant during the night. This distribution is usually maintained 
during weekdays and weekends. 
 
The ward is separated into high- and low-risk areas with the aim of limiting the spread 
of infection, and comprises 31 cots and four functional incubators. Cot occupancy is 
often more than 200% with neonates sharing cots and incubators during peak 
admission periods. Mothers are allowed unrestricted access to the ward for the purpose 
of regular breastfeeding.  
 
Figure	5.1	Staff	at	work	in	the	EFSTH	neonatal	ward	
Figure	5.2	Neonatal	admissions	at	the	EFSTH	neonatal	ward	
A) Preterm neonates sharing the bed under a radiant warmer due to shortage of incubators; B) A 
mother bonding with her preterm infant 
A	 B 
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Care is basic and mostly supportive, consisting of parenteral fluids and medications 
(antibiotics, phenobarbitone, and aminophylline), nasogastric tube feeding, and 
phototherapy. Fluids and medications are given via peripheral intravenous catheter, as 
central venous catheters are not used. Limited respiratory support in the form of 
oxygen administered from electricity-operated oxygen concentrators is available. 
During the period under review, there were only two oxygen concentrators available in 
the ward; using a splitter, up to ten infants can receive oxygen at one time from each 
concentrator. Kangaroo mother care (KMC) is not yet practiced although several staff 
have received the relevant training.  
Microbiology is performed in the main hospital laboratory, but haematology and 
chemical pathology services are provided by the paediatric department’s laboratory 
which is supported by the Medical Research Council (MRC) Unit in The Gambia. Full 
blood count and blood film for malaria parasites are the only laboratory investigations 
available during weekends. Blood glucose is measured on the ward using a glucometer; 
however, the glucometer strips are frequently out of stock. Laboratory sticks for protein 
measurement are not available. Only limited radiological services are available during 
weekends in the hospital. 
5.1.2	Study	design	
This was a retrospective analysis of routine neonatal inpatient data for the period 1 
January 2009 to 31 December 2013.  
5.1.3	Data	collection	
The medical records of neonates admitted during this period were retrieved from the 
Records Department. To determine the completeness of record retrieval, the ward 
admission books were reviewed to establish the total number of admissions for the 
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period, and an exhaustive search was made for all missing records. Data were extracted 
from available records detailing dates of birth, admission and outcome; gender; birth 
and/or admission weight; estimated gestation; mode and place of delivery; antenatal 
care, obstetric complications; maternal HIV status; anti-retroviral administration for 
prevention of mother-to-child transmission (PMTCT) of HIV; tetanus toxoid 
immunization and intermittent preventive treatment for malaria during pregnancy 
(IPTp); investigations and treatment, as well as admission and final diagnoses. Where 
available, gestational age was copied from the antenatal card (this is usually calculated 
from the fundal height, and infrequently from an ultrasound scan), and a few neonates 
were assessed for clinical maturity using the New Ballard Score.  
5.1.4	Definitions	and	outcome	
Diagnoses were mostly clinical. A diagnosis of pSBI or neonatal infectious syndrome 
(sepsis, meningitis or pneumonia) at admission was based respectively, on the presence 
of one or more of the WHO YICSSG diagnostic algorithm criteria8 or physician diagnosis. 
Prematurity was defined as a gestational age of less than 37 completed weeks or a 
birthweight of <1.5 kg when the gestational age was not available. 1.5kg (very low 
birthweight, VLBW) was used as the cut-off as the most likely cause of VLBW is preterm 
birth. Late preterm was defined as a gestational age of 34–36 completed weeks. For 
neonates admitted on the day of birth for which no birth-weight had been documented, 
the admission weight was used as the birth-weight. Where no final diagnoses were 
provided, the admission diagnoses were used.  
The primary outcome was death in the hospital. Age at admission and at death and 
length of hospital stay were calculated from the raw data. Times of admission and of 
death were examined using two different exposure categories. The first was based on 
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whether admission occurred at the weekend (commencing on Friday at 2.00 p.m., when 
weekday work ends, until Monday at 7.59 a.m.) or during the week (Monday 8.00 a.m. 
until Friday 1.59 p.m.). The second exposure category was based on an aggregation of 
the day of the week (weekday vs weekend) and time of the day, defined as on-call duty 
hours (4.00 p.m. to 7.59 a.m. Monday to Thursday or at the weekend) and regular 
working hours (8.00 a.m. to 4.00 p.m. weekdays except Friday when it is 8.00 a.m. to 
1.59 p.m.).  
5.1.5	Statistical	analysis	
All statistical analyses were performed with STATA version 13 (Stata Corp., College 
Station, TX, USA) and statistical significance was defined as alpha 0.05 (two-sided). 
Categorical and continuous variables were summarised, respectively, as percentages 
and median (inter-quartile range). Cross-tabulations with outcome were performed 
using the χ2 statistic for categorical variables. Neonates whose outcome could not be 
ascertained from their hospital records and those who were removed against medical 
advice (or absconded from care) were excluded from further analysis. 
Neonatal characteristics of interest were assessed as risk factors for death using logistic 
regression, adjusting for age, sex and admission weight as potential confounders. Odds 
ratios with accompanying 95% confidence intervals and Wald test P-values (two-tailed) 
for the univariate and multivariable analyses are reported. 
5.2	Results	
Between 1 January 2009 and 31 December 2013 there were 7161 admissions to the 
neonatal ward; medical records for 5285 neonates were recovered from the Records 
Department representing 74% of all admissions for the period under review. The 
proportions of records retrieved by year are shown in Table 5.1. Owing to low records 
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capture, data from 2009 were subsequently excluded from analysis, and the results for 
4944 admissions during 2010–2013 are presented.  
Table	5.1	Annual	neonatal	ward	admissions	and	numbers	of	records	retrieved	
Year Number	of	admissions (ward	register) 
Number of	records	
retrieved 
Records	retrieved	as	a	proportion	
of	admissions 
2009 1,463 341 23% 
2010 1,381 1,117 81% 
2011 1,245 1,048 84% 
2012 1,448 1,429 99% 
2013 1,484 1,350 91% 
Total 7,021 5,285 73% 
	
Characteristics	of	neonates	and	mothers	
The characteristics of admitted neonates are shown below in Table 5.2. The majority 
(64%, 3142/4944) of neonates were facility-born. Birthweight was only recorded for 
67% (3336/4944) of newborns, 50% (1672/3336) of which were <2500g. Of the 1289 
neonates born at <37 completed weeks of gestation, 30% (387/1289) were born 
between 34 and 36 weeks of gestation. 
Respiratory rate was the most commonly recorded vital sign, found in 4525 (92%) of 
case notes; 38% (1729/4525) of newborns had a respiratory rate >60 breaths/minute. 
48% (2282/4413) of newborns whose axillary temperature was documented at 
admission had hypothermia (temperature <36.5°C) and 28% (1310/4413) had fever 
(temperature ≥37.5°C). Hypothermia was more prevalent on admission in neonates 
born at EFSTH than in those born outside (69% vs 46%, P<0.001), and 80% of neonates 
admitted on the day of birth were hypothermic. Nearly two-thirds (62%) of those 
admitted with hypothermia weighed <2500g, and half of these were very small 
(<1500g). The prevalence of hypothermia decreased significantly with increasing 
admission weight: 83% <1500 g, 51% 1500–2499 g and 36% ≥2500 g (P<0.001). Of the 
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3455 neonates with an admission blood glucose measurement, hypoglycaemia (<2.6 
mmol/L) was detected in 666 (19%) and hyperglycaemia (>6.9 mmol/L) in 608 (18%). 
Table	5.2	Characteristics	of	4944	neonatal	inpatients	at	EFSTH,	Banjul	2010–2013	
Categories	 n	 %	
Sex	 	 	
Male 2782 56.3 
Female 2020 40.8 
Unknown/missing 142 2.9 
Age	on	admission	(days)	   
Day of birth 2242 45.4 
2–7 1550 31.3 
≥8 907 18.3 
Unknown/missing 245 5.0 
Gestational	age	(weeks)	   
Preterm, <37 1289 26.1 
Term, 37–42 500 10.1 
Post term, >42 17 0.3 
Unknown 3138 63.5 
Weight	on	admission	(grams)	   
<1500 942 19.1 
1500–2499 1411 28.5 
2500–3999 2347 47.5 
≥4000 148 3.0 
Unknown/missing 96 1.9 
Place	of	delivery	   
Home/Traditional birth attendant  437 8.8 
EFSTH 1590 32.2 
Other health facility 1552 31.4 
Born before arrival 14 0.3 
Unknown/missing 1351 27.3 
Mode	of	delivery	   
Vaginal 3452 69.8 
Caesarean 724 14.7 
Unknown/missing 768 15.5 
Maternal	age	(years)	   
<18 219 4.4 
18–35 2924 59.2 
>35 328 6.6 
Unknown/missing 1473 29.8 
 
Information on maternal antenatal care was documented for 83% (4106) of newborns; 
the majority (62%, 2565/4106) of mothers received antenatal care, of whom 51% 
(1316/2565) attended at least four times. Evidence of maternal HIV screening was 
recorded for 132 (3%) newborns. Of the 132 mothers who were documented to have 
received HIV counselling and testing with or without accessing PMTCT services; 30 
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(23%) were HIV-positive (mostly HIV-1, with only one case of HIV-1 and 2 dual 
infection). Only 11 (37%) of the 30 HIV-exposed newborns received a PMTCT drug 
(nevirapine). The presence or absence of obstetric complications was indicated in 59% 
(2937/4944) of records, most (70%, 2047/2973) of whom had at least one recorded 
complication. 
Clinical	diagnoses		
pSBI accounted for 44% (2166/4944) of admissions, 27% (1340/4944) of 
prematurity/low birthweight (LBW), and 20% of intrapartum-related conditions. 
Characteristics of newborns with pSBI are described further in Table 5. 3. 
Table	5.3	Characteristics	and	clinical	assessment	of	neonates	with	possible	severe	bacterial	
infection	(pSBI)	
Characteristics	 Total	no.	 pSBI	
n	(%)	
Non-pSBI	
n	(%)	
P	
	
Place	of	birth,	n=3593	    	
   Inborn (EFSTH) 1590 379 (28) 1212 (54) 	
   Other hospital facility 1556 715 (53) 851 (38) 	
   Home/TBA 437 249 (19) 188 (8) <0.001 
Mode	of	delivery,	n=4167	  	  	
   Vaginal 3452 1522 (89) 1930 (78) 		
   Caesarean section 724 193 (11) 531 (22) <0.001 
Age	at	admission,	days,	n=4699	     	
   1–3  2242 984 (49) 2313 (87) 		
   4–7 1550 413 (20) 83 (3) 	
   ≥8 907 629 (31) 278 (10) <0.001 
Admission	weight,	g,	n=4848	     	
   <1500 942 187 (9) 756 (28) 	
   1500–2499 1411 643 (31) 768 (28) 	
   ≥2500 2495 1280 (60) 1215 (44) <0.001 
Symptoms/signs*	     
   History of convulsions 393 264 (67) 129 (33) <0.001 
   History of difficulty feeding 2192 1079 (49) 1113 (51) <0.001 
   Fever, temp. ≥37.5°C 1259 1052 (81) 243 (19) <0.001 
   Hypothermia, temp. <36.5°C 2165 455 (21) 1711 (79) <0.001 
   Restlessness/irritability 474 359 (76) 115 (24) <0.001 
   Difficulty breathing  2351 917 (39) 1434 (61) <0.001 
   Lethargy/reduced movement 238 134 (56) 104 (44) <0.001 
* Row percentages 
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Jaundice was documented in 5% (243/4944) of newborns, two of whom had 
kernicterus; however, all were treated as cases of pSBI. Of the 2026 pSBI cases with 
known age on admission, nearly half (984, 49%) were early-onset infections (defined as 
infections within the first 72 hours of life). 
Outcome	
Overall, more than one-third (35%, 1734/4944) of neonates died during admission. 
There was evidence of a trend of increasing case-fatality from 33% in 2010 to 39% in 
2013 (P=0.03). Outcome could not be ascertained for 17 neonates, and 38 neonates 
were taken home against medical advice. These newborns represented 2% of the 
dataset and did not differ significantly from newborns alive and well at discharge with 
regard to the variables of interest, and were excluded from analysis of risk factors for 
mortality. The main causes of death in the unit were complications of pre-term birth, 
serious infections and intra-partum related events (Fig. 5.3A).  
 
Newborns admitted at weekends were more likely to die than those admitted during 
the remainder of the week (38% vs 35%, P=0.03); similarly, the risk of death was 
Figure	5.3	Distribution	of	causes	of	neonatal	death	in	The	Gambia		
A) Data from Edward Francis Small Teaching Hospital, 2010–2013.  
B) WHO/CHERG estimates for causes of neonatal death distribution in The Gambia, 2010–2013 
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greater for those admitted during on-call duty than for those admitted during regular 
working hours (38% vs 33%, P=0.004). 
More than half of all deaths (57%, 989/1734) occurred during the first 48 hours of 
admission. Fifty-four per cent (482/897) of preterm neonates died compared with 38% 
(186/494) of term and 41% (7/17) of post-term neonates (P<0.001). Case fatality was 
associated with lower weight on admission; 58% (539/932) of neonates weighing 
<1500g died compared with 34% (469/1399) of those weighing 1500–2499g, 29% 
(674/2320) of those weighing 2500–3999 g, and 15% (22/144) of those weighing 
≥4000 g (test for trend P<0.001). Of the 1673 deaths with known age at death, 1267 
(76%) were early neonatal deaths (defined as deaths occurring during the first 7 days of 
life), 67% (853/1267) of which occurred during the first 48 hours of life. Risk factors 
for death (excluding newborns who absconded or were taken home against medical 
advice) are presented below in Table 5.4.  
In the multivariable analysis, independent factors for neonatal death were weight 
<1500g on admission (OR 1.61, 95% CI 1.15–2.26), delivery outside EFSTH [at home or 
by a traditional birth attendant (OR 2.17, 95% CI 1.40–3.38), delivery at another health 
facility (OR 1.79, 95% CI 1.34–2.39)], lack of antenatal care (OR 1.68, 95% CI 1.17–2.41), 
hypothermia (OR 2.48, 95% CI 1.76–3.49), hypoglycaemia (OR 1.60, 95% CI 1.19–2.15) 
and hyperglycaemia (OR 1.62, 95% CI 1.19–2.19). 
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Table	5.4	Risk	of	death	among	neonatal	inpatients	2010	–	2013	
Categories	 Dead,	n	 Discharged,	n	 Unadjusted	OR	 P	 Adjusted	OR a	 P	
Sex	       
Male 695 1304 1.04 (0.92–1.17) 0.57 1.06 (0.85–1.34) 0.60 
Female 978 1772 1  1  
Age	on	admission	(days)	       
   Day of birth 996 1225 2.87 (2.40–3.43) <0.001 1.51 (0.93–2.45) 0.09 
   2–7 480 1052 1.61 (1.33–1.95) <0.001 1.27 (0.81–2.00) 0.30 
   ≥8 198 699 1  1  
Admission	weight	(grams)	       
   <1500 539 393 3.35 (2.86–3.92) <0.001 1.61 (1.15–2.26) 0.01 
   1500–2499 469 930 1.23 (1.07–1.42) 0.004 0.86 (0.64–1.14) 0.30 
   2500–3999 674 1646 1  1  
   ≥4000 22 122 0.41 (0.37–0.48) 0.001 0.75 (0.38–1.47) 0.40 
Place	of	birth	       
   Inborn (EFSTH) 529 1046 1  1  
   Other health facility 640 899 1.41 (1.22–1.63) <0.001 1.79 (1.34–2.39) <0.001 
   Home/TBA 180 254 1.40 (1.13–1.74) 0.002 2.17 (1.40–3.38) 0.001 
Mode	of	birth	       
   Vaginal 1325 2081 1  1  
   Caesarean 196 525 0.60 (0.49–0.70) <0.001 0.66 (0.48–0.91) 0.01 
Resuscitation	at	birth	       
   Resuscitated 535 717 1.52 (1.33–1.73) <0.001 1.33 (1.00–1.76) 0.05 
   Not resuscitated 1199 2438 1  1  
Maternal	age	(years)	       
   <18 99 119 1.45 (1.10–1.91) 0.01 1.35 (0.85–2.15) 0.21 
   18–35 1059 1840 1  1  
   >35 110 212 0.90 (0.70–1.15) 0.40 1.08 (0.73–1.58) 0.71 
Maternal	ANC	       
   None 535 978 1.30 (1.07–1.56) 0.01 1.68 (1.17–2.41) 0.01 
   1–4 visits 691 1084 1.51 (1.26–1.81) <0.001 1.15 (0.87–1.51) 0.34 
   >4 228 540 1  1  
Temperature	(°C)	       
   <36.5 966 1178 2.99 (2.50–3.56) <0.001 2.48 (1.76–3.49) <0.001 
   36.5–37.4 203 739 1  1  
   ≥37.5 341 942 1.32 (1.08–1.61) 0.01 1.17 (0.79–1.73) 0.42 
Blood	glucose	(mmol/L)	       
   <2.6 325 336 2.14 (1.79–2.56) <0.001 1.60 (1.19–2.15) 0.002 
   2.6–6.9 673 1490 1  1  
   >6.9 281 320 1.94 (1.62–2.34) <0.001 1.62 (1.19–2.19) 0.002 
Time	of	the	day	       
   Regular work hours 508 1013 1  1  
   On-call hours 
 
1095 
 
1805 
 
1.21 (1.06–1.38) 
 
0.004 
 
0.97 (0.76–1.25) 
 
0.84 
 
a adjusted for all variables in the univariate analysis 
Investigations	
A full blood count result was documented in 841 (17%) of the case notes, and 
haemoglobin concentration was documented in 1020 (21%). Serum bilirubin had been 
estimated in 36 (15%) of the 243 neonates with documented jaundice. Only 5% 
(104/2166) of pSBI cases had had at least one microbiological or radiological 
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investigation: 41 had a chest radiograph, 26 had a blood culture and 43 had a lumbar 
puncture. Two blood cultures were positive for S.	aureus, one for E.	coli and three for 
coagulase-negative staphylococci. All neonates with positive blood cultures recovered 
and were discharged. Only one infant, a 2-day-old home/TBA-born male neonate, had a 
positive cerebrospinal fluid (CSF) culture (Klebsiella species); he received antibiotics for 
25 days but finally died.  
Prescription	of	oxygen,	intravenous	(IV)	fluids,	and	antibiotics		
There were 2559 neonates who, according to their history and examination findings 
(respiratory distress, cyanosis), met the indications for oxygen therapy; however, only 
77% (1965/2559) of those in who needed oxygen were documented to have received it. 
Seventy per cent (3455/4944) of neonates had documentation of receiving IV fluids. 
Antibiotics were the most frequently administered medication, and 94% (4635/4944) 
of neonates received parenteral antibiotics during admission. The majority (65%, 
2995/4635) of these neonates received two antibiotics during admission, 27% 
(1235/4635) received three drugs, 5% (161/4635) received just one, and <1% 
(14/4635) received five or more. Antibiotics are usually provided free of charge by the 
hospital; however, when they are out of stock, parents have to provide them. Ampicillin 
and gentamicin were the most frequently used medications. Among neonates who 
received a single antibiotic, gentamicin was the most commonly administered 
(122/161), followed by ceftriaxone (28/161). Fifty-five per cent (2533/4635) of 
neonates who received antibiotics, lacked clinical evidence of pSBI and did not have any 
diagnostic work-up. The median duration of treatment was 4 days (IQR 2–7, range 0–30 
days) for both pSBI and non-pSBI neonates. Twenty-eight newborns received 
antibiotics for more than 21 days, of whom 50% (14/28) had a diagnosis of pSBI, and 
25% (7/28) had congenital malformations. Ten (36%) of these newborns were also 
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preterm and of low birthweight. Owing to a high case load and limited cot availability, 
most neonates were discharged once clinical improvement was obvious with oral 
antibiotics and advice on danger signs. I did not assess whether choice of fluid, fluid 
volumes, antibiotics, and antibiotic dosage complied with WHO guidelines. 
5.3	Discussion	
This study provides the first comprehensive description of morbidity and mortality and 
quality of care of sick newborns in a tertiary centre in The Gambia. As far as we know, 
this is the largest neonatal inpatient audit published from West Africa, and it provides a 
baseline from which to improve to clinical care and data collection.  
Case fatality in the neonatal unit is higher than reported from similar tertiary referral 
hospitals in West Africa: 7% in Senegal,289 13–20% in Nigeria290-293 and 13–15% in 
Burkina Faso.294, 295 The three most common causes of neonatal deaths in the unit are 
preventable, and are similar to the global and national WHO/Child Health Epidemiology 
Reference Group (CHERG) estimates for The Gambia for the same period296 (Figure 
3.3B) but rank differently. Whereas complications of preterm birth were the major 
cause of death in our unit, the WHO/CHERG estimates show intrapartum-related events 
to be the major cause of death in the country. This difference might be explained by the 
fact that most of the neonates admitted were facility-born and therefore more likely to 
reflect a selected population with obstetric complications, especially preterm birth. The 
risk of death in the unit was greatest on the day of birth and among very small infants. 
Small size at birth – owing to preterm birth or small-for-gestational-age (SGA), or both – 
is the greatest risk factor for most neonatal deaths.287 Globally, antenatal corticosteroids 
have been of great benefit in preventing complications of preterm birth;297 however, 
their use in preterm newborns admitted in the unit was not assessed. The majority of 
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deaths occurred within 48 hours of admission. The inability of health-care facilities to 
provide timely, good-quality care on arrival at hospital is reported to be a leading298 or 
secondary299 cause of in-hospital newborn deaths. Although an increased odd of deaths 
of newborns admitted at the weekend (as well as among those admitted during on-call 
hours, data not shown) was noted, there was a lack of a weekend effect on death in the 
adjusted analysis. Consequently, improved survival of newborns requires fast 
interventions at any time of day or night as the time to death can range from a few 
minutes for the inadequately resuscitated neonate who does not breathe at birth, to an 
hour for the infant suffering a severe hypoxic event, and a few hours for severe early-
onset sepsis.287 All facilities which provide maternity services should at least have a 
functioning mechanical suctioning device and a self-inflating bag and mask. Helping 
Babies Breathe (HBB) is an evidence-based educational programme to teach neonatal 
resuscitation techniques in resource-limited areas, with the goal of having at least one 
person who is skilled in neonatal resuscitation at every birth. Pre-service and in-service 
training curricula should be revised to support implementation of the HBB curriculum. 
As a tertiary referral hospital, EFSTH should in addition ensure that the appropriate 
equipment and expertise for endotracheal intubation are available for severely 
depressed infants.  
The seasonal variation in admissions in our unit mirrors seasonal variations in births in 
EFSTH and nationwide (data not shown). Although seasonal variation is a cardinal 
feature of paediatric diseases in West Africa,300 and accentuates the vulnerability of 
children in poor families, the reasons for it are not known. No seasonal variation was 
observed when stratified by admission weight; however, divergent patterns of 
seasonality have previously been reported in The Gambia for preterm birth and SGA.301 
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In this study, the peaks in prematurity closely paralleled increases in agricultural labour 
(July) and malaria infections (October). The incidence of SGA was highest at the end of 
the annual hungry season, from August to December (peaking in November), and has 
been attributed to seasonal deterioration of nutritional status owing to food shortages, 
and to an increase in agricultural labour which often coincides with seasonal epidemics 
of infectious and parasitic diseases.302 
Almost half of the neonates were admitted with clinical signs compatible with pSBI, and 
half of these presented as “early-onset sepsis” (within the first 3 days of birth). Early-
onset sepsis is usually associated with vertically acquired infection from the birth canal, 
while late-onset sepsis is associated with acquisition from the home or hospital 
environment, particularly through the umbilical cord.82 In developing countries, unclean 
delivery practices and initial care of the infant in hospital contribute to very early-onset 
infections.21 The very high cot occupancy in the unit makes it difficult to isolate infected 
patients. Being the only neonatal referral centre, there is a strict policy not to turn 
patients away, leading to sharing of cots and incubators during peak admission periods. 
Consequently, infection control practices would have been sub-optimal, making it 
difficult to ascribe ‘maternally acquired’ or ‘hospital-acquired’ status to those 
presenting with early-onset neonatal infections.  
There was a striking mismatch of high antibiotic usage and low laboratory 
investigations. Sick neonates do not routinely undergo microbiological investigations, 
mainly owing to an absence of ward protocols, unreliable diagnostic laboratory facilities 
with delayed results, and the general expectation of a ‘negative’ result by attending 
clinicians. The majority of newborns received only ‘first-line’ empirical treatment with 
the WHO-recommended ampicillin and gentamicin; however, many received additional 
110 
 
antibiotics or other regimens including third-generation cephalosporins, and some were 
on treatment for as long as 30 days. In the absence of clinical guidelines, one major 
reason for the widespread use of ampicillin and gentamicin is the fact that the pharmacy 
does not dispense cephalosporins if a consultant has not signed the prescription. Unlike 
culture-proven sepsis, which is treated with a full course of antibiotics on the basis of 
antimicrobial sensitivity, the appropriate duration of treatment for suspected neonatal 
sepsis when cultures are negative or not available is a challenge.303 Prolonged initial 
empirical antibiotic treatment (defined as ≥5 days of initial empirical antibiotic with 
sterile culture results) is associated with an increased risk of an adverse outcome, 
including invasive candidiasis and death, particularly in premature and extremely small 
newborns.304, 305 Moreover, antibiotic costs are not cheap and represent a significant 
proportion of the hospital drug budget. 
Point-of-admission hypothermia was present in 48% of neonates. The prevalence of 
hypothermia on admission among newborns in sSA ranges from 22% to 85%.306-308 
Newborns must be kept warm at birth (at home or in hospital) and, especially, if ill or 
being transferred from home or between hospitals or within a hospital to a neonatal 
care unit. Preterm and small newborns are especially vulnerable, and can rapidly 
become hypothermic, increasing the risk of respiratory distress, hypoglycaemia, 
infections and death. About one-third of the newborns with hypothermia in the unit 
weighed <1500 g, and most were intra-hospital transfers from the maternity unit. 
Despite taking place within the hospital environment, over relatively short distances 
with low apparent risk of complications, intra-hospital transfer can constitute an 
additional risk, especially to pre-term infants.309 Even in high-income settings, hospitals 
without a neonatal transport team and incubator may have significantly more deaths or 
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adverse events in low-birthweight infants with respiratory disease than do comparable 
hospitals with neonatal transport facilities.310 Multi-disciplinary transport teams are, 
however, a luxury in low-income settings. Prevention of hypothermia should commence 
before delivery by ensuring that the place of delivery is warm, and by maintaining a 
‘warm chain’ of procedures at birth and during the hours and days that follow.311 These 
simple, cost-effective procedures include skin-to-skin contact with the mother (KMC) 
during transfer, wearing of hats, and the use of plastic bags/wraps particularly for very 
small and low-birthweight (LBW) newborns, and should be encouraged. KMC is 
particularly suitable when there is a lack of sophisticated equipment such as radiant 
heaters and incubators, and has been shown to substantially reduce mortality among 
clinically stable preterm/LBW infants in hospital.312 It has also been shown to reduce 
the workload on the ward, thereby allowing nursing staff to focus attention on more 
unstable infants.313 Minimal instruction is required and it can also be used in the 
community or at home. The current Gambian health policy framework does not include 
implementation of KMC;273 there is therefore an urgent need to address barriers to 
scaling-up facility-based initiation of KMC in line with the post-2015 newborn health 
research priorities.314 
Hypoglycaemia is an important contributor to hypothermia, particularly among those at 
risk (pre-term or term small-for-gestational-age (SGA) or infant of a diabetic)315 and 
vice-versa: it maintains a vicious circle, which leads to weak sucking, weight loss and 
finally increased mortality. Nearly one-fifth of newborns in the unit were hypoglycaemic 
on admission, compared with one-third in a similar facility in Nigeria.316 Breastfeeding 
prevents hypothermia by warming through the mother, especially by skin-to-skin 
contact, and also by replenishing a newborn’s glucose levels. The Gambian national 
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health policy subscribes to the principles of the Baby-friendly Hospital Initiative to 
implement practices which protect, promote and support breastfeeding.317 Initiation of 
early breast-feeding is, however, difficult in newborns requiring admission, particularly 
if a mother is recovering from anaesthesia following caesarean delivery or is too ill with 
other post-partum complications. Delays in referral and transfer to the neonatal unit 
and establishing intravenous access further contribute to hypoglycaemia in those at 
risk.  
There are several possible reasons for the sub-optimal neonatal care in The Gambia. 
One is the lack of appropriate equipment and trained staff. The level of laboratory 
support in the unit falls short of essential newborn care standards for a district hospital, 
let alone a referral-level hospital.318 Although this deficiency highlights health system 
challenges in the provision of appropriate equipment (e.g. lack of blood culture bottles, 
laboratory reagents and equipment) and appropriately trained personnel (e.g. 
microbiologists and laboratory technicians), it also draws attention to the capabilities of 
the clinicians managing sick newborns as investigations were not requested for most of 
the neonates in whom there was clinical suspicion of infection.  
Poor knowledge and training of neonatal care-providers and a shortage of qualified staff 
are associated with sub-optimal care in developing countries.298, 299 As is the case in 
most other countries with very high maternal and neonatal mortality, The Gambia lacks 
the minimum requirement of 23 doctors, midwives and nurses per 10,000 population to 
provide a basic package of care.319 In 2015 there were 157 Gambian and 479 non-
Gambian medical doctors registered with the Gambian Medical and Dental Council. 
There are also non-registered Cuban, Egyptian and Syrian doctors providing medical 
care as part of bilateral agreements with their respective governments. From inception 
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in 1999 until 2015, 111 indigenous doctors have graduated from the University of The 
Gambia. Upon completion of a 2-year internship programme, the medical officers are 
usually retained at the EFSTH; since January 2014 however, the Ministry of Health has 
been posting medical officers to district hospitals and health centres to serve 
communities. The goal is for 80% of all hospitals and major health facilities to be 
managed by indigenous doctors by 2016. Unfortunately, postgraduate medical training 
is not available in The Gambia and so locally trained doctors lack affordable avenues to 
acquire specialized skills and competencies for neonatal care; the provision of specialist 
neonatal care depends solely on expatriate doctors who also work in EFSTH. Nurses are 
the most accessible health-care providers in The Gambia with more nurses than doctors 
per 1000 people. Basic training for nurses follows either a 2-year track to the level of 
state-enrolled nurse (SEN) or a 3-year track to the level of state-registered nurse (SRN). 
SENs wishing to become SRNs have to undergo an additional 2 years of training. Most 
nurses undergo additional training in midwifery but there is no formal training in 
paediatric or neonatal nursing, and competence is acquired through experience. The 
mix of nursing staff is not regulated, and, in health centres, care-givers might not have 
the necessary competence to provide neonatal care, and may not even be nurses but 
attendants with no clinical training at all. Uncompetitive salaries and benefits have 
resulted in high attrition rates, staff shortages and low motivation which have further 
contributed to the poor quality of care. Urgent systematic attention is required, 
including non-rotation of nurses with skills in neonatal care, and where appropriate, the 
development of a neonatal nurse cadre, as well as rewarding those who work against 
the odds in hard-to-serve areas.320  
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In developed countries, detailed quality-of-care protocols and ‘core nursing skills sets’ 
for almost every aspect of newborn care have improved quality and given more 
responsibility for care to skilled neonatal nurses, particularly with regard to infection 
prevention, feeding support and use of intravenous fluids.321 Hospitals providing 
neonatal care have service standards that take account of the nurse-to-patient ratio 
(maximum number of patients who may be assigned to a nurse during one shift) as well 
as nursing skills, training and development depending on the category of newborn 
care.322, 323 The British Association of Perinatal Medicine’s (BAPM) recommendations 
for neonate-to-nurse ratios for intensive care (IC), high dependency care (HDC) and 
special care (SC) in England are currently 1:1, 2:1 and 4:1, respectively.322 Similar 
recommendations and service standards for essential neonatal care are lacking in The 
Gambia and West Africa, despite studies in Ghana and Nigeria, which have shown that 
levels of nursing staff in a neonatal care unit affect patient outcomes (mortality and 
adverse events), patient experience, and quality as well as efficiency of care delivery.324, 
325 Appropriate nurse-to-patient ratios cannot be generalized because of factors such as 
patient load and characteristics, availability of nurses and work environment; the ratio 
that is sufficient for one unit might be insufficient for another. A nurse-to-patient ratio 
of 1:12.5–1:25 has been reported in the neonatal intensive care unit of a Ghanaian 
teaching hospital.324 WHO has developed a tool for calculating optimal health worker 
levels, known as the Workload Indicators of Staffing Need (WISN). The software 
calculates the number of health workers per cadre, based on health facility workload, 
and provides two indicators to assess staffing: the gap/excess between the current and 
required number of staff, and the WISN ratio, a measure of workload pressure. WISN 
has been used extensively in East and Southern Africa but there are no case studies of 
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its use in West Africa.315-317, 326 Owing to a lack of essential information, the staffing 
requirements for the EFSTH neonatal unit could not be calculated. 
Given the strong emphasis on improving referral pathways and promoting institutional 
delivery for high-risk births as a means of improving neonatal survival, more needs to 
be done to ensure that the EFSTH neonatal unit is suitably equipped and staffed. With 
just over 70,000 births annually, nearly 60% of which take place in health facilities, the 
30-cot EFSTH neonatal unit is grossly inadequate to meet the national need for referral-
level hospital care of sick newborns. As the proportion of neonates delivered in health 
facilities increases, it is necessary to accelerate coverage of essential newborn care. 
Urgent attention needs to be focused on scaling up the provision of appropriate 
packages of newborn care at district hospitals, and possibly major health centres, as 
recommended by the WHO.318 The packages of care with the greatest impact on 
preventing neonatal deaths and stillbirths include care during labour, childbirth and the 
first week of life, and care for the small and sick newborn.327 These packages, the focus 
of the WHO’s Every Newborn	 Action Plan to end preventable deaths, include 
management of preterm births (including the use of antenatal corticosteroids), essential 
newborn care (hygienic care, thermal control, support for breastfeeding and newborn 
resuscitation), interventions to deal with complications arising from preterm birth 
and/or SGA, and neonatal infections (sepsis, meningitis, pneumonia and diarrhoea).327 
Appropriate management of small sick newborns includes extra thermal care and 
support for feeding small or pre-term newborns, including KMC, antibiotic treatment 
for infections and full supportive facility care. Since endorsement of the newborn health 
action plan in 2014, only two West African countries, Ghana and Nigeria, have hosted 
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national newborn events and are in the process of developing their own national 
newborn action plans.328	
Insufficient government funding of the health service, lack of an integrated maternal 
and newborn health policy, and greater investment on addressing maternal rather than 
fetal and newborn outcome are further reasons for sub-optimal neonatal care in The 
Gambia. In 2001, The Gambia and other African Union governments pledged to commit 
at least 15% of their annual budgets to improve the health sector.329 At the end of 2013, 
only two West African countries, Togo and Liberia, had achieved this target.330 In The 
Gambia, priority areas for child health have been scaling-up immunization coverage and 
prevention of deaths from malaria, pneumonia and diarrhoea. It is only in the last 
decade that attention has turned to the contribution of neonatal deaths to child 
mortality.331, 332 The Gambian national health policy for 2012–2020 is focused on 
‘acceleration of quality health services and universal coverage’;273 however, newborn 
survival and health are not specifically addressed. There is therefore an urgent need to 
strengthen newborn health components in existing health sector plans and strategies, 
especially those which relate to reproductive, maternal and child health, as outlined in 
the Every Newborn action plan. 
The study has some limitations. Although data presented are from the main national 
tertiary referral hospital, it cannot be assumed that the findings represent neonatal 
morbidity and mortality in The Gambia as a whole. Furthermore, the results should be 
interpreted in the light of the following. Firstly, this is a retrospective study with data 
abstracted from routine medical records. About 26% of records for the period under 
review could not be located and data were missing for nearly all variables. Secondly, 
poor documentation of medical histories and examination findings, lack of systematic 
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assessment of gestation and possible ascertainment bias at the point of data abstraction 
from written records might have led to misclassification of diagnoses. Furthermore, 
diagnoses were based almost entirely on clinical assessment without laboratory 
support. A report on microbiological aetiology could not be presented as only six 
newborns had positive blood cultures and only one had a positive CSF culture. Lastly, 
poor documentation of care and the implicit assumption that written records reflect 
actual practice might have resulted in bias regarding quality of care.  
This study has provided a comprehensive overview of inpatient care for newborns in 
The Gambia, showing that over one-third of them die, even in the country’s teaching 
hospital. Further operational and research data are required on infections, notably 
regarding aetiologies and antimicrobial resistance. Education and training of health-
care workers, development of guidelines and standards of care, and regular audit are 
necessary for the provision of high-quality neonatal services. Creation of national and 
regional perinatal/neonatal databases for stillbirths, pre-term and very low-birthweight 
infants, as well as those meeting other eligibility requirements, will provide data for 
improving outcomes and increasing the quality, safety and value of newborn care 
through quality improvement collaborations with other countries in the sub-region. 
5.4	Changes	to	the	neonatal	ward	after	the	audit	and	during	the	period	of	the	PhD	
(2014	–	2017)	
The number of incubators increased from 4 to 11, with the addition of 3 radiant 
warmers. The unit also acquired a Bubble-CPAP machine that is, however, used 
sporadically. A KMC unit was opened in July 2017, and several staff from the ward 
underwent refresher training on KMC in preparation for a randomised controlled trial 
of early KMC for mild-to-moderately unstable hospitalised newborns with birth-weight 
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<2000g which commenced in August 2017 (personal communication with the Principal 
Investigator, Dr Helen Brotherton).  
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CHAPTER	6.	CASE	CONTROL	STUDY	OF	NEONATAL	INFECTION	
AETIOLOGY	
 
 
Bactec 9050 Instrument containing innoculated blood 
culture bottles 
Study nurses reviewing participants’ clinical 
record forms 
QuantStudio™ & Flex Real-time PCR 
Instrument for running TaqMan Array Cards 
Study nurse preparing a Case for phlebotomy 
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Overview		
The case-control study was carried out in two phases: a pilot case-control study 
involving 100 newborn-mother pairs, and a larger ‘main’ case-control study involving 
306 newborn-mother pairs. The aim of the pilot study was to test the feasibility and 
practicality of participant recruitment and other study-specific procedures in order to 
inform an appropriate design and sample size estimation for the main study. Other than 
slight differences in the inclusion criteria, participating health facilities, and samples 
collected (Table 6.1), the same methods were used for both pilot and main study. This 
chapter integrates the description of the methods employed in both studies. The study 
design and timelines are summarised in Figures 6.1 and 6.2.  
Table	6.1	Differences	between	the	Pilot	and	Main	Studies	
 Pilot	Study	 Reason	for	choice	 Main	Study	 Reasons	for	modification	
Inclusion 
criteria (Cases): 
admission 
weight 
≥1500g -Concerns regarding 
minimum blood 
sampling volume in 
smaller babies 
≥1000g -Many potentially eligible neonates 
were being excluded 
Site of Case 
recruitment 
EFSTH Neonatal 
Ward 
-The only neonatal 
unit in The Gambia 
-EFSTH Neonatal Ward 
-Kanifing General Hospital 
-Brikama Health Centre 
- To meet recruitment targets.  
- Referrals to EFSTH began to drop 
when these two facilities increased 
their capacity for neonatal inpatient 
care. 
Site of Control 
recruitment 
Polyclinic, Banjul -Nearest EPI Clinic to 
the EFSTH and 
therefore source of 
healthy controls 
Postnatal wards and/EPI 
clinics of the following 
facilities:  
-EFSTH  
-Polyclinic, Banjul 
-Brikama Health Centre 
-Kanifing General Hospital 
-Serekunda Health Centre 
-Fajikunda Health Centre 
-Bundung Maternal and 
Child Health Hospital 
-To make controls more comparable 
with cases in respect to age (In the 
Pilot study, controls were older 
(median 14 days IQR: 9 – 17 days) 
than the cases (median 3 days IQR: 1 
– 10 days). 
-These additional facilities are the 
main ones serving the study area 
Samples: 
Nasopharyngeal 
swabs (NPS) 
NPS collected 
from neonates 
only 
To assess correlation 
between newborn 
nasal and maternal 
genital colonisation  
NPS collected from 
neonates and their mothers 
Maternal NPS included in order to 
assess correlation between newborn 
and maternal nasal colonisation  
Samples: 
Newborn rectal 
swabs 
Not collected  Collected To assess correlation between gut 
colonisation and invasive isolates 
EPI = Expanded Programme on Immunisation; EFSTH = Edward Francis Small Teaching Hospital 
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Case	pair 
(Sick newborns 0 – 27 days of age admitted with possible 
serious bacterial infection at any participating 
government health facility) 
Infant-Mother	Control	pair 
(Healthy newborn 0 – 27 days of age 
recruited from one of 6 participating health 
facilities matched to a case) 
Newborn 
1. Physical examination 
2. Infection work-up: 
-Culture (Blood, CFS, NPS, RS 
-Bacterial/Viral PCR (Blood, NPS) 
-CXR (where clinically indicated) 
Mother 
1. Culture (RVS & NPS) 
2. Risk factor interview 
Mother 
1. Culture (RVS & NPS) 
2. Risk factor interview 
Newborn 
1. Culture (NPS & RS) 
2. Blood (PCR) 
No	organism	
detected 
Culture neg/ 
PCR neg 
Organism	detected 
Culture pos/PCR pos 
Culture pos/PCR neg 
Culture neg/PCR pos 
No 
 pathogen 
Clinically 
significant 
pathogen 
Clinically non-
significant 
pathogen 
Colonised with 
potential pathogen 
1. Blood culture vs Mother RVS 
2. Baby NPS vs Mother RVS 
3. Baby NPS vs Mother NPS 
4. Blood culture vs Baby RS 
[Strain confirmation, Serotyping, ± WGS] 
Compare	proportion	with	and	
without	rectovaginal colonisation 
Bacterial	
isolates 
Figure	6.1	Study	design	for	Pilot	and	Main	Studies	
2017	
Pilot study  
Last participant enrolled 
25th August 2015 
Main study 
Last participant enrolled 4th 
January 2017 
Main study  
First participant enrolled  
11th February 2016 
Molecular work 
completed 
18th March 2017 
Microbiology work 
completed (swabs) 
1st May 2017 
 
Pilot study  
First participant 
enrolled 9th April 2015 
2016	
April	 August	 February	 January	 March	 May	
2015	
Figure	6.2	Timelines	for	Pilot	and	Main	studies	
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6.1	Epidemiological	methods	
6.1.1	Choice	of	study	design	
The ideal study of neonatal infection aetiology would capture all cases of neonatal 
infections in a pre-defined study base (the reference population). The incidence of 
neonatal infection is quite low, even in high burden sub-Saharan African countries 
where it is reported to range from 5.46 – 21 cases per 1000 live births.112 A cohort study 
design therefore would be long and expensive to carry out. The case-control design is 
particularly efficient for outcomes that occur in a small fraction of exposed and 
unexposed individuals because participants are selected on the basis of their disease 
status, thereby permitting identification of adequate numbers of ‘diseased’ individuals, 
as well as not having to recruit/collect data on everyone without the outcome of 
interest.333 The role of controls is to provide valid information on the distribution of 
exposures within the population at risk of becoming a case.334 Identification of cases 
may occur in the community or the hospital; however, the site of identification and 
diagnostic challenges contribute to the likelihood of selection bias. Selection bias for 
cases is present whenever the cases identified are not representative of cases occurring 
in the reference population.  Correct control selection is crucial to the internal validity 
of case-control studies,334-337 and case-control comparisons are likely biased when 
controls are selected from an ill-defined study base and consequently do not represent 
the exposure experience of the true source population. For validity to be high, cases and 
controls must be recruited from the same source populations. This may, but does not 
have to, be the whole population and restrictions can be applied to case recruitment to 
ensure that they come from the same population as the controls, and vice versa. 
For a community- or population-based study of neonatal infection aetiology, the 
primary study base from which cases and controls should be drawn would be all babies 
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aged 0 – 27 days in a defined area. Ideally, the “cases” in the population would be all 
newborns within the base who develop symptoms and signs suggestive of pSBI, and 
“controls” would be all healthy newborns in the same primary study base. Defining the 
population and the complete ascertainment of all cases who meet the eligibility criteria 
arising from the study base would be challenging in the absence of a demographic 
health surveillance system or registry of all births in the area.338 Population-based 
identification of acute conditions such as neonatal infections can only be achieved with 
intense community surveillance, and most population-based case-control studies will 
not recruit all cases in the population, even if they try to. A second challenge would be 
the set-up of an appropriate strategy for sampling and evaluation of controls from the 
study base. Usually for studies of this kind, a large proportion of cases and a small 
proportion of available controls are evaluated. Selection bias is avoided when equal 
sampling fractions are achieved for exposed and non-exposed cases as well as for 
exposed and non-exposed controls, so that both cases and controls represent the 
exposure experience of their source populations, within strata that will be used for 
stratification in the analysis.335 Therefore, while the population-based approach is 
preferred because it is less prone to bias from factors that may have influenced the 
access to care such as the choice of a particular health facility or physician, the logistical 
and cost considerations make it impractical in most instances.333  
Hospital-based studies differ from population-based studies in that the study base is 
defined secondarily to the identification of cases. Cases are usually selected regardless 
of the population from which they arise (e.g. all cases from a given hospital that receive 
patients from different settings), although it is possible to place restrictions on who is 
recruited for example restricting recruitment to patients who reside in a defined 
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geographical area. An effort is then made to identify the study base corresponding to the 
selected cases in order to define the population from which the controls are to be 
selected.338 Several sources of bias may be present with hospital-based studies. 
Presentation at a health facility is influenced by health-seeking behaviour, access to care 
and resources with the potential for under-representation of cases that are distant from 
the hospital and over-representation of those with the resources to get there. Access to 
hospital care is also influenced by survival. Bias towards selection of survivors is 
inherent in hospital-based neonatal infection aetiology studies in developing countries 
where most neonatal births and deaths occur at home.331 However, compared with 
population-based studies, hospital-based studies are more practical and relatively 
inexpensive as procedures for both case and control selection and evaluation tend to be 
logistically less demanding.333  
With the exception of MRC-led malaria and vaccine surveillance (Haemophilus	
influenzae type b339 and Streptococcus pneumoniae340 vaccines) no intensive 
community-level disease surveillance exists in The Gambia. Consequently, health 
facilities are the most appropriate places to identify cases of severe paediatric illness.  In 
The Gambia, 63% of births take place in a health facility and 37% occur at home.279 In 
addition, births in urban areas are substantially more likely to be delivered at a health 
facility than those in rural areas (83% versus 44%). Given these considerations a 
hospital-based case-control study design with measures to minimise biases, was judged 
most appropriate to answer the questions posed within the bounds of the time and 
resources available in the context of this doctoral work.  While such a study cannot 
definitively establish all pathogens associated with neonatal infection in the study area, 
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it can potentially generate the much-needed evidence required to justify undertaking 
intervention trials including maternal vaccination. 
6.1.2	Study	setting	and	choice	of	facilities	
The study was conducted in the Western Health Region of The Gambia where 58% of 
the population reside279 (Figure 6.3). 
 
The region comprises three local government areas served by 13 government health 
facilities. An estimated 75% - 93% of women in the region deliver in a health facility, 
and the regional neonatal mortality rate is estimated at 24 – 27 deaths per 1000 live 
births.279 The EFSTH is the main referral hospital for the region and close to 70% of 
outborn neonates referred to the neonatal unit were delivered at the following five 
government health facilities: Kanifing General Hospital, and Bundung Maternal and 
Child Health Hospital, Brikama, Fajikunda, and Serekunda Health Centres.99  With the 
Figure	6.3	Map	of	study	area	showing	study	sites	(Hospitals	and	Health	Centres)	
Image sources : Public Domain, https://commons.wikimedia.org/w/index.php?curid=15379602 
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exception of Kanifing General Hospital and the EFSTH, these other facilities also run 
Expanded Programme on Immunization (EPI) clinics (the EFSTH provides EPI services 
through its Polyclinic, while Kanifing General Hospital provides EPI services through 
Serekunda Health Centre). These were the considerations for selection of these facilities 
as study sites  
6.1.3	Entry	criteria	and	definitions	
Selection	and	enrolment	of	cases	
Cases were recruited from EFSTH, Kanifing General Hospital and Brikama Major Health 
Centre. Up until 2015 when the Pilot study was conducted, the EFSTH was the only 
facility providing neonatal inpatient care. By the end of that year Kanifing General 
Hospital and Brikama Health Centre had increased their capacity for limited inpatient 
care of neonates with suspected infection. This resulted in reduced neonatal sepsis 
referrals to the EFSTH and necessitated the inclusion of these additional facilities as 
sites for the recruitment of cases during the main study. Potentially eligible newborns 
and their caregivers were screened at the point of admission by a study nurse. A 
newborn was enrolled as a case of suspected infection if all of the eligibility criteria and 
none of the exclusion criteria in Table 6.2 were met. 
Table	6.2	Case	enrolment	criteria		
Eligibility	criteria	 Exclusion	criteria	
1. Sick neonate presenting for admission with one or more 
clinical signs of possible serious bacterial infection 
(pSBI) 
2. Postnatal age 0 - 27 days 
3. Admission weight ≥1000g (≥1500g in pilot study) 
4. Mother is normally resident in the Western Health 
Region 
5. Mother attended antenatal care at any health facility 
(irrespective of location) 
6. Parental/Caregiver written informed consent given 
1. Already enrolled in another research study 
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The criteria for definition of pSBI used in this study (Table 6.3) were modified from the 
YICSSG8 and in keeping with definitions used in other neonatal infection studies: clinical 
trials of home-based simplified antibiotic regimens (African Neonatal Sepsis Trial 
(AFRINEST)341 and The Simplified Antibiotic Therapy Trials (SATT) in Bangladesh342 
and Pakistan343), and the Aetiology of Neonatal Infections in South Asia (ANISA) 
study.344 Definitions of clinical signs are provided in Appendix 4 
Table	6.3	Comparison	of	definitions	of	possible	serious	bacterial	infection	used	in	this	PhD	
study	and	other	studies	of	neonatal	infection	treatment	and	aetiology	
WHO	YICSSG	Study	 My	PhD	Study	a	 AFRINEST/SATT	Clinical	Trials	a	 ANISA	Study	a	
History of convulsion History of or	observed	
convulsion 
Excluded because home-based 
treatment is felt to be potentially unsafe 
for this group 
History of or	observed	
convulsion 
Fast breathing  
(respiratory rate 
≥60/min) 
Fast breathing (respiratory 
rate ≥60/min on	repeat	
count) only	if	>	3	days	
postnatal	age 
Excluded to increase specificity of 
diagnosis (data from previous studies 
in Bangladesh suggests that this sign 
alone is not predictive of severe illness) 
Fast breathing (respiratory 
rate ≥60/min on	repeat	
count) 
Severe chest in-drawing Severe chest in-drawing Severe chest in-drawing Severe chest in-drawing 
Axillary temperature 
>37.5°C 
Axillary temperature 
≥38°C	(confirmed	by	a	
second	reading) 
Axillary temperature ≥38°C;	
confirmed	by	a	second	reading 
(Cut-off increased to increase 
specificity of diagnosis) 
Axillary temperature ≥38°C	
(confirmed	by	a	second	
reading) 
Axillary temperature 
<35.5°C 
Axillary temperature 
≤35.5°C (confirmed	by	a	
second	reading)	
Axillary temperature ≤35.5°C 
(confirmed	by	a	second	reading) 
Axillary temperature 
≤35.5°C (confirmed	by	a	
second	reading)	
Lethargic or less than 
normal movement 
Movement only when 
stimulated (lethargy) or no 
movement at all 
(unconscious) 
Lethargic (movement only with 
stimulation) 
 
Movement only when 
stimulated or no movement 
at all 
History of feeding 
problems   
History of not feeding well,	
confirmed	by	feeding	
assessment	
Not	feeding	well	on	observation	
(confirmed	by	poor	suck	on	
examination	in	SATT	Bangladesh)	
History of not feeding well,	
confirmed	by	feeding	
assessment	
a Text in bold red indicate differences between individual study criteria and the original WHO criteria 
Selection	and	enrolment	of	controls	
When cases are ascertained from hospitals serving a defined geographic area, and 
where a list of the population exists, a probability sample of unaffected individuals from 
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the population of that geographic region can be selected as controls to enhance the 
likelihood that cases and controls come from the same source population. This is more 
challenging when such a list does not exist, and a concern with this approach is that 
population controls sampled from a convenient population register may not be 
representative of the true population at risk of being a member of a hospital case series; 
population controls may also lack comparability in recruitment fraction and recall of 
information.334-337, 345 But there are also concerns that hospital controls, especially those 
with other diseases, may fail to provide an unbiased sample of the population at risk 
with respect to exposure status. The options for selection of a control group along with 
the strengths and weaknesses of each option when subjected to the classic tests, are 
detailed in Table 6.4  
Taking into consideration the strengths, weaknesses, and practicalities of the different 
control groups, the decision was made to match controls to cases on neighbourhood 
using the EPI clinic location/coverage as a proxy for neighbourhood. For each enrolled 
case, the mother was asked to indicate which of the six participating EPI clinics she 
would normally take her baby to for their first infant vaccination.  The Gambian EPI 
schedule requires that all newborns receive BCG (Bacille Calmette-Guerin), HepB 
(Hepatitis B) and OPV (oral polio) vaccines at birth or shortly thereafter.346 Recent data 
shown that in the urban sections of the study area, the median age at BCG vaccination is 
just less than 2 weeks.346 A control was then recruited from among newborns brought 
to the aforementioned EPI clinic as follows: study nurses would screen successive 
mothers waiting at the EPI clinic until an eligible mother-newborn pair was identified 
and recruited.  To ensure that cases and controls were similar in age, where a case was 
enrolled within the first week of life, the matched control would be recruited from the 
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postnatal ward of the health facility where the EPI clinic is located. For this study 
recruiting one control for each case was operationally simpler and less expensive than 
recruiting multiple controls of any one type.  As it was anticipated that obtaining the 
required number of cases to meet the sample size requirements of the study would be 
feasible multiple controls were not needed.347 
Table	6.4	Options	for	selection	of	control	groups	for	the	hospital-based	neonatal	infection	case-control	
study	
Site	&	description	 Control	test	b	 Case	test	c	 Comments	
Neonatal	ward:	
Non-infection/sepsis 
admissions 
Yes, likely to be 
detected 
Yes, likely to be 
detected 
Strengths:  
- logistically convenient 
Weaknesses:  
- The baby is by definition ill. Diseased ( ill) controls may not have the 
same exposure distribution as the wider population of non-cases 
Post-natal	ward:	
Healthy newborns 
awaiting maternal 
discharge 
Yes, likely to be 
detected 
Yes, likely to be 
detected 
Strengths:  
- logistically convenient 
Weaknesses:  
- This control group is biased in favour of facility- born babies; 
- The median postnatal age of this control group would be 0 days 
(lower than that of cases presenting after the day of birth) 
EPI	clinics:	
Healthy newborns	a 
Yes, likely to be 
detected 
Yes, likely to be 
detected 
Strengths: 
- Clear case versus non-case boundaries; better recall of maternal and 
some neonatal risk factors.  
Weaknesses:  
- The median postnatal age of this control group would be older that 
cases 
Neighbourhood	of	
the	case:	
Random sample of all 
healthy newborns in 
the neighbourhood	
Uncertain: 
Might not get to 
the health centre 
or hospital clinic 
and may die at 
home 
Yes, same chance 
of being detected 
as other non-
cases 
Strengths: 
- Representative of all non-sepsis neonates from the same populations 
as the case reference population.  
- potentially controls for difficult to measure confounders, e.g. 
environmental factors 
Weaknesses:  
- Theoretically and logistically difficult in the absence of a well-
established demographic surveillance system that records all births.	
Neighbourhood	of	
the	case:	
Healthy newborns in 
the neighbourhood 
matched to cases on 
age/facility of birth 
Problem: Might 
not get to the 
health centre or 
hospital clinic 
and may die at 
home 
Probably; 
dependent on 
health-seeking 
behaviour of 
mother. 
Strengths: 
- May identify more home-born babies 
- potentially controls for difficult to measure confounders, e.g. 
environmental factors 
Weaknesses: 
- Logistically inconvenient;  
- Will prevent examination of neighbourhood as a potential risk factor 
a	For some babies, BCG, HepB and OPV0 (meant to be taken at or shortly after birth) are taken any time after the age of 7 days (when the 
naming ceremony occurs) 
b	Control Test: would a control, having developed the disease under study, be identified and recruited as a case? 
c Case Test: if someone identified in the study as a case were in fact to not have the disease under study would they have the same chance 
as other non-cases of being recruited as a control? 
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Potentially eligible newborns and their caregivers were screened at the EPI clinic (prior 
to vaccination) or the postnatal ward by a study nurse. A newborn was enrolled as a 
control if all of the eligibility criteria and none of the exclusion criteria in Table 4.5 were 
met.  
Table	6.5	Control	enrolment	criteria		
Eligibility	criteria	 Exclusion	criteria	
1. Healthy neonate with no clinical signs of infection 
on the postnatal ward OR presenting for vaccination 
at a participating EPI clinic  
2. Postnatal age 0 - 27 days 
3. Mother is normally resident in the Western Health 
Region 
4. Mother attended antenatal care at any health facility 
(irrespective of location) 
5. Parental/Caregiver written informed consent given 
1.   Already enrolled in another research study 
 
6.1.4	Follow-up	and	change	in	status	during	the	study	
All enrolled newborns were followed up on day 27 to determine final outcome. All 
mothers were encouraged to report to the study nurses any concerns or clinical signs of 
illness in the newborn as it was anticipated that some of the controls might develop 
serious infection within the period of follow-up.  
6.1.5	Sample	size	and	analysis	plan	
The basis for the sample size calculation for this study was to detect a difference in 
maternal recto-vaginal colonisation with the main organisms associated with serious 
neonatal infections (Klebsiella species, E.	 coli, S.	 aureus and GBS) between cases and 
controls. Klebsiella species, and S.	aureus were identified as causes of neonatal infection 
in the pilot study while E.	coli and GBS, although not identified in the pilot, are known 
causes of neonatal infections in the study area.348 Data obtained from recent studies of 
maternal carriage in The Gambia show that at least 20% of women in the population are 
colonised with either GBS253 or S.aureus. (A. Roca, personal communication) A total 
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sample size of 300 mothers (150 mothers of sick newborns (Cases) and mothers of 150 
mothers of healthy newborns (Controls) would have 80% power to detect a 30% 
absolute difference in maternal colonisation between the two groups at 5% significance 
level.  
Statistical analyses were carried out using STATA version 13 (Stata Corp, Texas). 
Descriptive statistics reported include the prevalence and aetiology of culture-
confirmed bacterial infection as well as the prevalence and aetiology of nasopharyngeal 
and rectal colonisation in Cases. The frequency of detection of concordant newborn 
blood and maternal rectovaginal isolates were calculated. In a secondary analyses, 
concordance rates were examined in early and late-onset infection. The prevalence of 
maternal rectovaginal colonisation with any of GBS, E.	coli,	S.	aureus or Klebsiella species 
between matched Case-Control pairs was compared by the McNemar test for paired 
data, reporting odds ratios and 95% confidence intervals.  
6.1.6	Study	procedures	
Cases	
At recruitment, each Case had a clinical assessment followed by laboratory work-up for 
infection comprising cultures of blood, cerebrospinal fluid (CSF), nasopharyngeal and 
rectal swabs. C-reactive protein (CRP) is not measured by the MRCG or EFSTH 
laboratories and was therefore not part of the infection work-up. Newborn and 
maternal samples were collected following detailed study-specific standard operating 
procedures (Appendix 5).  
• Blood:	 -	 Blood samples were collected, whenever possible, before the 
commencement of antibiotics and in the following sequence: Up to 3ml of venous 
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blood was collected and divided into 2 aliquots for culture and molecular 
diagnostic assay as shown in Table 6.6.  
Table	6.6	Blood	sample	volumes	
Blood	volume	
obtained	
Blood	culture		
(BACTEC	Peds	Plus™/F	culture	bottle)	
Molecular	diagnostics		
(K2EDTA	microtainer)	
0.5 ml– 1.0 ml Full volume (venpuncture repeated if <1.0ml) Nil (venepuncture repeated if possible) 
>1.0 ml– 2.0 ml 1.0ml – 1.5 ml 0.5 ml (venepuncture repeated if sample insufficient) 
>2.0 ml >1.0ml 0.5 ml 
 
Culture samples were collected using a strict no-touch aseptic technique as 
follows: once a suitable peripheral vein was chosen, the overlying skin was 
cleaned with 70% alcohol and allowed to dry for 30 seconds after which the 
same area was cleaned with 10% povidone iodine and allowed to dry for 60 
seconds. Once the skin was completely dry, blood was drawn from the vein 
taking absolute care not to touch the cleaned site. Only one blood culture bottle 
was routinely drawn for each Case. Blood culture bottles were not weighed 
before or after addition of the blood sample. Inoculated BACTEC	Peds Plus™/F 
culture vials were placed in a designated incubator in the neonatal ward set at 
37°C and transported to the MRCG Clinical Microbiology Laboratory before the 
close of work each day (within 6 hours of collection). Incubator temperature was 
monitored twice daily by study nurses and culture bottles were checked for 
validity. Blood cultures collected after hours were also placed in the same 
incubator, and transported to the MRCG Clinical Microbiology Laboratory as 
early as possible the following morning. Blood samples for molecular testing 
were put in a cold box before transfer to the Biobank at the MRCG within 6 hours 
of collection for storage at -70°C until tested. Samples collected after hours were 
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stored temporarily at -20°C in a designated sample freezer in the research study 
office, then transported to the MRCG Biobank as early as possible the following 
morning for storage at -70°C until tested. 
• Cerebrospinal	fluid	(CSF):	CSF samples were only collected from neonates with 
suspected meningitis where there were no contra-indications to do so, and only 
during working hours. Up to 2ml of CSF were collected and aliquoted for culture 
and biochemistry. Aliquots for microbiology and biochemistry were transported 
within 1 hour of collection to the respective clinical laboratories at the MRCG.  
• Nasopharyngeal	 (NPS),	 rectovaginal	 (RVS)	and	 rectal	 swabs	 (RS):	Two NPS 
and RS samples were collected from each newborn, while two NPS and two RVS 
samples were collected from each mother all using Copan flocked swabs™. Upon 
collection, swabs were immediately placed into vials containing Skim-milk 
Tryptone-Glucose-Glycerol (STGG) transport medium and put in a cold box 
before transfer to the MRCG.  One of each swab was used for microbiological 
culture (Clinical Microbiology Laboratory); the second newborn NPS was used 
for molecular detection of pathogens while other swabs were biobanked for 
future molecular work. Swabs for molecular testing were for stored at -70°C 
until tested. Samples collected after hours were stored temporarily at -20°C in a 
designated freezer in the research study office, then transported as early as 
possible the following morning to the Clinical Microbiology Laboratory (culture 
samples) or Biobank (molecular detection samples) for storage at -70°C until 
tested. 
Clinical	care:	Each case received the routine antibiotics currently used to treat serious 
neonatal infections at the respective facility of recruitment according to the discretion 
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of the attending physician; usually ampicillin (and cloxacillin where there is 
suspected/confirmed Staphylococcal infection), and gentamicin or ceftriaxone, 
according to the WHO pocket book of hospital care for children dosing guidelines (Table 
6.7) which are used in health facilities in The Gambia. 
Table	6.7	Antibiotic	dosing	for	serious	neonatal	infections	in	Gambian	health	facilities	
Antibiotic	 Dose	 Frequency	 Route	 Duration	
  <	7	days	of	age	 ≥	7	days	of	age	   
I.	Sepsis	or	pneumonia	
Ampicillin 50mg/kg/dose 12 hourly 8 hourly IV or IM 7 – 10 days 
Cloxacillin 50mg/kg/dose 12 hourly 8 hourly IV 7 – 10 days 
Gentamicin 2.5mg/kg/dose 12 hourly 8 hourly IV or IM 7 – 10 days 
Ceftriaxone 100mg/kg/dose daily daily IV 7 – 10 days 
II.	Meningitis	
Ampicillin 100mg/kg/dose 12 hourly 8 hourly IV  21 days 
Gentamicin 2.5mg/kg/dose 12 hourly 8 hourly IV 21 days 
Ceftriaxone 100mg/kg/dose daily daily IV 21 days 
IV= intravenous; IM=intramuscular 
The results of microbiological culture were made available in real time to the staff at 
each recruiting facility in order to inform patient care. For each patient the final 
diagnosis (sepsis, meningitis) was determined by the gold standard (cultures of blood 
and CSF). Pneumonia was diagnosed clinically and whenever possible, radiologically 
(chest X-ray).  
Controls		
To guide the interpretation of molecular aetiology results and understand the clinical 
significance of specific pathogens, similar samples were also collected from healthy 
newborn controls (nasopharyngeal and rectal swabs) and their mothers 
(nasopharyngeal and rectovaginal swabs). There was however, no clinical justification 
to collect blood culture samples from healthy babies and only 0.5 mls of venous blood 
was collected for molecular diagnostic tests. Samples were transported, processed and 
stored using the same procedures as that of cases. 
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6.1.7	Ethical	approval	
This study was considered and approved by the MRC Scientific Coordinating Committee 
and the Gambian Government/MRC Joint Ethics Committee (SCC 1384 – see Appendix 
6). It was also approved by the LSHTM Observational/ Interventions Research Ethics 
Committee (LSHTM Ethics Reference: 8622 – see Appendix 7).  
6.2	Laboratory	methods	
The laboratory analysis of samples collected during this study was carried out by 
others. I visited the laboratory and field sites of the ANISA study in Bangladesh before 
the start of the Pilot study, to familiarise myself with the flow of samples for the 
molecular diagnostic assays from collection to processing. The customized TACs (20 
Respiratory and 20 Blood cards) used for the pilot study molecular assays were 
provided courtesy of Professor Samir Saha, Principal Investigator of the ANISA Study, 
Child Health Research Foundation, Dhaka, Bangladesh. I spent further time at the MRC 
Clinical Microbiology and Molecular diagnostics laboratories to familiarise myself with 
sample processing and learn about quality control.  
The TAC experiments were done by Mrs. Awa L. Mendy and supervised by Dr Muna 
Affara, Mr. Sheikh Jarju and Dr Kirsty Le Doare (Imperial College, London). I checked all 
data for integrity and carried out the analyses of the output from the TAC experiments 
with the support of Dr Kirsty Le Doare (Imperial College, London), and Drs Maureen 
Diaz and Jonas Winchell (Centers for Disease Control and Prevention, Atlanta, Georgia, 
USA).  
Microbiology samples were processed by Mr. Buntung Ceesay, Mr. Ngange Kebbeh, Mr. 
Frank Thornton-Wood, Miss Shuling Appleby, Miss. Awa L. Mendy, and supervised by 
Mrs. Saffiatou Darboe. Some of the consumables used for the microbiology work were 
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provided courtesy of Dr Kirsty Le Doare and funded from her Thrasher Award 
(BK1350). 
6.2.1	Sample	processing	
All clinical samples were processed at the MRCG Fajara Field Station laboratories. The 
MRCG Laboratories consist of the ‘Clinical laboratories’ (microbiology, haematology and 
biochemistry/immunochemistry), and the ‘Research laboratories’ (TB diagnostics, 
serology and molecular diagnostics). The Clinical laboratories are located in the Clinical 
Services Department, and process samples from outpatients, inpatients, patients from 
peripheral health care facilities as well as samples from participants in MRCG research 
studies.  
The Clinical laboratories are accredited to the international quality standard for the 
quality and competence of medical laboratories (ISO15189) with regular quality control 
monitoring by assessment by The Kenya Accreditation Service in accordance with 
international quality systems for laboratories. The laboratories are also certified 
compliant with the Good Clinical Laboratory Practice (GCLP) standard,349 as published 
by the British Association of Research Quality Assurance (BARQA), 2003.350 The GCLP 
accreditation scheme involves the assessment of a clinical laboratory which undertakes 
the analysis of samples from clinical trials. Certification of compliance demonstrates to 
sponsors of clinical trials worldwide that the clinical laboratories operate to a standard 
that assures the reliability, quality and integrity of the work and results generated. The 
MRCG Research Laboratories, are also one of the WHO Regional Reference Laboratories 
for Invasive Bacterial Vaccine Preventable Diseases.  
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The flow of samples in both the pilot and main studies, and their processing is 
summarised below in Figure 6.4. The methods for specimen processing and testing 
were same for cases and controls. 
 
6.2.2	Microbiological	methods	
Blood	cultures	
All blood cultures were processed using BACTEC Peds Plus /F bottles and BACTEC 9050 
fluorescent series instrument (Becton Dickinson, Temse, Belgium).  The BD BACTEC 
Figure	6.4	Flow	chart	of	sample	collection	and	processing	
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Peds Plus /F medium is an enriched soybean-casein digest resin-containing broth for 
the qualitative culture and recovery of aerobic microorganisms (mainly bacteria and 
yeast) from blood samples which are generally less than 5 ml in volume. Each vial 
contains 40 ml of broth. The medium also contains an anticoagulant, Sodium 
polyanetholesulfonate (SPS) that inhibits bacteriocidal activities in the blood. The resins 
serve to neutralize a wide variety of antibiotics, allowing growth of microorganisms that 
may not occur with conventional media and thereby enhancing the recovery of 
organisms among patients under antibiotic treatment.  
Inoculated vials were inserted into the BACTEC 9050 fluorescent series instrument 
(Becton Dickinson, Temse, Belgium) for incubation, agitation, and periodic 
measurement. Each vial contains a chemical sensor that can detect increases in CO2 
produced by the growth of microorganisms. When microorganisms are present in the 
blood sample, they metabolize nutrients in the culture medium, releasing CO2 into the 
medium. A dye in the sensor reacts with the CO2, modulating the amount of light that is 
absorbed by the fluorescent material in the sensor. The instrument’s photo detectors 
monitor the sensor every ten minutes for an increase in its fluorescence and measure 
the level of fluorescence, which is proportional to the amount of CO2 present. 
Algorithms resident in the instrument rack’s microprocessor determine the positivity of 
a vial. The algorithms use the rate of CO2 production as well as the absolute increase in 
CO2 to interpret the data. A positive reading indicates the presumptive presence of 
viable microorganisms in the vial. Detection is limited to microorganisms that will grow 
in a particular type of culture medium. Culture vials flagged as presumptively positive 
were removed from the instrument for sub-culture, Gram-stain, and identification. For 
each positive vial, sub-cultures were carried out on solid media: blood agar (aerobic and 
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anaerobic), chocolate agar and MacConkey agar. Identification was by means of cultural 
morphology, biochemical test kits (BioMerieux Analytical Profile Index (API), API 20 E™ 
API 20 NE, API NH) and serological agglutination as appropriate for the pathogen. 
Culture vials that did not flag as positive remained in the instrument for five days 
(according to the manufacturer’s test protocol) after which negative vials were 
discarded. 
Clinical	significance	of	blood	culture	isolates	
The list of pathogens associated with infection in the newborn is diverse and varies 
geographically.6, 21, 22, 80  Many of the bacterial pathogens are also skin flora or colonisers 
of mucosal surfaces, and may ‘contaminate’ blood culture bottles during phlebotomy, 
inoculation of blood culture bottles and processing of samples and culture plates 
thereby leading to false-positive results.259 The clinical significance of organisms 
detected by blood culture is listed in Table 6.8.  
Table	6.8	Clinical	significance	of	bacteria	detected	by	blood	culture	
Clinically	significant	organisms	 	 Clinically	non-significant	organisms	
Acinetobacter species 
Citrobacter species 
Enterobacter species 
Enterococcus species 
Escherichia coli 
Group A Streptococcus 
Group B Streptococcus 
Group D Streptococcus 
Klebsiella pneumoniae 
Proteus mirabilis 
Pseudomonas aeruginosa 
Salmonella species 
Serratia marcescens 
Staphylococcus aureus 
Streptococcus pneumoniae 
 Bacillus species  
Coagulase negative staphylococci 
Diphtheroids 
Micrococcus species 
Propionibacterium species 
Viridans streptococcus 
 
In this study, Coagulase negative Staphylococcus	 (CoNS), usually associated with 
indwelling devices, was also considered clinically non-significant given that these 
devices are not used in The Gambia. This is in line with the MRCG clinical microbiology 
protocol, previous aetiology studies in The Gambia,348 and the classification used by the 
ANISA study group.260 In the ANISA study, a third category of pathogens was described 
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a being ‘Probably significant’. Organisms in this group were identified from regional 
data on environmental organisms that frequently colonise the skin of South Asian 
newborns and which may also cause bloodstream infections in newborns.351, 352 
Viridans Streptococci and S.	aureus were among the ‘Probably significant’ pathogens in 
the ANISA study. Data on surface colonisation among Gambian newborns is limited.253, 
353 Consequently, Viridans Streptococci was considered clinically non-significant, and S.	
aureus considered clinically significant based on the MRCG clinical microbiology 
laboratory protocol. 
Study personnel reviewed documentation for each case with a clinically non-significant 
blood culture to identify possible reasons for contamination as an ongoing quality 
check. However, laboratory personnel identified and recorded all organisms grown on 
blood culture, even if they were in the list of clinically non-significant organisms or 
there was growth of multiple organisms. Beyond the pre-determined contaminant list, 
some unexpected organisms of questionable clinical significance were isolated. The 
clinical and laboratory characteristics of these cases were reviewed at the end of the 
study by an independent panel of clinicians and microbiologists at the MRC review to 
determine their clinical significance. Any isolate classified as a clinically non-significant 
was not stored; all other organisms were identified then stored at –80°C for future 
work. 
Antibiotic	susceptibility	
Antibiotic susceptibility patterns of significant bacterial isolates were determined using 
approved disk-diffusion methods described in the Clinical Laboratory Standard Institute 
(CLSI) guidelines (2014). For each isolate, the antibiotic zone of inhibition diameter was 
recorded to enable translation of results with any possible future changes in CLSI 
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guidelines. Appropriate American Type Culture Collection (ATCC) controls were used 
consistently. 
Swabs		
All swabs were stored at -70°C and processed in batches. Stored samples were thawed 
at room temperature and then vortexed. 50µl of each vortexed specimen was plated on 
Chromagar media, which was the primary agar used in this study. From the primary 
plate, presumptive bacterial colonies were streaked onto appropriate agar plates and 
re-incubated overnight at 37°C for confirmatory testing. Priority was given to 
identification of bacteria only.  
All concordant bacterial isolates from mother-newborn dyads have been stored for 
future investigation including strain confirmation and Whole Genome Sequencing in 
order to determine whether the maternal recto-vaginal isolate is the cause of neonatal 
disease.  
CSF	
Part of each CSF specimen aliquoted for culture were immediately plated on chocolate, 
blood and MacConkey agar media. The second aliquot was sent to the biochemistry 
laboratory for glucose and protein estimation.  
6.2.3	Molecular	diagnostic	assays	
The multipathogen molecular detection platform used in this study was the TAC. Each 
TAC contains eight sample loading ports each with a microfluidic channel leading to 48 
different wells (Figure 6.5). The wells contain specific dried-down primers and 
hydrolysis probes for the detection of defined pathogen-specific or control targets. Once 
specimen nucleic acids are added to the wells, the system is closed (i.e. the reactions are 
completely contained within each well). This is of particular benefit in resource-poor 
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settings where risk of contamination with PCR amplicons is high due to the lack of 
dedicated rooms for different PCR steps. Other advantages of this methodology include 
the ability to customise a panel of pathogen targets, and ease of use, including minimal 
‘‘hands-on’’ setup.53  
 
The TAC has only ever been used in the diagnosis of neonatal infection in South Asia 
during the ANISA study,48 and not in sSA. One of the aims of this PhD was to explore the 
applicability of this technology for pathogen detection among sick Gambian newborns. 
Given the limited number of cards available for this study and the very high costs of 
customised manufacture and shipping, it was not possible to apply them to all study 
samples. Priority was therefore given to the neonatal blood and respiratory swab 
samples from the Pilot Study. The optimised ANISA-specific TAC configurations for the 
respiratory and blood cards in shown in Figures 6.6 and 6.7. Each customised TAC 
comprised fill ports for six specimens, a no template control (NTC),  and a positive 
control (PC).53 The respiratory TAC had two replicates of each assay while the blood 
TAC had four replicates of each assay. The higher number of assay replicates on the 
Figure	6.5	Layout	of	a	Taqman	Array	Card	
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blood TAC is to increase the proportion of the sample which is evaluated, and therefore 
improve detection.53 The ANISA study protocols for carrying out the TAC experiments 
were adhered to as much as possible. The only differences were in the equipment used 
for the nucleic acid extraction and running of the TACs; however, this was discussed 
with the ANISA/CDC collaborators who confirmed that this would not affect the validity 
and comparability of the results. 
 
Figure	6.6	ANISA-specific	TaqMan	Array	Card	configurations	for	the	Respiratory	cards	
NTC= Non-Template Control; S1 – S6= Specimens 1 – 6; PC=Positive control; IPCO=Internal Positive Control 
*Duplex assay consisting of Human RNP3 assay with FAM-labeled probe and IPCO assay with VIC-labeled probe. 
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Specimen	processing	and	nucleic	acid	extraction	
Total nucleic acid (TNA) was extracted from thawed blood and NPS specimens using the 
QIAxtractor® Robot instrument (QIAGEN, GmbH) with the cador	Pathogen 96 QIAcube 
HT Kit and Pre-treatment protocols for difficult-to-lyse bacteria in whole blood and 
liquid extracts from swabs. Pre-treatment was followed by nucleic acid purification 
using the nucleic acid purification. For NPS specimens, 400µl of STGG was extracted and 
eluted in 100µl. For extraction of whole blood, 300µl of blood in EDTA was mixed with 
100µl of freshly prepared solution of lytic enzymes consisting of consisting of 1.5 mg/ml 
lysostaphin, 2500 U/ml mutanolysin, and 200 mg/ml lysozyme (Sigma-Aldrich, St. 
Louis, MO, USA) in Tris-EDTA (TE) buffer and incubated at 37°C for 60 minutes prior to 
extraction on the QIAxtractor® Robot, with elution in 100µl. 
 
Figure	6.7	ANISA-specific	TaqMan	Array	Card	configurations	for	the	Blood	cards	
NTC= Non-Template Control; S1 – S6= Specimens 1 – 6; PC=Positive control; IPCO=Internal Positive Control 
*Duplex assay consisting of Human RNP3 assay with FAM-labeled probe and IPCO assay with VIC-labeled probe. 
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TAC	assay	performance	
The PCR mastermix for each TAC consisted of 1 x qScript XLT 1-Step RT-qPCR 
ToughMix, low ROX (Quanta Biosciences, Gaithersburg, MD, USA). The 2nd – 7th fill ports 
on each TAC were loaded with 50µL qScript XLT 1-Step RT-qPCR ToughMix and 50µL of 
TNA extract. In the first fill port, the TNA was replaced with nuclease-free water as a 
template (no-template control; NTC). The role of the NTC is to ensure no fluorescence 
amplification signal is observed in the absence of nucleic acid. In the eighth fill port, the 
TNA extract was replaced with a positive control consisting of combined RNA 
transcripts. Each card was centrifuged at 1200rpm for 1 minute twice, to distribute the 
fluid in the reaction wells, and then sealed to sequester individual reactions. All TACs 
were run on the Applied Biosystems™ QuantStudio™	7 Flex Real-Time PCR Instrument 
System (Life Technologies, Foster City, CA, USA). The purpose of the TAC is not to 
quantify the infectious agent and the assays are qualitative in nature.  
Analysis	and	interpretation	of	TAC	assay	output	
The data generated from each TAC experiment were exported to a designated folder on 
my desktop and analysed using QuantStudio™ Real-Time PCR Software v1.2 CDC 
(Thermo Fisher Scientific Inc). I carried out all analyses and interpretation of results 
according to Standard Operating Procedures used by the ANISA study (Appendix 8), 
with support from Dr. Kirsty Le Doare and collaborators at Centers for Disease Control 
and Prevention, Atlanta, USA, who reviewed and confirmed the final results. Relative 
levels of amplification directly correlate to the fluorescence data generated and 
measured during the reaction(s) using the QuantStudio™	 7 Flex Real-Time PCR 
Instrument System. Fluorescence amplification indicates the presence of the specific 
nucleic acid target.  A specimen is considered positive if any number of the pathogen-
specific replicates (1 of 2 replicates in NPS or <4 of 4 in blood specimens) is positive. 
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	6.3	Results	
This section integrates the epidemiological and laboratory results for both Pilot and 
Main studies. 
 
Eligibility, recruitment, sampling and diagnoses of Infant Case-Mother pairs and Infant 
Control-Mother pairs are summarised in Figures 6.8 and 6.9 respectively. The first 
results section presents the descriptive and comparative analyses of the 
epidemiological characteristics of the study participants. The second section presents 
descriptive and comparative analyses of the laboratory results, with a detailed analysis 
of conventional microbiology results. The third section presents the results from an 
investigation into two outbreaks that occurred in the neonatal unit during the course of 
the main study. 
Agar plates with bacterial 
colonies ready for identification 
Analysis screen of output from 
Taqman Array Card for 
nasopharyngeal swabs 
MRCG Clinical microbiology 
laboratory workbench with agar 
plates ready for reporting 
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Figure	6.8	Flow	chart	showing	overview	of	recruitment,	participation	and	results	of	Infant	Case-
Mother	pairs	for	pilot	and	main	studies	combined	
Infant-Mother	Case	pairs	recruited	(N=203)	
Sick	newborn-Mother	pairs	screened	at	admission	for	care	(N=1136)Infant-Mother	
Not recruited	(N=933):	
Consent refused	(N=478)	
Serious infection criteria not met (N=380) 
Baby too old (N=6) 
Live outside study area (N=54) 
Weight <1000g (N=8);		
Weight <1500g	[Pilot study]	(N=10)		
Non-ANC mother (N=5) 
Died before enrolment (N=1)	
Refused admission	(N=1)	
Infants wih positive cultures: 
Blood culture  (N=91)	
CSF culture (N=0)	
NPS culture (N=145)	
Rectal culture (N=144)	
Samples	collected:	
Blood (N=202)	[1 had insufficient sample] 
CSF (N=1) 
Baby NPS (N=203) 
Baby Rectal swab (N=153) [only in main study] 	
Mother RVS (N=202) [1 declined] 
Mother NPS (N=153) [only in main study]  
Infants with negative 
cultures: 
Blood culture (N=111)	
CSF culture (N=1)	
NPS	culture	(N=58)	
Rectal	swab	culture (N=9)	
Blood	
cultures	with	
clinically	
significant	
pathogen	
(N=52)	
Blood	cultures	
with		
clinically	non-
significant		
pathogen	
(N=40)	
Mothers colonised 
with potential 
pathogens: 
NPS	(N=84)	
RVS	(N=	195)	
Provisionally	matched	bacterial	isolates 
1. Baby blood culture vs Mother RVS, N=14 
2. Baby NPS vs Mother RVS, N=3 
3. Baby NPS vs Mother NPS, N=0 
4. Baby blood culture vs Baby Rectal Swab, N=4	
Compare	concordant	isolates 
Comparison	of	
rectovaginal	
colonisation	with	that	
of	Control	mothers	
Discharged (N=33) Discharged (N=29) 
Died (N=22) 
Discharged (N=82) 
Died (N=29) 
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6.3.1	Epidemiological	Results	
 Descriptive	analyses 
406 infant-mother case-control pairs were enrolled; 100 in the Pilot study (April – 
August 2015) and 306 in the Main study (February 2016 – January 2017). The clinical 
and maternal characteristics of the newborn cases (hereafter simply referred to as 
“Cases”) are detailed in Table 6.9, by phase of recruitment. Overall, the participants 
recruited during the both phases of the study were similar in these characteristics. More 
than half of the Cases [57% (144/203)] were aged ≤3 days at recruitment; and 7% 
(15/203) were recruited on the day of birth. Among the 184 facility-born Cases, 57% 
(105/184) were born at one of the three recruiting facilities; EFSTH 16% (29/184), 
Kanifing General Hospital 17% (32/184), and Brikama Health Centre 24% (44/184). 
Half of the Cases (51%, 103/203) were referred from Government health facilities, 31% 
(62/203) self-referred, 11% (23/203) were referred from private clinics, and 7% 
(15/203) were referred directly from the EFSTH labour ward. 
Samples	collected:	
Blood (N=202)	[1 had insufficient sample] 
Baby NPS (N=203) 
Baby Rectal swab (N=153) [only in main study] 	
Mother RVS (N=203) 
Mother NPS (N=153) [only in main study] 
Figure	6.9	Flow	chart	showing	overview	of	recruitment,	participation	and	results	of	Control-
Mother	pairs	
Not recruited,	N=106:	
Consent refused,	N=27	
Live outside study area, N=1 
Non-ANC mother, N=17 
Baby too old, N=61 
Infant-Mother	Control	pairs	recruited	(N=203)	
Healthy	newborn-Mother	pairs	screened	(N=309)	
Infants with 
positive cultures: 
NPS (N=133)	
Rectal	(N=134)	
Infants with 
negative cultures: 
NPS	(N=70)	
Rectal	(N=19)	
Mothers	colonised	
with	potential	
pathogens	
NPS	(N=90)	
RVS	(N=175)	
Comparison	of	rectovaginal	colonisation	with	that	of	Case	mothers 
1. GBS: Case mothers 11% vs Control mothers 8% (p=0.209) 
2. E.coli: Case mothers 68% vs Control mothers 55% (p=0.006) 
3. S.aureus: Case mothers 25% vs Control mothers 22% (p=0.446) 
4. Klebsiella: Case mothers 32% vs Control mothers 27% (p=0.281) 
5. Any of GESK: Case mothers 87% vs Control mothers 76% (p=0.006) 
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Table	6.9	Demographic	and	clinical	characteristics	of	203	infant-mother	case	pairs	stratified	by	
phase	of	recruitment	
Characteristic	 Pilot	Study	(N=50)	a	 Main	Study	(N=153)	a	 Total	(N=203)	a	
Neonatal	       
Sex       
Male 62%  (31) 60% (92) 61% (123) 
Female 38% (19) 40% (61) 39% (80) 
Median postnatal age in days(IQR) 3  (1 – 10) 3 (1 – 8) 3 (1 – 9) 
Aged 0 – 3 days 56%  (28) 57% (87) 57% (115) 
Aged 4 – 6 days 14%  (7) 14% (22) 14% (29) 
Aged 7 – 27 days 30%  (27) 29% (44) 29% (59) 
Median gestational age in weeks (IQR) 38  (36 – 39) 38  (37 – 40) 38 (36 – 39) 
28 - <32 weeks 4%  (2/48) 0 0 1% (2/193) 
32 - <37 weeks 31%  (15/48) 23% (33/145) 25% (48/193) 
≥37 weeks 65% (31/48) 77% (112/145) 74% (143/193) 
Median birth-weight in Grams (IQR) 3000  (2700 – 3400) 3000  (2600 – 3400) 3000 (2600 – 3400) 
≤1500g 2%  (1/47) 2% (3/141) 2% (4/188) 
1501 – 2500g 19%  (9/47) 21% (30/141) 21% (39/188) 
>2500g 79%  (37/47) 77% (108/141) 77% (145/188) 
Recruiting site       
EFSTH 100% (50) 70% (107) 77% (157) 
Kanifing General Hospital 0 (0) 3% (4) 2% (4) 
Brikama Heatth Centre 0 (0) 27% (42) 21% (42) 
Place of birth       
Facility-born 90% (45) 91% (139) 91% (184) 
Home/TBA 10% (5) 9% (14) 9% (19) 
Mode of delivery       
Spontaneous vaginal delivery 82% (41) 86% (132) 85% (173) 
Caesarean section/Assisted vaginal delivery b 18% (9) 14% (21) 15% (30) 
Clinical presentation       
Fast breathing (RR ≥60/min) 60% (33) 46% (70) 51% (103) 
Severe chest wall in-drawing 34% (17) 16% (25) 21% (42) 
Fever (≥38.0°C) 42% (21) 56% (85) 52% (106) 
Hypothermia (≤35.5°C) 10%  (5) 16% (25) 15% (30) 
Abnormal movement 16% (8) 18% (28) 18% (36) 
Convulsions 30% (15) 24% (37) 26% (52) 
Feeding difficulty 38% (19) 39% (60) 39% (79) 
Pre-admission antibiotic exposure 10% (5) 19% (29) 17% (34) 
Final diagnosis       
Culture-positive bacteraemia/sepsis C 26% (13) 25% (38) 25% (51) 
Clinical Meningitis 0% (0) 7% (11) 5% (11) 
Pneumonia 6% (3) 2% (3) 3% (6) 
Maternal	       
Median age in years (IQR) 27 (23 – 29) 26.5 (22 – 32) 27 (22 – 32) 
Aged < 18 years 4.5% (2/44) 6% (9/152) 6% (11/196) 
Aged 18 – 34 years 91% (40/44) 78% (119/152) 81% (159/196) 
Aged ≥35 years 4.5% (2/44) 16% (24/152) 13% (26) 
Nationality       
Gambian 84% (42) 91% (139) 89% (181) 
Mother’s education       
None 30% (15) 28% (43) 29% (58) 
Primary 26% (13) 18% (28) 20% (41) 
Secondary 40%  (20) 43% (66) 42% (86) 
Tertiary 4% (2) 11% (16) 29% (18) 
Married 100% (50) 93% (142) 95% (192) 
Median parity (IQR) 3 (2 - 5) 2 (1 – 4) 2 (1 – 5) 
Primiparous 24% (12) 33% (50) 31% (62) 
Multiparous 76% (38) 67% (103) 69% (141) 
a Denominators (X/Y) are presented for variables with missing data 
b Assisted vaginal delivery: Vacuum extraction (4) and assisted breech delivery (2) 
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In Table 6.10, the characteristics of the newborn controls (hereafter simply referred to a 
“Controls”) and their mothers are presented by phase of recruitment. 
Table	6.10	Demographic	and	clinical	characteristics	of	203	infant-mother	control	pairs	stratified	by	
phase	of	recruitment	
Characteristic	 Pilot	Study	(N=50)	a	 Main	Study	(N=153)	a	 Total	(N=203)	a	
Neonatal	       
Sex       
Male 50% (25) 52% (79) 51% (104) 
Female 50% (25) 50% (25) 49% (99) 
Median postnatal age in days(IQR) 14 (9 – 18) 2 (0 – 10) 4 (1 – 4) 
Aged 0 – 3 days 6% (3) 64% (98) 50% (101) 
Aged 4 – 6 days 2% (1) 5% (7) 4% (8) 
Aged 7 – 27 days 92% (46) 31% (48) 46% (94) 
Median gestational age in weeks (IQR) 38 (36 – 39) 38 (37 – 38) 38 (37 – 39) 
28 - <32 weeks 2% (1/47) 0% (0) 1% (1) 
32 - <37 weeks 28% (13/47) 18% (26/146) 20% (39/193) 
≥37 weeks 70% (33/47) 82% (120/146) 79% (153/193) 
Median birth-weight in Grams (IQR) 3150 (2950 – 3400) 3000 (2700 – 3300) 3000 (2800 – 3300) 
≤1500g 0% (0) 0% (0)   
1501 – 2500g 4% (2/48) 18% (28/152) 15% (30/200) 
>2500g 96% (46/48) 82% (124/152) 85% (170/200) 
Recruiting site       
EFSTH Postnatal ward 0% (0) 1% (1) <1% (1) 
Polyclinic banjul 10% (5) 4% (6) 5% (11) 
Serekunda Health Centre 34% (17) 21% (33) 25% (50) 
Fajikunda Health Centre 12% (6) 8% (12) 9% (18) 
Bundung Maternal & Child Health Hospital 22% (11) 25% (39) 25% (50) 
Brikama Health Centre 22% (11) 41% (62) 36% (73) 
Place of birth       
Facility-born 92% (46) 96% (147) 95% (193) 
Home/TBA 8% (4) 4% (6) 5% (10) 
Mode of delivery       
Vaginal delivery b 100% (50) 89% (136) 92% (186) 
Caesarean section 0% (0) 11% (17) 8% (17) 
Pre-admission antibiotic exposure       
Maternal	       
Median age in years (IQR) 27 (21 - 30) 25 (21 – 30) 25 (21 – 30) 
Aged < 18 years 6% (3) 4% (6) 4% (9) 
Aged 18 – 34 years 80% (40) 84% (127) 83% (167) 
Aged ≥35 years 14% (7) 12% (19) 13% (26) 
Nationality       
Gambian 96% (48) 95% (146) 96% (194) 
Mother’s education       
None 18% (9) 44% (67) 37% (76) 
Primary 28% (14) 9% (14) 14% (28) 
Secondary 50% (25) 41% (62) 43% (87) 
Tertiary 4% (2) 6% (10) 6% (12) 
Married 92% (46) 94% (144) 94% (190) 
Median parity (IQR) 2 (1 – 4) 3 (1 – 4) 3 (1 – 4) 
Primiparous 28% (14) 27% (41) 27% (55) 
Multiparous 72% (36) 73% (112) 73% (148) 
a Denominators (X/Y) are presented for variables with missing data 
b Assisted vaginal delivery: Vacuum extraction (4) and assisted breech delivery (2) 
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6.3.2	Microbiology	Results		
Prevalence	and	aetiology	of	neonatal	infection	
Blood	cultures	
Bacteria were cultured from the blood of 45% (91/202) of Cases, and 25% (52/202) 
had a clinically significant organism.  S.	aureus was highly prevalent accounting for 25% 
(13/52) of all clinically significant infections (Table 6.11). Coagulase-negative 
staphylococcus (CoNS) was the most abundant isolate and predominant clinically non-
significant organism accounting for 80% (32/40) of Cases. Others include Bacillus 
species (4), Micrococcus species (2), and Viridans streptococci (2). 
Table	6.11	Clinically-significant	bacteria	isolated	from	blood	cultures	of	cases	stratified	by	
phase	of	recruitment	
Isolate	 Pilot	Study	(N	=	13)	 Main	Study	(N	=	39)	 Total	(N	=	52)	
Gram	positive	       
Staphylococcus	aureus 8% (1) 31% (12) 25% (13) 
Enterococcus	species	 0% (0) 8% (3) 5% (3) 
Streptococcus	species	 0% (0) 5% (2) 4% (2) 
Gram	negative	       
Klebsiella	species a	 30% (4) 13% (5) 17% (9) 
Burkholderia	cepacia	 8% (1) 21% (8) 17% (9) 
Pseudomonas	species c	 46% (6) 3% (1) 14% (7) 
Acinetobacter	baumanii	 0% (0) 5% (2) 4% (2) 
Escherichia	coli	 0% (0) 5% (2) 4% (2) 
Achromobacter	xylosoxidans	 0% (0) 3% (1) 2% (1) 
Citrobacter	species	 0% (0) 3% (1) 2% (1) 
Enterobacter	cloacae b	 0% (0) 3% (1) 2% (1) 
Salmonella	species	 0% (0) 3% (1) 2% (1) 
Pantoea	species 8% (1) 0% (0) 2% (1) 
a Klebsiella pneumoniae (8) and Klebsiella oxytoca (1)	
b This baby had mixed infection with Escherichia	coli.	
c Pseudomonas luteola (6) and Pseudomonas species (1)	
Early-onset infection (≤ 3 days) accounted for 28% of Cases of clinically significant 
bloodstream infection. There was no difference in the prevalence of clinically significant 
bloodstream infection by age: 4- 7 days [21% (6/29), P=0.303] or ≥7 days [24% 
(14/59), P=0.942] compared with those aged ≤3 days [28% (32/114)], possibly due to 
the small sample size of clinically significant infections within the different age 
categories. Table 6.12 presents the distribution of clinically significant isolates by 
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postnatal age while Figure 6.10 shows the distribution of positive blood cultures and 
aetiology over the first week after birth. The predominant pathogens associated with 
early-onset infection were	S.	aureus, B.	cepacia, and Gram-negative rods (Klebsiella and 
Pseudomonas species).  
Table	6.12	Prevalence	of	clinically	significant	blood	culture	isolates	by	postnatal	age	
 Prevalence	Within	Different	Age	Groups		
Isolate Aged	≤3	days	(n=32)	
Aged	4-6	days		
(n=6)	
Aged	≥7	days		
(n=14)		
Staphylococcus	aureus 25% (8) 0% (0) 37% (5) 
Burkholderia	cepacia	 22% (7) 17% (1) 7% (1) 
Klebsiella	species b	 19% (6) 50% (3) 0% (0) 
Pseudomonas	species c	 13% (4) 17% (1) 14% (2) 
Enterococcus	species	 9% (3) 0% (0) 0% (0) 
Streptococcus	species	 6% (2) 0% (0) 0% (0) 
Acinetobacter	baumanii	 3% (1) 17% (1) 0% (0) 
Pantoea	species	 3% (1) 0% (0) 0% (0) 
Escherichia	coli	 0% (0) 0% (0) 14% (2) 
Achromobacter	xylosoxidans	 0% (0) 0% (0) 7% (1) 
Citrobacter	species	 0% (0) 0% (0) 7% (1) 
Enterobacter	cloacae	 0% (0) 0% (0) 7% (1) 
Salmonella	species 0% (0) 0% (0) 7% (1) 
a  Includes	clinically	non-significant	pathogens 
b  Klebsiella pneumoniae (8) and Klebsiella oxytoca (1) 
c Pseudomonas luteola (6) and Pseudomonas species (1) 
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Figure	6.10	Distribution	of	clinically	significant	blood	culture	isolates	in	the	first	week	after	birth	
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Clinical	characteristics	of	Cases	with	positive	blood	cultures	
The demographic and clinical characteristics of Cases stratified by blood culture results 
are detailed in Table 6.13. 
Table	6.13	Demographic	and	clinical	 characteristics	of	 cases	and	 their	mothers	stratified	by	blood	
culture	result	
 
Clinically	significant	
organism	(N=51)	a	
Clinically		
non-	significant	
organism	(N=40)	a	
Negative	culture	
(N=111)	a	 P*	
Neonatal	 	 	 	 	 	 	 	
Sex 	 	 	 	 	 	 	
Male 65% (33/51) 60% (24/40) 59% (65/111) 0.758	
Female 35% (18/51) 40% (16/40) 41% (46/111) 	
Median postnatal age in days (IQR) 2 (1 – 8) 2 (1 - 7) 3 (1– 10) 	
Aged 0 – 3 days 63% (32/51) 58% (23/40) 53% (59/111) 0.514	
Aged 4 – 6 days 12% (6/51) 20% (8/40) 14% (15/111) 	
Aged 7 – 27 days 25% (13/51) 22% (9/40) 33% (37/111) 	
Median gestational age in weeks (IQR) 38 (36 –  40) 38 (36 – 39) 38 (36 – 39) 	
28 - <32 weeks 0% (0/47) 0% (0/39) 2% (2/106) 0.984	
32 - <37 weeks 26% (12/47) 26% (10/39) 24% (25/106) 	
≥37 weeks 74% (35/47) 74% (29/39) 74% (79/106) 	
Median birth-weight in Grams (IQR) 3000 (2500 – 3430) 3000 (2800 – 3200) 3000 (2600 – 3400) 	
≤1500g 2% (1/48) 0% (0/38) 3% (3/101) 0.582	
1501 – 2500g 25% (12/48) 13% (5/38) 21% (21/101) 	
>2500g 73% (35/48) 87% (33/38) 76% (77/101) 	
Place of birth       	
Facility-born 94% (48/51) 93% (37/40) 88% (98/111) 0.448	
Home/TBA 6% (3/51) 7% (3/40) 12% (13/111) 	
Mode of delivery       	
Spontaneous vaginal delivery 90% (46/51) 95% (38/40) 79% (88/111) 	
Caesarean section/Assisted vaginal delivery 10% (5/51) 5% (2/40) 21% (23/111) 0.033	
Clinical presentation       	
Fast breathing (RR ≥60/min) 67% (34/51) 55% (22/40) 42% (47/111) 0.014	
Severe chest wall in-drawing 27% (14/51) 15% (6/40) 20% (22/111) 0.324	
Fever (≥38.0°C) 43% (22/51) 43% (17/40) 60% (67/111) 0.046	
Hypothermia (≤35.5°C) 18% (9/51) 13% (5/40) 14% (15/111) 0.731	
Abnormal movement 31% (16/51) 15% (6/40) 12% (13/111) 0.008	
Convulsions 27% (14/51) 35% (14/40) 22% (24/111) 0.240	
Feeding difficulty 37% (19/51) 43% (17/40) 39% (43/111) 0.163	
Pre-admission antibiotic exposure 20% (10/51) 20% (8/40) 14% (16/111) 0.597	
Maternal	       	
Median age in years (IQR) 27 (24 – 32) 27 (23 – 32) 26 (22 – 32) 	
Aged < 18 years 2% (1/49) 5% (2/39) 7% (8/107) 0.585	
Aged 18 – 34 years 80% (39/49) 85% (33/39) 80% (86/107) 	
Aged ≥35 years 18% (9/49) 10% (4/39) 12% (13/107) 	
Median parity (IQR) 3 (2 – 5) 2.5 (1 – 4) 2 (1 – 4) 	
Previous stillbirth 10% (5/51) 10% (4/40) 7% (8/111) 0.649	
Intrapartum fever 22% (11/51) 18% (7/40) 10% (11/111) 0.021	
Intrapartum antibiotic exposure 2% (1/51) 3% (1/40) 2% (2/111) 0.896	
a Denominators (X/Y) are presented for variables with missing data 
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Cases born by caesarean section or assisted vaginal delivery were significantly more 
likely to have a negative blood culture compared with those born by spontaneous 
vaginal delivery (P=0.033). With respect to clinical presentation, Cases with clinically 
significant bacteraemia were significantly more likely to present with fast breathing, 
abnormal movement and to have a maternal history of intrapartum fever. Interestingly, 
fever was a more common presentation among cases with a negative blood culture 
(P=0.046), although pre-admission antibiotic exposure did not significantly differ by 
culture result. 
Because CoNS was the most abundant pathogen isolated from blood cultures, Cases 
with CoNS infection were compared with Cases that had cultures positive for clinically 
significant bacteria. No major differences in relation to known risk factors (gestational 
age and birth-weight) were observed between the two groups. For gestational age at 
birth, 28% (9/32) of CoNS cases were born premature compared with 26% (12/47) of 
those with clinically significant bacteria (P = 0.798).	Of the four very low-birth-weight 
(VLBW) Cases enrolled in this study, only one had a positive blood culture which was 
for a clinically significant organism. Culture positive rates did not vary between 
facilities. 
CSF	cultures	
Fifty-Two Cases met the clinical criteria for a diagnostic lumbar puncture at admission 
but only one Case underwent the procedure within 24 hours of admission and before 
commencement of antibiotics. The CSF sample for this neonate was sterile on culture. 
Antibiotic	resistance	
Phenotypic antibiotic-susceptibility testing was carried out using a panel of antibiotics 
that are locally used (Table 6.14). For Klebsiella species, antibiotic resistance was 89% 
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for WHO-recommended first-line therapy (gentamicin), and ranges from 67% - 89% for 
WHO-recommended second-line therapy (third-generation cephalosporins). 
Table	6.14	Antibiotic	resistance	patterns	in	Cases	with	clinically	significant	bloodstream	infection	
	 Staphylococcus	
aureus	
Klebsiella	
species	
Burkholderia	
cepacia	
Pseudomonas	
species	
Escherichia		
coli	
Antibiotic	class	 No.	Resistant	(%)	
No.	Resistant	
(%)	
No.	Resistant	
(%)	
No.	Resistant	
(%)	
No.	Resistant	
(%)	
Penicillins	           
Ampicillin N T 8/8 (100%) 6/6 (100%) 1/1 (100%) 2/2 (100%) 
Amoxicillin/clavulanic acid N T 4/5 (80%) 4/5 (80%) 1/1 (100%) 1/2 (50%) 
Penicillin 12/13 (92%) 1/1 (100%) 1/1 (100%) N T N T 
Flucloxacillin 0/1 (0%) N T N T N T N T 
Cephalosporins	           
Cefuroxime N T 8/8 (100%) 5/5 (100%) 1/1 (100%) 1/2 (50%) 
Cefoxitin 0/12 (0%) 0/5 (0%) 0/1 (0%) N T N T 
Ceftriaxone  0/2 (0%) 2/3 (67%) 1/1 (100%) 0/2 (0%) N T 
Cefotaxime  0/1 (0%) 7/8 (88%) 3/4 (75%) 0/1 (0%) 1/2 (50%) 
Ceftazidime  N T 8/9 (89%) 0/7 (0%) 0/5 (0%) 1/2 (50%) 
Aminoglycoside	           
Gentamicin 0/11 (0%) 8/9 (89%) 1/8 (13%) 1/6 (17%) 2/2 (100%) 
Fluoroquinolone	           
Ciprofloxacin 0/12 (0%) 5/9 (56%) 0/9 (0%) 0/6 (0%) 1/2 (50%) 
 
Both E.	coli isolates were resistant to gentamicin but only one isolate was resistant to 
third-generation cephalosporins and fluoroquinolones. The S.	 aureus isolates 
demonstrated 100% sensitivity to flucloxacillin and to first-line gentamicin. 
Impact	of	culture	diagnosis	on	management	and	mortality	
The median blood culture reporting time during the study was 6 days (IQR, 5 – 7), but 
the median times to death or discharge were 2 (IQR, 1 – 6) and 7 (IQR, 4 – 9) 
respectively. Only 38% (35/91) of neonates with a positive blood culture received the 
result before discharge or death. 
The overall case-fatality rate (CFR) was 29% (59/203). The one neonate that did not 
have a blood culture also died during admission. When stratified by blood culture result, 
the overall CFR was higher among neonates with clinically significant bacteraemia [43% 
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(22/51)] compared with neonates with CoNS infection [13% (4/32) P= 0.004] and 
those with negative cultures [26% (30/111) P = 0.041].  
There were no differences in the CFR between Cases with a positive culture and those 
with a negative culture when stratified by age of onset.  However, when further 
stratified by clinical significance, the CFR among neonates aged 0 – 6 days was 
significantly higher among those Cases with clinically significant organisms [50% 
(18/36), P=0.020] compared with Cases with clinically non-significant organisms [27% 
(4/15)]. Among those aged ≥7 days, no differences in CFR by clinical significance was 
observed. 
Table 6.15presents case fatalities among those neonates with positive blood cultures 
stratified by the infecting organism. The CFR was lowest amongst neonates with S. 
aureus, and CoNS bacteraemia. The CFR was highest for E.	coli and Citrobacter infections 
Table	6.15	Outcome	among	culture-positive	Cases	according	to	infecting	pathogen	
Organism 
Discharged 
(n=62) 
Died during admission  
(n=29) 
	
Clinically	significant	      
Gram positive      
Staphylococcus	aureus 77% (10) 23% (3)  
Enterococcus	species	 33% (1) 67% (2)  
Streptococcus	species	 50% (1) 50% (1)  
Gram negative      
Burkholderia	cepacia	 44% (4) 56% (5)  
Klebsiella	species	 67% (6) 33% (3)  
Acinetobacter	baumanii	 50% (1) 50% (1)  
Escherichia	coli	 0% (0) 100% (2) a  
Achromobacter	xylosoxidans	 100% (1) 0% (0)  
Citrobacter	species	 0% (0) 100% (1)  
Pseudomonas	species	 43% (3) 57% (4)  
Salmonella	species	 100% (1) 0% (0)  
Pantoea	species	 100% (1) 0% (0)  
Clinically	non-significant	      
Coagulase-negative staphylococci 88% (28) 12% (4)  
Viridans streptococci 50% (1) 50% (1)  
Bacillus species	 100% (4) 0% (0)  
Micrococcus species 0% (0) 100% (2)  
a One baby had mixed infection with Enterobacter 
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Follow	up	and	outcome	on	Day	27		
Among the 144 Cases discharged from care, 15 were >27 days of age at discharge and 
129 were aged <27 days. Those neonates <27 days of age were followed up by 
telephone on Day 27 (end of the neonatal period) to ascertain their outcome. Figure 
6.11 summarises the Day 27 outcome for these Cases stratified by blood culture result. 
 
Neonatal	nasopharyngeal	colonisation:	prevalence	and	aetiologies	
The distribution of nasopharyngeal colonisation among Cases stratified by age is shown 
in Table 6.16. Colonisation by most organisms peaked at postnatal age 4 – 6 days. 
Table	6.16	Distribution	of	nasopharyngeal	colonisation	among	Cases	stratified	by	postnatal	age	
	 Prevalence	Within	Different	Age	Groups	
	 Number	a	 Overall	Prevalence	 Aged	≤3	days	 Aged	4-6	days		 Aged	≥7	days		
Any positive culture 145 71% (145/203) 65% (75/115) 90% (26/29) 75% (44/59) 
Staphylococcus	aureus	 89 44% (89/203) 34% (39/115) 69% (20/29) 51% (30/59) 
Klebsiella	species	 30 15% (30/203) 10% (12/115) 24% (7/29) 19% (11/59) 
Enterococcus	species	 22 11% (22/203) 12% (14/115) 10% (3/29) 8% (5/59) 
Escherichia	coli	 18 9% (18/203) 8% (9/115) 10% (3/29) 10% (6/59) 
Enterobacter	species	 8 4% (8/203) 4% (5/115) 7% (2/29) 2% (1/59) 
Group B Streptococcus	 5 2% (5/203) 3% (4/115) 0% (0/29) 2% (1/59) 
Pseudomonas	species 5 2% (5/203) 3% (4/115) 0% (0/29) 2% (1/59) 
Streptococcus	pneumoniae 4 2% (4/203) 0% (0/115) 3% (1/29) 5% (3/59) 
Others a 31 15% (31/203) 15% (17/115) 15% (4/29) 17% (10/59) 
b Others: Acinetobacter	species (3), Coagulase-negative	staphylococci (10), Unidentified	coliforms (10), Haemophilus	species (1), 
Streptococcus	species (3), Staphylococcus	species (4) 
Figure	6.11	Day	27	outcome	among	cases	discharged	from	care	
Discharged before Day 27 (N=129) 
Blood culture-positive (N=55) Blood culture-negative(N=74) 
Died at home c 
(N=2) 
LTFU 
(N=7) 
Alive and 
well (N=65) 
Died at home a 
(N=1) 
LTFU 
(N=8) 
Alive and 
well (N=43) 
Readmitted b 
(N=3) 
LTFU= lost to follow-up 
a Case of Klebsiella pneumoniae bloodstream infection with severe abdominal distension. Died at home on day of discharge 
b Two (2) re-admitted at EFSTH due to abdominal distension/Hirschprungs disease. The place and cause for admission of the 
third case could not be determined. Re-admission outcomes not ascertained 
c One (1) case is said to have had extensive skin infection. The cause of death of the second case could not be ascertained 
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Neonatal	rectal	colonisation:	prevalence	and	aetiologies	
The distribution of rectal colonisation among Cases stratified by age is shown in Table 
6.17. Colonisation by E.	 coli was most the most predominant, and increased with 
increasing postnatal age; over 90% of Cases admitted at 7 days of age or older were 
colonised.  
Table	6.17	Distribution	of	rectal	colonisation	among	cases	stratified	by	postnatal	age	
 Prevalence Within Different Age Groups 
 Number a Overall Prevalence Aged ≤3 days Aged 4-6 days  Aged ≥7 days  
Any positive culture 153 94% (145/153) 90% (78/87) 100% (22/22) 100% (44/44) 
	          
Enterobacter species	 20 13% (20/153) 9% (8/87) 14% (3/22) 20% (9/44) 
Escherichia	coli	 113 74% (113/153) 62% (54/87) 86% (19/22) 91% (40/44) 
Klebsiella	species	 85 56% (85/153) 47% (41/87) 68% (15/22) 66% (29/44) 
Enterococcus	species	 76 50% (76/153) 51% (44/87) 41% (9/22) 52% (23/44) 
Staphylococcus	aureus	 23 15% (23/153) 17% (15/87) 14% (3/22) 11% (5/44) 
Group B Streptococcus 3 2% (3/153) 2% (2/87) 0% (0/22) 2% (1/44) 
Unidentified coliforms 5 3% (5/153) 3% (3/87) 5% (1/22) 2% (1/44) 
Others 7 5% (7/153) 5% (4/87) 9% (2/22) 2% (1/44) 
          
a Rectal swabs only collected during the main study 
a Others: Proteus	species (3), Coagulase-negative	staphylococci (2), Streptococcus	species (1), Citrobacter	species (1) 
Maternal	recto-vaginal	colonisation	and	neonatal	infection	
Recto-vaginal swabs were collected from all Case-mothers except one who withheld 
consent for the procedure. Ninety-seven percent (195/202) of mothers were colonised 
with at least one organism, and 87% (176/202) colonised with at least one of the main 
organisms of interest in this study - GBS, E.	coli, S.	aureus or Klebsiella species. 
Concordance between organisms recovered from blood and vaginal cultures occurred in 
27% (14/51) of mother-newborn pairs suggesting possible mother-to-newborn 
transmission of organisms. Because confirmation of genetic relatedness of isolates can 
only be established by molecular methods such as whole genome sequencing, matching 
of concordant neonatal and maternal isolates is considered “provisional”. The two Cases 
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with E.	 coli infection and 54% (7/13) of Cases with S.	 aureus infection were born to 
mothers colonised by the same pathogen. Table 6.18 presents provisional matching of 
clinically significant isolates from neonatal blood cultures and maternal rectovaginal 
swabs stratified by the age of onset of neonatal infection. A quarter of neonates (8/32) 
with early-onset infection, and 30% (6/20) of those with late-onset infection were born 
to mothers rectovaginally colonised with the same pathogen. Based on provisional 
microbiological matching of isolates, more than 60% of early-onset S.	 aureus 
bacteraemia Cases might have been of maternal origin. 
Table	6.18	Provisional	matching	of	concordant	clinically	significant	bacterial	isolates	from	neonatal	
blood	culture	and	maternal	rectovaginal	swabs	stratified	by	age	of	onset	of	neonatal	infection	
  Newborn	with	clinically	significant	isolate	(N=51) 
  Early-onset	infection	[≤	3	days]	
(N=32)	 	
Late-onset	infection	[4	–	27	days]	
(N=20)	
Isolate	 (N)	
Mother colonised 
with same pathogen 
(N) 
Mother not colonised 
with same pathogen 
(N) 
 
Mother colonised 
with same pathogen 
(N) 
Mother not colonised 
with same pathogen 
(N) 
Staphylococcus	aureus	 (13) 63% (5) 37% (3)  40% (2) 60% (3) 
Klebsiella	species (9) 33% (2) 67% (4)  33% (1) 67% (2) 
Escherichia	coli (2)  (0)  (0)  100% (2)  (0) 
Enterococcus	species (3) 33% (1) 67% (2)   (0)  (0) 
Acinetobacter	baumanii (2)  (0) 100% (1)  100% (1)  (0) 
Streptococcus	species	 (2)  (0) 100% (2)   (0)  (0) 
Enterobacter	species (1)  (0)  (0)   (0) 100% (1) 
Pseudomonas	species (7)  (0) 100% (4)   (0) 100% (3) 
Salmonella	species	 (1)  (0)  (0)   (0) 100% (1) 
Citrobacter	species	 (1)  (0)  (0)   (0) 100% (1) 
Burkholderia	cepacia	 (9)  (0) 100% (7)   (0) 100% (2) 
Achromobacter	xylosoxidans	 (1)  (0)  (0)   (0) 100% (1) 
Pantoea	species	 (1)  (0) 100% (1)   (0)  (0) 
Total	 (52)	 25%	(8)	 75%	(24)	 	 30%	(6)	 70%	(14)	
 
Maternal	recto-vaginal	colonisation	and	neonatal	nasopharyngeal	colonisation	
Seventy percent of Cases were nasopharyngeally colonised, and predominantly with S.	
aureus [44% (89/203)] followed by Klebsiella [15% (30/203)]. Table 6.19 presents 
provisional matching of isolates from neonatal nasopharyngeal and maternal 
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rectovaginal swabs, suggesting possible mother-to-newborn transmission. The 
prevalence of neonatal nasopharyngeal colonisation among cases whose mothers were 
similarly colonised with the same organism was highest for S.	aureus [54% (27/50)]. 
Table	6.19	Provisional	matching	of	concordant	bacterial	isolates	from	neonatal	nasopharyngeal	and	
maternal	rectovaginal	swabs	
Organism	 (N)	
Newborn	with	nasopharyngeal	colonisation	
Mother	colonised	with	same	pathogen	(N)	 Mother	not	colonised	with	same	pathogen	(N)	
Group B Streptococcus (5) 60% (3) 40% (2) 
Staphylococcus	aureus (89) 30% (27) 70% (62) 
Klebsiella	species (29) 41% (12) 59% (17) 
Escherichia	coli (18) 61% (11) 39% (7) 
Enterococcus	species (22) 55% (12) 45% (10) 
Pseudomonas	species (5) 0% (0) 100% (5) 
 
Maternal	and	neonatal	nasopharyngeal	colonisation	
Maternal nasopharyngeal swabs were only collected during the main study. Table 6.20 
presents provisional matching of isolates from maternal and neonatal nasopharyngeal 
swabs, suggesting possible mother-to-newborn transmission.  
Table	 6.20	 Provisional	 matching	 of	 concordant	 bacterial	 isolates	 from	 neonatal	 and	 maternal	
nasopharyngeal	swabs	
Organism	 (N)	
Newborn	with	nasopharyngeal	colonisation	
Mother	colonised	
with	same	pathogen	(N)	
Mother	not	colonised	
with	same	pathogen	(N)	
Streptococcus	pneumoniae	 (2) 0% (0) 100% (2) 
Staphylococcus	aureus (73) 48% (35) 52% (38) 
Klebsiella	species (26) 4% (1) 96% (25) 
Escherichia	coli (15) 13% (2) 87% (13) 
Enterococcus	species (19) 37% (7) 66% (12) 
Pseudomonas	species (5) 0% (0) 100% (5) 
Enterobacter	species (3) 0% (0) 100% (3) 
 
Maternal colonisation was similar to that of the Cases, with S.	 aureus predominating 
[39% (60/153)], and less of S.	 pneumoniae [5% (7/153)]. The prevalence of neonatal 
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colonisation among Cases whose mothers were colonised with the same organism was 
highest for S.	aureus [58% (35/60)] and for Enterococcus [58% (7/12)].	
Neonatal	infection	and	rectal	colonisation	
Table 6.21 presents provisional matching of concordant isolates from neonatal blood 
cultures and rectal swabs, suggesting gut translocation as a route of infection among 
Cases with E.	coli and Enterococcus bacteraemia. 
Table	6.21	Provisional	matching	of	concordant	bacterial	isolates	from	neonatal	blood	culture	and	
rectal	swabs	
Organism	 (N)	
Newborn	with	clinically	significant	isolate	
Newborn	rectally	colonised	
with	same	pathogen	(N)	
Newborn	not	rectally	colonised	
with	same	pathogen	(N)	
Staphylococcus	aureus (12) 25% (4) 75% (8) 
Klebsiella	species (5) 60% (3) 40% (2) 
Escherichia	coli (2) 100% (2) 0% (0) 
Enterococcus	spp (3) 67% (2) 33% (1) 
Enterobacter	species (1) 0% (0) 100% (1) 
 
Comparative	analyses	
Table 6.22 compares the maternal and neonatal characteristics between the 203 Cases 
and community-matched Controls. Among Cases, significantly higher odds of a maternal 
history of intrapartum fever [OR 6.50, 95% CI (2.26 – 25.63), P=0.0001]; maternal 
history of multiple vaginal examinations [OR 3.40, 95% CI (1.64 – 7.72), P=0.0003]; LBW 
[OR 2.25, 95% CI (1.10 – 4.89), P=0.016]; and resuscitation at delivery [OR 7.57, 95% CI 
(3.43 – 19.74), P<0.0001] were observed compared with Controls. Mothers of Cases 
were also older and educated compared with mothers of Controls. 
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Table	6.22	Maternal	and	neonatal	characteristics	among	203	Cases	and	203	community-matched	
Controls	
 Case	 Control	 OR	(95%	CI)	 Pa	
Maternal	       
Maternal age (n=398)       
> 25 years 112 (57%) 95 (47%) 1.50 (0.98 – 2.32) 0.051 
≤ 25 years 84 (43%) 107 (53%)   
Educational level (n=406)       
Some education 145 (71%) 127 (63%) 1.51 (0.97 – 2.39) 0.055 
No education 58 (29%) 76 (37%)   
Parity (n=406)       
Multiparous 141 (69%) 148 (73%) 0.84 (0.52 – 1.33) 0.431 
Primiparous 62 (31%) 55 (27%)   
Tetanus toxoid during ANC (n=400)       
Yes 160 (79%) 165 (83%) 0.76 (0.45 – 1.27) 0.272 
No 42 (21%) 33 (17%)   
Intrapartum fever (n=402)       
Yes 29 (14%) 6 (4%) 6.50 (2.26 – 25.63) 0.0001 
No 172 (86%) 195 (97%)   
Number of vaginal exams (n=379)       
> 3 38 (21%) 15 (8%) 3.40 (1.64 – 7.72) 0.0003 
≤ 3 147 (79%) 179 (92%)   
Neonatal	       
Sex (n=406)       
Female 80 (39%) 99 (49%) 0.69 (0.46 – 1.04) 0.064 
Male 123 (61%) 104 (51%)   
Gestational age at birth (n=386)       
Preterm < 37 weeks 50 (26%) 40 (21%) 1.34 (0.81 – 2.25) 0.225 
Full term ≥ 37 weeks 143 (74%) 153 (79%)   
Birth-weight (n=388)       
Low birth weight <2500g 33 (18%) 22 (11%) 2.25 (1.10 – 4.89) 0.016 
Birth weight ≥2500g 155 (82%) 178 (89%)   
Postnatal age at recruitment (n=406)       
0 – 3 days 115 (57%) 101 (50%) 1.74 (0.96 – 3.23) 0.052 
4 – 27 days 88 (43%) 102 (50%)   
Place of delivery (n=406)       
Home/TBA born 19 (9%) 10 (5%) 2.00 (0.85 – 5.05) 0.083 
Facility-born 184 (91%) 193 (95%)   
Mode of delivery (n=406)       
Caesarean section  25 (12%) 17 (8%) 1.62 (0.77 – 3.51) 0.170 
Vaginal delivery  b 178 (88%) 186 (92%)   
Resuscitation at delivery       
Yes 58 (32%) 15 (8%) 7.57 (3.43 – 19.74) <0.0001 
No 124 (68%) 185 (92%)   
a McNemar chi-squared test for paired data 
Maternal	rectovaginal	colonisation	among	Cases	and	Controls	
The odds of being a Case were significantly higher among neonates whose mothers had 
a positive rectovaginal culture [OR 5.20, 95% CI (1.96 – 17.34), P=0.0002], and if the 
mother was colonised with at either GBS, E.	coli, S.	aureus or Klebsiella species [OR 2.11, 
95% CI (1.19 – 3.85), P=0.006] (Table 6.23). However, when stratified by individual 
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organisms, only maternal colonisation with E.	 coli was associated with significantly 
increased odds of being a Case [OR 1.79, 95% CI (1.16 – 2.82), P=0.006]. 
Table	6.23	Comparison	of	maternal	rectovaginal	colonisation	between	Cases	and	matched	
community	Controls	
 Case	 Control	 OR	(95%	CI)	 Pa	
Positive rectovaginal culture (n=405)       
Yes 195 (97%) 175 (86%) 5.20 (1.96 – 17.34) 0.0002 
No 7 (3%) 28 (14%)   
GBS-positive rectovaginal culture (n=405)       
Yes 23 (11%) 16 (8%) 1.58 (0.73 – 3.58) 0.209 
No 179 (89%) 187 (92%)   
E.	coli-positive rectovaginal culture (n=405)       
Yes 138 (68%) 111 (55%) 1.79 (1.16 – 2.82) 0.006 
No 64 (32%) 92 (45%)   
S.	aureus -positive rectovaginal culture (n=405)       
Yes 50 (25%) 44 (22%) 1.21 (0.71 – 2.08) 0.446 
No 152 (75%) 159 (78%)   
Klebsiella-positive rectovaginal culture (n=405)       
Yes 64 (32%) 54 (27%) 1.26 (0.81 – 1.99) 0.281 
No 138 (68%) 149 (73%)   
GESK-positive rectovaginal culture (n=405)       
Yes 176 (87%) 155 (76%) 2.11 (1.19 – 3.85) 0.006 
No 26 (13%) 48 (24%)   
       
a McNemar chi-squared test 
6.3.3	Molecular	assay	(PCR)	results	using	the	TaqMan	Array	Cards	
The multipathogen TaqMan Array Cards (TAC) were used to explore the applicability of 
this technology for pathogen detection using Pilot study samples. The blood and 
respiratory cards were insufficient to run all Pilot study samples (n=100) and were 
therefore used for the Cases (n=50) only, as the main purpose was to compare the yield 
from conventional microbiology cultures with this molecular tool.  
Comparison	of	TAC	PCR	and	blood	culture	results	among	Pilot	study	Cases	
One neonate did not have a blood culture sample taken but had a PCR sample which was 
negative. PCR samples for seven Cases (six of whom had positive blood cultures and one 
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with a negative blood culture result) could not be tested due to insufficient TACs. The 
yield from blood culture and PCR for the remaining 42 Cases who had results for both 
investigations is compared in Table 6.24 below. PCR was positive among 17% (3/18) of 
Cases with a positive blood culture and 17% (4/24) of Cases with a negative blood 
culture. 
Table	 6.24	 Comparison	 of	 BACTEC	 blood	 culture	 and	 TAC	 PCR	 for	 detection	 of	 pathogenic	
bacteria	in	blood	samples	from	42	Pilot	study	Cases	
	 Blood	Culture	b	 Total	
PCR	a	 Culture	positive	 Culture	negative	 	
PCR positive 3 4 7 
PCR negative 15 20 35 
Total	 18	 24	 42	
 
The pathogens identified by each method are listed in Table 6.25 (Cases with positive 
results for both methods presented in bold green font, and those with only positive PCR 
results presented in bold red font). The most frequently identified pathogen by PCR was 
S.	 aureus. None of the three Cases with positive results for both methods yielded the 
same pathogen. PCR identified GBS in two Cases both of whom had multiple organisms. 
The blood culture of one of the Cases with a GBS-positive PCR result was negative while 
the blood culture of the other Case was positive for CoNS. PCR did not detect any viruses 
from the blood samples. 
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Table	6.25	Comparison	of	culture	and	PCR	results	among	22	Pilot	study	Cases	with	positive	blood	
cultures	and/or	positive	TAC	blood	PCR	
Patient	 Blood	PCR	result	 Blood	culture	result	 Comments	
P0001	 E.	coli	 K.	pneumoniae	 Maternal	RVS culture yielded K.	pneumoniae	(GBS)	
P0005	 Negative	 S.	aureus	  
P0007	 S.	aureus	 No	growth	  
P0009	 Negative CoNS	 Infant received antibiotics before admission 
P0013	 Negative	 Pseudomonas	  
P0035	 Negative CoNS	  
P0041	 Negative	 P.	luteola	  
P0043	 Negative	 P.	luteola	  
P0049	 S.	aureus	 P.	Luteola	 	
P0053	 Negative	 K.	oxytoca  
P0063	 Negative CoNS  
P0065	 Negative	 K.	pneumoniae  
P0067	 Negative	 K.	pneumoniae  
P0069	 S.	aureus	 No	growth	  
P0071	 Negative CoNS	 Infant received antibiotics before admission 
P0079 Negative	 B.	cepacia  
P0083	 Negative CoNS  
P0085	 Negative CoNS  
P0089	 S.	aureus	 No	growth	  
P0091	 GBS	
S.	aureus	
CoNS	 Maternal RVS culture also yielded GBS. 
No maternal or infant antibiotic exposure. 
Infant discharged after 7 days on admission	
P0095	 Negative CoNS  
P0099		 GBS	
E.	coli	S.	aureus	
No	growth	 Maternal RVS culture yielded E.	coli and Streptococcus species. 
No maternal or infant antibiotic exposure.  
Infant died in hospital after 15 days on admission. 
Cases with positive results for both methods presented in bold green font, 
Cases with only positive PCR results presented in bold red font 
Comparison	of	PCR	and	NPS	culture	results	among	Pilot	Study	Cases	
For three Cases (all with positive NPS cultures), the corresponding respiratory PCR 
samples could not be tested due to insufficient TACs. The yield from PCR and NPS 
culture for the 47 Cases who had results for both tests is compared in Table 6.26.  
Table	 6.26	 Comparison	 of	 conventional	 culture	 and	 TAC	 PCR	 for	 detection	 of	 pathogenic	
bacteria	in	NPS	samples	from	47	Pilot	study	Cases	
	 NPS	Culture	b	 Total	
PCR	a	 Culture	positive	 Culture	negative	 	
PCR positive 21 3 24 
PCR negative 13 10 23 
Total	 34	 13	 47	
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PCR was positive among 62% (21/34) of Cases with a positive NPS culture and 23% 
(3/13) of Cases with a negative NPS culture. The pathogens identified by each method 
are listed in Table 6.27 (Cases with positive results for both methods presented in bold 
green font, and those with only positive PCR results presented in bold red font). Four 
(19%) of the 21 Cases with positive results for both methods yielded the same 
pathogen; K.	pneumoniae (P0015 and P0045), S.	pneumoniae (P0023), and GBS (P0065 
(this neonate’s mother’s RVS culture was also positive for GBS)). 
Table	6.27	Comparison	of	culture	and	PCR	results	among	38	Pilot	study	Cases	with	positive	NPS	
cultures	and/or	positive	TAC	NPS	PCR	
Patient	 NPS	PCR	result	 NPS	culture	result	 Comments	
P0001	 Negative	 K.	pneumoniae	
S.	aureus	
Infant blood culture and maternal RVS both yielded K.	
pneumoniae 
P0003	 S.	pneumoniae	
Ureaplasma	spp	
GDS	  
P0005	 S.	pneumoniae	
Rhinovirus	
S.	aureus	 Infant blood culture positive for S.	aureus 
P0007	 S.	pneumoniae	 S.	aureus	
GDS	
Maternal RVS culture positive for S.	aureus 
P0009	 S.	pneumoniae	
K.	pneumoniae	
A.	baumanii	  
P0011	 GBS		
Enterovirus	
Rhinovirus	
CoNS	 Infant had a clinical diagnosis of pneumonia 
Blood culture was negative 
P0013	 Negative	 S.	pneumoniae  
P0015	 K.	pneumoniae	 K.	pneumoniae	
GBS	
 
P0017	 S.	pneumoniae	
RSV	
H.	parainfluenzae	  
P0019	 Negative	 K.	pneumoniae	
E.	cloacae	
 
P0021	 S.	pneumoniae	
K.	pneumoniae	
S.	aureus	  
P0023	 S.	pneumoniae	
Enterovirus	
Rhinovirus	
S.	pneumoniae	
S.	aureus	
Maternal RVS culture positive for S.	aureus 
P0025 Negative	 E.	cloacae  
P0027 Negative CoNS  
P0035 K.	pneumoniae	
Parainfluenza	virus 
Acinetobacter	spp  
P0037	 K.	pneumoniae	
Ureaplasma	spp	
CoNS	  
P0039 Negative	 S.	aureus  
P0041	 S.	pneumoniae	
K.	pneumoniae	
S.	aureus	
E.	coli	
Maternal RVS culture positive for S.	aureus 
P0043	 S.	pneumoniae	
K.	pneumoniae	
Rhinovirus	
RSV	
S.	aureus	 Maternal RVS culture positive for S.	aureus 
167 
 
Table	6.27	(continued)	Comparison	of	culture	and	PCR	results	among	38	Pilot	study	Cases	with	
positive	NPS	cultures	and/or	positive	TAC	NPS	PCR	
Patient	 NPS	PCR	 NPS	culture	 Comments	
P0045	 K.	pneumoniae	 K.	pneumoniae	
E.	cloacae	
 
P0049 Negative	 S.	aureus	  
P0051	 S.	pneumoniae	
K.	pneumoniae		
Rhinovirus	
Negative	  
P0055	 GBS	
B.	pertussis	
Adenovirus	
Human	Parechovirus	
Rhinovirus	
Negative	  
P0057	 Chlamydia	
S.	pneumoniae	
Ureaplasma	spp	
S.	aureus	
GCS	
 
P0061 Negative	 S.	aureus  
P0063	 S.	pneumoniae	 S.	aureus	
E.	cloacae	
 
P0065	 GBS	 GBS	
S.	aureus	
Infant blood PCR positive for S.	aureus 
 
P0069	 GBS	
K.	pneumoniae	
Negative	 Maternal RVS culture positive for K.	pneumoniae 
P0071	 Adenovirus	 Negative	  
P0073	 K.	pneumoniae	
Ureaplasma	spp	
CoNS	  
P0075 Negative	 S.	aureus  
P0077	 GBS	 CoNS	 Maternal RVS culture positive for GBS 
P0079 Negative	 S.	aureus  
P0085 Negative E. coli  Maternal RVS culture positive for E.	coli 
P0087	 GBS	 P.	aeruginosa	 Maternal RVS culture positive for GBS 
P0089 Negative CoNS  
P0091 Negative GBS  Infant blood PCR positive for GBS 
Maternal RVS culture positive for GBS 
P0093	 K.	pneumoniae	 CoNS	 Maternal RVS culture positive for K.	pneumoniae 
Cases with positive and concordant results for both methods presented in bold green font. 
Cases with positive but discordant results for both methods presented in bold blue font. 
Cases with only positive PCR results presented in bold red font. 
6.3.4	Nosocomial	infection	Outbreaks	
During the study, two outbreaks occurred at the EFSTH neonatal ward - first with 
Burkholderia	cepacia, followed by K.	pneumoniae.  We proceeded to investigate these 
outbreaks in more detail. 
168 
 
Burkholderia	cepacia	
The first case of B.	cepacia bacteraemia was reported during the pilot study on 1st July 
2015. After the pilot study ended in August 2015, blood cultures were not performed 
until the initiation of the Main study in February 2016 following which five Cases were 
reported between March and May. The number of these isolates increased following 
commencement of routine blood cultures at the EFSTH Paediatrics laboratory from 
early June 2016 for neonates with severe clinical sepsis not enrolled in my PhD study. 
This laboratory is supported by the MRCG and all isolates are sent to the MRCG for 
confirmation. The total numbers of blood samples sent to the Paediatrics laboratory in 
June, July and August were 43, 30, and 38 and the proportion of B.	cepacia isolated from 
these samples were 35%, 27%, and 58%, respectively. However, case fatalities in these 
three months were no different from those observed during the same months in the 
previous three years. There were 49 episodes of B.	 cepacia bacteraemia from 47 
neonates admitted on the EFSTH neonatal ward from March to August 2016 (Figure 
6.12) shows the monthly distribution of cases over the course of the outbreak. The 
characteristics and outcomes of B.	Cepacia Cases are detailed in Table 6.28. 
 
Figure	6.12	Monthly	distribution	of	Burkholderia	cepacia	cases	during	an	outbreak	at	the	
neonatal	unit,	EFSTH	between	March	and	August	2016	
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Table	6.28	Characteristics	and	outcome	of	neonates	with	Burkholderia	cepacia	bloodstream	infection	
during	an	outbreak	at	the	neonatal	ward,	EFSTH,	March	–	August	2016	
ID	 Category	 Date	of	birth	
Date	of	
admission	
Date	of	
culture	
Age	at	
culture	 Sex	 Place	of	delivery	 Outcome	
Case B 1 Study participant 20-Feb-16 07-Mar-16 08-Mar-16 17 M ASB German Clinic Discharged 
Case B 2 Study participant 07-Mar-16 08-Mar-16 09-Mar-16 2 M Kanifing General Hospital Died 
Case B 3 Study participant 09-Mar-16 09-Mar-16 10-Mar-16 1 F Kanifing General Hospital Died 
Case B 4 Study participant 12-Apr-16 14-Apr-16 15-Apr-16 3 F Westfield Clinic Discharged 
Case B 5 Study participant 14-May-16 16-May-16 16-May-16 2 F Serekunda Health Centre Died 
Case B 6 Study participant 02-Jun-16 06-Jun-16 07-Jun-16 5 F Sukuta Health Centre Discharged 
Case B 7 Other inpatient 14-Jun-16 NA 16-Jun-16 2 F NA Discharged 
Case B 8 Other inpatient 12-Jun-16 14-Jun-16 16-Jun-16 4 F Sukuta Health Centre Died 
Case B 9 Other inpatient 09-Jun-16 09-Jun-16 16-Jun-16 5 M EFSTH Discharged 
Case B 10 Other inpatient 05-Jun-16 NA 16-Jun-16 11 M EFSTH Discharged 
Case B 11 Other inpatient 17-Jun-16 17-Jun-16 20-Jun-16 3 M EFSTH Discharged 
Case B 12 Other inpatient 12-Jun-16 14-Jun-16 20-Jun-16 8 F Gunjur Health Centre Died 
Case B 13 Study participant 20-Jun-16 21-Jun-16 22-Jun-16 2 M Sukuta Health Centre Died 
Case B 14 Other inpatient 22-Jun-16 22-Jun-16 23-Jun-16 1 M NA NA 
Case B 15 Other inpatient 16-Jun-16 NA 23-Jun-16 7 M NA NA 
Case B 16 Other inpatient 16-Jun-16 NA 24-Jun-16 8 F NA NA 
Case B 17 Other inpatient 25-Jun-16 NA 29-Jun-16 4 F NA NA 
Case B 18 Other inpatient 26-Jun-16 27-Jun-16 30-Jun-16 4 M Bundung MCH Hospital Discharged 
Case B 19 Other inpatient 28-Jun-16 NA 30-Jun-16 2 M NA NA 
Case B 20 Study participant 04-Jul-16 04-Jul-16 09-Jul-16 1  F Sukuta Health Centre Died 
Case B 21 Other inpatient 29-Jun-16 30-Jun-16 11-Jul-16 3 M Serekunda Health Centre Discharged 
Case B 22 Other inpatient 08-Jul-16 10-Jul-16 13-Jul-16 3 M Essau Health Centre Discharged 
Case B 23 Other inpatient 12-Jul-16 13-Jul-16 13-Jul-16 1 M Fajikunda Health Centre Died 
Case B 24 Other inpatient 25-Jun-16 NA 13-Jul-16 19 M NA NA 
Case B 25 Other inpatient 13-Jul-16 13-Jul-16 14-Jul-16 1 F MRC Keneba Died 
Case B 26 Other inpatient 23-Jul-16 25-Jul-16 27-Jul-16 4 F Fajikunda Health Centre Died 
Case B 27 Other inpatient 24-Jul-16 24-Jul-16 27-Jul-16 3 M Brikama Health Centre Died 
Case B 28 Other inpatient 27-Jul-16 28-Jul-16 02-Aug-16 6 M Kanifing General Hospital Died 
Case B 29 Other inpatient 28-Jul-16 28-Jul-16 03-Aug-16 6 F Kanifing General Hospital Discharged 
Case B 30a Other inpatient 01-Aug-16 01-Aug-16 03-Aug-16 2 F Bansang General Hospital Died 
Case B 31 Other inpatient 29-Jul-16 07-Mar-16 03-Aug-16 5 F  Discharged 
Case B 32 b Other inpatient 01-Aug-16 02-Aug-16 03-Aug-16 2 F NA  
    08-Aug-16 9 F   
    23-Aug-16 22 F  Died 
Case B 33 c Other inpatient 03-Aug-16 03-Aug-16 04-Aug-16 1 M Kanifing General Hospital Died 
Case B 34 Other inpatient 05-Aug-16 05-Aug-16 08-Aug-16 3 F Kanifing General Hospital Discharged 
Case B 35 Other inpatient 03-Aug-16 04-Aug-16 08-Aug-16 5  F Brikama Health Centre NA 
Case B 36 Other inpatient 03-Aug-16 NA 09-Aug-16 6  M NA NA 
Case B 37 Other inpatient 25-Jul-16 NA 09-Aug-16 15  M NA NA 
Case B 38d Study participant 08-Aug-16 08-Aug-16 09-Aug-16 1 F Kanifing General Hospital Discharged 
Case B 39 Other inpatient 03-Aug-16 NA 11-Aug-16 8  F NA Discharged 
Case B 40 Other inpatient 05-Aug-16 05-Aug-16 12-Aug-16 7   F Bundung MCH Hospital Discharged 
Case B 41 Other inpatient 06-Aug-16 06-Aug-16 12-Aug-16 6  M Home Died 
Case B 42 Other inpatient 14-Aug-16 16-Aug-16 16-Aug-16 2  M NA Discharged 
Case B 43 Other inpatient 09-Aug-16 NA 22-Aug-16 13 F NA NA 
Case B 44e Study participant 10-Aug-16 18-Aug-16 22-Aug-16 12 M Brikama Health Centre Died 
Case B 45 Other inpatient 20-Aug-16 NA 22-Aug-16 2 F NA NA 
Case B 46 Other inpatient 17-Aug-16 NA 23-Aug-16 6  M NA Died 
Case B 47 f Other inpatient 15-Aug-16 NA 29-Aug-16 12  F NA Discharged 
a This baby had mixed infection with Acinetobacter	baumanii. 
b This baby had 3 consecutively positive blood cultures with Burkholderia	cepacia 
c This baby had mixed infection with Acinetobacter	baumanii. 
d This study participant had a previous (admission) blood culture positive for Acinetobacter	baumanii  
e This study participant had a previous (admission) negative blood culture 
f  This baby had mixed infection with Staphylococcus	aureus. 
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Outcome data from some of the non-study participants were not available to me. The 
CFR was 50% (18/36) for the 36 B.	Cepacia cases with available outcome data. One of 
the Cases (Case B32) had three separate positive blood cultures and succumbed to 
infection.	
All B.	 cepacia isolates were sensitive to co-trimoxazole, gentamicin, ciprofloxacin, 
ceftazidime, and chloramphenicol, but demonstrated resistance to tetracycline and 
amoxicillin-clavulanate.	
Outbreak	investigation	
An outbreak investigation team comprising staff from the EFSTH and MRCG was set up 
on 1st September 2016 to detect the potential reservoir(s) of B.	cepacia infection and the 
modes of transmission of the infection to the neonates in the neonatal ward. The team, 
led by an epidemiologist, consisted of the neonatologist, three paediatricians (including 
myself), two microbiologists, a molecular biologist and the head of the hospital Infection 
Control Unit. Fortnightly meetings were held where the members of the team discussed 
the progress of the investigation and took decisions on implementation of interventions. 
An epidemiologic investigation was carried out and 90 environmental samples were 
collected from the neonatal ward between 5th – 8th September 2016.  Table 6.29 lists all 
the different samples collected and the yield of B.	cepacia. All clinical and environmental 
Burkholderia were sent to Imperial College London, for species level identification by 
whole genome sequencing, the results of which are not yet available. 
 
 
 
171 
 
Table	6.29	EFSTH	neonatal	ward	samples	and	isolation	of	Burkholderia	cepacia	
Samples	(number	of	sources/samples	collected)	 Type	of	sample	 Date	of	collection	 Culture	result	
IV fluid – 10% Dextrose with/without NaCl and KCl [In use] Fluid 05/09/2016 B.	cepacia isolated 
Injection - Gentamicin - diluted with Normal saline [In use] Fluid 05/09/2016 B.	cepacia isolated 
IV fluid – 10% Dextrose with/without NaCl and KCl [In use] Fluid 08/09/2016 B.	cepacia isolated 
IV fluid – 10% Dextrose with/without NaCl and KCl [In use] Fluid 08/09/2016 B.	cepacia isolated 
Injection - Metronidazole [In use] Fluid 08/09/2016 B.	cepacia isolated 
IV fluid – Normal saline [In use] Fluid 08/09/2016 B.	cepacia isolated 
Water from O2 humidifier (1) Fluid 05/09/2016 Negative 
Hand sanitizer (2) Fluid 05/09/2016 Negative 
Tap water from main ward (1) Fluid 05/09/2016 Negative 
Tap water from critical care ward (1) Fluid 08/09/2016 Negative 
Water from O2 humidifier (2) Fluid 08/09/2016 Negative 
IV fluid – Ringer lactate [In use] (1) Fluid 08/09/2016 Negative 
IV fluid – 10% dextrose [Stock] (2) Fluid 08/09/2016 Negative 
IV fluid – Normal saline [In use] (1) Fluid 08/09/2016 Negative 
IV fluid – Norman saline [Stock] (1) Fluid 08/09/2016 Negative 
IV fluid – Ringer lactate [Stock] (2) Fluid  08/09/2016 Negative 
Injection - Gentamicin [In use] (1) Fluid 08/09/2016 Negative 
Injection - Ciprofloxacin [In use] (2) Fluid 08/09/2016 Negative 
Injection - Ceftriaxone [In use] (1) Fluid 08/09/2016 Negative 
Injection - Metronidazole [In use] (1) Fluid 08/09/2016 Negative 
Injection - Ceftazidime [In use] (1) Fluid 08/09/2016 Negative 
Injection - Gentamicin [Stock] (2) Fluid 08/09/2016 Negative 
Injection - Vitamin K (1) Fluid 08/09/2016 Negative 
Injection - 5 % glucose [Stock] (2) Fluid 08/09/2016 Negative 
Injection - Metronidazole [Stock] (1) Fluid 08/09/2016 Negative 
Water for injection (1) Fluid 08/09/2016 Negative 
Povidone iodine (1) Fluid 08/09/2016 Negative 
Clean magic [Cleaning fluid; concentrated & diluted] (1) Fluid 08/09/2016 Negative 
Feeding pot (2) Swab 05/09/2016 Negative 
Incubator surface (1) Swab 05/09/2016 Negative 
Kidney dish (2) Swab 05/09/2016 Negative 
Sink surface (2) Swab 05/09/2016 Negative 
Bed surface (4 beds) Swab 05/09/2016 Negative 
BACTEC Peds blood culture vials (1) Swab 05/09/2016 Negative 
BACTEC 9050 Instrument surface (1) Swab 05/09/2016 Negative 
Umbilicus (3 babies) Swab 05/09/2016 Negative 
Nasal prong [In use] (4) Swab 05/09/2016 Negative 
Stethoscope (2) Swab 05/09/2016 Negative 
Radiant heater (3) Swab 05/09/2016 Negative 
IV cannula (3) Swab 05/09/2016 Negative 
Suction tube (1) Swab 05/09/2016 Negative 
Thermometer (1) Swab 05/09/2016 Negative 
Weighing scale (1) Swab 05/09/2016 Negative 
Staff hands (2 staff) Swab 05/09/2016 Negative 
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All neonates on admission are given a bed-bath 2-3 times a week (personal 
communication with ward Matron). This is meant to be carried out by the nursing staff 
however, due to shortage of nursing staff, it is done by the mothers who use foam 
sponges. During the outbreak investigation, these sponges were noticed to be lying 
about the ward (often soaking wet in plastic containers on the floor or window sill) and 
10 samples of these sponges were randomly collected for culture. Although none grew 
B.	cepacia, all 10 samples grew multiple pathogenic bacteria (Table 6.30) 
Table	6.30	Pathogens	isolated	from	randomly	selected	foam	sponges	used	by	mothers	to	bath	
babies	admitted	on	the	EFSTH	neonatal	ward	during	an	investigation	of	a	Burkholderia	cepacia	
outbreak	
Sample	 Location	 Date	of	
collection	
Culture	result	
Sponge 1 Critical care ward 05/09/2016 Acinetobacter	baumanii,	Escherichia	coli,	Rhizobium	radiobacter	
Sponge 2 Critical care ward 05/09/2016 Klebsiella	pneumoniae,	Pseudomonas	aeruginosa,	Acinetobacter	baumanii	
Sponge 3 Critical care ward 05/09/2016 Acinetobacter	baumanii,	Vibrio	metselinlavii,	Chryseobacterium	intogenes	
Sponge 4 Critical care ward 05/09/2016 Klebsiella	pneumoniae,	Acinetobacter	baumanii	
Sponge 5 Stable ward 05/09/2016 Acinetobacter	baumanii,	Chryseobacterium	intogenes	
Sponge 6 Stable ward 05/09/2016 Chryseobacterium	intogenes,	Klebsiella	pneumoniae,	CoNS	
Sponge 7 Stable ward 05/09/2016 Pseudomonas	luteola,	Acinetobacter	baumanii	
Sponge 8 Stable ward 05/09/2016 Acinetobacter	baumanii,	CoNS	
Sponge 9 Sepsis ward 05/09/2016 Klebsiella	pneumoniae,	Pseudomonas	luteola	
Sponge 10 Sepsis ward 05/09/2016 Acinetobacter	haematolyticus,	Escherichia	coli,	
 
As part of the epidemiological investigation, clinical procedures and practices by the 
staff were observed in order to identify potential sources of infection. The infection 
control review revealed lapses in nursing procedures (Figure 6.13) and suboptimal 
adherence to hand hygiene. Practices observed included the use of a single bottle of 
normal saline to dissolve/dilute all antibiotics with repeated insertions of a single 
syringe into the infusion bottle; storage of injections and intravenous fluids in use on an 
open medicine trolley next to the sink; and failure to wash and dry hands properly after 
contact with a newborn. 
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Infection	control	interventions	
Several infection control measures were initiated in phases after detection of an 
increase in the number of cases, and before the outbreak was formally investigated 
(Table 6.31). Although no further Cases of B.	cepacia were identified in September and 
A) Intravenous fluids mixing area with used and 
unused bottles of intravenous fluids and repeated-
use syringes (Kidney dish)  
 
B) The medication trolley during the 
adminsitration drug rounds.  
Figure	6.13	Potential	sources	of	infection	on	the	EFSTH	neonatal	ward	–	intravenous	
fluids,	parenteral	injections,	drug	storage	and	hand	washing	facilities	
C) Drug and consumables cupboard D) Hand washing and sterilisation area. Containers 
underneath the sink contain water (red-capped can, 
blue bucket), and re-useable devices soaked in 
disinfectant solution (transparent and yellow 
buckets) 
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October, infection surveillance continued until the end of the year with environmental 
sampling every 2 months. One further Case was identified in November but with a 
different susceptibility profile from those isolated during the initial outbreak.  
Table	6.31	Phased	infection	control	measures	instituted	following	outbreak	of	Burkholderia	
cepacia	on	the	EFSTH	neonatal	ward	
Infection	control	measures	 Implementation	date	
Reduction in the course of antibiotics to 72 hours in cases classified as high risk of sepsis March 2016 
Established the changes in cannulas at 5 days or when signs of phlebitis are present. March 2016 
Implemented daily disinfection of incubators and cribs done by nurses and nurse attendances April 2016 
Established changing incubators and cribs at five days of admission April 2016 
Instruct mothers not to use a sponge when bathing the newborn and institute the use of two 
washcloths for babies’ bath: one for the face and the second for rest of the body.  
August 2016 
Established storage of all drugs and IV fluids, both used and unused, in a refrigerator located in the 
neonatal unit. 
September 2016 
 
Stop diluting gentamicin with dextrose or normal saline. Water for injection to be used for dilution if 
needed. One-ml syringes to be used for small neonates. 
September 2016 
 
Water for injection to be used for re-constituting antibiotics September 2016 
Hand washing – fully implemented using WHO guidelines September 2016 
Use different syringes for mixing different fluids September 2016 
Move the medicine tray away from the sink September 2016 
Use hand towels September 2016 
Educate mothers to dry towel in a proper place September 2016 
Health education – emphasize on infection control using health talks September 2016 
Visitor control improved September 2016 
Restricted access to mothers of critically ill babies during ward rounds.  October 2016 
 
Multi-drug	resistant	extended-spectrum	beta	lactamase	(ESBL)	K.	pneumoniae	
On 26th October 2016, two months after the last case of B. cepacia, multi-drug resistant 
extended-spectrum beta lactamase (ESBL) K.	pneumoniae was isolated from the blood 
of a six-day old neonate on admission at the EFSTH neonatal ward. Between October 
and December, 25 neonatal blood culture samples from non-study participants were 
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sent to the MRCG, 18 of which were positive for K.	pneumoniae with the same antibiotic 
susceptibility profile indicating a common source. The characteristics and outcomes of 
the ESBL K.	pneumonia-positive cases are summarised in Table 6.32 (study participants 
in bold red). Outcome data from the non-study participants were not available to me. 
Table	6.32	Characteristics	and	outcome	of	neonates	with	Klebsiella	pneumoniae	infection	
during	an	outbreak	at	the	neonatal	ward,	EFSTH,	October	–	December	2016	
ID	 Category	 Date	of	blood	culture	 Age(days)	 Sex	 Place	of	delivery	 Outcome	
Case K 1 Other inpatient 26-Oct-16 6 F NA NA 
Case K 2 Other inpatient 07-Nov-16 2 M NA NA 
Case K 3 Other inpatient 07-Nov-16 18 M NA NA 
Case K 4 Other inpatient 07-Nov-16 7 M NA NA 
Case	K	5	 Study	participant	 08-Nov-16	 5	 F	 EFSTH	 Discharged	
Case K 6 Other inpatient 10-Nov-16 6 M NA NA 
Case K 7 Other inpatient 10-Nov-16 39 M NA NA 
Case K 8 Other inpatient 10-Nov-16 8 F NA NA 
Case K 9 Other inpatient 12-Nov-16 4 M NA NA 
Case	K	10	 Study	participant	 15-Nov-16	 1	 F	 EFSTH	 Died	
Case K 11 Other inpatient 16-Nov-16 5 M NA NA 
Case K 12 Other inpatient 16-Nov-16 15 F NA NA 
Case K 13 Other inpatient 16-Nov-16 6 F NA NA 
Case K 14 Other inpatient 25-Nov-16 3 M NA NA 
Case K 15 Other inpatient 25-Nov-16 5 F NA NA 
Case K 16 Other inpatient 28-Nov-16 14 F NA NA 
Case K 17 Other inpatient 30-Nov-16 57 F NA NA 
Case K 18 Other inpatient 30-Nov-16 1 M NA NA 
Case K 19 Other inpatient 30-Nov-16 1 M NA NA 
Case K 20 Other inpatient 30-Nov-16 6 NA NA NA 
Case K 21 Other inpatient 30-Nov-16 27 M NA NA 
Case K 22 Other inpatient 05-Dec-16 NA M NA NA 
Case K 23 Other inpatient 05-Dec-16 NA M NA NA 
Case K 24 Other inpatient 05-Dec-16 NA M NA NA 
Case K 25 Other inpatient 07-Dec-16 3 M NA NA 
Case K 26 Other inpatient 07-Dec-16 9 M NA NA 
Case K 27 Other inpatient 08-Dec-16 NA M NA NA 
Case	K	28	 Study	participant	 19-Dec-16	 2	 F	 Mbowen	Clinic	 Discharged	
Case	K	29	 Study	participant	 19-Dec-16	 2	 M	 EFSTH	 Died	
Case	K	30	 Study	participant	 19-Dec-16	 1	 M	 Mbowen	Clinic	 Died	
Case-Control study participants presented in bold red 
NA = information not available 
176 
 
Only study participants had rectal swabs; three of the study participants (Cases K5, K28 
and K29) were also rectally colonised with K.	pneumoniae. Eight samples of intravenous 
fluids and parenteral antibiotics were collected to determine the potential source, and 
three were positive with multi-drug resistant K.	 pneumoniae.	 All clinical and 
environmental K.	 pneumoniae	 were also sent to Imperial College London, for whole 
genome sequencing along with the B.	cepacia isolates. 
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CHAPTER	7.	DISCUSSION	
 
 
 
 
 
 
 
 
 
 
A happy mother and her newborn - recovered from sepsis and ready for 
discharge 
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Overview	of	main	findings	
This PhD set out to describe the aetiology of neonatal infections in The Gambia and to 
evaluate the potential role of maternal bacterial colonisation in the acquisition of 
neonatal infections with a focus on inpatient care and sick neonates admitted with pSBI.  
In Chapter 3, the systematic review of neonatal infection aetiology studies in sSA, 
showed Klebsiella species, Escherichia coli, Staphylococcus aureus, Group B Streptococci, 
and Enterococcus to be the top five reported bacterial pathogens across all regions. 
Application of the Strengthening the Reporting of Observational Studies in 
Epidemiology for Newborn Infection (STROBE-NI) checklist highlighted wide variation 
in clarity and completeness of reporting, impeding comparability and utility. 
In Chapter 4, it was shown that despite significant improvements in child survival in 
The Gambia over a 25-year period between 1990 and 2016, neonatal mortality had 
remained stagnant. Over the same period, there had not been any formal study on the 
aetiology of neonatal infections. Pathogens associated with infection in Gambian 
newborns had only been described within the context of four published studies 
investigating infections in infants and children, and one unpublished laboratory 
surveillance study. 
In chapter 5, The four-year audit of neonatal admissions and quality of care at The 
Gambia’s largest referral hospital showed that possible serious bacterial infection 
(pSBI) accounted for 44% (2166/4944) of admissions. There was a striking mismatch 
of high antibiotic use (95%) and low microbiological investigation for infection was 
evident (1% of babies had a blood culture and 2% underwent a lumbar puncture).  
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In chapter 6, a hospital-based study was undertaken in three major urban/periurban 
health facilities in The Gambia to describe neonatal infection aetiology, and evaluate the 
role of maternal bacterial colonisation. This was a case-control study carried out over 
17 months involving 203 sick newborn-mother case pairs admitted at three major 
urban/peri-urban health facilities in The Gambia, and 203 healthy newborn-mother 
control pairs recruited from the same communities in which the families of the cases 
were resident. Colonisation parameters were compared with healthy newborns and 
their mothers in the community There were 6  key findings from this case control study:  
(a) infection is a significant problem among hospitalised newborns in The Gambia with 
pathogenic bacteria isolated from 45% of 203 blood cultures; (b) results of blood 
cultures and speciation were available before discharge or death in only 38% of Cases; 
(c) S.	aureus is the predominant clinically-significant organism associated with neonatal 
infection; (d) potential mother-to-newborn rectovaginal transmission of infection 
occurred in 14 Cases with positive blood cultures; (e) a high prevalence of neonatal 
infection associated with nosocomial outbreaks of B.	 cepacia and extended spectrum 
beta lactamase (ESBL) multi-drug resistant K.	pneumoniae was documented in the main 
tertiary referral hospital; and (f) Klebsiella isolates demonstrated high resistance to 
third-generation cephalosporins. 
The rest of this chapter presents an in-depth discussion of the findings from the case-
control study in relation to the results and conclusions from earlier chapters. 
7.1	Aetiology	of	infections	
7.1.1	Conventional	microbiology	
Although 45% of blood cultures were positive, the overall prevalence of clinically-
significant culture-positive infection was 25% (52/202). This is less than the pooled 
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prevalence of 30% from 73 previous studies identified in my systematic review of 
neonatal infection aetiology in sub-Saharan Africa (irrespective of culture method).120, 
125, 127-129, 131, 135-139, 144, 145, 148, 149, 151, 152, 154, 157-164, 173, 176, 177, 179, 180, 183, 187, 191, 195, 201, 207, 208, 
213-219, 221-223, 225, 226, 229, 231-235, 238-248, 250-252, 256   
Blood cultures appeared to have limited clinical benefit on patient management as the 
median blood culture reporting time on the study was 6 days (IQR: 5 – 7), and only 38% 
(35/91) of cases with a positive blood culture received the result before discharge or 
death. Although still representing a significant delay, this is quicker than reported in a 
similar neonatal infection prevalence and aetiology study in Zambia where the median 
time was 7 days (IQR: 5 – 9), and only 25% of Cases had blood culture results available 
before discharge or death.191  The routine practice in the MRCG clinical microbiology 
laboratory is to report both species and drug-susceptibility testing data together. Even 
when an ‘early’ preliminary result is provided for a positive culture, it is just the Gram-
stain report without speciation and antibiotic susceptibility information, as these take 
an extra couple of days. In all cases, antibiotics were started empirically while waiting 
for the diagnostic information, and therefore such preliminary results are not of great 
additional value for clinical decision-making.  
Prompt identification of microorganisms grown in blood cultures has the potential to 
enable earlier targeted clinical intervention for patients with sepsis. Matrix assisted 
laser desorption ionization time-of-flight (MALDI-ToF) mass spectrometry is a rapid 
method for identification of cultured bacterial isolates.354 It is also able to correctly 
identify up to 85% of bacteria directly from positive blood culture broths, further 
reducing the waiting time.355-357  Faster identification using MALDI-ToF has been shown 
to assist the clinician in assessing the significance of a blood culture isolate as early as 
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day one of positivity.358 This can allow earlier appropriate choice of antimicrobial agent, 
even in the absence of susceptibility testing. Unfortunately, this technology is not 
available in most low- and middle-income settings and was not available to us in The 
Gambia. More important however, is the fact that neonatal blood cultures are not 
routinely done in any of the study sites and were only available because of this study. 
Even with the donation of an incubator, a BACTEC machine to the EFSTH Paediatrics 
department’s laboratory and refresher microbiological training for the laboratory staff, 
blood cultures could not be continued due to the lack of the BACTEC Peds plus culture 
bottles.   
Staphylococcus	aureus	
S.	aureus	was the predominant [25% (13/52)] clinically significant blood culture isolate 
accounting for an equal proportion (8/32) of early-onset infection Cases and 37% 
(5/14) of late-onset infection Cases. Our finding of S.	aureus predominance is in keeping 
with an earlier study of infection aetiology among young Gambian infants in the early 
1990s (conducted at the now EFSTH and the MRCG) where Gram-positive bacteria were 
the leading cause of bacteraemia among neonates, with S.	aureus	as the major isolate.254 
Similarly, retrospective laboratory surveillance data from the MRCG Clinical 
microbiology laboratory for the period 2005 – 2015 showed S.	 aureus as the 
predominant isolate from neonatal blood cultures (Darboe et al; unpublished data; 
Chapter 4, Table 4.2).   
S.	aureus is also very highly prevalent across sSA where it has been reported among the 
top five pathogens associated with neonatal infections in hospital-based studies, and is 
the predominant pathogen in West Africa (Chapter 3; Figure 3.4). The role of S.	aureus 
as a true neonatal pathogen in sSA remains unclear, and its consistent identification as a 
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possible pathogen might be due to several reasons. First is because of horizontal 
transmission in facility-based deliveries and person-to person transmission in home 
deliveries resulting in colonization and infection.359 Lack of appropriate hygiene during 
labour (including repeated intrapartum vaginal examinations), and failure to use 
fastidious aseptic technique during delivery and initial care of the baby can lead to 
infections with very early onset, as well as transmission of pathogens from one mother 
in labour to another.21 Second is possible contamination at the time of sampling due to 
inadequate site sterilization resulting in the inoculation of bacteria into the blood 
culture bottles particularly where there is S.	 aureus skin carriage.360 In this study, 
stringent aseptic measures were taken to avoid contamination during phlebotomy; 
however, eliminating the access of skin flora and/or environmental bacteria into blood 
specimens during phlebotomy and inoculation of blood culture bottles is not possible.260 
Lastly, contamination can occur in the laboratory while processing the specimens and 
culture plates.360 In developed countries, S.	 aureus infection is more commonly 
associated with late-onset nosocomial sepsis and neonatal unit outbreaks, the main 
source of infection being the hands of health-care providers.82, 360 
The true burden of disease in this setting is likely underestimated since most neonatal 
staphylococcal disease develops 1 – 3 weeks after discharge from hospital.361 Cases in 
this study were not followed up beyond the end of the neonatal period (Day 27), but 
among the culture-negative Cases discharged before 27 days postnatal age, one died at 
home with a history of widespread severe skin infection suggesting S.	aureus infection. 
Klebsiella	species	
Klebsiella species (K.	 pneumoniae and K.	 oxytoca) were the second most commonly 
isolated clinically significant pathogen in this study. Klebsiella is the second leading 
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reported pathogen responsible for neonatal infections across sSA after S.	 aureus	
(Chapter 3; Figure 3.4). Klebsiella was not previously identified by Mulholland et al348 as 
a cause of neonatal bacteriaemia in The Gambia; however, MRCG laboratory 
surveillance data reveal it to be the second most commonly isolated pathogen from 
neonatal blood cultures (Darboe et al; unpublished data; Chapter 4, Table 4.2). As 
mentioned previously, the observed change may represent a methodological change 
rather than an epidemiologic difference. During the Main study, an outbreak of K.	
pneumoniae occurred in one of the study sites and is discussed below. Again, this 
outbreak may have skewed the results leading to an overestimation of bacteraemia in 
this study. 
Pseudomonas	species	and	Burkholderia	cepacia	
Pseudomonas	 species and Burkholderia	 (previously Pseudomonas)	 cepacia	 together 
accounted for 31% (16/52) of clinically significant blood culture isolates in this study 
(Table 6.11), and were both among the leading causes of early-onset infection (Table 
6.12). These Gram-negative, aerobic bacteria are commonly found in soil and moist 
environments and are capable of surviving and growing in nutrient-poor water.362 Both 
pathogens are known to cause common-source outbreaks because they thrive in multi-
use containers of medications, liquid soaps, antiseptics and disinfectants, as well as on 
inadequately reprocessed equipment or hospital tap water; the so-called “water 
bugs”.21, 82, 363, 364 365 366, 367 Although long recognised as a neonatal pathogen,368 
Burkholderia	 is mostly associated with respiratory infections in persons with cystic 
fibrosis.369 Neither pathogen had previously been  identified as a cause of neonatal 
sepsis in The Gambia,348 but Pseudomonas was the third most commonly reported 
neonatal blood culture isolate after S.	 aureus and Klebsiella species in the MRCG 
laboratory surveillance data. Although the MRCG was one of the sites for the study by 
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Mulholland et al,348 the observed change may represent a methodological change rather 
than an epidemiologic difference, and is to be interpreted with caution. The choice of 
blood culture bottle and system are among the important factors in the ability of blood 
cultures to detect significant organisms.370, 371 The earlier study employed manual 
culture methods using tryptic soy broth (TSB) and brain-heart infusion containing 
sodium polyanethol sulfonate (Roche Diagnostica, Basel, Switzerland). Since 2004, 
MRCG has used the BACTEC automated blood culture system. Secondly, sick neonates 
are not routinely admitted at the MRC Clinical services department except as 
participants of ongoing studies and only where referral is not possible. The laboratory 
surveillance data is therefore not representative of neonates in the same catchment 
area in which the earlier study was carried out.   
The isolation of B.	cepacia in a Case during the Pilot study was the first time it had been 
reported in The Gambia, and its subsequent isolation in increased numbers in one of the 
study sites during the main study led to an outbreak investigation discussed below. The 
outbreak may have skewed the results in this study leading to an over-estimation of the 
prevalence of neonatal infection. 
Other	Gram-positive	bacteria	
One of the striking findings of our study was the paucity of clinically-significant Gram-
positive organisms other than S.	 aureus. This is again in keeping with the report by 
Mulholland et al348	where one Case each of S.	pneumoniae, Group A Streptococci (GAS) 
and GBS were reported  from 19 neonatal blood cultures compared with 9 Cases of S.	
aureus over a 25-month period. The MRCG clinical laboratory surveillance data similarly 
showed fewer cases of S.	pneumoniae (4) and GBS (3) compared with S.	aureus (33) over 
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an 11-year period. Interestingly, none of these organisms were isolated in this study but 
rather three Enterococci and two Streptococcus species. 
GBS is a leading neonatal sepsis pathogen globally, and the dominant pathogen in 
developed countries.271 In high neonatal and infant mortality regions like sSA, whether 
GBS is as important a cause of neonatal disease remains a major question.264, 266  In the 
previously discussed review of neonatal infection aetiology in sSA, there appear to be 
regional variations in disease burden, with the highest burden reported from Southern 
Africa and the lowest burden reported from West Africa (Chapter 3; Figure 3.4 and 
Table 3.5). Intra-regional variations in disease burden is also apparent: almost 60% of 
reported GBS cases in Southern Africa were reported by 15 studies from South 
Africa,130, 171, 172, 174, 175, 177, 179-182, 184, 185, 187-189 where the incidence of invasive GBS 
disease has been shown to again vary markedly at provincial level.261 These findings 
from South Africa may shed some light on some of the reasons for the apparent wide 
variation in neonatal GBS disease in sSA: widespread empiric antibiotic treatment 
before referral, operational factors such as sampling techniques, blood culturing 
practices by attending physicians, variability in laboratory capacity, and suboptimal 
laboratory methods.99, 112, 261 Other possible explanations include fundamental 
differences in disease epidemiology due to differences in strain virulence, or antibody 
levels, under identification of early-onset cases especially among home births due to 
challenges in accessing healthcare, or use of delivery practices promoting Gram-
negative infections in some settings.22, 261 
It is difficult to ascertain which of these reasons is at play in The Gambia. The EFSTH is 
the only public-sector hospital in The Gambia with blood and CSF culture facilities. 
Variability in laboratory capacity between the EFSTH and the MRCG is well 
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recognised.99 The MRCG uses state-of-the-art automated blood culture methods in 
accredited laboratories; the EFSTH main hospital laboratory uses older manual 
methods and is plagued by stock-outs of laboratory supplies (personal communication 
with Head of Microbiology Laboratory) which has partly contributed to the poor 
practice of  undertaking microbiological tests, including blood and CSF culture, in 
neonates with suspected sepsis. In a review of studies reporting neonatal GBS disease 
from developing countries, neonatal GBS incidence rates were consistently higher 
among studies using automated culture methods (0.80–3.06 per 1000 live births 
automated vs 0–0.39 per 1000 live births manual).261 The greatest risk for the 
development of GBS neonatal sepsis is within the first 2 days after birth and under-
ascertainment of early-onset GBS cases is possible if a significant proportion of the 
population gives birth outside of the hospital and access to healthcare is challenging, as 
most neonates will die before diagnosis.261  Under-ascertainment of home births may 
play a less significant role in this setting as 75% - 93% of women in the study area 
deliver in a health facility279 and less than 10% of neonates admitted to the EFSTH 
neonatal unit are born at home.99 Maternal colonisation is the leading risk factor for 
both early and late onset GBS disease.372 Newborns of mothers with colonisation or 
chorioamnionitis have been found to develop sepsis faster and are at higher risk of 
developing sepsis compared with non-exposed newborns.373 Maternal chorioamnionitis 
was not examined in this study although data was collected on reported maternal 
intrapartum fever which showed that Cases with clinically significant infection were 
significantly more likely to have been born to mothers with reported intrapartum fever 
(Table 6.13). Recent data from Gambia show that GBS colonisation is present in 34% of 
women at delivery 253 which is similar to the reported pooled prevalence of 30.4% in 
South African women.374 However, unlike South Africa where serotypes III and Ia are 
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the dominant serotypes among vaginal and neonatalcolonising isolates 375rectovaginal 
and neonatal colonisation among Gambian women and their infants is dominated by 
serotype V.253 Globally, type III is the most virulent and common invasive serotype in 
neonates <7 days of age).375, 376 Although data is lacking on GBS serotypes causing 
invasive neonatal disease in The Gambia, the rarity of GBS disease in Gambian 
newborns may be due to lower rates of maternal carriage with the more virulent GBS 
serotypes. 
Other	Gram-negative	bacteria	
Cases of infection due to other Gram-negative bacteria - E.	 coli,	 Acinetobacter,	
Salmonella,	 Citrobacter	 and	 Enterobacter - collectively accounted for 14% of all 
clinically-significant isolates in this study. This is different from the report by 
Mulholland et al,348 in which Salmonella was identified as the main Gram-negative 
pathogen associated with neonatal bacteraemia in The Gambia. In the 10 years covered 
by the MRCG clinical laboratory surveillance, there were only three cases of neonatal 
bacteraemia due to E.	 coli, two due to Enterobacter, and one due to Acinetobacter 
(Darboe et al; unpublished data; Chapter 4, Table 4.2).   Again, the observed change may 
represent a measurement change rather than an epidemiologic difference, and is to be 
interpreted with caution. Enterobacter and Acinetobacter are not major pathogens 
reported in sSA, while E.	 coli is more commonly reported in Central African studies 
compared with other regions. 
Unusual	bacteria	
Two unusual pathogens were isolated from cases in this study. The first was 
Achromobacter xylosoxidans (formerly known as Alcaligenes xylosoxidans). This non-
fermentative non-enteric Gram-negative bacillus inhabits aquatic environments, 
including well water, intravenous fluids, and water in humidifiers, and is considered one 
188 
 
of the “water bugs”.364, 377, 378 A.	xylosoxidans can be confused with other non-fermenting 
Gram-negative bacteria, especially Pseudomonas and correct identification of this 
organism is of clinical importance as A.	xylosoxidans is usually multi-drug resistant and 
the source of infection needs to be pursued.379 In this study, the identity of non-enteric 
bacteria was done using the manual API 20NE identification system (bioMérieux) which 
is known to consistently identify A.	xylosoxidans correctly.380  Septicaemia caused by this 
organism is rare and occurs usually in immunocompromised hosts and neonates.381-383 
The mortality rate of neonatal infections ranges from 13% to 75%.382, 383  Preterm or 
SGA term infants are at particular risk of acquiring severe Achromobacter infections. 
Although most neonatal infections are nosocomial, vertical transmission from mother to 
baby has been described.382 The case of A.	xylosoxidans in this study was an 8-day old 
male born at (and recruited from) Brikama Health Centre. He was discharged after 6 
days on admission but his blood culture result only became available 2 days after he 
was discharged. Whilst on admission, he received ampicillin, cloxacillin and gentamicin 
but the antibiotic susceptibility profile showed that this isolate was resistant to all three 
antibiotics and susceptible only to ceftazidime. At follow-up on day 27, this neonate was 
found to be alive and well. The fact that this neonate recovered and remained well even 
weeks after discharge despite A.	xylosoxidans being resistant to the antibiotics received 
strongly suggests that this isolate might have been a contaminant, the source of which is 
not readily explained.  
The second unusual pathogen was Pantoea	species, a genus of Gram-negative bacteria 
of the family Enterobacteriaceae, usually isolated from soil, fruit, and vegetables. Among 
the species of this genus, only P.	 agglomerans, formerly known as Enterobacter 
agglomerans, is most commonly isolated in hospitals.384 It is an unusual cause for 
neonatal sepsis, and infections are usually associated with outbreaks traced to 
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contaminated parenteral nutrition, intravenous anaesthetics, or packed 
erythrocytes.384-389 The index case was a term day-old female born through assisted 
breech delivery at the EFSTH and referred to the EFSTH neonatal ward from the 
postnatal ward. The blood culture result was received within 3 days of sampling. The 
isolate was resistant to the three antibiotics that were administered (ampicillin, 
cloxacillin, and gentamicin) and sensitive to the only third-generation cephalosporin 
available, ceftriaxone. However, the antibiotics were not changed based on the 
sensitivity report; the newborn improved after 7 days of antibiotics and was discharged 
in good health. She was however lost to follow-up and her outcome on day 27 could not 
be ascertained. The fact that she improved on her initial treatment despite the contrary 
antibiotic susceptibility profile, strongly suggests that this isolate might also have been 
a contaminant.  
Coagulase-negative	staphylococci		
CoNS were the most abundant pathogen isolated in this study accounting for 35% 
(32/91) of all positive blood cultures, but are considered clinically non-significant based 
on the MRCG clinical laboratory protocol and therefore not subjected to antibiotic 
susceptibility testing. CoNS are common inhabitants of the skin and mucous 
membranes; although a small proportion of neonates acquire CoNS by vertical 
transmission, acquisition primarily occurs horizontally from the hospital environment, 
the hands of their parents and hospital staff.390, 391 In developed countries, CoNS is a 
major pathogen involved in late-onset infection, particularly among preterm and VLBW 
(<1500g) neonates.73, 79 Within the first week of life, neonates become rapidly colonised 
by microorganisms originating from the environment.95, 390, 392 During this period and 
among those admitted on neonatal intensive care units (NICUs), the risk of CoNS 
infection increases substantially with the use of ventilator support, indwelling devices, 
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parenteral nutrition, and exposure to other invasive skin or mucosa-breaching 
procedures.393-395  
The role of CoNS is less well defined in developing countries where the burden of 
preterm birth is high and associated mortality even higher.396, 397 Facilities for 
supportive care are much more limited in these settings; consequently, indwelling 
devices and invasive ventilation are much less frequently used, and if used, are 
restricted to urban referral centres.99, 398, 399 In this context, the extent to which CoNS 
acts as a neonatal pathogen is unclear. In sSA, some studies reported it as a pathogen138, 
139, 144, 145, 148, 152, 154, 156, 157, 160, 172, 177, 180, 181, 183, 184, 188, 191, 201, 204, 208, 214, 219, 221-223, 225, 226, 233, 
234, 237, 240, 241 and others excluded it as a contaminant.124, 159, 254   
Despite the high likelihood that CoNS usually represents a contaminant when isolated 
from blood cultures, determining the likelihood of true bacteraemia can be challenging 
for clinicians and cannot be decided solely on the identity of the organism.360 There is 
no blanket approach to classifying CoNS as a true neonatal pathogen or contaminant.  A 
careful examination of clinical and laboratory data (e.g. CRP levels) is necessary in order 
to determine the clinical relevance of the isolated strains.400  In this study, no major 
differences in relation to gestational age or birth-weight or previous antibiotic use were 
identified between Cases with CoNS infection and those with clinically significant 
bacteria. CRP levels were not measured. It is therefore difficult to determine the clinical 
significance of Cons in this setting, as it is possible that in some Cases it is a true 
pathogen and in others a contaminant.   
Neonatal	meningitis	
Notable in this study is the poor practice of performing diagnostic lumbar punctures at 
the time of admission for neonates that met the clinical criteria for the procedure, the 
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reason being that such neonates are deemed to be too ill and unstable to undergo the 
procedure at the time. Most diagnostic lumbar punctures were performed after more 
than 72 hours on admission by which time the neonates had received several doses of 
antibiotics. These CSF samples were all processed at the EFSTH main hospital 
laboratory and all were sterile on culture. 
Antimicrobial	resistance		
The success of treatment for an infectious disease depends on the isolated pathogens 
being susceptible to treatment choices. For Klebsiella, there was near universal 
resistance to both first-line (gentamicin and penicillin/ampicillin) and second-line 
therapy (third-generation cephalosporins) driven by ESBLs. Pooled resistance data 
from neonatal infection aetiology studies in sSA show similar high levels of resistance 
(Chapter 3, Table 3.6), consistent with the high degree of antimicrobial resistance 
documented in other regions of the world.115  In the light of these data, the current WHO 
guidelines appear to be inadequate for the treatment of drug-resistant infections in 
neonates in community and hospital settings, particularly outbreaks of ESBL 
Enterobacteriaceae. Alternative therapeutic options, such as carbapenems, are limited 
and expensive for most countries in sSA; although in those countries where they are 
used, resistance rates as high as 50% to carbapenems have been reported for Klebsiella, 
E.	 coli and S.	 aureus, and the prevalence of carbapenemase-producing 
Enterobacteriaceae is increasing.401  
Antibiotic resistance arises from poor infection control practices and gross overuse or 
inappropriate or prolonged use of antibiotics.402 In a review of antibiotic prescribing 
patterns among neonatal admissions at the EFSTH, 27% of newborns received three 
antibiotics or more during admission in the absence of guidance from culture and 
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sensitivity results; treatment lasted as long as 3 – 4 weeks in some.99 Reductions in 
price and local clinical experience is leading to third-generation cephalosporins being 
commonly used as first-line treatment for severe sepsis in many developing countries 
raising concerns about the spread of bacteria that are dually resistant to both first and 
second-line treatment.402 In this study, 14% (27/195) of Cases that were treated with 
antibiotics on admission received ceftriaxone as first-line treatment; 63% (17/27) of 
these (all recruited at EFSTH) had not previously been exposed to any antibiotic. It is 
not clear why ceftriaxone was the first-line treatment for these 17 neonates given that 
they had not been exposed to antibiotics prior to admission. The ‘antibiotic guidelines’ 
in use at the study sites recommend the use of ampicillin and gentamicin as first-line 
treatment for pSBI (with addition of cloxacillin where there is suspicion of S.	 aureus 
infection) and ceftriaxone used as second-line. The EFSTH neonatal ward has the most 
staff with one neonatologist, and several junior doctors (usually one1 - 2 medical 
officers and between 4 – 6 house officers); the neonatal wards in other sites are 
overseen by medical officers only. Sick newborns are usually admitted by the more 
junior doctors (at the EFSTH this is the house officer) and reviewed by the medical 
officer; prescription of medications is therefore subject to the clinical assessment of the 
admitting doctor who might judge the newborn ‘too ill’ for the recommended first-line 
medications.  
Simple and scalable infection control interventions can reduce the burden of multidrug-
resistant bloodstream infections in neonates. In a before-and-after study conducted in 
the neonatal unit of the Hôpital Principal de Dakar, Senegal, Landre-Peigne and 
colleagues demonstrated the efficacy of a multifaceted hospital infection control 
programme in decreasing in the rate of neonatal nosocomial bloodstream infections 
(especially for K.	 pneumoniae ESBL sepsis) and the prevalence of resistant strains 
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without additional expenditure or work for the staff.252 The interventions included 
clustering of nursing care, a simple algorithm for empirical therapy of suspected early-
onset sepsis, minimal invasive care, and promotion of early discharge of neonates. 
Clustering of nursing care procedure involved sharing patients rather than duties. Each 
nurse or attendant was supposed to perform all care for each newborn for which she 
was responsible, and to wash her hands before attending to another infant. Previously, 
the nursing care staff shared duties and performed them serially for all newborns. The 
clustering of nursing care procedures reduced the number of patient contacts and thus 
the risk of cross-contamination in this unit with limited physical space. Protocols to help 
support decision-making for common situations were established. Changing the 
antibiotic prescribing policy resulted in a dramatic reduction in antibiotic use in 
newborns at risk for infection. Limitations were placed on indications for, and duration 
of, invasive care such as peripheral venous catheters, nasogastric feeding tubes, and 
blood tests. Finally, prompt discharge was actively promoted. In principle, such a 
strategy would be applicable to our neonatal unit although current operational 
conditions, if not addressed, would impede the success of the strategy. One of the 
challenges of implementing such a programme would be the common problem of 
correct hand washing in the absence of running water. This could be combated by using 
alcohol-based hand solutions, which have proven effectiveness and safety in neonatal 
units.403, 404  Other challenges include 200% bed occupancy with sharing of cots and 
overcrowding (which promote horizontal transmission of infection); non-availability of 
routine laboratory investigations in the context of sub-optimal local laboratory 
capacity.99 
The findings from both the neonatal unit audit and this case-control study will serve as 
the basis for development of the first-ever neonatal unit antibiotic stewardship 
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programme in The Gambia, beginning with the EFSTH and later including all public 
facilities providing neonatal inpatient care. Antimicrobial stewardship refers to 
coordinated interventions designed to improve and measure the appropriate use of 
antimicrobials by promoting the selection of the optimal antimicrobial drug regimen, 
dose, duration of therapy, and route of administration, thereby improving patient 
outcomes, reducing microbial resistance, and decreasing the spread of infections caused 
by multidrug-resistant organisms.405 Such a programme would necessitate the 
development and implementation of policies to support optimal antibiotic prescribing 
including facility-specific treatment guidelines based on local susceptibility data, and 
documentation of the dose, duration and indication for all courses of antibiotics so that 
they are readily identifiable.406 
Vertical	transmission	
Maternal recto-vaginal colonization by pathogenic microorganisms is an important step 
in early-onset neonatal infection and to a lesser extent late-onset infection. In this study, 
concordant clinically significant bacteria were recovered from blood and maternal 
vaginal cultures in the same newborn-mother pairs in 25% (8/32) of early-onset 
infection cases suggesting possible vertical transmission of infection. The risk of 
transmission was highest for neonates with early-onset S.	 aureus infection of whom 
63% (5/8) had mothers with concordant S.	aureus rectovaginal colonisation. This is the 
first study in sSA where concordance between neonatal blood organisms and maternal 
vaginal flora has been demonstrated, although further molecular evidence for vertical 
transmission will be provided by whole genome sequencing of paired isolates. In a 
similar study in Uganda, no concordant organisms were identified although a broadly 
similar range of organisms was recovered from neonatal blood and maternal vaginal 
specimens.407  
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The risk of vertical transmission of bacterial infection acquired through direct maternal-
foetal contact via maternal colonisation has been most widely studied with GBS.75  
Maternal vaginal colonization with GBS is essentially a prerequisite for both early 
colonization of the newborn infant and early-onset GBS sepsis.92 Rectovaginal 
colonization rates exceed vaginal colonization rates by at least 50% or more.408, 409 GBS 
vaginal and rectal colonization in pregnant woman may be persistent, transient, or 
intermittent410, 411 but not much is known about post-partum maternal flora and 
whether there are substantial changes in the days after birth. Colonisation with S.	
aureus has been reported in 4%–22% of pregnant women and is associated with an 
increased risk of post-partum infections in women but not in their infants.412 Early-
onset maternal-foetal infections have however been reported following antenatal 
invasive procedures performed within a day of delivery.413  
Inadequate hand hygiene and glove use, and excessive vaginal examinations may have 
contributed to the high rate of maternal S.	 aureus colonisation in our setting, and a 
potentially increased risk of vertical transmission. The study was not designed to 
distinguish between maternal, other caregiver, and environmental sources; it is 
therefore possible that the concordant isolates are not genetically related. The next step 
is to confirm genetic relatedness of paired neonatal and maternal isolates by whole 
genome sequencing. 
7.1.2	Molecular	diagnostics	
Bacteraemia	
PCR was positive in 17% (4/24) of Cases with a negative blood culture, two of which 
were of GBS infection. One of the Cases (P0091) had a CoNS-positive blood culture and 
maternal RVS culture positive for GBS. The other (P0099) had a negative blood culture, 
and GBS was not isolated from maternal RVS. Both Cases were 1-day old at the time of 
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recruitment and sampling. The identification of GBS by PCR suggests that GBS might be 
a ‘missed’ cause of early-onset neonatal infection in this setting. This seems reasonable 
given that up to 30% of pregnant women in The Gambia are rectovaginally colonised by 
GBS (predominantly serotype V) 253and that GBS has previously been identified as a 
cause of neonatal sepsis348 and meningitis253, 255, 348 in The Gambia. Colonising serotypes 
among Gambian newborns born to colonised mothers are mostly dependent on 
maternal serotypes; nevertheless, neonates are most likely to be colonised with 
serotype V irrespective of maternal colonisation status.253 However, the serotypes 
responsible for invasive neonatal disease in The Gambia are not known, and will be 
difficult to determine retrospectively given that historical isolates are not available for 
serotyping and PCR does not provide serotype information. 
Respiratory	infection.	
The performance of the respiratory TAC with regards to pathogen detection was better 
than the blood TAC; PCR was positive in 62% (21/34) of culture-positive, and 23% 
(3/13) of culture-negative NPS specimens. Furthermore, PCR detected four concordant 
bacteria. Although the same limitations apply to the respiratory TAC with regards to 
small sample volume, the sensitivity of TAC for respiratory pathogens is much higher.54 
This is evident in the number of viruses identified; several of which are mixed infections 
with bacteria, and therefore difficult to interpret. Indeed, three of the Cases with a 
diagnosis of pneumonia were PCR-positive for bacterial and viruses (Table 5.19).   
Interpretation	of	results	
Other than the detection of GBS, the added value of the TAC PCR as an adjunct test for 
the diagnosis of bacteraemia/sepsis in this study was limited given that PCR failed to 
identify concordant bacteria among the three Cases in whom both PCR and blood 
culture were positive. Apart from the Case whose PCR was positive for GBS but blood 
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culture positive for CoNS (considered clinically non-significant in this study, and also 
not a target on the TAC), it is unclear why there was no concordance between the blood 
culture and PCR results. In a recent randomised clinical trial, multiplex PCR systems 
performed better than blood culture by BACTEC in identifying the causative organism in 
newborns with suspected sepsis, and demonstrated 100 % concordance with blood 
culture results. Diagnosis was also made earlier and mortality reduced.414 Interpreting 
the mostly discordant microbiology and molecular diagnostic data is challenging and 
presents two possibilities. The first possibility is that the microbiology results are 
wrong and the ‘more sensitive’ PCR results are correct. This is rather unlikely as it 
would suggest either gross contamination of specimens or inadequacy of the 
microbiology laboratory. This MRCG also has a track record of carrying out excellent 
research involving diverse specimen types. This is further supported by the fact that the 
MRCG Clinical Laboratories are GCLP compliant and therefore operate to a standard 
that assures the reliability, quality and integrity of the work and results generated. 
The second possibility is that there are inherent limitations with the TACs in their 
current form that might hinder their clinical applicability. One limitation of PCR assays 
is the risk of contamination at various stages of the experiments. This is a particular 
problem with open systems like the Fast-Track Diagnostics (FTD; Malta). The use of an 
automated extraction platform in this study reduced the potential for contamination, 
and the closed system format of TAC further limits the possibility of cross-
contamination.53  
Molecular detection of pathogens in blood suffers from poor sensitivity and may be 
affected by exposure to antibiotics,415 although only three of the Cases with positive 
blood culture and negative PCR were exposed to antibiotics. The requirement of small 
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volumes of specimen by TAC, an obvious advantage when working with neonatal blood 
samples, is also one of its limitations. Each TAC well takes only 1.0µl of specimen; the 
sensitivity of the reaction therefore might be less than a typical individual singleplex 
real-time PCR which utilises more specimen volume. The is particularly important with 
neonatal blood specimens which contain a low pathogen load.48 TAC has also been 
shown to be 10-fold less sensitive than individual real-time PCR assays with the same 
primers and probes.54 During optimization of the TAC for the ANISA study, detection of 
bacteria in blood was found to significantly impaired relative to saline, with complete 
lack of detection of the lowest concentration of bacteria.53  The first evaluation of the 
performance of the TAC on human blood was with the ANISA study, the results of which 
are yet to be published. There is therefore no yardstick against which to compare the 
performance of TAC on blood specimens in this study. Currently, TAC appears to be well 
suited only to the detection of respiratory pathogens and has been demonstrated to 
perform as reliably as the FTD platform in this regard.416 
The TAC did not add much to my study, and my experience using it in a resource-limited 
African setting has highlighted several challenges that would preclude expansion of this 
technology to a regional clinical setting. The first challenge is cost of using this method. 
It needs a special platform to run the cards as well as sophisticated laboratory 
equipment and expensive reagents, all of which are unlikely to be a priority for health 
systems struggling with more basic infrastructural needs. Second is the level of 
expertise required to process specimens. Although using the TAC is simple and 
straightforward, upstream procedures such as DNA extraction require skilled 
personnel. The laboratory staff that ran the TAC assays in this study all had to undergo 
training in the molecular diagnostics lab.  The MRCG laboratories are research and 
regional reference laboratories with 70 years of investment in infrastructure and 
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training of personnel, an asset not easily replicable in resource-poor countries. A third 
challenge is in the analysis of the generated data. Analysis of data is complicated 
involving interpretation of the individual amplification curves for all 384 wells on each 
card, and requiring unique software provided by the CDC, Atlanta, Georgia, USA.  
Without having a laboratory background, learning about PCR reactions and 
interpretation of results was a steep learning curve for me, made enjoyable with the 
continuous guidance and support of Dr. Kirsty Le Doare and collaborators at CDC who 
originally developed the cards.  
7.2	Outbreak	of	hospital	acquired	infections		
The identification of the outbreaks of B.	 cepacia and K.	 pneumoniae on the EFSTH 
neonatal ward and subsequent investigation to determine the source was the first 
reported outbreak in the history of the hospital. B.	 cepacia, K.	 pneumoniae, and other 
Gram-negative bacilli are associated with common-sources outbreaks of nosocomial 
neonatal bloodstream infections. Both pathogens were isolated from intravenous fluids 
and parenteral antibiotics in use in the ward: plain 10% dextrose; normal saline, 10% 
Dextrose plus sodium, potassium and chloride; metronidazole infusion and gentamicin 
injection. However,	neither	was isolated from any of the unused intravenous fluids that 
were in stock or from surfaces swabs.  
According to ward protocol, neonates requiring intravenous fluids for the first 24 hours 
after birth receive 10% Dextrose, which is usually available as a commercially prepared 
500ml bottle. Some months before the outbreak occurred, there was a nationwide 
stock-out of 10% Dextrose. The nurses on the neonatal ward improvised by mixing pre-
calculated volumes of normal saline and 50% Dextrose (or used 5% Dextrose where 
50% Dextrose was unavailable). Starting at 24 hours of age, assuming that urine 
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production is adequate, supplemental electrolytes (sodium, potassium and chloride) are 
required. An appropriately constituted fluid is not locally available and so this is 
routinely prepared on the ward by mixing pre-calculated volumes of 10% Dextrose, 
Normal saline, and Potassium chloride. Antibiotic powders for parenteral use are 
dissolved with Normal saline (or water-for-injection infrequently), and other injections 
similarly diluted in order to be able to draw up the small neonatal doses. All these 
procedures require stringent aseptic techniques. 
The investigation suggests contamination of the intravenous fluids at the point of 
preparation, and contamination of intravenous medications at the point of dilution with 
already contaminated intravenous fluid. However, the outbreak source can only be 
confirmed by determining the genetic relatedness of neonatal and environmental 
isolates.417, 418. Demonstrating strain relatedness will also provide insight as to whether 
the outbreaks were a single event or simultaneous independent outbreaks from several 
sources. All isolates neonatal and environmental isolates were shipped to the UK for 
whole genome sequencing. 
Several risk factors have been associated with the development of nosocomial infection 
in newborns, the most important being birth weight, immaturity of the immune system, 
type and duration of invasive procedures, and colonization by bacteria from hospital 
environment.392, 419, 420 In developing countries, substandard sterilisation and 
disinfection practices are common.21 In our setting, single-use nasal-prongs and 
intravenous fluid burettes are routinely re-used and soaked in disinfectant solution and 
without re-used without adequate sterilisation in-between use; single-use antibiotic 
vials are pooled with inappropriate storage and use of multiple-dose vials and 
containers of medications (Chapter 5, Figure 5.6).  
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Gram-negative bacilli are most often transmitted among neonates from the hands of 
colonised staff,421 although patient-to-patient spread of infection has been reported.366 
In this study, the hands of personnel did not appear to be implicated in the transmission 
of infection although this is inconclusive, as the full complement of staff was not 
swabbed. The outbreak investigation however revealed numerous lapses in hand-
hygiene practices. Running water is not always available and water is stored in plastic 
containers beneath the sink accessed using a common cup (Chapter 6, Figure 6.13). 
Patient-to-patient transmission in this study is certainly possible due to overcrowding 
with sharing of cots.99  Nosocomial infection due to Gram-negative bacilli usually occurs 
in neonates already colonised with Gram-negative bacilli in the pharynx or intestine, 
and the risk of colonisation with hospital strains of Gram-negative bacilli (which are 
often resistant to multiple antibiotics) increases dramatically the longer a baby stays in 
intensive care. Neonates in whom intestinal colonisation with Gram-negative bacilli 
develops are a particularly important reservoir of Gram-negative bacilli in the nursery; 
once colonised, infants may harbour antibiotic-resistant hospital strains of Gram-
negative bacilli in their stool for up to a year or more.392 Four out of the five study 
participants with suspected hospital-acquired K.	 pneumoniae	 bacteraemia	 were also 
rectally colonised with Gram-negative bacilli but only three were colonised with K.	
pneumoniae. The spread of K.	 pneumoniae among different hospitals and even across 
country borders through the transfer of infected or colonised patients has also been 
documented.422 Although eligibility in this study was restricted to neonates whose 
mothers were resident in the study area, this is a potential cause for concern in The 
Gambia where the cultural practice of a woman staying with relatives after delivery is 
widespread. Many families have relatives in neighbouring countries (Senegal, Guinea-
Bissau) and there is a lot of cross-border movement.  
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7.3	Strengths	and	limitations	
This is the first study of neonatal infections in The Gambia where an attempt has been 
made to ascertain the role of maternal transmission at birth to neonatal infection by 
correlating neonatal blood organisms with maternal vaginal and perineal flora.  It is also 
the first study in sSA to explore the use of the TaqMan Array Card in the diagnosis of 
neonatal bloodstream infection notably for culture-negative cases and possible viral 
causes. Another strength of this study is its global comparability resulting from the use 
of clear inclusion criteria, and the reporting of the findings according to the STROBE-NI 
guidelines. The use of ISO accredited laboratories with validated standard operating 
procedures and protocols ensure confidence in the results. The study however, had 
several limitations.  
Firstly, being a hospital-based study, complete ascertainment of neonatal infection cases 
in the study area that did not make it to hospital was not possible. The majority of the 
population in the study area however, give birth in health facilities and home-born 
neonates have good access to referral-level care, thereby supporting a reasonable level 
of case ascertainment. The hospital environment is also a hot bed of infection 
transmission through unclean delivery and unhygienic practices. Given that over 90% of 
cases in this study were facility-born and that all the pathogens in this study are known 
to be associated with neonatal nosocomial bloodstream infections177, 423 and outbreaks, 
infections in this study might all have been hospital-acquired and not just those 
associated with the outbreaks. However, for non-outbreak pathogens, this would be 
difficult to prove in the absence of environmental samples. 
Secondly, modification of the WHO YICSSG criteria for temperature and respiratory rate 
may have led to the exclusion of some Cases especially neonates in the first few days 
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presenting with only increased respiratory rate. This might have affected capture of 
neonates with GBS, as neonatal GBS colonisation (a prerequisite for invasive disease) 
has been associated with neonatal respiratory distress;424 although historical data 
suggest that the incidence of neonatal GBS disease in The Gambia might be low with 
only seven reported cases between 1990 and 2015 (Chapter 4, Table 4,2).  
Thirdly, there was non-accurate measure of gestational age and deliberate selection 
bias against babies with lower birth weight, who were underrepresented in the sample. 
Obtaining specimens for analysis and maternal consent are more challenging for 
premature and LBW neonates, although the reasons for refusal of consent were not 
documented.  
A fourth limitation was the post-partum timing of maternal swab collection. It is 
possible that the maternal flora changes substantially in the days following birth, 
progressively obscuring the source of causative pathogens with delayed bacterial 
culture, particularly among mothers of newborns with late-onset infections. 
Lastly, was the inability to carry out PCR on all study isolates, as well as further 
sequencing studies to determine clonal relatedness of maternal and newborn isolates. 
These were beyond the funding and time available for this PhD but are planned for part 
my post-doctoral work. 
Inasmuch as the study findings may not be generalisable to all health facilities in the 
entire country, the multisite recruitment across the levels of care (teaching hospital, 
general hospital and major health centers) ensured good representation. The findings of 
this study have also been reported along the STROBE-NI guidelines, thereby permitting 
comparability with future neonatal infection studies. 
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7.4	Conclusion	
In summary, this study has shown that while S.	aureus is an important cause of neonatal 
infection in hospitalised newborns in The Gambia, with the majority of cases possibly 
maternally acquired, GBS is an under-diagnosed cause of early-onset neonatal infection. 
K.	 pneumoniae and B.	 cepacia are also important causes of infection, but their 
association with separate nosocomial outbreaks in the neonatal ward strongly suggests 
that the hospital environment plays a very important role in the acquisition of infection 
among Gambian newborns. Infection is associated with high levels of mortality, and 
WHO-recommended first- and second-line antibiotics are redundant in the face of multi-
drug resistant infections and inadequate infection control. In this setting, blood culture 
remains a valuable diagnostic tool despite being slow and offering modest tangible 
benefit for high mortality risk neonates, with results available before discharge or death 
for only 38% (35/91) of cases. An exploratory Pilot study of a novel molecular 
diagnostic tool, the TaqMan Array Card, demonstrated limited additional benefit of this 
technology over blood cultures. Sensitive point-of-care diagnostics for bacterial 
bloodstream infections similar to those developed for HIV and malaria are needed. 
There is a need for improved infection control and antimicrobial stewardship to 
preserve limited antibiotic choices.  
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CHAPTER	8.	IMPLICATIONS	FOR	PROGRAMME,	POLICY	&	RESEARCH	
 
 
 
 
Nursing staff during a consultant ward round at the main neonatal ward, EFSTH 
Banjul 
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Overview	
This chapter discusses the problem of neonatal infection in the Gambia in the context of 
implications for programme and health policy, and priority areas for neonatal infection 
research - The ‘3 Ps’ (Box 8.1). Mention is also made of more general priority areas for 
neonatal infection research such as discovery of new biomarkers and development of 
more sensitive diagnostic tools. The chapter ends with an overall conclusion of this PhD. 
Box	8.1	Neonatal	infections	in	The	Gambia:	The	3	P’s	
Problem	of	neonatal	infections	
What	is	already	known	about	neonatal	infections	
• Infections are the 3rd most common cause of the 2.7 million annual neonatal deaths globally 
• Antimicrobial resistance is a growing global threat to the treatment of neonatal infections  
• Newborns are at a higher risk of hospital-acquired infections with infection rates in developing countries 3-20 times 
higher than in high-income countries.   
• There is limited regional and local data on the aetiology of neonatal infections and antibiotic susceptibility profiles in 
sSA 
What	the	systematic	review	of	neonatal	infection	aetiology	in	sub-Saharan	Africa	presented	in	this	thesis	adds	
• The main causes of neonatal infection in sSA are S.	aureus, Klebsiella species, Group B Streptococcus, Escherichia	coli 
and Enterococcus species. 
• Reported antimicrobial resistance to WHO-recommended first- and second-line antibiotics is a problem, with 
documented resistance to alternative regimens including carbapenens 
What	the	audit	of	neonatal	care	in	The	Gambia’s	largest	hospital	presented	in	this	thesis	adds	
• At the Gambia’s largest and national referral hospital, 94% of neonates admitted over a 4-year period received 
antibiotics yet only 3% were investigated by culture of blood or CSF 
What	the	Case-Control	study	adds	
• The commonest cause of bacteraemia/sepsis among hospitalised newborns in The Gambia is S.	aureus. 
• GBS is an under-diagnosed case of early-onset infection 
• Hospital outbreaks due to multidrug resistant Gram-negative bacteria –K.	pneumoniae and	B.	cepacia - are responsible 
for a significant proportion of neonatal infections that would have gone unnoticed without microbiological 
investigation. 
• Sub-optimal hygiene practices and poor infection control measures during preparation of intravenous fluids and 
parenteral injections are responsible for nosocomial infection outbreaks on the neonatal ward. 
• WHO currently recommended first- and second-line antibiotics are redundant in the face of multi-drug resistant 
infections and inadequate infection control. 
Programme	Implications	&	Protocols	(patient/community,	hospital	and	national	level)	
• Infection prevention and control should encompass intrapartum care both in the hospital and at home. 
• Routine hospital care of the sick newborn should include microbiological investigations to determine aetiology and 
antimicrobial susceptibility patterns. 
• Infection control protocols for preventing and detecting hospital outbreaks are necessary.  
• Infection treatment protocols should include guidelines for management of hospital-acquired infections. 
• Antibiotic stewardship programmes 
Priority	areas	for	neonatal	infection	research	
• Epidemiological research 
• Health systems and policy research 
• Implementation research 
• Discovery research into diagnostic and prognostic host biomarkers of infection with sufficient sensitivity and 
specificity for potential use as point-of-care diagnostics 
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8.1	Problem	of	neonatal	infections		
Neonatal infection remains a big problem. With the global emphasis placed on 
improvement of referral pathways and promotion of institutional delivery for high-risk 
births, an estimated 50% of the 36 million births in sSA are now in facilities.425  Most 
developing country hospitals are hotbeds of infection transmission because of poor 
intrapartum and postnatal infection-control practices, and during outbreaks of neonatal 
infection in nurseries. In South-East Asia and sSA, HAIs are responsible for 75% of all 
causes of death in the neonatal period.426 In these settings, the expectations of improved 
neonatal outcomes in hospitals are consequently subverted by HAIs and their 
associated morbidity, mortality, and cost.21 HAIs also have an indirect detrimental effect 
on neonatal survival; families, especially in poor communities, are less likely to seek 
facility-based care when hospitals are seen as institutions where children experience 
poor outcomes associated with high out-of-pocket expenses for antibiotics and 
prolonged hospital stay cost.21 Although in the Gambia antibiotics are usually provided 
free of charge by the hospital and parents only buy them when they are out of stock; 
hospital stays place other burdens on families (including the problem of care for other 
children at home, transport and feeding costs etc.). In this setting, poor neonatal 
inpatient outcomes are also related to operational factors including, but not limited to, 
lack of laboratory capacity, lack of appropriate antibiotics, shortage of intravenous 
fluids, over-crowding of wards with sharing of cots and radiant warmer beds, as well as 
shortage of staff.99 
8.2	Programme	implications	and	protocols	
The Gambia is yet to develop its own national newborn action plan. This is an important 
first step in setting national newborn health targets and identifying priority areas for 
action. Focus is necessary in facilities and at home. In spite of the increasing trend in 
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facility births in The Gambia, an estimated 37% of the 83, 000 annual births still take 
place at home with or without a skilled attendant. In this study, just over 90% of Cases 
were facility-born implying that many home-born babies do not make it to the hospital, 
and probably die at home unreported.427 Improving data on where newborn deaths 
occur and understanding of delays in the receipt of care are a priority for design of 
context-specific community and health system strategies.287 Improving the quality of 
neonatal care in hospital requires education and training of staff with the support of 
standardised protocols on all aspects of hospital-based newborn care.   
Another area for priority action is the development strategies that strengthen standard 
infection-control practices including WASH conditions,96 hand hygiene,428 minimization 
of vaginal examination,429 and cord care.430 Handwashing or use of an alcohol-based 
antiseptic hand rub before and after contact with each woman or newborn and after 
contact with bodily fluids is critical for infection prevention. Clean birth practices at 
home with no skilled attendant could reduce neonatal sepsis deaths by as much as 
15%.429, 431 At the community level, handwashing has been shown to significantly 
reduce mortality432 and risk of cord infection.433 Compliance with handwashing is 
however challenging in the context of poor access to clean water. In such settings, 
alcohol-based hand gel may provide an alternative option that is bacteriocidal against a 
broad range of Gram-negative and Gram-positive aerobic bacteria, including those 
commonly associated with neonatal infections.434 Recently concluded clinical trials in 
sSA have evaluated  whether the provision of alcohol hand gel to pregnant women and 
postpartum mothers is a clinically- and cost-effective way of preventing neonatal 
infections in settings without running water.435 For newborns who are born at home, 
and in settings with high neonatal mortality (30 or more neonatal deaths per 1,000 live 
births), the application of antiseptics to the cord may have additional benefit.430, 436, 437  
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HAIs can be attributed to failures in knowledge and training regarding basic infection 
control processes, inadequate infrastructure, systems of care, and resources.21 Detailed 
quality-of-care protocols and ‘core nursing skills sets’ for all aspects of newborn care 
will improve quality and give more responsibility for care to nurses, particularly with 
regard to infection prevention, feeding support and use of intravenous fluids. A shift in 
the hospital-based management of sick newborns with suspected infection is urgently 
needed to include routine blood cultures. The comprehensive management ‘package’ 
should include routine microbiological surveillance (including HAIs and and AMR 
surveillance, as well as antibiotic stewardship.  
8.3	Priority	areas	for	research	
Major data gaps remain for high-quality, locally available data that can be used for 
planning and decision making and tracking the impact of policies and programmes on 
improving newborn survival. Now that most births occur in facilities, a crucial 
opportunity to improve the collection of epidemiological data is through establishing a 
standardised facility-based perinatal minimal dataset that will promote comparability 
of data with other units and regions.287 Creation of a national perinatal/neonatal 
database for stillbirths, preterm births, CAI and HAI, as well as other key neonatal 
health indicators, will provide data for improving outcomes and increasing the quality, 
safety and value of  newborn care. Extension of such a database to include other 
countries in the West African sub-region will facilitate comparability of data and quality 
improvement collaborations.  
Epidemiological data draw attention to priorities to maximise progress towards 
improving newborn survival, but targets and data alone do not save lives; only changes 
in health systems and coverage of effective interventions do.287 Effective interventions 
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exist which can reduce neonatal mortality by as much as 70% if they reach all mothers 
and newborns; the greatest challenge is to increase coverage of these interventions.438 
439 Research priorities for neonatal health in The Gambia should therefore include 
health systems and health policy research. Equally important is operations research and 
research that addresses political, economic, social, cultural, behavioural, and 
infrastructural issues involved in addressing mortality due to neonatal infections.438  
Such implementation research is critical for generating the new knowledge needed to 
achieve high coverage with life-saving interventions. Areas of focus relating to 
prevention and management of neonatal infections are listed in Table 8.1 below. 
Table	8.1	Priority	areas	for	neonatal	infection	research	in	The	Gambia	and	beyond	
 Problem	of	neonatal	infections Programme	Implications	&	Protocols 
Epidemiological	
research	
priorities	a 
Incidence of nosocomial neonatal infection in 
postnatal wards and neonatal nurseries 
Identification of sources of lethal Gram-negative rod 
infections that cause early-onset infection using 
conventional microbiological and molecular 
approaches. 
 
Health	systems	
and	health	policy	
research	
priorities	a 
Feasibility, effectiveness, and cost of approaches to 
increase clean delivery practices in facilities and in 
homes 
Feasibility and effectiveness of approaches to 
improve aseptic practices in labour rooms, 
maternity and neonatal wards 
Detailed assessment of the entire process of health care 
delivery including patient population and flow, referral 
systems, key health processes, information management, 
staff competence and organisation, supplies, facility design 
and infrastructure 
Development of strategies to improve error-prone 
processes that lead to HAI, including behaviour change. 
Feasibility, cost and effectiveness of setting up newborn 
care corners in first referral units and district hospitals 
Feasibility and effectiveness of approaches to increase 
quality of care in hospitals using standardised protocols for 
management of newborn conditions. 
Implementation	
research	
priorities 
Facility-based cluster-randomised trials evaluating 
the multi-faceted hand-hygiene promotion 
programmes (alcohol-based hand gel) 
Clinical trials of targeted interventions to interrupt 
contamination and transmission of pathogens. 
Evaluation of cord-care regimens to reduce 
colonisation and infection (e.g single application of 
4% chlorhexidine vs. daily application for 7 days)440 
 
Discovery	
research	
priorities	(Global) 
Improved clinical syndrome identification 
More sensitive and discriminatory biomarkers 
Maternal GBS and S. pneumoniae vaccines 
Point-of-care diagnostics 
Microfluidic technologies 
 
a Source: adapted from Bahl et	al.438 ; Zaidi et	al.21 ; Edmond45  
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At the global level, more research is needed to identify and validate more sensitive and 
discriminatory biomarkers of infection that can be used as adjunct diagnostic tools with 
the potential for incorporation into point-of-care diagnostics. Well-designed clinical 
trials evaluating new clinical diagnostic algorithms are needed. Such clinical algorithms 
would be based on a combination of clinical signs and host biomarkers that would 
discriminate between the neonatal infection syndromes – sepsis, meningitis and 
pneumonia. 
Microfluidics is the study of the behaviour, precise control, and manipulation of fluids 
geometrically constrained to submillimetre (nanolitre or picolitre) channels. 441 
Microfluidic technology has also allowed sample preparation and a number of different 
assays to be combined in small, disposable, single-use diagnostic cartridges or cards 
that have been called a ‘‘lab on-a-chip’’ or LOC.45 For the detection of various pathogens, 
microfluidics-based platforms offer many advantages, including speed, cost, portability, 
high throughput, and automation. LOCs have been reported to perform assays at 
sensitivity, specificity, and reproducibility levels similar to those of central laboratory 
analysers, but yet require little user input other than the insertion of the sample. Single 
drops of blood, faeces, and saliva have all been tested with encouraging results.  In a 
study in Rwanda, the ‘mChip assay’ had excellent performance in the diagnosis of HIV 
using only 1 μl of unprocessed whole blood and an ability to simultaneously diagnose 
HIV and syphilis with sensitivities and specificities that rival those of reference 
benchtop assays. 442 There are however several challenges to practical implementation 
of this technology especially in developing countries.443 
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8.4	Overall	Conclusion	
The burden of neonatal infection in sSA and its contribution to morbidity and mortality 
remains great. Preventing infection depends on improving our understanding of 
maternal health, including maternal colonisation, as well as vertical transmission (HIV, 
malaria, other congenital infections, and ascending bacterial infections) and hospital-
acquired infections, particularly with multi-resistant Gram-negative bacteria. Infection 
control management is important, and interventions, isolated or as part of care bundles, 
need detailed, prospective evaluation in outbreak situations.444  
I have presented new data on size of the problem, and the pathogens associated with 
neonatal infection across sSA, and in three main referral health facilities in The Gambia. 
Although more population-based data are needed; over 60% of births in The Gambia 
occur in health facilities and high-quality surveillance data can provide important 
information on cause and AMR. Routine programmatic data require significant 
resources, including strengthening laboratory quality control and assurance measures, 
and use and appropriate interpretation of molecular diagnostics to detect pathogens 
(including viruses).  More research is also essential and investing in research to better 
measure and reduce the burden of neonatal infection, especially in sSA should therefore 
be a priority. 
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APPENDICES	
Appendix	1:	Strengthening	the	Reporting	of	Observational	Studies	in	
Epidemiology	for	Newborn	Infection	(STROBE-NI)	Checklist	
	 	 TITLE	AND	ABSTRACT	
		 STROBE 1(a) Indicate the study's design with a commonly used term in the title or abstract 
			 STROBE 1(b) Provide in the abstract an informative and balanced summary of what was done and what 
was found 
INTRODUCTION	
Background		
/	rationale	
STROBE 2 Explain the scientific background and rationale for the investigation being reported 
Objectives	 STROBE 3 State specific objectives, including any pre-specified hypotheses 
METHODS	
Study	design	 STROBE 4 Present key elements of study design early in the paper 
		 STROBE-NI 4.1 Clearly state case ascertainment methods (e.g. physician diagnosis, clinical algorithm), 
documenting individual clinical signs used for diagnosis of possible serious bacterial 
infection. Give microbiological and/or laboratory and/or radiological criteria for other 
infectious syndromes (e.g. meningitis, sepsis, pneumonia). Include indications for clinical 
investigations (e.g. lumbar puncture) 
		 STROBE-NI 4.2 Give criteria used to differentiate between new infection episodes and relapses  
		 STROBE-NI 4.3 For facility-based studies, indicate if the study is of community and/or hospital acquired 
infections (HAI), defining HAI using an international standard and presenting specific HAI 
clinical syndromes separately 
		 STROBE-NI 4.4 State whether this is an outbreak study, and if so define an outbreak, with reference to an 
international standard 
		 STROBE-NI 4.5 Describe sampling strategy (e.g. clinical indication vs. routine surveillance) and sampling 
details, (e.g. minimum volumes; timing in relation to antimicrobial administration) 
		 STROBE-NI 4.6 Describe conventional and/or molecular microbiological methods used, with details (e.g. 
automation, enrichment steps), and the use of controls 
		 STROBE-NI 4.7 List pathogens that are likely to be identified by microbiological methods used, and criteria 
used to determine clinical significance  
		 STROBE-NI 4.8 Describe antimicrobial susceptibility tests and thresholds used, with reference to an 
international standard (e.g. CLSI or EUCAST) 
Setting	 STROBE 5 Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection 
		 STROBE-NI 5.1 Describe the study context in terms of incidence of neonatal mortality, stillbirth and 
preterm birth.  
	 STROBE-NI 5.2 Describe the population included e.g. facility live births, referrals from home, referrals from 
another facility 
		 STROBE-NI 5.3 For community-based studies, describe care-seeking and adherence and time to referral 
		 STROBE-NI 5.4 For facility-based studies, describe obstetric care (basic or comprehensive), including 
proportion of births by caesarean section. Report annual number of live births per facility 
and state proportion of births in the study area that occur in hospital (vs. community) 
		 STROBE-NI 5.5 For facility-based studies, indicate if the facility is public or private, and give the number of 
health care staff and their training. Indicate the level of neonatal care available (e.g. 
ventilatory support, indwelling catheters) and investigations available (e.g. biochemistry, 
radiology). Report antimicrobial guidelines used for the empiric management of neonatal 
sepsis. 
	 STROBE-NI 5.6 State the laboratory location and capacity to process different sample types, and give 
quality control and assurance measures in place. 
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Participants	 STROBE  6(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up 
		 Case-control study—Give the eligibility criteria, and the sources and methods of case 
ascertainment and control selection. Give the rationale for the choice of cases and controls 
		 Cross-sectional study—Give the eligibility criteria, and the sources and methods of 
selection of participants 
		 STROBE 6(b) Cohort study—For matched studies, give matching criteria and number of exposed and 
unexposed 
		 Case-control study—For matched studies, give matching criteria and the number of 
controls per case 
		 STROBE-NI 6.1 State age of participants (e.g. 0-27 days defines neonates; 'day 0' as day of birth). 
Disaggregate neonatal data from that of older infants and from stillbirths 
Variables	 STROBE 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
		 STROBE-NI 7.1 State criteria used to define clinically significant organisms for each sample type 
Data	sources	
measurement	
STROBE 8 For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one 
group 
Bias	 STROBE 9 Describe any efforts to address potential sources of bias 
Study	size	 STROBE 10 Explain how the study size was arrived at 
Quantitative	
variables	
STROBE 11 Explain how quantitative variables were handled in the analyses. If applicable, describe 
which groupings were chosen and why 
Statistical	
methods	
STROBE 12(a) Describe all statistical methods, including those used to control for confounding 
		 STROBE 12(b) Describe any methods used to examine subgroups and interactions 
		 STROBE 12(c) Explain how missing data were addressed 
		 STROBE 12(d) Cohort study—If applicable, explain how loss to follow-up was addressed 
		 Case-control study—If applicable, explain how matching of cases and controls was 
addressed 
		 Cross-sectional study—If applicable, describe analytical methods taking account of 
sampling strategy 
		 STROBE 12(e) Describe any sensitivity analyses 
RESULTS	
Participants	 STROBE 13(a) Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, 
examined for eligibility, confirmed eligible, included in the study, completing follow-up, 
and analysed 
		 STROBE 13(b) Give reasons for non-participation at each stage 
		 STROBE 13(c) Consider use of a flow diagram 
		 STROBE-NI 13.1 See Figure 3 for suggested components of a flow diagram for neonatal infections 
Descriptive	
data	
STROBE 14(a) Give characteristics of study participants (e.g. demographic, clinical, social) and 
information on exposures and potential confounders 
		 STROBE-NI 14.1 Describe maternal infections (clinical or on screening, e.g. GBS or HIV) or risk factors for 
infection (e.g. PROM, peripartum fever).   
		 STROBE-NI 14.2 Describe key neonatal characteristics, including sex, postnatal and gestational age 
categories (range and median), birth-weight categories (range and median), birth place, 
feeding (breast milk or other) and comorbidities 
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	Descriptive	
data	
STROBE-NI 14.3 Report data on occurrence of individual signs (e.g. fast breathing), according to case 
definitions 
		 STROBE-NI 14.4 Give proportion of mothers and neonates with peripartum antibiotic exposure (+/- pre-
admission exposure for neonates). Report details of antimicrobials (or supportive care) 
given during the study 
		 STROBE 14(b) Indicate number of participants with missing data for each variable of interest 
		 STROBE 14(c) Cohort study—Summarise follow-up time (e.g., average and total amount) 
Outcome	data	 STROBE-NI 15 Cohort study—Report numbers of outcome events or summary measures over time 
		 Case-control study—Report numbers in each exposure category, or summary measures of 
exposure 
		 Cross-sectional study—Report numbers of outcome events or summary measures 
		 STROBE-NI 15.1 Report the number (+/- proportion) of samples microbiologically tested (including lumbar 
punctures for meningitis cases); the number (+/-proportion) that were positive (including 
thresholds for detection, where applicable); all isolates obtained (including clinically 
significant and non-significant); and antimicrobial susceptibilities of pathogens, where 
done. 
		 STROBE-NI 15.2 Report number (+/- proportion) of babies with microbiologically proven infection (and 
number of infections per baby), and include this in the flow chart (see Figure 3). 
	 STROBE-NI 15.3 Report infections by day, for days 0-6. State age categories, if used, defining ‘early-onset’ 
and ‘late-onset’ infection (e.g. <72 hours and ≥ 72 hours respectively).  
		 STROBE-NI 15.4 Report deaths and any sub-analyses by risk groups  
Main	results	 STROBE 16(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their 
precision (e.g. 95% confidence interval). Make clear which confounders were adjusted for 
and why they were included 
		 STROBE 16(b) Report category boundaries when continuous variables were categorized 
		 STROBE 16(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period 
		 SPRING 16.1 For incidence, give risk per 1000 live births, or if alternative denominator used (e.g. total 
births or bed days), define this clearly 
Other	analyses	 STROBE 17 Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity 
analyses 
DISCUSSION	
Key	results	 STROBE 18 Summarise key results with reference to study objectives 
Limitations	 STROBE 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias 
	 STROBE-NI 19.1 Discuss sources of recruitment bias, particularly regarding the period of time shortly after 
birth. State source of denominator data and discuss possible related biases 
Interpretation	 STROBE 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
Generalisability	 STROBE 21 Discuss the generalisability (external validity) of the study results 
OTHER	INFORMATION	
Funding	 STROBE 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based 
Ethics	 STROBE-NI 23.1 Report any ethical considerations, including the recruitment of young mothers (minors), 
and the consent process for early recruitment of neonates after delivery. Provide details of 
research ethics approval. 
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Appendix	2:	Search	Strategies	for	Systematic	Review	of	Neonatal	Infection	
Aetiology	in	sub-Saharan	Africa	
Search	Terms	for:	Global	Health	<1910	to	2016	Week	23>,	Embase	Classic+Embase	
<1947	to	2016	June	17>,	Epub	Ahead	of	Print,	In-Process	&	Other	Non-Indexed	
Citations,	Ovid	MEDLINE(R)	Daily	and	Ovid	MEDLINE(R)	<1946	to	Present>	
1     Cameroon/ (15402) 
2     Central African Republic/ (2324) 
3     Chad/ (2458) 
4     Congo/ or "Democratic Republic of the Congo"/ (18017) 
5     Gabon/ (4145) 
6     Burundi/ (1768) 
7     Djibouti/ (749) 
8     Eritrea/ or Ethiopia/ (28122) 
9     Kenya/ (42174) 
10     Rwanda/ (5557) 
11     Somalia/ (4219) 
12     Sudan/ or South Sudan/ (16774) 
13     Tanzania/ (30655) 
14     Uganda/ (32332) 
15     Angola/ (2934) 
16     Botswana/ (4603) 
17     Lesotho/ (1259) 
18     Malawi/ (12965) 
19     Mozambique/ (6473) 
20     Namibia/ (2638) 
21     South Africa/ (98929) 
22     Swaziland/ (1615) 
23     Zambia/ (11936) 
24     Zimbabwe/ (16127) 
25     Benin/ (4985) 
26     Burkina Faso/ (9486) 
27     Cote d'Ivoire/ (9344) 
28     Gambia/ (7220) 
29     Ghana/ (20392) 
30     Guinea/ or Equatorial Guinea/ or Guinea-Bissau/ (6983) 
31     Liberia/ (3440) 
32     Mali/ (7100) 
33     Mauritania/ (1278) 
34     Niger/ (3815) 
35     Nigeria/ (81701) 
36     Senegal/ (16235) 
37     Sierra Leone/ (4128) 
38     Togo/ (3367) 
39     Comoros/ (741) 
40     Madagascar/ (9438) 
41     Mauritius/ (1982) 
42     Seychelles/ (923) 
43     "Sao Tome and Principe".mp. (451) 
44     Cape Verde/ (622) 
45     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 
or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 
37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 (502033) 
46     sub-Saharan Africa.mp. or "Africa South of the Sahara"/ (209260) 
47     45 or 46 (533218) 
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Search	Terms	for:	Global	Health	<1910	to	2016	Week	23>,	Embase	Classic+Embase	
<1947	to	2016	June	17>,	Epub	Ahead	of	Print,	In-Process	&	Other	Non-Indexed	
Citations,	Ovid	MEDLINE(R)	Daily	and	Ovid	MEDLINE(R)	<1946	to	Present>	(continued	
from	overleaf) 
48     exp Infant, Newborn/ or (newborn* or neonat*).tw. (1461719) 
49     exp sepsis/ or exp infection/ or (infection* or pathogen* or organism* or bacter* or virus or viral 
or etiology).tw. (9570459) 
50     limit 49 to "etiology(sensitivity)" [Limit not valid in Global Health,Embase; records were retained] 
(7014498) 
51     (neonat* adj3 sepsis).tw. (10161) 
52     48 and 50 (206620) 
53     51 or 52 (209193) 
54     47 and 53 (9030) 
55     limit 54 to ("all infant (birth to 23 months)" or "newborn infant (birth to 1 month)") [Limit not 
valid in Global Health,Embase; records were retained] (8854) 
56     limit 55 to yr="1980 - 2017" (8161) 
57     limit 56 to ("diagnosis (maximizes sensitivity)" or "diagnosis (maximizes specificity)" or 
"diagnosis (best balance of sensitivity and specificity)" or "causation-etiology (maximizes sensitivity)" 
or "causation-etiology (maximizes specificity)" or "causation-etiology (best balance of sensitivity and 
specificity)") [Limit not valid in Global Health; records were retained] (7506) 
58     limit 57 to humans [Limit not valid in Global Health; records were retained] (7394) 
59     limit 58 to (cab reviews archive or cab reviews: perspectives or cabi full text or cabi full text 
bundle) [Limit not valid in Embase,Ovid MEDLINE(R),Ovid MEDLINE(R) Daily Update,Ovid 
MEDLINE(R) In-Process,Ovid MEDLINE(R) Publisher; records were retained] (5644) 
60     remove duplicates from 59 (4693) 
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Search	strategy	for	PubMed	(Date	17th	June	2016) 
User	query:	 (((((Neonatal Sepsis) OR Neonatal bacteraemia) OR Neonatal infection)) AND etiology) 
AND (((((sub-Saharan Africa) OR West Africa) OR East Africa) OR Central Africa) OR 
Southern Africa) 
Query	Translation:	 ((((Neonatal[All Fields] AND ("sepsis"[MeSH Terms] OR "sepsis"[All Fields])) OR 
(Neonatal[All Fields] AND ("bacteraemia"[All Fields] OR "bacteremia"[MeSH Terms] OR 
"bacteremia"[All Fields]))) OR (Neonatal[All Fields] AND ("infection"[MeSH Terms] OR 
"infection"[All Fields]))) AND ("etiology"[Subheading] OR "etiology"[All Fields] OR 
"causality"[MeSH Terms] OR "causality"[All Fields])) AND ((((("africa south of the 
sahara"[MeSH Terms] OR ("africa"[All Fields] AND "south"[All Fields] AND "sahara"[All 
Fields]) OR "africa south of the sahara"[All Fields] OR ("sub"[All Fields] AND "saharan"[All 
Fields] AND "africa"[All Fields]) OR "sub saharan africa"[All Fields]) OR ("africa, 
western"[MeSH Terms] OR ("africa"[All Fields] AND "western"[All Fields]) OR "western 
africa"[All Fields] OR ("west"[All Fields] AND "africa"[All Fields]) OR "west africa"[All 
Fields])) OR ("africa, eastern"[MeSH Terms] OR ("africa"[All Fields] AND "eastern"[All 
Fields]) OR "eastern africa"[All Fields] OR ("east"[All Fields] AND "africa"[All Fields]) OR 
"east africa"[All Fields])) OR ("africa, central"[MeSH Terms] OR ("africa"[All Fields] AND 
"central"[All Fields]) OR "central africa"[All Fields] OR ("central"[All Fields] AND 
"africa"[All Fields]))) OR ("africa, southern"[MeSH Terms] OR ("africa"[All Fields] AND 
"southern"[All Fields]) OR "southern africa"[All Fields] OR ("southern"[All Fields] AND 
"africa"[All Fields]))) 
Result:	 489 
Translations: 
Sepsis "sepsis"[MeSH Terms] OR "sepsis"[All Fields] 
bacteraemia "bacteraemia"[All Fields] OR "bacteremia"[MeSH Terms] OR "bacteremia"[All Fields] 
infection "infection"[MeSH Terms] OR "infection"[All Fields] 
etiology "etiology"[Subheading] OR "etiology"[All Fields] OR "causality"[MeSH Terms] OR 
"causality"[All Fields] 
sub-Saharan Africa "africa south of the sahara"[MeSH Terms] OR ("africa"[All Fields] AND "south"[All Fields] 
AND "sahara"[All Fields]) OR "africa south of the sahara"[All Fields] OR ("sub"[All Fields] 
AND "saharan"[All Fields] AND "africa"[All Fields]) OR "sub saharan africa"[All Fields] 
West Africa "africa, western"[MeSH Terms] OR ("africa"[All Fields] AND "western"[All Fields]) OR 
"western africa"[All Fields] OR ("west"[All Fields] AND "africa"[All Fields]) OR "west 
africa"[All Fields] 
East Africa "africa, eastern"[MeSH Terms] OR ("africa"[All Fields] AND "eastern"[All Fields]) OR 
"eastern africa"[All Fields] OR ("east"[All Fields] AND "africa"[All Fields]) OR "east 
africa"[All Fields] 
Central Africa "africa, central"[MeSH Terms] OR ("africa"[All Fields] AND "central"[All Fields]) OR 
"central africa"[All Fields] OR ("central"[All Fields] AND "africa"[All Fields]) 
Southern Africa "africa, southern"[MeSH Terms] OR ("africa"[All Fields] AND "southern"[All Fields]) OR 
"southern africa"[All Fields] OR ("southern"[All Fields] AND "africa"[All Fields]) 
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Search	strategy	for	Africa-Wide	Information	Database	(Date	17th	June	2016) 
Search	ID#	 Search	Terms	 Search	Options Results 
S8 S6 AND S7  Search	modes - 
Boolean/Phrase 3,826 
S7 Cameroon or Central African Republic or Chad or 
Congo or “Democratic Republic of the Congo” or 
Gabon or Burundi or Djibouti or Eritrea or Ethiopia 
or Kenya or Rwanda or Somalia or Sudan or 
Tanzania or Uganda Angola or Botswana or Lesotho 
or Malawi or Mozambique or Namibia or South 
Africa or Swaziland or Zambia or Zimbabwe or 
Benin or Burkina Faso or Cape Verde or Cote 
d’Ivoire or Gambia or Ghana or Guinea or Guinea-
Bissau or Liberia or Mali or Mauritania or Niger or 
Nigeria or Senegal or Sierra Leone … 
Search	modes - 
Boolean/Phrase 1,653,716 
 
S6 S4 AND S5  Search	modes - 
Boolean/Phrase 8,989 
 
S5 S1 OR S2 OR S3  Search	modes - 
Boolean/Phrase 
167,149 
S4 neonate or neonatal or newborn or infant  Search	modes - 
Boolean/Phrase 
39,578 
S3 meningitis or pneumonia  Search	modes - 
Boolean/Phrase 
14,374 
S2 bacteremia  Search	modes - 
Boolean/Phrase 
1,288 
S1 sepsis or infection  Search	modes - 
Boolean/Phrase 
158,384 
 
 
 
 
Neonatal admissions, quality of care and
outcome: 4 years of inpatient audit data from
The Gambia’s teaching hospital
Uduak A. Okomo1,2,3, Tida Dibbasey3, Kalipha Kassama3, Joy E. Lawn2,4,
Syed M. A. Zaman1,2, Beate Kampmann1,5, Stephen R. C. Howie1,6,7,
Kalifa Bojang1,3
1Medical Research Council Unit, The Gambia, 2Department of Infectious Disease Epidemiology, Faculty of
Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, UK, 3Department of
Paediatrics, Edward Francis Small Teaching Hospital, Banjul, The Gambia, 4Maternal Reproductive and Child
Health Centre, London School of Hygiene and Tropical Medicine, 5Department of Paediatrics, Imperial College
London, UK, 6Department of Paediatrics, School of Medicine, University of Auckland, 7Centre for International
Health, School of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
Background: National facility-based neonatal mortality audits are an important source of data to identify
areas for improvement of service delivery and outcome of care.
Objectives: To examine admissions to the neonatal unit, Edward Francis Small Teaching Hospital, Banjul,
The Gambia and make recommendations for programme action to reduce mortality through improvements
in the quality of care, particularly with respect to suspected neonatal infections.
Methods: Case notes were reviewed for all neonates admitted to the neonatal unit during a 5-year period
(1 January 2009 to 31 December 2013) to assess outcome and quality of care. Data for 2009 were
subsequently excluded because of the low proportion of records retrieved.
Results: Of the 4944 admissions between 1 January 2010 and 31 December 2013, 1734 infants (35%)
died, with 57% of all deaths occurring within the first 48 hours of admission. There were 1267 early
neonatal deaths (deaths occurring during the first 7 days of life), 67% of which occurred during the first
48 hours of life. Independent predictors of neonatal death in the multivariable analysis were; maternal
lack of antenatal care, non-teaching hospital delivery, admission weightv1500g, abnormal blood glucose
concentration (v2.6 mmol/L orw6.9 mmol/L) and hypothermia (axillary temperaturev36.5˚C). Forty-eight
per cent of newborns had point-of-admission hypothermia. Possible severe bacterial infection (pSBI)
accounted for 44% (2166/4944) of admissions, prematurity/low birthweight for 27% (1340/4944) and intra-
partum-related conditions for 20%. Only 5% (104/2166) of pSBI cases had at least one supportive inves-
tigation; 41 had a chest radiograph, 26 had a blood culture and 43 had a lumbar puncture. Although 94%
of the newborns received intravenous antibiotics, 55% of those who did lacked clinical evidence of pSBI
and had no diagnostic work-up.
Conclusion: Priority areas for action include infection prevention and improved diagnosis and manage-
ment. There is also scope to reduce hypothermia with feasible interventions particularly targeting preterm
infants. Improved patient records and audit data with linked action and accountability are interventions
which could prevent such deaths of newborns in The Gambia and other developing countries.
Keywords: Neonate, Newborn, Mortality, Infection, Audit, Quality of care, Antimicrobial
Introduction
The Millennium Development Goals (MDGs) era has
witnessed a remarkable decline in child mortality world-
wide but not in the neonatal period. With an estimated
2.9 million neonatal deaths each year, accounting for
44% of under-5 child deaths globally, neonatal survival
is an ‘unfinished agenda’ of MDG 4 for child health
and remains a priority for the post-2015 period.1 The
highest risk of neonatal deaths is in sub-Saharan Africa
(SSA), with epicentres in West and Central Africa
where the neonatal mortality rate (NMR) is estimated
to be 35/1000 live births.2 The risk of a West African
infant dying in the first 28 days of life is almost ten
times that of an infant born in a high-income country,
Correspondence to: U A Okomo, MRC Unit, The Gambia, Atlantic
Boulevard, PO Box 273, Banjul, The Gambia, West Africa. Email:
uokomo@mrc.gm
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yet these countries are also making the slowest progress
in reducing newborn mortality.3 More than 80% of
these deaths result from three preventable and treatable
conditions: complications of prematurity, intrapartum-
related deaths (including birth asphyxia) and neonatal
infections.4 Owing to limited laboratory resources and
infrastructure, in most health facilities in SSA there are
difficulties in diagnosing neonatal infection and in disag-
gregating it fromother potential causes of death. In these
settings, diagnosisdependsonsimplifiedclinical diagnos-
tic algorithms that have high sensitivity and low speci-
ficity and often without laboratory confirmation.5
The Gambia is the smallest country in mainland
Africa. In descending order, its neonatal mortality
rate (NMR) (28/1000 live births) ranks 9th among
the 15 countries of West Africa, and, globally, 30th
of 194.6 Data from the Farafenni Demographic Sur-
veillance System located in a rural area on the North
Bank region of The Gambia showed a 56% drop in
under-5 mortality between 1992 and 2008, but the
corresponding decline in neonatal mortality was
only 38%.7 Since 1990, there has been marked
improvement in maternal and child health, despite
high levels of poverty, limited resources and a short-
age of adequately and appropriately trained staff
(Box 1). However, The Gambia has not met the
MDG4 target for child survival, and progress
beyond 2015 now depends on reducing newborn
deaths which account for 39% of under-5 mortality.2
The public health sector comprises village health
services (primary care), 38 minor and six major
health centres, five general hospitals, a regional eye
hospital and a university teaching hospital spread
across eight local government areas and 43 districts.8
Access to health facilities is relatively good, and over
85% of the population live within three kilometres of
a primary health-care or outreach health post and
97% of the population within five kilometres.9 The
prevalence of HIV in adults aged 15–49 years was
1.2% in 2013,10 and access to prevention of mother-
to-child transmission (PMTCT) services is relatively
high (80%). In 2011, the national prevalence of
HIV1 and HIV2 infection in women attending ante-
natal clinics was estimated to be 1.65% and 0.07%,
Neonatal care in The Gambia Uduak et al.
Paediatrics and International Child Health 2015 VOL. 35 NO. 3 253
respectively.11 Among antenatal clinic attendees in
Banjul, the prevalence of HIV1 was 1.9%; no case
of HIV2 was detected.11
Patterns in newborn survival are a sensitive indi-
cator of the functionality of a health system and its
response to its most vulnerable population.3 National
facility-based neonatal mortality audits are an import-
ant source of data to identify areas for improvement
in relation to service delivery and outcomes of care.
In this paper, 4 years of neonatal inpatient audit
data from the main national referral hospital in The
Gambia between 2010 and 2013 are summarised.
The aim was to examine admissions and outcome in
newborns on the neonatal ward, and make recommen-
dations for programme action to reduce mortality by
improving the quality of care, particularly with respect
to suspected neonatal infections.
Methods
Setting
The Edward Francis Small Teaching Hospital
(EFSTH) in Banjul is the national teaching hospital
and tertiary government referral hospital in The
Gambia, to which patients come from all over the
country.12 It is the largest hospital in The Gambia,
and the maternity unit delivers an average of 6000
newborns each year. In the labour ward, a sink,
clean running water, soap and alcohol hand rubs
are usually available. The midwife or attending medi-
cal officer mainly perform resuscitation of newborns
as trained paediatricians or anaesthetists are not rou-
tinely available. Asphyxiated newborns receive
oxygen by face-mask from a cylinder but on arrival
at the neonatal unit, receive oxygen by nasal
prongs from an oxygen concentrator. Bag-mask ven-
tilation is not routinely performed because appropri-
ately sized bags and masks are not always available.
This is because they are often locked up (to prevent
being stolen) and therefore not accessible when
needed (personal communication with the Head of
the Department of Obstetrics and Gynaecology).
Endotracheal intubation of severely depressed infants
is also not available.
The Edward Francis Small Teaching Hospital the
only health facility in the country with a dedicated
neonatal with 31 cots, separated into high- and low-
risk areas. Cot occupancy is often more than 200%
with neonates sharing cots and incubators during
peak admission periods. Care is mostly supportive,
consisting of intravenous fluids, antibiotics, nasogas-
tric tube feeding, phototherapy, phenobarbitone, ami-
nophylline and oxygen if indicated. Oxygen is
administered from electricity-operated oxygen concen-
trators. During the period under review, there were
only two oxygen concentrators available in the ward;
using a splitter, up to ten infants could receive
oxygen at one time from each concentrator. Skin-to-
skin contact (kangaroo mother care, KMC) is not
practiced. Neonatal intensive care facilities and
major surgery are not available. A neonatologist,
two medical officers and house officers staff the unit.
In-house departmental training is occasionally con-
ducted for medical and house officers as well as mid-
wives, sometimes in conjunction with visiting foreign
medical personnel. Trained nurses assisted by nurse
attendants provide nursing care. There are usually
between two and four trained nurses with an equal
number of nurse attendants during the day (morning
and afternoon shifts), and only one trained nurse
and one nurse attendant during the night. This distri-
bution is usually maintained during weekdays and
weekends. Haematology and chemical pathology ser-
vices are provided by the paediatric department’s lab-
oratory which is supported by the Medical Research
Council (MRC) Unit in The Gambia. Microbiology
is performed in the main hospital laboratory but
blood culture samples are mostly sent to the MRC
for processing. Full blood count and blood film for
malaria parasites are the only laboratory investi-
gations available during weekends. Blood glucose is
measured on the ward using a glucometer; however,
the glucometer strips are frequently out of stock. Lab-
oratory sticks for protein measurement are not avail-
able. Only limited radiological services are available
during weekends in the hospital.
Data collection
Data were collected retrospectively for the period
1 January 2009 to 31 December 2013. The medical
records of neonates admitted during this period were
retrieved from the Records Department. To determine
the completeness of record retrieval, the ward admis-
sion books were reviewed to establish the total
number of admissions for the period, and an exhaus-
tive search was made for all missing records. Data
were extracted from available records detailing dates
of birth, admission and outcome; gender; birth and/
or admission weight; estimated gestation; mode and
place of delivery; antenatal care, obstetric compli-
cations; maternal HIV status; anti-retroviral adminis-
tration for PMTCT; tetanus toxoid immunization
and intermittent preventive treatment for malaria
during pregnancy (ITPp); investigations and treat-
ment; admission and final diagnoses. Where available,
gestational age was copied from the antenatal card
(this was usually calculated from the fundal height,
and infrequently from an ultrasound scan), and few
neonates were assessed for clinical maturity using the
New Ballard Score.
Definitions and outcome
Diagnoses were mostly clinical. Sepsis, meningitis and
pneumonia (possible severe bacterial infection, pSBI)
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were diagnosed according to the diagnostic algorithms
defined by the WHO Young Infants Clinical Signs
Study Group.13 Prematurity was defined as a gesta-
tional age of less than 37 completed weeks or a birth-
weight of v1.5 kg when the gestational age was not
available; 1.5 kg (very low birthweight, VLBW) was
used as the cut-off as preterm birth is the most likely
cause of VLBW. Late preterm was defined as a gesta-
tional age of 34–36 completed weeks. For neonates
admitted on the day of birth for whom no birthweight
had been documented, the admission weight was used
as the birthweight. Where no final diagnoses were pro-
vided, the admission diagnoses were used.
The primary outcome was death in the hospital.
Age at admission and at death and length of hospital
stay were calculated from the raw data. Times of
admission and of death were examined using two
different exposure categories. The first was based
on whether admission occurred at the weekend (com-
mencing on Friday at 2.00 p.m., when weekday work
ends, until Monday at 7.59 a.m.) or during the week
(Monday 8.00 a.m. until Friday 1.59 p.m.). The
second exposure category was based on an aggrega-
tion of the day of the week (weekday vs weekend)
and time of the day, defined as on-call duty hours
(4.00 p.m. to 7.59 a.m. Monday to Thursday or at
the weekend) and regular working hours (8.00 a.m.
to 4.00 p.m. weekdays except Friday when it is 8.00
a.m. to 1.59 p.m.).
Statistical analysis
All statistical analyses were performed with STATA
version 13 (Stata Corp., College Station, TX, USA)
statistical significance defined as alpha 0.05 (two-
sided). Categorical and continuous variables were
summarised, respectively, as percentages and
median (inter-quartile range). Cross-tabulations
with outcome were performed using the x2 statistic
for categorical variables. Neonates whose outcome
could not be ascertained from their hospital records
and those who were removed against medical
advice (or absconded from care) were excluded
from further analysis.
Neonatal characteristics of interest were assessed
as risk factors for death using logistic regression,
adjusting for age, sex and admission weight as poten-
tial confounders. Odds ratios with accompanying
95% confidence intervals and Wald test P-values
(two-tailed) for the univariate and multivariable ana-
lyses are reported.
Ethical considerations
The Gambia Government/Medical Research Council
Unit’s Joint Ethics Committee approved the audit.
Approval was also obtained from the Publications
and Research Committee of the University of The
Gambia School of Medicine and Allied Health
Sciences.
Results
Between 1 January 2009 and 31 December 2013,
there were 7161 admissions to the neonatal ward.
There were on average 1432 admissions each year,
with the fewest admissions (1307) recorded in 2011
and the highest (1502) in 2013. A total of 5285 neo-
natal medical records were recovered from the
Records Department, representing 74% of all admis-
sions for the period under review: 24% of records
were retrieved for 2009, 77% for 2010, 80% for
2011, 98% for 2012 and 90% for 2013. Owing to
low records capture, data from 2009 were sub-
sequently excluded from analysis, and the results
for 4944 admissions during 2010–2013 are presented.
Seasonality of admissions
The highest number of admissions (169) was
recorded in October 2012, and the lowest (37) in
February 2011 (Fig. 1). Between November and
May, there is uninterrupted dry weather in
The Gambia, and hot, humid weather predominates
during the rest of the year, with a rainy season
from June to October. A seasonal pattern of admis-
sions was observed with increased admissions
between September and December (peaking in
October) each year. No seasonality was observed
by place of delivery or admission weight.
Characteristics of neonates and mothers
The characteristics of admitted neonates are shown
in Table 1. The majority (64%, 3142/4944) of births
were at a health facility; however, birthweight was
recorded in 67% (3336/4944) of all case notes. Gesta-
tional age records were missing for nearly two-thirds
of neonates; of the 1289 neonates born at v37 com-
pleted weeks of gestation, 30% (387/1289) were
between 34 and 36 weeks of gestation.
Respiratory rate was the most commonly recorded
vital sign, found in 4525 (92%) of case notes; 38%
(1729/4525) of newborns had a respiratory
rate w60 breaths/minute. Forty-eight per cent (2282/
4413) of newborns whose axillary temperature was
documented at admission had hypothermia (tempera-
turev36.5uC)and28%(1310/4413) had fever (tempera-
ture i37.5uC). Hypothermia was more prevalent on
admission in neonates born at EFSTH than in those
born outside (69% vs 46%, Pv0.001), and 80% of neo-
nates admitted on the day of birth were hypothermic.
Nearly two-thirds (62%) of those admitted with
hypothermia weighed v2500g, and half of these were
very small (v1500 g). The prevalence of hypothermia
decreased significantly with increasing admission
weight: 83% v1500 g, 51% 1500–2499 g and 36%
i2500 g (Pv0.001). Of the 3455 neonates with an
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admission blood glucose measurement, hypoglycaemia
(v2.6mmol/L)wasdetected in666 (19%)andhypergly-
caemia (w6.9 mmol/L) in 608 (18%).
Information on maternal antenatal care was docu-
mented for 83% (4106) of newborns; the majority
(62%, 2565/4106) of mothers received antenatal
care, of whom 51% (1316/2565) attended at least
four times. Evidence of maternal HIV screening
was recorded for 132 (3%) newborns. Of the 132
mothers who were documented to have received
counselling and testing, and/or PMTCT services, 30
(23%) were HIV-positive (mostly HIV-1, with only
one case of HIV-1 and 2 dual infection). Only 11
(37%) of the 30 HIV-exposed newborns received a
PMTCT drug (nevirapine). The presence or absence
of obstetric complications was indicated in 59%
(2937/4944) of records, most (70%, 2047/2973) of
whom had at least one recorded complication.
Outcome
Overall, more than one-third (35%, 1734/4944) of
neonates died during admission. There was evidence
of a trend of increasing case-fatality from 33% in
2010 to 39% in 2013 (P50.03). Outcome could not
be ascertained for 17 neonates, and 38 neonates
were taken home against medical advice. These new-
borns represented 2% of the dataset and did not
differ significantly from newborns alive and well at
discharge with regard to the variables of interest
(data not shown); they were excluded from analysis
of risk factors for mortality. The main causes of
death in the unit were complications of pre-term
birth, severe infections and intra-partum related
events (Fig. 2A). Newborns admitted at weekends
were more likely to die than those admitted during
the remainder of the week (38% vs 35%, P50.03);
Figure 1 Seasonal pattern of admissions to the neonatal ward, EFSTH, Banjul, The Gambia between 1 January 2010 and 31
December 2013
Table 1 Characteristics of 4944 neonatal inpatients at
EFSTH, Banjul, 2010–2013
Categories n (%)
Male 2782 (56.3)
Unknown/missing 142 (2.9)
Age on admission, days
Day of birth 2242 (45.4)
2–7 1550 (31.3)
i8 907 (18.3)
Unknown/missing 245 (5.0)
Gestational age, wks
Pre-term,v37 1289 (26.1)
Term, 37–42 500 (10.1)
Post-term,w42 17 (0.3)
Unknown 3138 (63.5)
Weight on admission, g
v1500 942 (19.1)
1500–2499 1411 (28.5)
2500–3999 2347 (47.5)
i4000 148 (3.0)
Unknown/missing 96 (1.9)
Place of delivery
Home/TBA* 437 (8.8)
EFSTH 1590 (32.2)
Other health facility 1552 (31.4)
BBA{ 14 (0.3)
Unknown/missing 1351 (27.3)
Mode of delivery
Vaginal 3452 (69.8)
Caesarean 724 (14.7)
Unknown/missing 768 (15.5)
Maternal age, yrs
v18 219 (4.4)
18–35 2924 (59.2)
w35 328 (6.6)
Unknown/missing 1473 (29.8)
* Traditional birth attendant; { born before arrival at a health facility
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similarly, the risk of death was greater for those
admitted during on-call duty than for those admitted
during regular working hours (38% vs 33%, P50.004)
More than half of all deaths (57%, 989/1734)
occurred during the first 48 hours of admission.
Fifty-four per cent (482/897) of preterm neonates
died compared with 38% (186/494) of term and
41% (7/17) of post-term neonates (Pv0.001). Case
fatality was associated with lower weight on admis-
sion; 58% (539/932) of neonates weighing v1500 g
died compared with 34% (469/1399) of those weigh-
ing 1500–2499 g, 29% (674/2320) of those weighing
2500–3999 g, and 15% (22/144) of those weighing
i4000 g (test for trend Pv0.001).
Of the 1673 deaths with known age at death, 1267
(76%) were early neonatal deaths (defined as deaths
occurring during the first 7 days of life), 67% (853/
1267) of which occurred during the first 48 hours
of life. Only 5% (83/1267) of neonates died after
21 days of age.
On multivariable analysis (Table 2), risk factors for
neonatal death were weight v1500 g on admission
(OR 1.61, 95% CI 1.15–2.26), delivery outside
EFSTH [at home or by a traditional birth attendant
(OR 2.17, 95% CI 1.40–3.38), delivery at another
health facility (OR 1.79, 95% CI 1.34–2.39)], lack
of antenatal care (OR 1.68, 95% CI 1.17–2.41),
hypothermia (OR 2.48, 95% CI 1.76–3.49), hypogly-
caemia (OR 1.60, 95% CI 1.19–2.15) and hypergly-
caemia (OR 1.62, 95% CI 1.19–2.19).
Clinical diagnoses
Possible severe bacterial infection (pSBI) accounted
for 44% (2166/4944) of admissions, 27% (1340/4944)
prematurity/low birthweight (LBW), and 20% of
intrapartum-related conditions. Jaundice was docu-
mented in 5% (243/4944) of newborns, two of
whom had kernicterus; however, all were treated as
cases of pSBI. Characteristics of newborns with
pSBI are described further in Table 3. Of the 2026
pSBI cases with known age on admission, nearly
half (984, 49%) were early-onset infections (defined
as infections within the first 72 hours of life)
Skin and/or soft tissue infections were observed in
9% (421/4944) newborns; the most common soft
tissue infections were mastitis and omphalitis. Conge-
nital malformations accounted for 5% (241/4944) of
admissions; the most common were neural tube
defects/central nervous system malformations (20%,
48/241), cardiac chamber malformations (10%, 40/421),
malformations of the intestinal tract (7%, 30/
421) and musculo-skeletal malformations (5%,
21/421). Over the study period, there were 48 cases
of ophthalmia neonatorum, 17 cases of tetanus and
seven cases of diarrhoea, each accounting for less
than 1% of admissions.
Investigations
The full blood count was recorded in 841 (17%) of
the case notes, and haemoglobin concentration was
documented in 1020 (21%). Serum bilirubin had
been estimated in 36 (15%) of the 243 neonates
with documented jaundice. Only 5% (104/2166) of
pSBI cases had had at least one microbiological or
radiological investigation: 41 had a chest radiograph,
26 had a blood culture and 43 had a lumbar punc-
ture. Two blood cultures were positive for Staphylo-
coccus aureus, one for Escherichia coli and three for
coagulase-negative staphylococci. All neonates with
positive blood cultures recovered and were dis-
charged. Only one infant, a 2-day-old home/TBA-
born neonate, had a positive cerebrospinal fluid
(CSF) culture (Klebsiella species); he received anti-
biotics for 25 days but finally died.
Prescription of oxygen, intravenous (IV) fluids
and antibiotics
There were 2559 neonates who, according to their
history and examination findings (respiratory
distress, cyanosis), met the indicators for oxygen
therapy, but only 1965 (77% of cases in whom it was
indicated) were documented to have received it. Sev-
enty per cent (3455/4944) of neonates had documen-
tation of receiving IV fluids. Antibiotics were the
most frequently administered medication, and 94%
(4635/4944) of neonates received parenteral (intrave-
nous) antibiotics during admission. The majority
(65%, 2995/4635) of these neonates received two anti-
biotics during admission, 27% (1235/4635) received
three drugs, 5% (161/4635) received just one, and
v1% (14/4635) five or more. Antibiotics are usually
provided free of charge by the hospital; however,
when they are out of stock, parents have to provide
them. Ampicillin and gentamicin were the most
Figure 2 Distribution of causes of neonatal death in the
neonatal ward, Edward Francis Small Teaching Hospital,
2010–2013 (Severe infections includes sepsis, meningitis
and pneumonia)
Neonatal care in The Gambia Uduak et al.
Paediatrics and International Child Health 2015 VOL. 35 NO. 3 257
Table 2 Risk of death among neonatal inpatients 2010–2013 (excluding newborns who absconded or were taken home
against medical advice
Categories Dead, n Discharged, n Unadjusted OR P Adjusted OR P
Male 695 1304 1.04 (0.92–1.17) 0.57 1.06 (0.85–1.34) 0.60
Female 978 1772 1 1
Age on admission, days
Day of birth 996 1225 2.87 (2.40–3.43) v0.001 1.51 (0.93–2.45) 0.09
2–7 480 1052 1.61 (1.33–1.95) v0.001 1.27 (0.81–2.00) 0.30
i8 198 699 1 1
Admission weight, g
v1500 539 393 3.35 (2.86–3.92) v0.001 1.61 (1.15–2.26) 0.01
1500–2499 469 930 1.23 (1.07–1.42) 0.004 0.86 (0.64–1.14) 0.30
2500–3999 674 1646 1 1
i4000 22 122 0.41 (0.37–0.48) 0.001 0.75 (0.38–1.47) 0.40
Place of birth
Inborn (EFSTH) 529 1046 1 1
Other health facility 640 899 1.41 (1.22–1.63) v0.001 1.79 (1.34–2.39) v0.001
Home/TBA 180 254 1.40 (1.13–1.74) 0.002 2.17 (1.40–3.38) 0.001
Mode of birth
Vaginal 1325 2081 1 1
Caesarean 196 525 0.60 (0.49–0.70) v0.001 0.66 (0.48–0.91) 0.01
Resuscitation at birth
Resuscitated 535 717 1.52 (1.33–1.73) v0.001 1.33 (1.00–1.76) 0.05
Not resuscitated 1199 2438 1 1
Maternal age, yrs
v18 99 119 1.45 (1.10–1.91) 0.01 1.35 (0.85–2.15) 0.21
18–35 1059 1840 1 1
w35 110 212 0.90 (0.70–1.15) 0.40 1.08 (0.73–1.58) 0.71
Maternal ANC
None 535 978 1.30 (1.07–1.56) 0.01 1.68 (1.17–2.41) 0.01
1–4 visits 691 1084 1.51 (1.26–1.81) v0.001 1.15 (0.87–1.51) 0.34
w4 228 540 1 1
Temperature, uC
v36.5 966 1178 2.99 (2.50–3.56) v0.001 2.48 (1.76–3.49) v0.001
36.5–37.4 203 739 1 1
i37.5 341 942 1.32 (1.08–1.61) 0.01 1.17 (0.79–1.73) 0.42
Blood glucose, mmol/L
v2.6 325 336 2.14 (1.79–2.56) v0.001 1.60 (1.19–2.15) 0.002
2.6–6.9 673 1490 1 1
w6.9 281 320 1.94 (1.62–2.34) v0.001 1.62 (1.19–2.19) 0.002
Time of day
Regular work hours 508 1013 1 1
On-call hours 1095 1805 1.21 (1.06–1.38) 0.004 0.97 (0.76–1.25) 0.84
Table 3 Characteristics and clinical assessment of neonates with possible severe bacterial infection (pSBI)
Characteristics Total no.
pSBI
n (%)
Non-pSBI
n (%) P
Place of birth, n53593
Inborn (EFSTH) 1590 379 (28) 1212 (54)
Other hospital facility 1556 715 (53) 851 (38)
Home/TBA 437 249 (19) 188 (8) v0.001
Mode of delivery, n54167
Vaginal 3452 1522 (89) 1930 (78)
Caesarean section 724 193 (11) 531 (22) v0.001
Age at admission, days, n54699
1–3 2242 984 (49) 2313 (87)
4–7 1550 413 (20) 83 (3)
i8 907 629 (31) 278 (10) v0.001
Admission weight, g, n54848
v1500 942 187 (9) 756 (28)
1500–2499 1411 643 (31) 768 (28)
i2500 2495 1280 (60) 1215 (44) v0.001
Symptoms/signs*
History of convulsions 393 264 (67) 129 (33) v0.001
History of difficulty feeding 2192 1079 (49) 1113 (51) v0.001
Fever, temp.i37.5uC 1259 1052 (81) 243 (19) v0.001
Hypothermia, temp.v36.5uC 2165 455 (21) 1711 (79) v0.001
Restlessness/irritability 474 359 (76) 115 (24) v0.001
Difficulty breathing 2351 917 (39) 1434 (61) v0.001
Lethargy/reduced movement 238 134 (56) 104 (44) v0.001
*Row percentages
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frequently used medications (Fig. 3); among neonates
who received a single antibiotic, gentamicin was the
most commonly administered (122/161), followed by
ceftriaxone (28/161). Fifty-five per cent (2533/4635)
of neonates who received antibiotics, lacked clinical
evidence of pSBI and did not have any diagnostic
work-up. The median duration of treatment was 4
days (IQR 2–7, range 0–30) for both pSBI and non-
pSBI neonates. Twenty-eight newborns received anti-
biotics for more than 21 days, of whom 50% (14/28)
had a diagnosis of pSBI, and 25% (7/28) had congenital
malformations. Ten (36%) of these newbornswere also
preterm and of low birthweight. Owing to a high case
load and limited cot availability, most neonates were
discharged once clinical improvement was obvious
with oral antibiotics and advice on danger signs.
Whether choice of fluid, fluid volumes, antibiotics
and antibiotic dosage complied with WHO guidelines
was not assessed.
Discussion
This study provides the first comprehensive
description of morbidity and mortality and quality
of care of sick newborns in a tertiary centre in The
Gambia. As far as we know, this is the largest neo-
natal inpatient audit published from West Africa,
and it provides a baseline from which to improve
to clinical care and data collection.
Case fatality in the neonatal unit is higher than
reported from similar tertiary referral hospitals in
West Africa: 7% in Senegal,14 13–20% in Nigeria15–18
and 13–15% in Burkina Faso.19,20 The three most
common causes of neonatal deaths in the unit are
preventable, and are similar to the global and
national WHO/Child Health Epidemiology Reference
Group (CHERG) estimates for The Gambia for the
same period21 (Fig. 4), but rank differently. Whereas
complications of preterm birth were the major cause
of death in our unit, the WHO/CHERG estimates
show intrapartum-related events to be the major
cause of death in the country. This difference might
be explained by the fact that most of the neonates
admitted were facility-born and therefore more
likely to reflect a selected population with obstetric
complications, especially preterm birth. The risk of
death in the unit was greatest on the day of birth
and among very small infants. Small size at birth –
owing to preterm birth or small-for-gestational-age
(SGA), or both – is the greatest risk factor for
most neonatal deaths.3 Globally, antenatal corticos-
teroids have been of great benefit in preventing com-
plications of preterm birth;22 however, their use in
preterm newborns admitted in the unit was not
assessed. The majority of deaths occurred within 48
hours of admission. The inability of health-care
facilities to provide timely, good-quality care on
arrival at hospital is reported to be a leading23 or
secondary24 cause of in-hospital newborn deaths.
Although an increased odd of deaths of newborns
admitted at the weekend (as well as among those
admitted during on-call hours, data not shown)
was noted, there was a lack of a weekend effect on
death in the adjusted analysis. Consequently,
improved survival of newborns requires fast interven-
tions at any time of day or night as the time to death
can range from a few minutes for the inadequately
resuscitated neonate who does not breathe at birth,
to an hour for the infant suffering a severe hypoxic
event, and a few hours for severe early-onset
sepsis.3 All facilities which provide maternity services
Figure 4 WHO/CHERG estimates for causes of neonatal
death distribution in The Gambia, 2010–2013
Figure 3 Parenteral antibiotic prescription patterns among
4635 neonatal inpatients at the EFSTH, Banjul, 2010–2013.
(Amp, ampicillin; Gent, gentamicin; Fluclox, flucloxacillin;
Ceftri, ceftriaxone; Amika, amikacin; Cipro, ciprofloxacin;
Co-amoxiclav, amoxicillin and clavulanic aci)
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should at least have a functioning mechanical
suctioning device and a self-inflating bag and mask.
Helping Babies Breathe (HBB) is an evidence-based
educational programme to teach neonatal resuscita-
tion techniques in resource-limited areas, with the
goal of having at least one person who is skilled in
neonatal resuscitation at every birth. Pre-service
and in-service training curricula should be revised
to support implementation of the HBB curriculum.
As a tertiary referral hospital, EFSTH should in
addition ensure that the appropriate equipment and
expertise for endotracheal intubation are available
for severely depressed infants.
The seasonal variation in admissions in our unit mir-
rors seasonal variations in births in EFSTHand nation-
wide (data not shown). Although seasonal variation is a
cardinal feature of paediatric diseases in West Africa,25
and accentuates the vulnerability of children in poor
families, the reasons for it are not known. No seasonal
variation was observed when stratified by admission
weight; however, divergent patterns of seasonality
have previously been reported in The Gambia for pre-
term birth and SGA.26 In this study, the peaks in pre-
maturity closely paralleled increases in agricultural
labour (July) and malaria infections (October). The
incidence of SGA was highest at the end of the
annual hungry season, from August to December
(peaking in November), and has been attributed to sea-
sonal deterioration of nutritional status owing to food
shortages, and to an increase in agricultural labour
which often coincides with seasonal epidemics of infec-
tious and parasitic diseases.27
Almost half of the neonates were admitted with
clinical signs compatible with pSBI, and half of
these presented as ‘early-onset sepsis’ (within the
first 3 days of birth) as against ‘late-onset sepsis’
(after the first 3 days of birth until the end of the neo-
natal period). Early-onset sepsis is usually associated
with vertically acquired infection from the birth
canal, while late-onset sepsis is associated with acqui-
sition from the home or hospital environment,
particularly through the umbilical cord.28 In develop-
ing countries, unclean delivery practices and initial
care of the infant in hospital contribute to very
early-onset infections.29 The very high cot occupancy
in the unit makes it difficult to isolate infected
patients. Being the only neonatal referral centre,
there is a strict policy not to turn patients away, lead-
ing to sharing of cots and incubators during peak
admission periods. Consequently, infection control
practices would have been sub-optimal, making it
difficult to ascribe ‘maternally acquired’ or ‘hos-
pital-acquired’ status to those presenting with early-
onset neonatal infections.
There was a striking mismatch of high antibiotic
usage and low laboratory investigations. Sick neonates
do not routinely undergo microbiological investi-
gations, mainly owing to an absence of ward proto-
cols, unreliable diagnostic laboratory facilities with
delayed results, and the general expectation of a ‘nega-
tive’ result by attending clinicians. The majority of
newborns received only ‘first-line’ empirical treatment
with the WHO-recommended ampicillin and gentami-
cin; however, many received additional antibiotics or
other regimens including third-generation cephalos-
porins, and some were on treatment for as long as
30 days. In the absence of clinical guidelines, one
major reason for the widespread use of ampicillin
and gentamicin is the fact that the pharmacy does
not dispense cephalosporins if a consultant has not
signed the prescription. Unlike culture-proven sepsis,
which is treated with a full course of antibiotics on
the basis of antimicrobial sensitivity, the appropriate
duration of treatment for suspected neonatal sepsis
when cultures are negative or not available is a chal-
lenge.30 Prolonged initial empirical antibiotic treat-
ment (defined as i5 days of initial empirical
antibiotic with sterile culture results) is associated
with an increased risk of an adverse outcome, includ-
ing invasive candidiasis and death, particularly in pre-
mature and extremely small newborns.31,32 Moreover,
antibiotic costs are not cheap and represent a signifi-
cant proportion of the hospital drug budget.
Point-of-admission hypothermia was present in
48% of neonates. The prevalence of hypothermia
on admission among newborns in SSA ranges from
22 to 85%.33–35 Newborns must be kept warm at
birth (at home or in hospital) and, especially, if ill
and being transferred from home or between hospi-
tals or within a hospital to a neonatal care unit. Pre-
term and small newborns are especially vulnerable,
and can rapidly become hypothermic, increasing the
risk of respiratory distress, hypoglycaemia, infections
and death. About one-third of the newborns with
hypothermia in the unit weighed v1500 g, and
most were intra-hospital transfers from the maternity
unit. Despite taking place within the hospital
environment, that the distances involved are rela-
tively short and the apparent risk of complications
is low, intra-hospital transfer can constitute an
additional risk, especially to pre-term infants.36
Even in high-income settings, hospitals without a
neonatal transport team and incubator may have sig-
nificantly more deaths or adverse events in low-birth-
weight infants with respiratory disease than do
comparable hospitals with neonatal transport facili-
ties.37 Multi-disciplinary transport teams are, how-
ever, a luxury in low-income settings. Prevention of
hypothermia should commence before delivery by
ensuring that the place of delivery is warm, and
maintaining a ‘warm chain’ of procedures at
birth and during the hours and days that follow.38
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These simple, cost-effective procedures include skin-
to-skin contact with the mother (KMC) during trans-
fer, wearing of hats, and the use of plastic bags/wraps
particularly for very small and low-birthweight
(LBW) newborns, and should be encouraged. KMC
is particularly suitable when there is a lack of sophis-
ticated equipment such as radiant heaters and incu-
bators, and has been shown to substantially reduce
mortality among clinically stable preterm/LBW
infants in hospital.39 It has also been shown to
reduce the workload on the ward, thereby allowing
nursing staff to focus attention on more unstable
infants.40 Minimal instruction is required and it can
also be used in the community or at home. The cur-
rent Gambian health policy framework does not
include implementation of KMC;8 there is therefore
an urgent need to address barriers to scaling-up facil-
ity-based initiation of KMC in line with the post-
2015 newborn health research priorities.41
Hypoglycaemia is an important contributor to
hypothermia, particularly among those at risk (pre-
term or term SGA, large, infant of a diabetic),42
and vice-versa: it maintains a vicious circle, which
leads to weak sucking, weight loss and finally
increased mortality. Nearly one-fifth of newborns in
the unit were hypoglycaemic on admission, compared
with one-third in a similar facility in Nigeria.43
Breastfeeding prevents hypothermia by warming
through the mother, especially by skin-to-skin con-
tact, and also by replenishing a newborn’s glucose
levels. The Gambian national health policy sub-
scribes to the principles of the Baby-friendly Hospital
Initiative to implement practices which protect, pro-
mote and support breastfeeding.44 Initiation of
early breast-feeding is, however, difficult in newborns
requiring admission, particularly if a mother is reco-
vering from anaesthesia following caesarean delivery
or is too ill with other post-partum complications.
Delays in referral and transfer to the neonatal unit
and establishing intravenous access further contrib-
ute to hypoglycaemia in those at risk.
There are several possible reasons for the sub-opti-
mal neonatal care in The Gambia. One is the lack of
appropriate equipment and trained staff. The level of
laboratory support in the unit falls short of essential
newborn care standards for a district hospital,
let alone a referral-level hospital.45 Although this
deficiency highlights health system challenges in the
provision of appropriate equipment (e.g. lack of
blood culture bottles, laboratory reagents and
equipment) and appropriately trained personnel
(e.g. microbiologists and laboratory technicians),
it also draws attention to the capabilities of the clin-
icians managing sick newborns as investigations were
not requested for most of the neonates in whom there
was clinical suspicion of infection.
Poor knowledge and training of neonatal care-
providers and a shortage of qualified staff are
associated with sub-optimal care in developing
countries.23,24 As is the case in most other countries
with very high maternal and neonatal mortality, The
Gambia lacks theminimum requirement of 23 doctors,
midwives and nurses per 10,000 population to provide
a basic package of care.46 There are currently
157 Gambian and 479 non-Gambian medical doctors
registered with the Medical and Dental Council.
There are also non-registered Cuban, Egyptian and
Syrian doctors providing medical care as part of bilat-
eral agreements with their respective governments.
Since its inception in 1999, 111 indigenous doctors
have graduated from the University of The Gambia.
Upon completion of a 2-year internship programme,
the medical officers are usually retained at the
EFSTH; since January 2014 however, the Ministry of
Health has begun posting medical officers to district
hospitals and health centres to serve communities.
The goal is for 80% of all hospitals and major health
facilities to be managed by indigenous doctors by
2016. Unfortunately, postgraduate medical training
is not available in The Gambia and so locally trained
doctors lack affordable avenues to acquire specialized
skills and competencies for neonatal care; the pro-
vision of specialist neonatal care depends solely on
expatriate doctors who also work in EFSTH. Nurses
are the most accessible health-care providers in
The Gambia with more nurses than doctors per 1000
people. Basic training for nurses follows either a
2-year track to the level of state-enrolled nurse (SEN)
or a 3-year track to the level of state-registered nurse
(SRN). SENs wishing to become SRNs have to
undergo an additional 2 years of training. Most
nurses undergo additional training in midwifery but
there is no formal training in paediatric or neonatal
nursing, and competence is acquired through experi-
ence. The mix of nursing staff is not regulated, and,
in health centres, care-giversmight not have the necess-
ary competence to provide neonatal care, and may not
even be nurses but attendants with no clinical training
at all. Uncompetitive salaries and benefits have
resulted in high attrition rates, staff shortages and
low motivation which have further contributed to the
poor quality of care. Urgent systematic attention is
required, non-rotation of nurses with skills in neonatal
care, and, where appropriate, the development of a
neonatal nurse cadre, as well as rewarding those who
work against the odds in hard-to-serve areas.47
In developed countries, detailed quality-of-care
protocols and ‘core nursing skills sets’ for almost
every aspect of newborn care have improved quality
and given more responsibility for care to skilled neo-
natal nurses, particularly with regard to infection
prevention, feeding support and use of intravenous
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fluids.48 Hospitals providing neonatal care have ser-
vice standards that take account of the nurse-to-
patient ratio (maximum number of patients who
may be assigned to a nurse during one shift) as well
as nursing skills, training and development depend-
ing on the category of newborn care.49,50 The British
Association of Perinatal Medicine’s (BAPM) rec-
ommendations for neonate-to-nurse ratios for inten-
sive care (IC), high dependency care (HDC) and
special care (SC) in England are currently 1:1, 2:1
and 4:1, respectively.49 Similar recommendations
and service standards for essential neonatal care are
lacking in The Gambia and West Africa, despite
studies in Ghana and Nigeria which have shown
that levels of nursing staff in a neonatal care unit
affect patient outcomes (mortality and adverse
events), patient experience, quality of care and the
efficiency of care delivery.51,52 Appropriate nurse-
to-patient ratios cannot be generalized because of
factors such as patient load and characteristics, avail-
ability of nurses and work environment; the ratio
that is sufficient for one unit might be insufficient
for another. A nurse-to-patient ratio of 1:12.5–1:25
has been reported in the neonatal intensive care unit
of a Ghanaian teaching hospital.51 WHO has devel-
oped a tool for calculating optimal health worker
levels, known as the Workload Indicators of Staffing
Need (WISN). The software calculates the number of
health workers per cadre, based on health facility
workload, and provides two indicators to assess staff-
ing: the gap/excess between the current and required
number of staff, and the WISN ratio, a measure of
workload pressure. WISN has been used extensively
in East and Southern Africa but there are no case
studies of its use in West Africa.42–44,53 Owing to a
lack of essential information, the staffing requirements
for the EFSTH neonatal unit could not be calculated.
Given the strong emphasis on improving referral
pathways and promoting institutional delivery for
high-risk births as a means of improving neonatal
survival, more needs to be done to ensure that the
EFSTH neonatal unit is suitably equipped and
staffed. With just over 70,000 births annually,
nearly 60% of which take place in health facilities,
the 30-cot EFSTH neonatal unit is grossly
inadequate to meet the national need for referral-
level hospital care of sick newborns. As the pro-
portion of neonates delivered in health facilities
increases, it is necessary to accelerate coverage of
essential newborn care. Urgent attention needs to
be focused on scaling up the provision of appropriate
packages of newborn care at district hospitals, and
possibly major health centres, as recommended by
WHO.45 The packages of care with the greatest
impact on preventing neonatal deaths and stillbirths
include care during labour, childbirth and the first
week of life, and care for the small and sick new-
born.54 These packages, the focus of WHO’s Every
Newborn action plan to end preventable deaths,
include management of preterm births (including
the use of antenatal corticosteroids), essential new-
born care (hygienic care, thermal control, support
for breastfeeding and newborn resuscitation), inter-
ventions to deal with complications arising from pre-
term birth and/or SGA, and neonatal infections
(sepsis, meningitis, pneumonia and diarrhoea).54
Appropriate management of small sick newborns
includes extra thermal care and support for feeding
small or pre-term newborns, including KMC, anti-
biotic treatment for infections and full supportive
facility care. Since endorsement of the newborn
health action plan in 2014, only two West African
countries, Ghana and Nigeria, have hosted national
newborn events and are in the process of developing
their own national newborn action plans.55
Insufficient government funding of the health ser-
vice, lack of an integrated maternal and newborn
health policy, and greater investment on addressing
maternal rather than fetal and newborn outcome
are further reasons for sub-optimal neonatal care
in The Gambia. In 2001, The Gambia and other
African Union governments pledged to commit at
least 15% of their annual budgets to improve the
health sector.56 At the end of 2013, only two West
African countries, Togo and Liberia, had achieved
this target.57 In The Gambia, priority areas for
child health have been scaling-up immunization
coverage and prevention of deaths from malaria,
pneumonia and diarrhoea. It is only in the last
decade that attention has turned to the contribution
of neonatal deaths to child mortality.58,59 The Gam-
bian national health policy for 2012–2020 is focused
on ‘acceleration of quality health services and univer-
sal coverage’;8 however, newborn survival and health
are not specifically addressed. There is therefore an
urgent need to strengthen newborn health com-
ponents in existing health sector plans and strategies,
especially those which relate to reproductive,
maternal and child health, as outlined in the Every
Newborn action plan.
The study has some limitations. Although data
presented are from the main national tertiary referral
hospital, it cannot be assumed that the findings rep-
resent neonatal morbidity and mortality in The
Gambia as a whole. Furthermore, the results
should be interpreted in the light of the following.
Firstly, this is a retrospective study with data
abstracted from routine medical records. About
26% of records for the period under review could
not be located and data were missing for nearly all
variables. Secondly, poor documentation of medical
histories and examination findings, lack of systematic
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assessment of gestation and possible ascertainment
bias at the point of data abstraction from written
records might have led to misclassification of diag-
noses. Furthermore, diagnoses were based almost
entirely on clinical assessment without laboratory
support. A report on microbiological aetiology
could not be presented as only six newborns had
positive blood cultures and only one had a positive
CSF culture. Lastly, poor documentation of care
and the implicit assumption that written records
reflect actual practice might have resulted in bias
regarding quality of care.
This study has provided a comprehensive overview of
inpatient care for newborns in The Gambia, showing
that over one-third of them die, even in the country’s
teaching hospital. Further operational and research
data are required on infections, notably regarding
aetiologies and antimicrobial resistance. Education
and training of health-care workers, development of
guidelines and standards of care, and regular audit are
necessary for the provision of high-quality neonatal ser-
vices. Creation of national and regional perinatal/neo-
natal databases for stillbirths, pre-term and very low-
birthweight infants, as well as those meeting other eligi-
bility requirements, will provide data for improving
outcomes and increasing the quality, safety and value
of newborn care through quality improvement
collaborations with other countries in the sub-region.
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Appendix	4:	Definition	of	Clinical	Signs	Of	Possible	Serious	Bacterial	Infection	
Fever	 If the newborn’s axillary temperature is found ≥38.0°C, the infant is unwrapped and 
hydrated (breast feed for breastfed infants) during a 30 minutes period. A second 
temperature reading is taken 30 minutes after unwrapping. The baby is considered as 
having fever only if the second reading after 30 minutes is ≥38.0°C	
Hypothermia	 If the newborn’s axillary temperature is found ≤35.5°C, the infant is wrapped with warm 
dry clothes including head and extremities (using e.g. a woollen cap, woollen sweater or 
woollen socks) and then wrapped in a blanket for 30 minutes. A second temperature 
reading is taken 30 minutes after unwrapping. The baby is considered as having fever only 
if the second reading after 30 minutes is ≤35.5°C	
Lethargy	 The newborn only moves (e.g. limb movement or eye opening) on tactile stimulation, but is 
not otherwise moving OR wakes up but does not stay awake after a disturbance.	
Convulsions	 During an episode of convulsion, the child’s arms and legs stiffen because the muscles are 
contracting. The child may lose consciousness or not be able to respond to any other 
external stimulus. There may also be random or roving eye movements, eyelid blinking or 
fluttering, eyes rolling up, eye opening, staring, sucking, smacking, chewing and protruding 
tongue, unusual bicycling or pedalling movements of the legs, thrashing or struggling 
movements; long pauses in breathing (apnea) 
Fast	breathing	 If when quiet, at rest or sleeping, the newborn breathes 60 times or more in one minute, 
count again. The baby is considered as having fast breathing only if the second count is ≥60 
breaths/minute. 
Severe	chest	
indrawing	
Lower chest indrawing present each and every breath observed for one minute	
Poor	feed	with	poor	
suck	
According to the mother or care giver, the newborn (without any congenital malformation 
of the mouth) is not sucking the breast well; in a non-nutritive suck, the infant is reluctant to 
turn the head towards the stimulus; even after touching the roof of the mouth, he initiates 
only few sucks then becomes reluctant to suck again; not adequate for breastfeeding.  
 
If the infant has not fed in the previous hour, the mother is asked to put her infant to the 
breast and breastfeeding observed for 4 minutes. If the infant was fed during the last hour, 
the mother is asked to inform the study nurse when the infant is willing to feed so that the 
feeding can be observed.  During feeding assessment, the baby is placed in comfortable 
position, well attached and the mother helped to keep the baby in the correct position. 
Feeding difficulty is then measured.  
The newborn is considered to have feeding difficulty if there is a complete suspension of 
sucking motion and if the infant is consistently refusing the mother’s breast or other liquid. 
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Appendix	5:	Staff	Training	Manual	for	Collection	of	Study	Samples		
 
 
	
	
Study	Specific	Procedure	(SSP)	
SSP	Title:	
BLOOD, NASOPHARYNGEAL SWAB, RECTAL, GENITAL (RECTO-
VAGINAL) SWAB & CEREBROSPINAL FLUID COLLECTION 
SSP	Number:	 01 Version and date: 1.0 25 January 2016 
Category:	 Clinical 
SCC/Protocol	Number	 1384 
Prepared	by:	
(Name and job title)	
Dr. Uduak Okomo,  
MRC Clinical Research Fellow  
Signature	and	date*	
    
Reviewed	by:	  Muhammed Camara, Junior Clinical Trials Monitor 
Signature	and	date*	
    
Approved	by:	
(Name of Principal Investigator) 
Dr. Uduak Okomo 
 
Signature	and	date*	
    
Date	effective:	 25 January 2016 
* to be hand-written to indicate approval.  
 
 
 
 
Aetiology	of	Serious		
Neonatal	Infections		
in	The	Gambia	
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1.	Abbreviations,	contractions	and	definitions		
ANC Assistant Nurse Coordinator 
BC Blood Culture 
BHC Brikama Health Centre 
CRF Case Report Form 
CSF Cerebrospinal fluid 
DM Data Manager 
EFSTH Edward Francis Small Teaching Hospital 
FHC Fajikunda Health Centre 
FW Field Worker 
JFPH Jammeh Foundation for Peace Hospital 
LT Laboratory Team 
Lab Tech Laboratory Technician 
MRC Medical Research Council; representing MRC Unit, The Gambia 
NPS Nasopharyngeal Swab 
NFW Nurse Field Worker 
PI Principal Investigator 
PCB Polyclinic Banjul 
SKGH Serrekunda General Hospital 
SHC Serrekunda Health Centre 
SukHC Sukuta Health Centre 
SO Scientific Officer 
SOP Standard Operating Procedure 
SSP Study Specific Procedure 
STTG Skim-milk tryptone glucose glycerol   
RC Research Clinician 
RP Research Paediatrician 
RS Rectal Swab 
RVS Recto-vaginal Swab 
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2.	Background	
2.1. This is an observational study aiming to describe the aetiology of serious neonatal infections at 
the Edward Francis Small Teaching Hospital, Banjul and examine the role of maternal 
colonisation in these infections by examining the recto-vaginal flora in mothers of neonates with 
confirmed bacterial infection, comparing isolates from mother–newborn pairs in order to 
understand the extent to which the same isolates are found in both mother and newborn, and 
also compare the recto-vaginal flora in mothers of these sick neonates with that of mothers who 
have healthy newborns. 
2.2. According to section B3 of the study SCC proposal the following samples will be collected from 
consented participants at enrollment (Appendix 1):  
  
Participant	 Samples	to	be	collected	
Case 1. Venous blood (for culture & molecular studies)  
2. Nasopharyngeal swab (NPS) for culture and PCR 
3. Rectal swab (RS) for culture and PCR 
4. Cerebrospinal fluid (CSF) for culture, biochemistry and PCR 
Healthy Control 1. Venous blood (for molecular studies only)  
2. Nasopharyngeal swab (NPS) for culture and PCR 
3. Rectal swab (RS) for culture and PCR 
Mother of infant 1. Nasopharyngeal swab (NPS) for culture and PCR 
2. Recto-vaginal swab (RVS) for culture and PCR 
 
2.3. Collected samples will be transported to the following locations at MRC, Fajara as appropriate: 
• The Clinical Microbiology Lab, Kuyateh building AND/OR 
• The Biobank (Freezer Room), Himsworth building  
3.	Purpose	&	Scope	
3.1. This SSP describes the collection of blood, NPS, RVS, RS and CSF samples from study participants 
and the transportation of these samples to the relevant laboratories at MRC Fajara.  
3.2. The SSP applies to research clinicians (RC), nurses, fieldworkers (FW), who will be involved in 
the collection, transportation and receipt of blood samples. 
4.	Safety	Precautions	
Infection can be transmitted from patient to staff and from staff to patient during collection of 
blood and other body fluids. Viral agents are the greatest hazard and in some instances, are 
potentially lethal. Of particular importance are the viruses causing hepatitis and acquired 
immune deficiency syndrome (AIDS).  
All study staff MUST follow appropriate safety precautions detailed below when drawing, 
handling and transporting blood samples and other body fluids to different laboratory units at 
Fajara.  
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4.1	Venepuncture	(for	collection	of	venous	blood	specimen)	
4.1.1. Ensure all study staff follow body fluid precaution according to the MRC safety manual when 
collecting, handling and transporting samples to the lab. 
4.1.2. Wear disposable latex gloves that are impermeable to liquids whilst performing the procedure 
and used gloves will be disposed of in waste bags (yellow colour) for biological waste. 
4.1.3. Change gloves between patients; 
4.1.4. The used needle(s) must be discarded in the “sharpsafe” box after the procedure. 
4.1.5. Used syringes will be disposed of in waste bags (yellow colour) for biological waste.  
4.1.6. Use new needles and a new syringe(s) for each participant; 
4.1.7. Maintain a clean, clutter-free and disinfected work space at all times. 
4.2	Lumbar	Puncture	(LP)	
4.2.1. Ensure all study staff follow body fluid precaution according to the MRC safety manual when 
collecting, handling and transporting samples to the lab. 
4.2.2. Wear sterile latex gloves that are impermeable to liquids whilst performing the procedure and 
used gloves will be disposed of in waste bags (yellow colour) for biological waste. 
4.2.3. The used needle(s) must be discarded in the “sharpsafe” box after the procedure. 
4.2.4. Use new needles for each participant; 
4.2.5. Maintain a clean, clutter-free and disinfected work space at all times.  
4.3	Nasopharyngeal	swab	(NPS)	
4.3.1. Ensure all study staff follow body fluid precaution according to the MRC safety manual when 
collecting, handling and transporting samples to the lab. 
4.3.2. Wear disposable latex gloves that are impermeable to liquids whilst performing the procedure 
and used gloves will be disposed of in waste bags (yellow colour) for biological waste. 
4.3.3. The swab stick must be discarded in the “sharpsafe” box after the Floqswab tip has been cut off. 
4.4 Recto-vaginal swab (RVS) and newborn Rectal swab (RS) 
4.4.1. Ensure all study staff follow body fluid precaution according to the MRC safety manual when 
collecting, handling and transporting samples to the lab. 
4.4.2. Wear disposable latex gloves that are impermeable to liquids whilst performing the procedure 
and used gloves will be disposed of in waste bags (yellow colour) for biological waste. 
The swab stick must be discarded in the “sharpsafe” box after the Floq swab tip has been cut off. 
4.4.3. Use new needles and a new syringe(s) for each participant; 
4.4.4. Maintain a clean, clutter-free and disinfected work space at all times.  
5.	Equipment	/	Materials	/	Supplies	/	Reagents	
5.1	Nasopharyngeal	swab	
§ Tray 
§ Gloves 
§ Swab stick (Floq swab) 
§ Scissors 
§ STGG cryovials  
§ Sticker labels sheet 
§ Leak-proof specimen transportation 
bags 
§ “Sharpsafe” box 
§ Ice packs 
§ Cold box 
§ Waste disposal bag (yellow) 
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5.2	Genital	(Recto-vaginal)	swab	
§ Tray 
§ Gloves  
§ Swab stick (Floq swab) 
§ Scissors 
§ STGG cryovials  
§ Sticker labels sheet 
§ Leak-proof specimen transportation 
bags 
§ “Sharpsafe” box 
§ Ice packs 
§ Cold box 
§ Waste disposal bag (yellow) 
5.3	Rectal	swab	
§ Tray 
§ Gloves  
§ Swab stick (Floq swab) 
§ Scissors 
§ STGG cryovials  
§ Sticker labels sheet 
§ Leak-proof specimen transportation 
bags 
§ “Sharpsafe” box 
§ Ice packs 
§ Cold box 
§ Waste disposal bag (yellow) 
5.4	Blood	(Venepuncture) 
§ Tray 
§ Tourniquet; 
§ Well-fitting non-sterile gloves; 
§ 70% alcohol swab pads for skin 
disinfection; 
§ 10% povidone-iodine swab pads for 
skin disinfection; 
§ Sterile no. 23 butterfly needle (blue); 
§ Sterile 1ml or 2 ml syringe, 
§ Sterile 21G (green) needle 
§ Bactec peds plus/F blood culture bottle 
(pink top); 
§ EDTA microtainer tube (lavender top) 
§ Sterile cotton ball to be applied over the 
puncture site; 
§ Stella strip or adhesive plaster  
§ Laboratory specimen labels; 
§ Laboratory forms 
§ Leak-proof specimen transportation 
bags; 
§ “Sharpsafe” box 
§  Waste disposal bag (yellow)
5.5	Lumbar	puncture	
§ Well-fitting sterile	gloves; 
§ Masks – for person performing 
procedure and assistant 
§ 70% alcohol swab pads for skin 
disinfection 
§ 10% Povidone-Iodine swab pads for 
skin disinfection 
§ 1% Lignocaine 
§ 1 ml syringe 
§ Tuberculin (25G) needle 
§ Neonatal spinal needle (Size 25G) OR 
Size 23G needle 
§ 2 Sterile Bijou bottles 
§ Glucometer  
§ Pulse oximeter  
§ Aprons  
§ NaF tubes for glucose and protein 
estimation (grey top) 
§ Sterile gauze or cotton ball to be applied 
over the puncture site 
§ Sterile drapes 
§ Adhesive plaster 
§ Laboratory specimen labels 
§ Laboratory forms 
§ Leak-proof specimen transportation 
bags; 
§ “Sharpsafe” box 
§  Waste disposal bag (yellow)
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6.	Responsible	Persons		
6.1 The principal investigator (PI) has the overall responsibility of ensuring that this SSP is 
appropriately followed to enable timely collection and transportation of study samples to the 
appropriate laboratories at MRC Fajara. 
6.2 The PI and The Nurse coordinator (NC) are responsible for ensuring that: 
• Staff are appropriately trained on these procedures 
• Accurate documentation/records are maintained 
6.3 The nurse coordinator (NC) supported by the assistant nurse coordinator (ANC) are responsible 
for ensuring that:  
• All the necessary supplies are available at the EFSTH and other sites (SKGH, BHC, FHC, PCB, 
JFPH, SHC), as appropriate;  
• Samples are collected, labeled and transported in a timely manner;  
• Accurate and complete sampling logs are maintained at the EFSTH and other sites as 
appropriate;  
• “Sharpsafe” containers are transported to Fajara for incineration.  
• All samples (except CSF) are transported back to the laboratories at Fajara within three 
hours. Note	–	CSF	samples	must	be	in	the	labs	in	Fajara	within	one	hour	of	collection.   
6.4 The NC and study nurses are responsible for collecting required blood, NPS, RVS and RS samples 
from study subjects. 
6.5 Only Clinicians will collect CSF samples. 
6.6 The NC is responsible for establishing a rota for the transportation of samples to MRC Fajara 
when required.  
6.7 The Field worker (FW) or designated Nurse is responsible for transporting samples in a timely 
manner to the Clinical Microbiology Laboratory (when collected at the site) and Biobank (Freezer 
room) units at MRC, Fajara and for ensuring the samples are handed over to a member of the 
laboratory team and that this is documented  
6.8 Scientific officer (SO) and laboratory technicians (LT) are responsible for the receipt of blood 
samples in the laboratories at MRC Fajara and for subsequent processing of these samples 
7.	Procedures	
7.1	Collection	of	materials	&	preparation	of	work	spaces	
	 Description	 Person(s)	
responsible	
7.1.1. Ensure that the materials and equipment listed in section 5 are available.  NCs 
7.1.2. Make sure that materials to be used have not reached their expiry date  NCs & Nurses 
7.1.3. Deliver materials listed in section 5 to the site(s) and monitor stock levels  NCs 
7.1.5. Ensure that the sample collection room is fully equipped daily before 
participants are brought for sample collection.  
NCs 
7.1.6. Maintain an up-to-date inventory of study supplies  NCs 
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7.1.7. Ensure that the sample collection room and work space are clean and free from 
clutter.  
NCs & Nurses 
7.1.8. Inspect the materials for each procedure to confirm that they have not reached 
their expiry dates.  
Nurse 
7.1.9. Arrange the material required for the procedure on a tray and ensure that this 
is visible, accessible and safe.  
Nurse 
7.1.10. Ensure that the rack for sample collection is close by, but away for the patient 
to avoid accidental knocking over.  
Nurse 
7.1.11. Two nurses must be present during procedures. The role of the second staff 
member is to assist in the procedure, to cross-check the identity of the subject 
from whom samples will be obtained, complete/cross-check relevant 
documentation  
Nurse 
7.1.12. Cross check the subject’s identity against the CRF folder to ensure that these 
match. This step must be confirmed by a second person. This is to ensure that 
the samples are collected from the right subject.  
Nurse 
7.1.13. Affix the pre-printed barcoded labels on their corresponding tubes 
immediately after the sample is collected and dispensed into the sample 
container, ensuring that these labels contain the correct information (study 
number and sample type).  
Nurse 
 
7.2	Collection	of	samples			
Procedure(s)	 Responsible	person(s)	
NPS, RVS, RS All study nurses  
Venepuncture All study nurses /Clinician 
LP (CSF collection)  Clinician assisted by any study nurse 
 
 The NC/Nurse will telephone the designated laboratory staff (Lab Tech/SO) at the Clinical 
Microbiology and notify that samples being transported to the lab. This advance telephone 
notification is necessary to enable laboratory staff to prepare and receive the samples.  
7.2.1	Nasopharyngeal	swab	in	newborns	
7.2.1.1. Collect all the equipment needed for the procedure and place it within safe and easy reach 
on a tray or trolley, ensuring that all the items are clearly visible. Use required swab sticks 
for NPS (small tip).  
7.2.1.2. Explain the procedure to the mother. Ensure that informed consent has been given  
7.2.1.3. Use clean dry cotton swab to clean off mucous from the nose of the newborn. 
7.2.1.4. Estimate the distance to the nasopharynx before insertion of the swab and whilst it is still in 
the package, measure the distance from the corner of the nose to the front of the ear.  
7.2.1.5. Peel off the protective wrapping around the swab stick and remove the swab stick.  Do not 
let your fingers touch the cotton end of the swab 
7.2.1.6. When swabbing the baby, ask your assistant (the mother or another study nurse) to help 
support the baby’s head. Tip the baby’s head slightly backward and pass the swab directly 
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backwards, parallel to the floor of the nasopharynx keeping close to the midline/nasal 
septum. The swab should pass without resistance until it reaches the posterior pharynx, 
which is about half the distance from the nostril to the ear lobe (Figure	1). 
 
 
 
 
 
 
7.2.1.7. If resistance is encountered, remove the swab and dispose safely into the “sharpsafe” box. 
Use a new swab and try the other nostril.  
7.2.1.8. Once the swab is in place, leave in position for five seconds to saturate the tip, and then 
rotate the swab to the left and right before removing it slowly. 
7.2.1.9. Remove the cap from the sterile vial containing 1.5ml of STGG transport media and place the 
tip of the swab into the tube. 
7.2.1.10. Using a pair of scissors wiped with alcohol, cut off the excess swab stick handle, leaving the 
tip in the transport media. Ensure the cap fits firmly. Put the vial containing the swab into 
the transport bag and place the bag on wet ice in the cold box. 
7.2.1.11. Dispose what remains of the swab stick handle into the yellow waste bag for safe disposal. 
7.2.1.12. Stick the appropriate labels on the vial containing the swab tip, the laboratory form and the 
corresponding CRF section. 
7.2.1.13. Repeat the procedure with a second swab stick. 
7.2.1.14. Complete the sample	collection	log. 
7.2.1.15. Ensure that both specimens and are transported to the MRC Fajara within six hours of 
collection.  
• The swab labelled “Baby	NPS	culture” should be given to the designated staff 
(study Lab Tech) at the microbiology laboratory, Clinical services department. 
• The swab labelled “Baby	NPS	PCR” should be taken to the Biobank (Freezer Room) 
and stored in the designated Freezer.  
7.2.1.16. Complete the appropriate sample	receipt	logs	that are kept at the laboratory and Freezer 
room respectively.   
7.2.2	Nasopharyngeal	swab	in	mothers	
7.2.2.1. Collect all the equipment needed for the procedure and place it within safe and easy reach 
on a tray or trolley, ensuring that all the items are clearly visible. Use required swab sticks 
for NPS (large tip). 
7.2.2.2. Explain the procedure to the mother 
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7.2.2.3. Estimate the distance to the nasopharynx before insertion of the swab and whilst it is still in 
the package, measure the distance from the corner of the nose to the front of the ear.  
7.2.2.4. Peel off the protective wrapping around the swab stick and remove the swab stick.  Do not 
let your fingers touch the cotton end of the swab 
7.2.2.5. Tip the mother’s head slightly backward and pass the swab directly backwards, parallel to 
the floor of the nasopharynx keeping close to the midline/nasal septum (Figure	2). The 
swab should pass without resistance until it reaches the posterior pharynx, which is about 
half the distance from the nostril to the ear lobe. 
 
7.2.2.6. If resistance is encountered, remove the swab and dispose safely into the “sharpsafe” box. 
Use a new swab and try the other nostril.  
7.2.2.7. Once the swab is in place, leave in position for five seconds to saturate the tip, and then 
rotate the swab to the left and right before removing it slowly. 
7.2.2.8. Remove the cap from the sterile vial containing 1.5ml of STGG transport media and place the 
tip of the swab into the tube. 
7.2.2.9. Using a pair of scissors wiped with alcohol, cut off the excess swab stick handle, leaving the 
tip in the transport media. Ensure the cap fits firmly. Put the vial containing the swab into 
the transport bag and place the bag on wet ice in the cold box. 
7.2.2.10. Dispose what remains of the swab stick handle into the yellow waste bag for safe disposal. 
7.2.2.11. Stick the appropriate labels on the vial containing the swab tip, the laboratory form and the 
corresponding CRF section. 
7.2.2.12. Repeat the procedure with a second swab stick. 
7.2.2.13. Complete the sample	collection	log.  
7.2.2.14. Ensure that both specimens and are transported to the MRC Fajara within six hours of 
collection.  
• The swab labelled “Mother	NPS	culture” should be given to the designated staff 
(Lab Technician) at the microbiology laboratory, Clinical services department. 
• The swab labelled “Mother	NPS	PCR” should be taken to the Biobank (Freezer 
Room) and stored in the designated Freezer.  
7.2.2.15. Complete the appropriate sample	receipt	logs	that are kept at the laboratory and Freezer 
room respectively.   
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7.2.3	Genital	(Recto-vaginal)	swab	in	mothers	
7.2.3.1. Collect all the equipment needed for the procedure and place it within safe and easy reach 
on a tray or trolley, ensuring that all the items are clearly visible. Use the required swab 
sticks for genital swab (large tip).  
7.2.3.2. Explain the procedure to the mother.  
7.2.3.3. Wipe the lower vagina (vaginal introitus) for 5 seconds with large enough sterile cotton 
swab.  Do not let your gloved fingers touch the mother’s skin. 
7.2.3.4. Peel off the protective wrapping around the swab stick and remove the swab stick.  Do not 
let your fingers touch the cotton end of the swab 
7.2.3.5. Insert the swab a distance of 2cm into the lower vagina. Gently rotate the swab from left to 
right swabbing the sides and then remove. (Figure	3A) 
7.2.3.6. Next, insert the	same	swab a distance of 1cm into the anus (Figure	3B) 
 
7.2.3.7. Remove the cap from the sterile vial containing 1.5ml of STGG transport media (Figure	3C), 
and place the tip of the swab into the tube (Figure	3D). 
7.2.3.8. Using a pair of scissors wiped with alcohol, cut off the excess swab stick handle, leaving the 
tip in the transport media. Ensure the cap fits firmly. Put the vial containing the swab into 
the transport bag and place the bag on wet ice in the cold box.  
7.2.3.9. Dispose what remains of the swab stick handle into the yellow waste bag for safe disposal. 
7.2.3.10. Stick the appropriate labels on the vial containing the swab tip, the laboratory form and the 
corresponding CRF section. 
7.2.3.11. Repeat the procedure with a second swab stick. 
7.2.3.12. Complete the sample	collection	log. 
7.2.3.13. Ensure that both specimens and are transported to the MRC Fajara within six hours of 
collection.  
• The swab labelled “Mother	RVS	culture” should be given to the designated staff 
(study Lab Tech) at the microbiology laboratory, Clinical services department.  
• The swab labelled “Mother	RVS	PCR” should be taken to the Biobank (Freezer 
Room) and stored in the designated Freezer 
7.2.3.14. Complete the appropriate sample	receipt	logs	that are kept at the laboratory and Freezer 
room respectively. 
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7.2.4	Rectal	swab	in	newborns	
7.2.4.1. Collect all the equipment needed for the procedure and place it within safe and easy reach 
on a tray or trolley, ensuring that all the items are clearly visible. Use required swab sticks 
for RS (Small tip).  
7.2.4.2. Explain procedure to mother 
7.2.4.3. Ask your assistant (the mother or another study nurse) to help you hold the baby in position 
lying in bed with the legs lifted up. 
7.2.4.4. Peel off the protective wrapping around the swab stick and remove the swab stick.  Do not 
let your fingers touch the cotton end of the swab. 
7.2.4.5. Insert the swab a distance of 1cm into the anus (Figure	4). Gently rotate the swab from left 
to right swabbing the sides and then remove. 
  
 
7.2.4.6. Remove the cap from the sterile vial containing 1.5ml of STGG transport media and place the 
tip of the swab into the tube. 
7.2.4.7. Using a pair of scissors wiped with alcohol, cut off the excess swab stick handle, leaving the 
tip in the transport media. Ensure the cap fits firmly. Put the vial containing the swab into 
the transport bag and place the bag on wet ice in the cold box. 
7.2.4.8. Dispose what remains of the swab stick handle into the yellow waste bag for safe disposal. 
7.2.4.9. Put the appropriate labels on the vial containing the swab tip, the laboratory form and the 
corresponding CRF section. 
7.2.4.10. Repeat the procedure with a second swab stick. 
7.2.4.11. Complete the sample	collection	log.  
7.2.4.12. Ensure that both specimens and are transported to the MRC Fajara within six hours of 
collection.  
• The swab labeled “Baby	Rectal	Swab	culture” should be given to the designated 
staff (study Lab Tech) at the microbiology laboratory, Clinical services department.  
• The swab labeled “Baby	Rectal	Swab	PCR” should be taken to the Biobank (Freezer 
Room) and stored in the designated Freezer.  
7.2.4.13. Complete the appropriate sample	receipt	logs	that are kept at the laboratory and Freezer 
room respectively.   
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7.2.5	Venepuncture	(Newborn)	
7.2.5.1. Collect all the equipment needed for the procedure and place it within safe and easy reach 
on a tray or trolley, ensuring that all the items are clearly visible. 
7.2.5.2. Look carefully with a tourniquet for the most suitable vein. Remember that in newborns the 
best vein may not necessarily be palpable. Use a pocket pen light to display the veins. Choose 
a vein in the order of preference shown in Figure	5: 
 
Figure	5: Preferred areas for venepuncture on a neonate’s body.  
(Numbers are described below) 
1. Antecubital fossa 
2. Dorsum (back) of hands 
3. Dorsum (top) of feet 
4. Greater saphenous vein at the ankle 
5. Vein in the centre of the volar aspect of the wrist. 
6. Scalp 
 
7.2.5.3. Palpate the chosen vein, and to dilate the vein, apply a tourniquet to the limb proximal to 
(above) the intended site of puncture. Be careful of pinching skin or compressing artery.  
7.2.5.4. Immobilise the vein by applying traction on the skin around the puncture site. Ask your 
assistant to stabilise the limb by holding joint above & joint below if necessary.  
7.2.5.5. Vigorously wipe of the skin of the chosen area with a 70% alcohol swab, and wait for 30 
seconds. DO	NOT	use	chlorhexidine	on	children	under	2	months	of	age. 
7.2.5.6. Next, swab the area with 10% povidone-iodine. Apply firm but gentle pressure starting from 
the centre of the venepuncture site and work downward and outwards to cover an area of 2 
cm or more until the whole area is saturated with iodine. Allow the area to dry for 60 
seconds. Failure to allow enough contact time increases the risk of contamination.  
7.2.5.7. DO	NOT touch the cleaned site; in particular, DO	NOT place a finger over the vein to guide 
the shaft of the exposed needle. If the site is touched, repeat the disinfection. 
7.2.5.8. When the skin is completely dry, proceed with the venipuncture. 
7.2.5.9. Attach a sterile size 23G butterfly needle in at the tip of a sterile 1ml or 2ml syringe after the 
disinfectant has dried. 
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7.2.5.10. Insert the needle into the vein with the bevel of the needle face up (Figure	6). Puncture the 
skin 3–5 mm distal to (i.e., away from) the vein; this allows good access without pushing the 
vein away. If the needle enters alongside the vein rather than into it, withdraw the needle 
slightly without removing it completely, and angle it into the vessel. 
 
 
 
7.2.5.11. Draw blood slowly and steadily. Target to draw 2mls of blood. (If using a 1ml syringe, 
remove the syringe once full, replace with another one and draw blood again. 
7.2.5.12. After obtaining blood, release the tourniquet (if used) and place a sterile cotton-ball over the 
puncture site while holding the butterfly needle in place. Withdraw the butterfly needle and 
have your assistant hold the cotton-ball firmly in place until the wound has stopped 
bleeding. 
7.2.5.13. Put a plaster/Stella strip on the puncture site. 
7.2.5.14. Remove the butterfly needle and attach the 21G (green) needle to the syringe. 
7.2.5.15. Remove the flip-off cap from BACTEC PEDS PLUS/F culture bottle top and inspect the bottle 
for cracks, contamination, excessive cloudiness and bulging or indented stoppers (Cases	
Only). 
7.2.5.16. Before inoculating blood into the culture bottle (Cases	Only), swab the top with the 70% 
alcohol swab (DO	NOT	use	povidone-iodine), and immediately (within 1 minute) 
aseptically inject appropriate volume of the blood in the culture bottle. (See Table 1.1) 
Dispense the rest of the blood (0.5ml) into the EDTA tube. 
Table 4.1: Volume of blood to be dispensed in different vials 
Blood	volume	drawn	
Blood	in	EDTA	
microtainer	tube	
Blood	in	BACTEC	blood	
culture	bottle	
≤1.0 ml Nil Everything 
>1.0 ml to 2 ml 0.5 ml The rest 
 
7.2.5.17. On occasions it may not be possible to obtain the volume of blood required in a particular 
subject at a particular visit. Generally, up to three attempts may be made if a parent remains 
willing but judgment must be used with this regard to limit distress (and subsequent 
potential withdrawal of consent). Indicate on the CRF and inform the PI in the event that no 
blood sample could be collected. 
7.2.5.18. Mix the contents of the EDTA microtainer and the culture bottle by eight gentle inversions. 
Wipe any residual blood from the outside of the bottle/microtainer before removing gloves. 
7.2.5.19. Dispose of everything used for this procedure into the appropriate waste disposal bags. 
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7.2.5.20. Affix the appropriate labels to the Blood culture bottle and EDTA microtainer tube and the 
corresponding CRF section, and ensure that the appropriate laboratory forms are completed 
with the relevant information (study number; hospital number, sex, age, etc.). 
7.2.5.21. Complete the field	sample	log	sheet	kept at the study office.  
7.2.5.22. Put the Blood culture bottle in the incubator. Make sure that the incubator temperature is 
set at 37°C 
7.2.5.23. Place the EDTA microtainer tube containing the blood sample on ice packs in the cold box. 
7.2.5.24. If there is more than one eligible participant, repeat the above procedures. Use new needles 
and a new syringe(s) for each participant. 
7.2.5.25. Ensure that specimens are transported to the MRC Fajara within six hours of collection. 
Transport the blood culture bottle in the field bag. Do	not	place	the	blood	culture	bottle	in	
the	cold	box.  
• The Blood	culture	bottle(s) should be given to the designated staff (study Lab 
Tech) at the microbiology laboratory, Clinical services department.  
• EDTA microtainer tube labelled “Blood	PCR” should be taken to the Biobank 
(Freezer Room) and stored in the designated Freezer.  
7.2.5.26. Complete the appropriate sample	logs	that are kept at the laboratory and Freezer room 
respectively.   
7.2.6	Lumbar	puncture	(Case	ONLY)	
7.2.6.1. Collect all the equipment needed for the procedure and place it within safe and easy reach 
on a tray or trolley, ensuring that all the items are clearly visible.  
7.2.6.2. The nurse should assess and document the temperature, pulse, respiratory rates and oxygen 
saturation in the observation chart.  
7.2.6.3. The clinician must ensure that there are no contraindications to the procedure (Appendix 2). 
Ensure infant has not been fed in previous hour (aspirate infant's stomach if fed within the 
past hour). 
7.2.6.4. A random glucose estimation should be taken using a glucometer at the bedside, before the 
lumbar puncture is performed.  
7.2.6.5. The spinal cord in neonates extends further down the spinal canal than in older children.  
Lumbar punctures should be performed at or below the L4 level. Once the infant is in 
position, palpate the iliac crest and slide your finger centrally toward the L4 vertebral body. 
This created imaginary line will help identify the L4-L5 interspace as the preferred site of 
neonatal lumbar puncture (Figure	7). 
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7.2.6.6. A reliable assistant should restrain the infant in a sitting or lateral decubitus position (the 
head and legs must be flexed - knee-chest position) without compromising the infant’s 
cardio-respiratory status, and making sure airway patency is maintained at all times.  
Some degree of flexion of the spine is helpful since it opens up the interspinous spaces and 
also stretches the skin over the processes, allowing better definition of landmarks.  It is not 
necessary to flex the neck with compromise of the airway and increase in cerebral venous 
pressure. Infants may not tolerate the procedure well. This is usually because of excessive 
flexion of the infant. 
Alternatively, term infants may be placed in a seated position on the edge of the table, with 
trunk flexed forwards, stabilised from the front by the assistant. The infant's shoulders and 
hips are held in order to maintain vertical alignment of the hips and shoulders during the 
procedure. This has been shown to be the best tolerated and to also have the best chance of 
obtaining CSF. 
7.2.6.7. Apply face mask. Wash hands with soap and water. Put on sterile gloves.  
7.2.6.8. Open the sterile pack, while ensuring the spinal needle and specimen bottles (2 bijou bottles 
and 1  NaF bottle) are within easy reach.  
7.2.6.9. Clean the skin over the site with sterile cotton pad soaked in 70% alcohol in circular motion 
from the centre outwards. Allow the alcohol to evaporate. Don’t touch the cleaned area.  
7.2.6.10. Subcutaneous infiltration with 0.1ml/kg of 1% lignocaine using a 25G tuberculin needle 
over the L4-L5 space at least 2minutes before the procedure  
7.2.6.11. Advancing the needle in the chosen intervertebral space, aiming towards the navel. Once 
through the skin, STOP. Wait for the infant to resettle. 
7.2.6.12. Reorient yourself, making sure that you are still in the midline and advancing at the 
appropriate angle.  The subsequent advance of the needle is less distressing than the initial 
insertion.  
7.2.6.13. Advance needle about 0.5 cm. Remove stylet and observe for CSF flow.  If negative, fully 
reinsert the stylet and advance a little further. Repeat this process until CSF is obtained.  
7.2.6.14. A ‘pop’ or ‘give’ may be felt as the needle passes through the posterior ligaments and dura, 
but do not rely on this. The ‘stop-start’ approach is less likely to give a bloody tap. 
7.2.6.15. Allow CSF to drip into each of the sample bottles (See	Figure	8) as follows: 
• Bijou bottle 1 - microscopy, culture & sensitivity (5 drops) 
• Bijou bottle 2 - PCR (5 drops) 
• NaF tube (grey top) -  protein estimation (5 drops) 
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7.2.6.16. When adequate CSF has been obtained, replace the stylet and then remove the needle. Apply 
pressure to the puncture site with a sterile cotton wool ball or gauze to control ooze.  When 
ooze has ceased, use a piece of plaster or Stella strip. 
7.2.6.17. Place baby on its back for 60 minutes after the procedure to minimise the chance of 
headache. 
7.2.6.18. Document the procedure, and CSF appearance in the case note stating the date and time. 
7.2.6.19. Send all CSF samples to the MRC Fajara	immediately.  
• The sample labelled “CSF	culture” should be given to the designated staff (study 
Lab Tech) at the microbiology laboratory, Clinical services department.  
• The samples labelled “CSF	protein” and “CSF	glucose” should taken to the 
biochemistry laboratory, Clinical services department.  
• The swab labelled “CSF	PCR” should be taken to the Biobank (Freezer Room) and 
stored in the designated Freezer 
7.2.6.20. Ensure the child is clinically stable after the procedure with the documentation of vital signs 
immediately after LP. Continue routine monitoring, including checking the temperature. Any 
clinical deterioration must be reported immediately to the clinician/neonatologist for 
urgent attention. 
7.2.6.21. Discontinue cardio-respiratory and oxygen saturation monitoring 1 hour following 
procedure, unless ongoing monitoring is otherwise indicated. 
7.2.6.22. Continue oxygen saturation monitoring for 4 hours post procedure if sedation with 
narcotics was administered prior to procedure. Sedated infants should remain nil orally for 
2 hours post procedure.  
7.2.6.23. Contraindications to lumbar puncture (LP) can be absolute or relative.  
• Increased intracranial pressure (ICP) is an absolute contraindication. 
• For patients with a bleeding diathesis or cardiopulmonary instability, the 
contraindications are relative to the importance of cerebrospinal fluid (CSF) results for 
immediate management decisions. (E.g. an unstable patient who may have bacterial 
meningitis should receive a blood culture and antibiotics. LP can be performed when 
the child's condition stabilizes) 
7.2.6.24. Specific contraindications are as follows: 
• Increased	intracranial	pressure	(ICP)	— Children with elevated ICP are at risk for 
cerebral herniation when LP is performed. Consequently, CT of the head should be 
obtained before LP for all patients with clinical suspicion for increased ICP, including 
those at risk for brain abscess (immunocompromise or congenital heart disease with a 
right-to-left shunt). 
• Bleeding	diathesis — Evidence regarding the safety of performing LP in patients with 
thrombocytopenia or coagulation factor deficiency is limited. Nevertheless, because of 
the risk of subdural or epidural hematoma formation, it is not advised to perform LP in 
patients with coagulation defects who are actively bleeding, have severe 
thrombocytopenia (eg, platelet counts <50,000/microL), or an INR >1.4, without 
correcting the underlying abnormalities. When LP is considered essential for a patient 
with an abnormal INR  or platelet counts in whom the cause is not obvious, please 
consult with a haematologist to provide the best advice for safe correction of the 
coagulopathy prior to performing the LP. In all cases, the relative risk of performing LP 
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has to be weighed against the potential benefit (eg, diagnosing meningitis due to an 
unusual or difficult-to-treat pathogen).  
• Cardiopulmonary	instability — The position in which the patient must be placed in 
order to perform LP may result in further cardiopulmonary compromise. 
Administration of antibiotics must not be delayed for the child with suspected 
meningitis who cannot tolerate an LP. 
• Soft	tissue	infection	at	the	puncture	site 
8.	References	
§ SCC 1384 
§ Aetiology of Neonatal Infection in South Asia (ANISA): Manual of Operation Version	
4.0_12.09.2011 
§ Lumbar puncture (LP) for neonates. Neonatal ehandbook. 
http://www.health.vic.gov.au/neonatalhandbook/procedures/lumbar-puncture.htm [accessed 
29 December 2015] 
§ Lumbar Punctures in Neonates: Improving Success Rates and Minimizing Pain. 
https://clinicaltrials.gov/ct2/show/record/NCT01606150 [accessed 29 December 2015] 
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Sampling	summary	table	
	
Case	(EFSTH,	Kanifing	General	Hospital,	Brikama	Health	Center)	
Participant	 Type	of	Sample	 Comments	 Responsibility	
Newborn	
• Blood culture 
• Blood PCR 
• 2 NPS (Culture & PCR) 
• 2 Rectal swabs (Culture & PCR) 
• CSF (Culture, protein, glucose, PCR) 
Collect	at	admission	
after	consenting	and	
recruitment	
(as much as possible 
collect samples before 
antibiotics are given) 
Nurse		
(and Clinician for 
CSF) 
Mother	 • 2 NPS (Culture & PCR) 
• 2 RVS (Culture & RVS) 
Collect at the time of 
recruitment (as much 
as possible – if mother 
is at the postnatal ward, 
collect sample on the 
ward) 
Nurse	
 
 
Control	(SKGH,	PCB,	BHC,	FHC,	JFPH,	SHC)	
Participant	 Type	of	Sample	 Comments	 Responsibility	
Newborn	
• Blood PCR 
• 2 NPS (Culture & PCR) 
• 2 Rectal swabs (Culture & PCR) 
Collect immediately 
after consenting and 
recruitment 
Nurse		
Mother	
• 2 NPS (Culture & PCR) 
• 2 RVS (Culture & RVS) 
Collect immediately 
after consenting and 
recruitment 
Nurse	
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Appendix	8:	ANISA	SOP	for	analysis	of	TaqMan	Array	Cards	
Initial	Data	Analysis 
1. After the run is complete, the software will automatically proceed to the “Analysis” option in 
the “Experiment Menu.” The amplification plot will resemble Figure 1 
 
Figure 1: Amplification curves for all wells following run completion. 
 
2. Click the green “Analysis” button near the top of the screen (Figure 2) to initiate automated 
analysis. 
 
Figure 2: Initial analysis 
 
3. The curves and thresholds for ALL assays will appear on the screen (Figure 3). Each 
threshold must be independently adjusted. The next section describes how to adjust 
individual thresholds. 
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Figure	3:	Post-analysis data 
	
Validating	Run	Results 
Run results will be validated by analyzing performance of internal positive control (IPCO_1) 
reactions and all assay results for the NTC and PC. 
1.  Identify IPCO_1 wells: 
To assess results of IPCO_1 assay, highlight column 11 in the plate layout display on the right 
side of the screen (Figure 4). The manufacturing control assay (GADH_1) is present in 
alternating rows of column 11 (A, C, E, G, I, K, M, and O). GADH_1 results will not be analyzed 
for this study. 
a.    Blood v2: On the blood TAC, IPCO_1 and	RNaseP (RNP3_1) control are present in the 
same well (column 11: B, D, F, H, J, L, N, and P), but different fluorescent reporters are 
used for each assay. When these wells are selected, amplification curves for both assays 
(IPCO_1 (VIC) and RNP3_1 (FAM)) will appear on the amplification plot. 
b.   Respiratory v2: The wells in column 11 (B, D, F, H, J, L, N, and P) correspond to 
internal positive control (IPCO_1) on the respiratory TAC. 
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Figure 4: Identification of IPCO_1 assay 
2.   Select the IPCO_1 assay: 
Select “IPCO_1” from the “Target” drop-down menu on the “Options” tab under the 
amplification plot display. Only curves and threshold for IPCO_1 assay will be displayed on the 
plot (Figure 5). 
 
 
 
 
 
  
Figure 5: Selection of IPC amplification curves 
 
3. Adjusting the threshold in log view: 
De-select the “Auto” checkmark under the options tab to freely move the threshold. Use the 
cursor to adjust the threshold line for this assay so that it is just above background 
fluorescence (Figure 6). 
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Figure 6: Adjustment of threshold line in log mode 
4. Adjusting the threshold in linear view: 
Select “Linear” from the “Graph Type” field in the “Plot Settings” tab above the 
amplification plot display. The graph will update displaying the curves in linear format. 
Again you must de-select the “Auto” checkmark under the options tab to move the 
threshold with your cursor. Refer to Figures 7a and 7b for examples of “correct” and 
“incorrect” threshold settings. 
 
  
 
Figure 7a: Threshold set correctly   Figure 7b: Threshold set incorrectly. 
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5. Interpretation of amplification curve (IPCO_1): 
In linear display mode, all specimens, including the NTC, should exhibit exponentially 
increasing (sigmoidal or “S”-shaped) amplification curves that cross the threshold for the 
IPCO_1 assay. Refer to “Interpretation of Results and Reporting” on pages 48-50 for 
additional guidance. 
a.   If ALL	assays exhibit an amplification curve for the IPCO_1 assay, proceed to analyzing 
results for NTC and PC. 
b.   If ALL	specimens fail to exhibit an amplification curve for the IPCO_1 assay, invalidate the 
run by selecting the checkbox corresponding to “No” next to “Run Results Valid?” 
Specimens from an invalid TAC run need to be repeated on a new TAC.  Refer to the 
“Repeat Testing” section on page 50 for more guidance. 
c.   If an individual	specimen(s) does not exhibit an exponential amplification curve that 
crosses the threshold line for the IPCO_1 assay, invalidate results for all assays for this 
specimen only. Refer to “Assigning Interpretation Comments for Each Reaction” section 
on page 38 
Important!	If a specimen is positive for one or more assays, even in the presence of a failed 
IPCO_1 reaction, the assay-specific result should be considered valid. A negative IPCO_1 
reaction does not preclude a positive result in another reaction well. However, it is strongly 
recommended that the specimen be repeated. 
6.   Validating NTC reaction wells: 
There should be no amplification in NTC wells, except for the IPCO_1 assay. Select rows 
corresponding to NTC sample (A and B). Ensure no amplification curves are observed in 
NTC wells (except IPCO_1). Refer to the section “Interpretation of Results and Reporting” 
for additional guidance. 
7. Validating PC reaction wells: 
All of the assays, except GADH_1, should display a sigmoidal amplification curve for the PC 
wells. Select the rows corresponding to PC sample (O and P). Ensure amplification curve is 
present in every well for PC reactions, except GADH_1. Refer to “Interpretation of Results 
and Reporting” on pages 48-50 for additional guidance. 
8. Confirming validation: 
If ALL	controls have performed as expected, validate the run by selecting the radio 
button corresponding to “Yes” next to “Run results valid?” in the box below the plate 
layout on the right side of the screen (Figure 8). 
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Figure 8: Validation of TAC run 
 
Analysing	Other	Assays 
1. Highlight the assay to be analyzed by selecting the entire column. The target (assay) in the 
drop-down menu will automatically update when a new column is selected. Placing the 
cursor over an individual well will bring up a box displaying the information for that 
particular reaction well (target, sample, etc.) (Figure 9) 
 
 
 
 
 
 
 
  
Figure	9:	Assay selected in “Plate Layout” matches target in “Amplification Plot”. 
 
2. De-select the “Auto” checkbox under the “Options” tab (under Amplification Plot) to move 
the threshold by clicking and dragging with your cursor. Adjust the assay threshold so that it 
crosses the amplification curve for the positive control at the starting point of exponential 
increase. The threshold should be slightly above background fluorescence (Figure 10). 
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Figure 10: Proper adjustment of threshold 
 Note: The level of background fluorescence may vary between assays on a single TAC. In 
 some cases, the background fluorescence may be high such that setting the threshold 
 above this level would artificially increase the Ct value of the PC and any other positive 
 results. In this case, the threshold should be set below background fluorescence; the 
 threshold line should cross amplification curve for PC at the inflection point. Although the 
 background will cross the threshold (and have a Ct value) in this case, results should be 
 interpreted as “Negative” as described in the following section 
3. Repeat this process for all remaining assays (columns). 
4. After ALL	thresholds have been adjusted individually, click on the “Analysis” button to allow 
the software to recalculate the Ct values based on the adjusted thresholds (Figure 11). 
 
Figure 11: Analysis of all assays with thresholds adjusted 
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Assigning	Interpretation	Comments	for	Each	Reaction 
1. To assign an interpretation to an individual reaction (well), right click on the corresponding 
well position in the “Plate Layout” on the right side of the screen. Choose “Select Comments” 
from the menu. A box will open with a drop-down menu allowing three possible selections: 
“Positive,” “Negative,” or “Indeterminate” (Figure 12). 
 
 
 
 
 
 
 
  
Figure 12: Assigning interpretation to a single well 
 
2. If an amplification curve is observed and determined to be of the proper shape, select 
“Positive” from the drop-down menu (Figure 13). 
 
 
 
 
 
 
  
Figure 14: Selection of “Positive” interpretation 
 
3. If no amplification curve is observed for an individual reaction (well), select “Negative” from 
the drop-down menu (Figure 15) 
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Figure 15: Selection of “Negative” interpretation 
 
Note:	All wells should be considered individually. Comments should reflect result in an 
individual well. An interpretation is required for ALL wells in the plate, except the wells 
containing GADH_1. The next section provides detailed methods to assign comments for 
each well. 
Note:	A red mark will appear in the corner of each well after it has been assigned an 
interpretation (Figure 16). 
Important!	Only one comment can be entered for each well. Therefore, for the wells 
containing both RNP3_1 (FAM-labeled) and IPCO_1 (VIC-labeled) on the ANISA Blood v2 
TAC, comments should be assigned for the RNP3 target ONLY 
 
Figure 16: Red corner marks indicating well has been interpreted 
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Assigning	Interpretations	to	Multiple	Wells	Simultaneously 
1. To assign interpretations for multiple wells, select the appropriate wells in the “Plate 
Layout” display. Use the “Shift” and “Ctrl” keys to select multiple rows, columns, or wells in 
order to assign the same comment to all selected wells (Figure 17). 
 
Figure	17:	Assigning the same comments to multiple wells. 
 
2. Right-click, and choose “Select Comments” from the menu. Assign the correct interpretation, 
and click the “×” in the upper right corner of the box to exit (Figure 18) 
 
Figure	18:	Assigning the same comments to multiple wells. 
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3. All selected wells will now be labelled with the same interpretation (Figure 19). 
 
Figure	19:	Same comments assigned to all selected wells. 
 
Note: The same comment can be assigned to multiple wells by selecting multiple wells in the “Well 
Table” tab, then returning to the plate layout and assigning comments as described in steps 2-3 
above 
 
Saving	Interpretations	and	exporting	data 
After all results have been analysed and interpretations have been assigned for each well, 
select “Save” from the main tool bar  
Click the “Export” button on the bottom left side of the screen. This will bring up the export portion 
of the software, which will allow you to transfer all data to a Microsoft Excel format 
Interpretation	of	Results	and	Reporting 
Internal	Positive	Control	(IPCO_1) 
All specimens, including the NTC, should exhibit exponentially increasing (sigmoidal or “S”- 
shaped) amplification curves that cross the threshold line for the IPCO_1 assay. 
· If ALL specimens fail to exhibit an amplification curve for the IPCO_1 assay: 
o Invalidate the run by selecting the checkbox corresponding to “No” next to “Run 
results valid?” 
o Repeat testing is required for all specimens; refer to the “Repeat Testing” section for 
additional guidance. 
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· If an individual specimen or subset of specimens fail to exhibit an amplification curve for 
the IPCO_1 assay: 
o Assign “Negative” comment for the well corresponding to the IPCO_1 assay for the 
individual specimen(s). 
o Assign “Indeterminate” comment for all other assays corresponding to that 
specimen. See note below for exception to this convention. 
o Repeat testing is required for the affected specimen(s); refer to the “Repeat Testing” 
section on page 50 for additional guidance. 
Note:	If a specimen is positive for one or more assays, even in the presence of a failed IPCO_1 
reaction, the assay-specific result should be considered valid. A negative IPCO_1 reaction 
does not preclude a positive result in another reaction well. However, it is strongly 
recommended that the specimen be repeated. 
 
No	Template	Control	(NTC) 
The NTC consists of using sterile nuclease-free water in the real-time RT-PCR reactions instead of 
TNA extract. The NTC reactions for all assays should not exhibit amplification curves that cross 
the threshold line; amplification in NTC wells, except IPCO_1 assay, indicates contamination may 
have occurred in the laboratory. All assays should be considered individually. 
· If an amplification curve that crosses the threshold line occurs in the well(s) 
corresponding to the NTC for an individual assay: 
o Assign “Positive” comment for the wells corresponding to the indicated assay. 
o Assign “Indeterminate” comment for the wells corresponding to all other specimens 
for the indicated assay(s). 
o Refer to “Precautions” section on page 9-10 for recommended decontamination 
procedures. After decontamination, repeat the assay with strict adherence to the 
instructions. Refer to the “Repeat Testing” section for additional guidance. 
Note:	Occasionally, amplification may occur in an NTC reaction for the human nucleic acid control 
assay (RNP3_1). This usually indicates contamination with human cells during the assay setup. In 
this case, the results for the affected specimen(s) should still be considered valid. Do NOT 
invalidate all results. Decontaminate work areas and adhere more closely to guidelines during 
future testing. See “Precautions” section for additional guidance on decontamination procedures. 
 
Note:	The E.coli	(ECSH_1) and Rubella virus (RUBV_1) assays may show amplification with the 
NTC. Refer to “Assay Specifications and Limitations” for additional guidance. 
 
 
 305 
 
RNase	P	(Human	Nucleic	Acid	Control)	(RNP3_1) 
All human clinical samples should exhibit fluorescence amplification curves in the RNP3_1 reaction 
that cross the threshold line within 38 cycles (Ct < 38). Failure to detect RNase P in any clinical 
specimens may indicate: 
· Improper extraction of nucleic acid from original specimen 
· Absence of sufficient human cellular material due to poor specimen collection, handling, or 
storage 
· Improper assay setup and performance 
· Reagent or equipment malfunction 
If the RNase P assay does not produce a positive result for a clinical specimen(s), interpret as 
follows: 
· If a specimen is positive for one or more assays, even in the presence of a negative 
RNP3_1 result, the assay-specific result should be considered valid and the 
interpretation assigned as “Positive.”  A negative RNP3_1 result does not preclude the 
presence of a pathogen in a clinical specimen. However, it is strongly recommended that 
the specimen be repeated. 
· If all markers AND RNase P are negative for the specimen, the assay results are 
 “indeterminate” for that specimen. 
o Select “Negative” from the drop-down menu in the well table for the wells 
corresponding to the RNase P assay. 
o Select “Indeterminate” from the drop-down menu in the well table for the wells 
corresponding to all other assays for the indicated specimen(s). 
o If residual specimen is available, repeat the extraction procedure and repeat the test on a new 
TAC.  Refer to the “Repeat Testing” section for additional guidance.	
 
E.	coli/Shigella	(ECSH_1)	assay 
Amplification may occur in NTC or specimen extracts due to the presence of residual E.	coli	nucleic 
acid in the enzyme preparation. Therefore, this assay is only interpretable when Ct ≤ 30. 
Comments should be assigned as follows: 
· Ct value ≤ 30: positive 
· Ct value > 30: indeterminate 
· No amplification: negative 
 
Rubella	virus	(RUBV_1)	assay 
Non-specific amplification may occur in NTC or specimen extracts after 35 cycles. Therefore, 
this assay is only interpretable when Ct ≤ 35. Comments should be assigned as follows: 
· Ct value ≤ 35: positive 
· Ct value > 35 or no amplification: negative 
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Repeat	Testing 
Repeat testing using TAC is required for a specimen if any of the following apply: 
· IPCO_1 failure for individual specimen 
· RNP3_1 failure for individual specimen 
Note:	If RNP3_1 failure occurs, original specimen should be re-extracted prior to repeat 
testing on TAC. 
· Invalid TAC run results due to: 
o Failure of ALL IPCO_1 reactions 
o Complete failure of PC reactions (lack of amplification in all wells) 
o Complete failure of NTC reactions (amplification in all wells) 
o Instrument failure during run 
o Other run errors which result in invalid results 
Repeat testing for individual assays may be required in some cases. These specimens will be 
considered on an individual basis. 
All specimen extracts requiring repeat testing should be stored at ≤ -70°C until the end of the 
specimen collection and testing period 
	
Assay	Specifications	and	Limitations 
Assay	name Organism(s)	detected Limitations 
ADEV_1 Adenovirus  
BOP1_1 Bordetella	pertussis,	
Bordetella	holmesii 
Cross-reactive with B.	holmesii	for a small 
proportion of isolates. 
CHPN_1 Chlamydophila	pneumoniae  
CHTR_1 Chlamydia	trachomatis  
CYMV_1 Cytomegalovirus  
ECSH_1 Escherichia	coli	(all), 
Shigella	spp. (except S.	
dysenteriae	serotype I) 
Interpret positive results when Ct < 30 only. 
Specimens exhibiting amplification after cycle 
30 should be marked as “Indeterminate.”  
Sporadic amplification may occur after cycle 
30 due to contaminating E.	coli	nucleic acid in 
enzyme mix. 
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ENTV_1 enterovirus  
FLUA_1 Influenza type A  
FLUB_1 Influenza type B  
GADH_1 Glyceraldehyde-3-
phosphate dehydrogenase 
Manufacturing control. Results from this 
assay should be disregarded. 
GAST_1 Streptococcus	pyogenes  
GBST_1 Group B Streptococcus	(all 
serotypes: IA, IB, II, III, IV, V, 
VI, VII, VIII, IX) 
 
HIAT_1 Haemophilus	influenzae  
HMPV_1 Human Metapneumovirus  
HPEV_1 Human Parechovirus  
IPCO_1 Internal Positive Control Positive result should be observed for ALL 
specimens, NTC, and PC. 
KLPN_1 Klebsiella	pneumoniae  
MYPN_1 Mycoplasma	pneumoniae  
NMEN_1 Neisseria	meningitidis  
PIV1_1 Parainfluenza virus-1  
PIV2_1 Parainfluenza virus-2  
PIV3_1 Parainfluenza virus-3  
PSAE_1 Pseudomonas	aeruginosa  
RESV_1 Respiratory Syncytial Virus  
RHIV_1 Rhinovirus  
RNP3_1 Human RNase P gene  
RUBV_1 Rubella virus Interpret positive result when Ct ≤35.  
Specimens exhibiting amplification after cycle 
35 should be marked as “Negative.” 
SALS_1 Salmonella	spp.  
 
 308 
 
STAU_1 Staphylococcus	aureus  
STPN_1 Streptococcus	pneumoniae  
URUP_1 Ureaplasma	parvum	(biovar 
1; serovars 1, 3, 6,14), 
Ureaplasma	urealyticum	
(biovar 2; serovars 2, 4, 5, 7-
13) 
URUP_1 
 
